Radiation doses and risks from paediatric computed tomography by Brady, Z
Radiation Doses and Risks from Paediatric
Computed Tomography
Zoe Brady
B.Sc. (Hons)
A thesis submitted for the degree of
Doctor of Philosophy
School of Applied Sciences
College of Science, Engineering and Health
RMIT University
February 2012

Declaration
I certify that except where due acknowledgement has been made, the work is that of the
author alone; the work has not been submitted previously, in whole or in part, to qualify
for any other academic award; the content of the thesis is the result of work which has
been carried out since the official commencement date of the approved research program;
any editorial work, paid or unpaid, carried out by a third party is acknowledged; and,
ethics procedures and guidelines have been followed.
Zoe Brady
February 2012
i

Supervisors
Prof. Peter N. Johnston
Branch Director, Medical Radiation Services
Australian Radiation Protection and Nuclear Safety Agency (ARPANSA)
Commonwealth Government of Australia
Adjunct Professor, RMIT University
Melbourne, Australia
Dr. Timothy M. Cain
Director, Medical Imaging
Royal Children’s Hospital (RCH) Melbourne
Melbourne, Australia
iii

Acknowledgements
Thank you to my supervisors Prof Peter Johnston and Dr Tim Cain who have provided
insightful guidance. Luke Wilkinson at St Vincent’s Hospital and Matthew Haynes at the
William Buckland Radiotherapy Centre (WBRC) in Melbourne have provided invaluable
advice, both intellectually and personally. I would also like to thank a number of people
who have been very helpful with providing resources, support and assistance. These
include Anthony Wallace at ARPANSA; John Mathews, Anna Forsythe and Jo Chesson
at the University of Melbourne; Greta Toncheva at Duke Medical Centre in the US; Paul
Shrimpton and Jan Jansen at the UK Health Protection Agency; Choonsik Lee at the
US National Cancer Institute; Corynne Smythe and Mark Fitzgerald at the Australian
Department of Health and Ageing; Rick Franich at RMIT; the physics/engineering staff
at the Peter MacCallum Cancer Centre in East Melbourne: Tomas Kron, Jim Cramb
and Jim Hagekyriakou; the physics/engineering staff at WBRC: Craig Lancaster, Neil
Brouwer and Trevor Ackerly; and my employers, Australian Radiation Services Pty Ltd
and Alfred Health. A special thank you to all of the staff, including Fiona Ramanauskas
and Mita Pedersen, in the Medical Imaging Department at the Royal Children’s Hospital
Melbourne. Finally, thank you to Cam, Annie, Scott, Dave, Jack, Emily and Evie and
my other family and friends who have supported me throughout and experienced this
rewarding, yet challenging, journey with me.
v

Contents
Declaration i
Supervisors iii
Acknowledgements v
Contents vii
List of Figures xi
List of Tables xiii
List of Abbreviations xvii
Summary 1
1 Introduction 5
1.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2 Thesis Scope and Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.3 Thesis Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.4 Ethical Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.4.1 Assessment of CT Imaging Trends . . . . . . . . . . . . . . . . . . . 9
1.4.2 Patient Dose Survey . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.5 List of All Publications Arising from this Thesis . . . . . . . . . . . . . . . 10
1.5.1 Peer-Reviewed Publications . . . . . . . . . . . . . . . . . . . . . . . 10
1.5.2 Conference Presentations . . . . . . . . . . . . . . . . . . . . . . . . 10
2 Medical Radiation Exposure 13
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.2 Radiation and Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.3 Radiation Exposure from CT . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.4 Children and CT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.4.1 Dose Reduction Techniques . . . . . . . . . . . . . . . . . . . . . . . 24
2.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.6 Publications Arising from this Chapter . . . . . . . . . . . . . . . . . . . . . 33
vii
CONTENTS
3 Experimental Dosimetry 35
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.2.1 CT Examinations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.2.2 Anthropomorphic Phantom . . . . . . . . . . . . . . . . . . . . . . . 39
3.2.3 Thermoluminescence Dosimetry . . . . . . . . . . . . . . . . . . . . . 40
3.2.4 Measurement of Organ and Tissue Absorbed Dose . . . . . . . . . . 47
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
3.4.1 Comparison of Organ and Tissue Absorbed Doses . . . . . . . . . . 57
3.4.2 ICRP 60 versus ICRP 103 Effective Dose . . . . . . . . . . . . . . . 61
3.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.6 Publications Arising from this Chapter . . . . . . . . . . . . . . . . . . . . . 64
4 MOSFET Dosimetry Comparison 71
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5 Computational Dosimetry 79
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.2 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5.2.1 Computational Anthropomorphic Phantoms . . . . . . . . . . . . . . 80
5.2.2 CT Scanner-Dependent Computational Methods . . . . . . . . . . . 81
5.2.3 CT Scanner-Independent Computational Methods . . . . . . . . . . 82
5.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.5.1 Patient Modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.5.2 CT Scanner Modelling . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.5.3 Scan Parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
5.5.4 Which Method(s) is Best? . . . . . . . . . . . . . . . . . . . . . . . . 100
5.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5.7 Publications Arising from this Chapter . . . . . . . . . . . . . . . . . . . . . 104
viii
CONTENTS
6 Survey of Patient Doses in Paediatric CT to Establish Local DRLs at
RCH 111
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
6.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
6.4.1 Scan Parameters and Patient Age . . . . . . . . . . . . . . . . . . . 122
6.4.2 Comparison with Physical Phantom . . . . . . . . . . . . . . . . . . 125
6.4.3 Optimisation in Australian Paediatric CT Practice . . . . . . . . . . 126
6.4.4 International Paediatric CT DRLs . . . . . . . . . . . . . . . . . . . 131
6.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
6.6 Publications Arising from this Chapter . . . . . . . . . . . . . . . . . . . . . 138
7 Assessment of Australian Paediatric CT Imaging Trends 139
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
7.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
7.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
7.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
7.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
7.6 Publications Arising from this Chapter . . . . . . . . . . . . . . . . . . . . . 154
8 Projected Cancer Risks for Paediatric CT in Australia 157
8.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
8.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
8.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
8.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
8.4.1 Limitations of Risk Modelling . . . . . . . . . . . . . . . . . . . . . . 162
8.4.2 Comparison of Risks from CT Examinations . . . . . . . . . . . . . 165
8.4.3 Comparison of Calculated and Published Risks . . . . . . . . . . . . 166
8.4.4 Projected Cancer Risks . . . . . . . . . . . . . . . . . . . . . . . . . 169
8.4.5 Risks in Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
8.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
8.6 Publications Arising from this Chapter . . . . . . . . . . . . . . . . . . . . . 172
9 Conclusions 177
Appendices
A Overview of CT Scanner Design, Technology and Dosimetry 183
A.1 CT X-ray Production and Detection . . . . . . . . . . . . . . . . . . . . . . 183
A.2 CT Scanner Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
A.3 CT Image Formation and Display . . . . . . . . . . . . . . . . . . . . . . . . 198
ix
CONTENTS
A.4 CT Image Quality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
A.5 Formalism for CT Dosimetry . . . . . . . . . . . . . . . . . . . . . . . . . . 207
B Effective Dose Computation 213
C Introduction to Thermoluminescence Dosimetry 217
C.1 Thermoluminescence Dosimetry . . . . . . . . . . . . . . . . . . . . . . . . . 217
C.2 Advantages and Disadvantages . . . . . . . . . . . . . . . . . . . . . . . . . 218
C.3 High Sensitivity TLDs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219
D International Paediatric CT Diagnostic Reference Levels 223
E Phantom Composition and Dimensions 225
F TLD Phantom Measurement Locations 229
G Factors for Red Bone Marrow and Bone Surface Dosimetry 233
H Tube Current Modulation – Phantom 241
I Organ and Tissue Absorbed Doses – Phantom 245
J Phantom Scan Regions 251
K Paediatric Fitting Parameters and Conversion Coefficients 255
L RCH Patient Dose Survey – CT Examination Parameters 259
M RCH Patient Dose Survey – Age and Gender Demographics 261
N Comparison of Doses for Typical Paediatric CT Examinations 263
O Cancer Incidence and Mortality Risks 265
Bibliography 269
x
List of Figures
2.1 Excess relative risk of radiation induced cancer as a function of dose . . . . 18
2.2 Radiation induced cancer risk modelling with age at exposure . . . . . . . . 18
3.1 CT X-ray photon spectra . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.2 CIRS anthropomorphic phantoms . . . . . . . . . . . . . . . . . . . . . . . . 66
3.3 CT images of anthropomorphic phantom . . . . . . . . . . . . . . . . . . . . 67
3.4 TLD loaded phantom slab . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3.5 TLD chips . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3.6 Calibration using a linear accelerator . . . . . . . . . . . . . . . . . . . . . . 68
3.7 TLD measurement locations in the lung and liver . . . . . . . . . . . . . . . 68
3.8 Measured absorbed doses from paediatric CT and over-ranging length . . . 69
4.1 Schematic of a MOSFET . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.2 Mobile MOSFET modules . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.3 MOSFET calibration configuration . . . . . . . . . . . . . . . . . . . . . . . 73
4.4 MOSFET sensitivity for different beam qualities . . . . . . . . . . . . . . . 74
4.5 MOSFET wires protruding from assembled phantom . . . . . . . . . . . . . 74
4.6 Comparison of MOSFET and TLD measurements . . . . . . . . . . . . . . 78
5.1 TLD measured absorbed doses for a CT brain examination . . . . . . . . . 105
5.2 TLD measured absorbed doses for a CT chest examination . . . . . . . . . 106
5.3 TLD measured absorbed doses for a CT abdomen/pelvis examination . . . 107
5.4 Range of calculated effective dose values for paediatric CT . . . . . . . . . . 108
5.5 Comparison of ICRP 60 calculated effective dose values . . . . . . . . . . . 108
5.6 Comparison of ICRP 103 calculated effective dose values . . . . . . . . . . . 109
6.1 DLP16 as a function of CTDIvol,16 from the patient survey . . . . . . . . . . 118
6.2 CT parameters as a function of age from the patient survey . . . . . . . . . 119
6.3 Comparison of CT parameters from the patient survey . . . . . . . . . . . . 120
6.4 Comparison of mean RCH values with international DRLs . . . . . . . . . . 133
7.1 Number of CT and MRI services billed to Medicare, Australia (1994-2010) . 143
7.2 Number of paediatric CT services billed to Medicare, Australia (1986-2008) 143
7.3 Age distribution of CT services in Australia (2009) . . . . . . . . . . . . . . 145
7.4 Age and gender distribution of the Australian CT imaging rate (2009) . . . 145
xi
LIST OF FIGURES
7.5 Gender distribution of the Australian paediatric CT imaging rate (1994-2009)146
7.6 Annual percentage change in the Australian CT imaging rate (1995-2009) . 146
7.7 Paediatric CT imaging rate in Australia (1986-2008) . . . . . . . . . . . . . 147
7.8 Australian imaging rates for diagnostic modalities (1994-2009) . . . . . . . 147
7.9 RCH and Medicare Victoria age distribution of CT patients (2008) . . . . . 155
8.1 Site-specific incidence LAR for a 10 year old child from CT exposures . . . 163
8.2 Site-specific mortality LAR for a 10 year old child from CT exposures . . . 164
8.3 Overall LAR for a 10 year old child from CT exposures . . . . . . . . . . . 167
8.4 Progression to death of radiation induced incident cancers . . . . . . . . . . 167
A.1 Components of an X-ray tube . . . . . . . . . . . . . . . . . . . . . . . . . . 185
A.2 X-ray emission spectra from a tungsten target produced at 120 kVp . . . . 185
A.3 First generation CT scanner (translate-rotate) . . . . . . . . . . . . . . . . . 190
A.4 Second generation CT scanner (translate-rotate) . . . . . . . . . . . . . . . 190
A.5 Third generation CT scanner (rotate-rotate) . . . . . . . . . . . . . . . . . . 190
A.6 Fourth generation CT scanner (rotate-stationary) . . . . . . . . . . . . . . . 192
A.7 Fifth generation electron beam CT (stationary-stationary) . . . . . . . . . . 192
A.8 Helical CT scanning with different pitch factors . . . . . . . . . . . . . . . . 192
A.9 SDCT and MDCT detector rows . . . . . . . . . . . . . . . . . . . . . . . . 194
A.10 MDCT detector array designs . . . . . . . . . . . . . . . . . . . . . . . . . . 194
A.11 Penumbra caused by finite focal size . . . . . . . . . . . . . . . . . . . . . . 196
A.12 Used X-ray beam region for SDCT and MDCT . . . . . . . . . . . . . . . . 196
A.13 Iterative method of CT image formation . . . . . . . . . . . . . . . . . . . . 201
A.14 Back projection method of CT image formation . . . . . . . . . . . . . . . . 201
A.15 Radon transform . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
A.16 Radiation dose distribution for a single X-ray tube rotation . . . . . . . . . 209
A.17 Radiation dose distribution from multiple adjacent rotations . . . . . . . . . 209
C.1 Energy response for LiF:Mg,Ti and LiF:Mg,Cu,P chips . . . . . . . . . . . . 221
E.1 Comparison of elemental composition of CIRS and PCXMC phantoms . . . 227
F.1 TLD measurement locations in phantom . . . . . . . . . . . . . . . . . . . . 232
H.1 Modulated tube current for CT brain examination of phantom . . . . . . . 242
H.2 Modulated tube current for CT body examinations of phantom . . . . . . . 243
I.1 TLD measured absorbed doses for CT examinations of a phantom . . . . . 249
J.1 Phantom diagrams with CT scan lengths indicated . . . . . . . . . . . . . . 253
xii
List of Tables
2.1 BEIR VII Lifetime Attributable Risk . . . . . . . . . . . . . . . . . . . . . . 17
2.2 ICRP detriment adjusted nominal exposure risk coefficients . . . . . . . . . 19
2.3 Number of CT scanners by country . . . . . . . . . . . . . . . . . . . . . . . 20
2.4 Contribution of CT to diagnostic examinations and effective dose . . . . . . 21
2.5 Average dose per CT examination and chest radiograph . . . . . . . . . . . 22
2.6 ICRP levels of justification . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.1 Current CT protocols at the RCH for a child aged over 10 years . . . . . . 38
3.2 CIRS paediatric anthropomorphic phantom range . . . . . . . . . . . . . . . 40
3.3 Random and systematic uncertainties for TLD calibration and measurement 43
3.4 Values for systematic uncertainties in TLD measurements . . . . . . . . . . 45
3.5 Organ and tissue photon mass energy absorption coefficients . . . . . . . . . 46
3.6 Upper and lower large intestine organ masses (10 year old child) . . . . . . 49
3.7 Skin surface area proportions (10 year old child) . . . . . . . . . . . . . . . 54
3.8 Irradiated proportion of skin surface area for specific CT examinations . . . 54
3.9 Values of normalised CTDIvol displayed on the console and measured . . . . 55
3.10 Values of mA and mAs for the phantom CT examinations . . . . . . . . . . 56
3.11 Average values of CTDIvol, DLP and length for the CT examinations . . . . 57
3.12 TLD measured absorbed doses for the phantom CT examinations . . . . . . 58
3.13 Colon TLD measured absorbed doses for the phantom CT examinations . . 59
3.14 Values of effective dose calculated from TLD measurements . . . . . . . . . 59
5.1 Organ and effective dose derivation methods and quantities . . . . . . . . . 85
5.2 Scan length parameters for the computational and physical phantoms . . . 86
5.3 Values of effective dose from the experimental and computational methods . 91
5.4 Calculated DLP to effective dose conversion coefficients . . . . . . . . . . . 92
5.5 Comparison of measured CTDI100 values with ImPACT and CT-Expo . . . 97
5.6 Comparison of CTDIw values with ImPACT and CT-Expo values . . . . . . 98
5.7 Calculation of the ImPACT Factor to enable scanner matching . . . . . . . 99
6.1 DLP to E conversion coefficients . . . . . . . . . . . . . . . . . . . . . . . . 117
6.2 Recommended LDRLs at the RCH for typical paediatric CT examinations . 118
6.3 Estimated effective doses for typical CT examinations at the RCH . . . . . 121
6.4 Comparison between dose indicators for the phantom and for patients . . . 126
xiii
LIST OF TABLES
6.5 RCH examination parameters compared with an earlier Australian survey . 127
6.6 RCH examination parameters compared with a study at RCH Brisbane . . 131
7.1 Number of CT services and imaging rate in Australia (1994 and 2009) . . . 142
7.2 Gender and age distribution for paediatric CT imaging in Australia (2008) . 148
7.3 Average annual change in the Australian paediatric CT imaging rate . . . . 150
8.1 Organ and tissue absorbed doses measured by TLD (10 year old child) . . . 158
8.2 Site specific BEIR VII LAR for exposure at 10 years of age . . . . . . . . . 159
8.3 Predicted number of radiation induced non-fatal and fatal cancers . . . . . 162
8.4 Comparison of sex-averaged paediatric cancer mortality risks . . . . . . . . 173
8.5 Comparison of male and female paediatric cancer incidence risks . . . . . . 174
8.6 Lifetime risk of dying for the Australian population from various causes . . 175
A.1 Comparison of CT detector properties . . . . . . . . . . . . . . . . . . . . . 188
A.2 Automatic tube current modulation techniques for different manufacturers . 197
B.1 ICRP 26, 60 and 103 tissue weighting factors . . . . . . . . . . . . . . . . . 214
B.2 ICRP primary and remainder organs for effective dose computation . . . . . 215
D.1 Comparison between international paediatric CT DRLs . . . . . . . . . . . 224
E.1 CIRS Model 706-D phantom materials (10 year old child) . . . . . . . . . . 226
E.2 Comparison of elemental composition of CIRS and PCXMC phantoms . . . 226
E.3 Characteristics of CIRS, CT-Expo and PCXMC child phantoms . . . . . . 227
F.1 Comparison of measurement locations in anthropomorphic phantoms . . . . 230
G.1 Active marrow in bone groups for different ages . . . . . . . . . . . . . . . . 234
G.2 Red bone marrow dose enhancement factors . . . . . . . . . . . . . . . . . . 235
G.3 Distribution of active marrow, inactive marrow and trabecular bone . . . . 236
G.4 Spongiosa masses in different bones (10 year old child) . . . . . . . . . . . . 237
G.5 Percentage distribution of bone spongiosa (10 year old child) . . . . . . . . 238
G.6 Spongiosa distribution and mass energy absorption coefficients . . . . . . . 239
I.1 TLD measured absorbed doses for a CT brain examination . . . . . . . . . 246
I.2 TLD measured absorbed doses for a CT chest examination . . . . . . . . . 247
I.3 TLD measured absorbed doses for a CT abdomen/pelvis examination . . . 248
K.1 mAs normalised organ and effective dose (ORNL and UF phantoms) . . . . 255
K.2 Fitting parameters for estimating organ absorbed doses for CT chest exam-
inations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256
K.3 Exponential regression coefficients for organ dose estimates . . . . . . . . . 256
K.4 Normalised effective dose per DLP coefficients . . . . . . . . . . . . . . . . . 257
xiv
LIST OF TABLES
K.5 ICRP normalised effective dose per DLP coefficients . . . . . . . . . . . . . 257
K.6 Fitting parameters for size-dependent DLP conversion coefficients . . . . . . 258
K.7 Normalised effective dose per CTDIw . . . . . . . . . . . . . . . . . . . . . . 258
L.1 RCH patient survey CT parameters . . . . . . . . . . . . . . . . . . . . . . 260
M.1 Gender and age distribution for patients in the RCH dose survey . . . . . . 262
N.1 Comparison of measured absorbed doses with values in the literature . . . . 264
O.1 Natural and radiation induced cancer risks . . . . . . . . . . . . . . . . . . . 266
O.2 Natural and radiation induced cancer population risks . . . . . . . . . . . . 267
xv

List of Abbreviations
2D Two dimensional
AEC Automatic Exposure Control
ALARA As low as reasonably achievable
AP Anterior-posterior
ARL Australian Radiation Laboratory (now ARPANSA)
ARPANSA Australian Radiation Protection and Nuclear Safety Agency (formerly
ARL)
BEIR Biological Effects of Ionising Radiation
CIRS Computerized Imaging Reference Systems
CT Computed Tomography
CTDI Computed Tomography Dose Index
CTDIvol Volumetric Computed Tomography Dose Index
CTDIw Weighted Computed Tomography Dose Index
CT-Expo Monte Carlo CT dosimetry calculator (Stamm and Nagel, 2011b)
DDREF Dose and Dose Rate Effectiveness Factor
DLP Dose Length Product
DRL Diagnostic Reference Level
EAR Excess Absolute Risk
ERR Excess Relative Risk
FWHM Full Width Half Maximum
GSF German National Research Centre for Environment and Health
Gy Gray
HPA United Kingdom Health Protection Agency (formerly NRPB)
HVL Half Value Layer
HREC Human Research Ethics Committee
IAEA International Atomic Energy Agency
ICRP International Commission on Radiological Protection
ICRP 26 ICRP Publication 26: 1977 Recommendations (ICRP, 1977)
ICRP 60 ICRP Publication 60: 1990 Recommendations (ICRP, 1991)
ICRP 103 ICRP Publication 103: 2007 Recommendations (ICRP, 2007b)
xvii
LIST OF ABBREVIATIONS
ICRU International Commission on Radiation Units and Measurements
ImPACT Monte Carlo CT dosimetry calculator (ImPACT, 2011)
kV kilovoltage
kVp peak kilovoltage
LAR Lifetime Attributable Risk
LDRL Local Diagnostic Reference Level
LET Linear Energy Transfer
LiF Lithium fluoride
LiF:Mg,Cu,P Lithium fluoride doped with magnesium, copper and phosphorous (TLD-
100H)
LiF:Mg,Ti Lithium fluoride doped with magnesium and titanium (TLD-100)
LNT Linear No Threshold
mAs Current (mA) multiplied by time (seconds)
LSS Life Span Study
MDCT Multiple row Detector CT
MOSFET Metal oxide semiconductor field effect transistor
MRI Magnetic Resonance Imaging
MSAD Multiple Slice Average Dose
NRPB United Kingdom National Radiological Protection Board (now HPA)
ORNL Oak Ridge National Laboratory
PA Posterior-anterior
PCXMC Monte Carlo radiography dosimetry calculator (STUK, 2008)
QUDI Quality Use of Diagnostic Imaging
RANZCR Royal Australian and New Zealand College of Radiologists
RBM Red Bone Marrow
RCH Royal Children’s Hospital Melbourne
RR Relative Risk
SNR Signal to Noise Ratio
SPR Society for Pediatric Radiology
Sv Sievert
TLD Thermoluminescence Dosimetry/Dosemeters
TLD-100 LiF:Mg,Cu,P
TLD-100H LiF:Mg,Ti
UF University of Florida
UK United Kingdom
UNSCEAR United Nations Scientific Committee on the Effects of Atomic Radiation
US United States
xviii
Summary
The use of computed tomography (CT) worldwide has increased dramatically since its
introduction. In Australia, more than two million CT services are billed to the government
health care system every year and the rate of imaging is increasing beyond population
growth. CT imaging currently accounts for the largest source of ionising radiation exposure
to the population from all diagnostic procedures. There is a small, theoretical risk of
carcinogenesis attributable to low doses of ionising radiation based on epidemiological
evidence at higher doses and dose rates. The doses from CT examinations fall into this low
dose range. Recognition of the potential radiation risks combined with the high utilisation
of CT imaging has led to greater awareness of population health risks. Furthermore, the
exposure risks from radiation are higher for children than for adults due to their increased
radiosensitivity and greater prospective life expectancy. There is only limited information
on Australian paediatric CT imaging rates, doses and risks. This thesis aims to assess the
medical radiation exposure of children in Australia from CT examinations.
For the past 10 years, there has been an international focus on the risks to children from
CT scanning. Despite this, it is acknowledged that radiation doses and risks in CT still
need to be addressed. Since radiation induced cancer risk is specific to the organ or tissue
irradiated, there is a particular need for CT organ dosimetry. In this thesis, a method has
been developed using thermoluminescence dosemeters (TLDs) placed in a physical anthro-
pomorphic phantom to measure organ and tissue absorbed doses. This method takes into
account the energy dependency of photon interaction processes, electronic disequilibrium
in small bone cavities and bone marrow and trabecular bone distributions which vary
with age. In addition, a TLD material (LiF:Mg,Cu,P) which is new to diagnostic radi-
ology applications has been used for the absorbed dose measurements. This material is
more sensitive to low radiation doses and has a relatively linear energy and dose response
allowing calibration at megavoltage energies on a linear accelerator. This ensured unifor-
mity and reproducibility of output for the calibration exposures, which are limitations of
using conventional TLD materials at diagnostic energies.
The TLD dosimetry method was used to quantify organ absorbed doses for typical pae-
diatric CT examinations of the brain, chest and abdomen/pelvis for clinical protocols in
use at the Royal Children’s Hospital (RCH) Melbourne, Australia. The measurements
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were undertaken using a physical anthropomorphic phantom representative of a 10 year
old child. The mean absorbed dose to an organ is the appropriate quantity for assessing
the detrimental stochastic effects of radiation exposure. However, for radiation protection
purposes, effective dose is a more useful quantity allowing comparison of different partial
body exposure situations to assess risk in more general terms and facilitate optimisation.
Therefore, effective dose has been estimated from the measured organ absorbed doses for
the typical paediatric CT examinations and the impact of the newly introduced tissue
weighting factors by the International Commission on Radiological Protection has been
evaluated.
The ability to reliably estimate organ absorbed doses and effective dose in the clinical
environment is necessary to ensure that the principles of radiation protection are being
employed. Therefore, the experimentally measured organ absorbed doses and the derived
effective doses were compared with doses calculated using several different computational
methods in order to identify a feasible clinical tool for paediatric CT dosimetry. The
methods investigated included standard CT dose calculators which make use of pre-existing
Monte Carlo data sets of organ dose conversion coefficients. A novel application of a Monte
Carlo simulation tool designed for radiography exposure situations was also utilised to
simulate the CT exposure situation. Further emerging scanner-independent methodologies
based on normalised organ doses as a function of patient size were also assessed. Finally,
simpler conversion methods for estimating effective dose were compared. A variety of
anthropomorphic phantoms including physical, mathematical (stylised), voxel and hybrid
models were used in the range of CT dosimetry methods assessed.
A retrospective audit of patient CT dose records at the RCH was also undertaken. This
allowed the derivation of local diagnostic reference levels (DRLs), which is considered
an essential process for dose optimisation. Furthermore, the patient data was used to
verify the measurements made with the physical anthropomorphic phantom. A method
for assessing and benchmarking the sampled dose data was developed and this will be of
use to other practices undertaking dose surveys, which is now a regulatory requirement
in most Australian jurisdictions. The benchmarking process also recognised protocols for
which significant dose reductions at the RCH have already been achieved.
The first comprehensive analysis of paediatric CT imaging frequency and trends in Aus-
tralia was undertaken. This involved assessing the amount of paediatric CT imaging that
is funded by the government health care system and determining a process to reflect cur-
rent Australian usage. These results provide an important foundation for paediatric CT
research in Australia.
Finally, using the measured organ absorbed doses and Australian CT imaging frequency,
cancer risk projections for CT examinations on Australian children have been made. It
was found that the risk to an individual patient is small when compared with the over-
all natural cancer rate. A CT examination for an individual child is justified if there is
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reasonable likelihood that it will produce a health benefit or inform patient management.
The population is advantaged when the summed positive health benefits from those whose
management is positively influenced by the imaging are greater than the summed detri-
mental effects. The net positive health effects of the CT examination will be greater when
appropriate imaging is performed and is optimised for both image quality and dose. How-
ever, in a society where the threshold for conducting a CT examination is becoming ever
lower, it is important that we remain attentive to the overall population health detriment
from medical imaging radiation exposure.
This thesis provides an experimental method for paediatric CT organ dosimetry and a com-
prehensive evaluation of paediatric CT doses and imaging trends in Australia. Typical
doses for paediatric CT examinations have been quantified using various methods, both
experimental (direct) and computational (indirect). Local DRLs have been established
based on the dose distributions from patient data and will provide a useful benchmark
for future local and national dose surveys. Finally, cancer risk projections for incidence
and mortality from paediatric CT scanning have been made for the Australian popula-
tion.
3

Chapter 1
Introduction
1.1 Background
X-ray diagnostic imaging is one of the most useful and valuable medical tools available
today. It allows us to non-invasively “peer” inside the human body to study anatomy
and physiology, and to diagnose and investigate disease. Advances in technology have
led to improved image quality and the ability to gain added diagnostic information that
affects patient management. However, there is potential for the increased risk of radia-
tion induced cancer to offset these benefits. This risk arises not only from higher dose
techniques, but also from the increased uptake of imaging. As with all fields of medicine,
diagnostic imaging involves an element of risk that must be balanced by the benefit that
it provides.
Many studies have investigated the correlation between radiation exposure and cancer
risk. Epidemiological studies, such as the Life Span Study of the atomic bomb survivors,
medical studies and experimental animal research have established a relationship between
exposure and cancer induction and cellular damage. However, there is a lack of consensus
on the effects of radiation at low doses and low dose rates, with the linear no threshold
hypothesis being widely accepted and the basis of the international system of radiation
protection (ICRP, 2007b). Medical radiation exposure for diagnostic purposes usually falls
into this low dose category, where the radiation risks are yet to be observed and modelled
by epidemiological studies.
Amongst diagnostic imaging modalities, computed tomography (CT) has been shown to
account for the highest contribution to population dose (NCRP, 2009). Despite the un-
certainties inherent in risk assessments for low dose exposures, some researchers (Brenner
et al., 2001a; Brenner and Hall, 2007) have contended that when considering population
health, the lifetime cancer risk attributable to CT examinations is not negligible. Fur-
thermore, this risk is higher in children who are more radiosensitive than adults and have
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a longer remaining lifetime for cancer to become evident. Since 2001 and the publication
of a series of articles (Brenner et al., 2001a; Donnelly et al., 2001; Paterson et al., 2001)
about the risks of radiation induced cancer in children from diagnostic CT scans, there
has been a strong international focus on paediatric CT dose.
It is remarkable that CT has been used in medicine for almost 40 years, yet only recently
has the radiation exposure from CT become more widely recognised as a public health
issue. Worldwide, there is a large volume of published material on CT and radiation
attributable risk, although there is a lack of specific information for the Australian popu-
lation that combines these aspects, particularly for children. Furthermore, in practice, it
has been observed that there is limited understanding of the magnitude of doses and as-
sociated risks. Therefore, there is a strong research interest in this area from the medical,
public and government sectors in Australia.
1.2 Thesis Scope and Objectives
The objective of this thesis is to assess the medical radiation exposure of children in Aus-
tralia from CT examinations. The risk of radiation induced cancer is anatomy-specific and
therefore determined from organ and tissue absorbed doses. Currently, the most accurate
and reliable methods of determining these doses are by measurement or Monte Carlo ra-
diation transport simulation. This thesis evaluates both experimental and computational
dosimetry methods for paediatric CT. An important emphasis was on assessing clinical
practice rather than theoretical exposure conditions. This is becoming increasingly impor-
tant with modern CT technology, which utilises features such as tube current modulation
rather than fixed exposures. This results in organs being exposed to different X-ray beam
output depending on the attenuation characteristics in each body region, hence making
the examination patient-specific.
There are very few publications describing organ absorbed dose measurements in the
context of paediatric CT using clinical protocols (Fujii et al., 2007, 2009; Hollingsworth
et al., 2007; McDermott et al., 2009; Nishizawa et al., 2008). In this thesis, an experimental
method using thermoluminescence dosemeters (TLDs) was implemented to measure organ
absorbed doses for standard paediatric clinical protocols using a physical anthropomorphic
phantom representing a 10 year old child. High sensitivity TLD chips (LiF:Mg,Cu,P) were
used for the dose measurements. There are limited applications using these TLDs for
measuring doses encountered in the diagnostic energy range (Brisse et al., 2009b; Duggan
et al., 2003). However, this type of TLD material exhibits a relatively linear energy
and dose response compared with conventional TLD material (LiF:Mg,Ti). This allowed
calibration to be undertaken on a linear accelerator at a megavoltage energy overcoming
limitations of output reproducibility and uniformity associated with traditional calibration
on CT scanners or beam quality matched diagnostic X-ray units. This was considered
a significant advantage in using the high sensitivity TLD material and ensured greater
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precision for measuring the relatively low doses common to paediatric CT. Using this type
of TLD material necessitated the development of a calibration technique at megavoltage
energy, which was validated against a calibration performed at kilovoltage energy on a
superficial X-ray therapy unit.
This thesis is not limited to a basic measurement of organ absorbed dose, but rather de-
velops a detailed formalism for calculating organ and tissue absorbed doses for children
from TLD measurements. This takes into account the energy dependence of photon in-
teractions in different tissues in the energy range typical of CT spectra and the lack of
secondary electron equilibrium in the small cavities containing bone marrow. Further-
more, the distribution of active marrow, inactive marrow and trabecular bone varies with
age and this has been considered in the organ and tissue absorbed dose calculations. Due
to the complexity of determining the absorbed dose to the bone marrow and bone sur-
face, these types of considerations are generally only taken into account for Monte Carlo
simulations (Lee et al., 2006b).
Measurement of organ absorbed dose is impractical in the diagnostic radiology clinical en-
vironment as it is time and resource intensive. Therefore, several computational dosimetry
methods were also evaluated in this thesis. While there are some assessments between ex-
perimental and computational methods in the literature for CT examinations (Brix et al.,
2004; Geleijns et al., 1994; Groves et al., 2004; Lechel et al., 2009), these are for adults
and do not include inter-comparison of the breadth of methods considered in this thesis.
The different methods were compared using parameters and conditions that best matched
the “real-life” scenario to assess their reliability for clinical implementation. It is often
challenging to use these tools for dose estimates when the clinical conditions are difficult
to simulate.
Epidemiological studies are necessary to model the relationship between radiation expo-
sure and risk, but these are impeded by the large cohort sizes needed to observe effects at
low radiation doses. However, risk projection models are useful for providing more timely
theoretical estimates of radiation detriment to the population. In order to project the
population cancer risks in this thesis, the Australian paediatric CT imaging trends and
the number of examinations undertaken nationally needed to be quantified. This infor-
mation is difficult to collate as there is no single repository of diagnostic imaging data in
Australia. Previous studies have relied on the government health care system data (Wise
and Thomson, 2004), which is limited in its completeness. A more thorough approach was
used in this thesis involving multiple sources of paediatric imaging data over longer time
scales. This permitted more realistic estimates of the number of CT examinations per-
formed in Australia on children. This information is essential for any research and analysis
being conducted in the area of paediatric CT. Furthermore, it considerably extends the
current literature on trends and patterns of paediatric CT imaging, both nationally and
internationally.
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1.3 Thesis Structure
Chapter 2 provides an overview of medical radiation exposure. The current knowledge
of risk associated with exposure to low radiation doses is explored and worldwide trends
in CT imaging are considered. These issues are further discussed in relation to children
and dose reduction techniques for paediatric CT are reviewed. More detailed background
information on CT scanner design, operation, image quality and dosimetry is provided in
Appendix A.
Chapter 3 outlines a TLD measurement method for paediatric CT dosimetry using a physi-
cal anthropomorphic phantom representing a 10 year old child. Organ and tissue absorbed
doses are quantified for CT brain, chest and abdomen/pelvis examinations performed at
the Royal Children’s Hospital (RCH) Melbourne, Australia. Chapter 3 also provides esti-
mates of effective dose for the three types of CT examinations assessed. The differences,
predominantly due to changes in tissue weighting factors, between recent definitions of
effective dose according to the Recommendations of the International Commission on Ra-
diological Protection (ICRP, 1991, 2007b) are discussed. Appendix B provides further
information on effective dose and Appendix C on TLDs.
While TLD organ dosimetry is currently the most widely accepted physical measurement
method, it is unlikely to find regular application in the clinical environment as it is a labo-
rious technique. Chapter 4 provides a comparison of a subset of the TLD measurements
with dose measurements made using metal oxide semiconductor field effect transistors
(MOSFETs). It is envisaged that MOSFETs may become a viable alternative to TLDs
for organ dosimetry in the future and may be more readily implemented in the clinical
environment.
Several computational methods for calculating organ absorbed dose and effective dose
for paediatric CT are assessed in Chapter 5. In total, 11 computational methods were
investigated and compared with TLD measured doses. Evaluation of these methods also
involved assessment of several anthropomorphic phantoms, including physical, mathemati-
cal (stylised), voxel and hybrid models. The computational methods investigated included
standard CT dose calculators that make use of pre-existing Monte Carlo generated data
sets of organ dose conversion coefficients; a novel application of a radiography Monte Carlo
program; emerging methodologies based on normalised organ doses that were generally
size-specific and in some cases scanner-independent; and simpler conversion methods for
estimating effective dose.
Chapter 6 provides the results of a retrospective audit undertaken at RCH of paediatric
patient CT records. An assessment method for analysing the local scan parameters to
enable identification of areas for optimisation is also presented. In the audit, the parame-
ters used for the CT protocols and the dose indicators were sampled, along with patient
demographics. This allowed comparison with the dose indicators resulting from scanning
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the physical phantom and the effective doses values derived from the TLD measurements.
From the sampled data, local diagnostic reference levels (DRLs) were established based
on the mean value of the patient dose distribution for each age group and type of CT
examination. The local DRLs were compared with other Australian published data and
international DRLs to facilitate benchmarking.
The paediatric CT imaging trends in Australia are explored in Chapter 7 based on Medi-
care and RCH data. This is the first comprehensive analysis of paediatric CT imaging
trends in Australia. A limitation of the Medicare data is that it does not capture CT
services that are not funded by the public health care system. Therefore, Chapter 7 de-
scribes a method for adjusting Medicare paediatric CT data to account for non-funded
services.
The measured anatomy-specific doses combined with Australian paediatric CT imaging
trends enabled cancer risk projections, which are detailed in Chapter 8. For the informa-
tion from this thesis to be useful on a day-to-day basis it is essential to provide a context
for the risk from a CT scan. Few people, particularly members of the public, understand
what a specific radiation dose means. The results in this chapter allow members of the
medical profession to better explain the risks associated with CT examinations of children
for the doses actually received in an Australian hospital. Risk comparators in terms of
other causes of death to the Australian population are also provided. Although projected
cancer risk estimates are limited by the substantial uncertainties involved and caution
should be exercised in their use and application, these risk projections for Australian
children will be of significant value and interest.
1.4 Ethical Considerations
1.4.1 Assessment of CT Imaging Trends
Approval was granted by the RCH Human Research Ethics Committee (HREC) to conduct
a clinical audit/quality assurance activity (reference no. CA29052, 5 May 2009) to assess
the number of CT scans performed at the RCH. An exemption was granted by the RMIT
Human Research Ethics Network of the College of Science Engineering & Health to utilise
Medicare and RCH data to assess CT imaging trends in Australia. The exemption was
provided on the basis that ethics approval to collect the data had been given by the
appropriate ethics bodies (RCH HREC) and/or is publicly available (Medicare data), and
the project involves analysis of coded and non-identifiable data (reference no. 41-09, 18
August 2009).
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1.4.2 Patient Dose Survey
Approval was granted by the RCH HREC to conduct a clinical audit/quality assurance
activity (reference no. CA30013, 5 February 2010) to derive local diagnostic reference levels
based on an analysis of extracted information from a sample of patient CT examinations.
The RMIT Human Research Ethics Network of the College of Science Engineering &
Health endorsed and affirmed the decision made by the RCH HREC (reference no. 21-10,
15 April 2010).
1.5 List of All Publications Arising from this Thesis
1.5.1 Peer-Reviewed Publications
1. Brady, Z., Cain, T. M. and Johnston, P. N., Comparison of organ dosimetry meth-
ods and effective dose calculation methods for paediatric CT, Australasian Physical
& Engineering Sciences in Medicine, 2012 (published online 11 April 2012 ) (Brady
et al., 2012b).
2. Brady, Z. and Einsiedel, P. A Computed Tomography wish list, from a medical
physicist’s perspective, Australasian Physical & Engineering Sciences in Medicine,
2012, 35:1-5 (Invited Editorial) (Brady and Einsiedel, 2012).
3. Brady, Z., Cain, T. M. and Johnston, P. N., Paediatric CT imaging trends in
Australia, Journal of Medical Imaging and Radiation Oncology, 2011, 55:132-142
(Brady et al., 2011d).
4. Brady, Z., Cain, T. M. and Johnston, P. N., Differences in using the International
Commission on Radiological Protection’s Publications 60 and 103 for determining
effective dose in paediatric CT examinations, Radiation Measurements, 2011, 55:132-
142 (Brady et al., 2011e).
5. Brady, Z., Cain, T. M. and Johnston, P. N., Justifying referrals for paediatric CT,
Medical Journal of Australia, 2012 (accepted) (Brady et al., 2012a).
6. Brady, Z., Ramanauskas, F., Cain, T. M. and Johnston, P. N., Assessment of
paediatric CT dose indicators for the purpose of optimisation, British Journal of
Radiology, 2012 (accepted) (Brady et al., 2012c).
1.5.2 Conference Presentations
* = Invited Presentation
1. *Brady, Z., Doses and risks in paediatric imaging in Australia, presented at the
Siemens Low Dose Academy, 2012, Sydney, Australia (Brady, 2012a).
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2. *Brady, Z., DLP practical breakdown - how best to adjust parameters to reduce
dose, presented at the Siemens Low Dose Academy, 2012, Sydney, Australia (Brady,
2012b).
3. Brady, Z., Cain, T. M. and Johnston, P. N., Effective dose calculation in CT using
high sensitivity TLDs (EPSM ABEC 2010 Conference Proceedings), Australasian
Physical & Engineering Sciences in Medicine, 2011, 34(1):111 (Brady et al., 2011b).
4. Brady, Z., Cain, T. M. and Johnston, P. N., Calculations of effective dose for
paediatric CT examinations presented at the 16th International Conference on Solid
State Dosimetry, 2010, Sydney, Australia (Brady et al., 2010b).
5. Brady, Z., Cain, T. M. and Johnston, P. N., Assessing CT protocols in a paediatric
hospital using a patient dose survey (EPSM ABEC 2011 Conference Proceedings),
Australasian Physical & Engineering Sciences in Medicine, 2011, 34(4):590 (Brady
et al., 2011c).
6. Brady, Z., Cain, T. M. and Johnston, P. N., Paediatric CT in Australia - trends
and risk (EPSM ABEC 2010 Conference Proceedings), Australasian Physical & En-
gineering Sciences in Medicine, 2011, 34(1):110 (Brady et al., 2011a).
7. *Brady, Z., Radiation - a risky business? presented at the Medical Imaging Nurses
Association Victorian State Conference, 2010, Melbourne, Australia (Brady, 2010).
8. *Brady, Z., Ackland, H.M. and Varma, D.K. Too much radiation in trauma? pre-
sented at the SWAN XVIII Trauma Conference, 2010, Sydney, Australia (Brady
et al., 2010a).
9. *Brady, Z., Cain, T. M. and Johnston, P. N., Computed tomography - are we
imaging more or less? presented at the RANZCR/AIR/FRO/ACPSEM Combined
Scientific Meeting, 2009, Brisbane, Australia (Brady et al., 2009).
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Chapter 2
Medical Radiation Exposure
2.1 Introduction
Ionising radiation is indispensable to modern medicine for diagnosis and treatment. In
countries with advanced health care systems, there is now more than one diagnostic ex-
amination performed per person across the population every year (UNSCEAR, 2010a).
Medical practices involving ionising radiation include diagnostic examinations, interven-
tional procedures and radiotherapy treatments typically undertaken in radiology, nuclear
medicine and radiation oncology departments or clinics. Globally, approximately 3.6 bil-
lion diagnostic examinations and six million therapeutic treatments are performed annu-
ally (UNSCEAR, 2010a).
Primarily the people exposed to ionising radiation for medical purposes are the patients
themselves. These exposure situations are deliberate and voluntary with some diagnostic
or therapeutic health benefit to be gained (ICRP, 2007b,c). However, excluding therapeu-
tic exposure, the intention is not to deliver a radiation dose, although this is an inevitable
outcome. Recent figures show that diagnostic medical exposures, including radiology and
nuclear medicine, account for about one-fifth of the average annual per caput dose to the
global population from all sources (UNSCEAR, 2010a). Amongst diagnostic modalities,
CT is the highest contributor to population dose, although it accounts for a much smaller
proportion of the total number of examinations (NCRP, 2009).
There is irrefutable evidence from epidemiological studies that ionising radiation exposure
at high doses is associated with an increase in cancer incidence and morbidity (ICRP,
2005). However, quantifying this risk in the low dose range, typical of CT doses, is complex
and contentious. Despite the uncertainty surrounding low dose exposure, the societal risk
may not necessarily be negligible and must still be considered (Brenner and Hricak, 2010;
Brenner et al., 2003). This risk is even higher for children who are more radiosensitive
than adults. Due to the sample size required to have the necessary statistical power to
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establish a low dose response, it is unlikely that risks at these very low levels will ever be
precisely known (Brenner et al., 2003; ICRP, 2005).
The following discussion reviews the current stance of major groups regarding risk from
radiation exposure at the low doses encountered in medical imaging. The largest diagnostic
imaging contributor to population dose, CT, is then considered in more detail, including
global examination frequency and dose. This leads to a more focused discussion of the
radiation risks associated with paediatric CT and a summary of current attitudes towards
this topic. Finally, a literature review of dose reduction techniques for paediatric CT is
provided.
2.2 Radiation and Risk
Epidemiological studies provide a major source of information for quantifying the risk of
radiation induced cancer. It is often acknowledged that these types of studies in the low
dose range below 100 millisieverts (mSv) are inherently difficult to collate due to the need
to obtain sufficient sample sizes and include extensive follow-up to account for radiation
induced cancer latency (Brenner et al., 2003; ICRP, 2005, 2007a,b). It is extremely dif-
ficult to observe the weak carcinogenic effects of radiation above the high natural cancer
incidence with any statistical significance, and consequently the risks at very low levels of
exposure may never be precisely known (Brenner et al., 2003; ICRP, 2005). Another source
of data for estimating the risk of cancer induction is provided by situations in which high
radiation exposures have occurred, such as medical treatments for radiotherapy patients
(UNSCEAR, 2000). Furthermore, radiobiological data based on animal studies, as well as
medical, occupational, and environmental data on cancer incidence, also inform radiation
induced cancer risk determination (ICRP, 2007b). However, observational epidemiological
studies largely remain the basis for radiation risk modelling (ICRP, 2007b; NRC, 2006;
UNSCEAR, 2000).
The most important epidemiological study is the Life Span Study (LSS) of the atomic
bomb survivors because of the large exposed cohort, including men, women and children,
and the extensive long-term follow-up that has been undertaken (Preston et al., 2003).
Furthermore, the doses for the exposed individuals are reasonably well characterised by
individual dose estimates for 85% of the exposed cohort (Brenner et al., 2003; Preston
et al., 2003). The study group includes 86,572 people with specific dose estimates, almost
40% of whom received an estimated dose of between 5 to 100 mSv (Preston et al., 2003).
The lifetime follow-up of the group is almost complete, with the remaining cohort com-
prising mainly those survivors who were younger than 20 years of age at exposure (NRC,
2006).
The most recent results from the LSS appear to confirm a linear response of excess solid
tumours with dose (Preston et al., 2003). In the lower dose region (<100 mSv) there is
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no statistical difference between a linear or linear-quadratic fit for solid cancer incidence
relative to the uncertainties in the risk estimation (Figure 2.1). Since the linear-quadratic
model offers no significant improvement over the linear model, the latter is adopted (NRC,
2006). The latency period (time from exposure to cancer induction) for leukaemia is less
than that for solid tumours, and earlier LSS results show that most excess deaths from
leukaemia occurred in the first 15 years post exposure (Pierce et al., 1996). Leukaemia
exhibits a linear-quadratic dose response (see inset of Figure 2.1), while for much higher
doses (>3 Sv) responses for both leukaemia and solid tumours flatten out, most likely due
to cell death (Heggie et al., 1997).
Based predominantly, but not solely, on the analysis and review of LSS data, the United
Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) and the US
National Academy of Sciences (NAS)/National Research Council (NRC) Committee on the
Biological Effects of Ionising Radiation (BEIR) demonstrate that a linear dose-response
exists at low doses (NRC, 2006; UNSCEAR, 2000). The International Commission on
Radiological Protection (ICRP) has a mandate to make recommendations for a system of
radiological protection and provide guidance on managing the risks of radiation exposure.
The latest ICRP recommendations based on all available evidence consider a linear no
threshold (LNT) model to be the best practical approach for radiation protection purposes
(ICRP, 2007b). The use of this dose response hypothesis infers that any increase in
dose will lead to the same increase in the probability of incurring cancer or heritable
effects attributable to radiation. Furthermore, the International Atomic Energy Agency
(IAEA) also adopt the LNT model based on the recommendations of the ICRP and are
responsible for publishing Safety Standards to establish basic requirements for protection
against radiation risks (IAEA, 1996). However, there are other organisations such as the
American Nuclear Society (ANS, June 2001) and the French Academy of Sciences and
National Academy of Medicine (30 March 2005) that believe insufficient evidence exists
to support this model.
There is some evidence of protective effects from low doses of radiation or a hormetic
response, but these are yet to be confirmed through epidemiological studies (Sykes and
Day, 2007). Furthermore, there is no observable increase in cancer incidence in areas of
high background radiation such as Kerala, India (Nair et al., 2009). At present, the LNT
model remains the most reasonable assumption regarding the dose response relationship
at low levels despite the lack of epidemiological evidence (ICRP, 2007b). The LNT model
is often described as conservative (Blecher, 2010; Mendelson et al., 2010), however other
plausible extrapolations in the low dose region demonstrate that the linear model may
overestimate some risks, but underestimate others (Brenner et al., 2003).
To account for the extrapolation from high doses and dose rates to low doses and dose
rates, a Dose and Dose Rate Effectiveness Factor (DDREF) is used. The ICRP (2007b)
recommend a factor of two in agreement with UNSCEAR (2000), while the BEIR VII
15
CHAPTER 2. MEDICAL RADIATION EXPOSURE
Report (NRC, 2006) uses a factor of 1.5 for solid tumours and one for leukaemia. However,
the ICRP acknowledge that a factor of two corresponds with the data used to derive
the BEIR VII factors and that the DDREF includes uncertainty and is not intended
as a precise figure (ICRP, 2007b). Various DDREFs in the range from 2-10 have been
proposed (Preston, 2008; Wall et al., 2006), which fall within the large uncertainty in the
value (Hricak et al., 2011).
Another issue that arises in applying risk estimations from the LSS to other populations
is the method of “transporting” the risk from the Japanese population. One method
termed relative risk transport assumes excess risk is proportional to the baseline risks for
that population (i.e. the additional risk from radiation exposure multiplies the population
cancer rate by a specific amount (Berrington de Gonzalez and Darby, 2004)). Therefore,
in this model excess relative risk (ERR) will be the same for the Japanese population as
for any other population. An alternative model is one of absolute risk, where it is assumed
that excess risk does not depend on baseline risk, but is added to the population rate. In
this case, excess absolute risk (EAR) will be the same between populations. The BEIR
VII Committee (NRC, 2006) use a weighted average of both ERR and EAR risk models
to transport risk from the Japanese population to the US population. The weighting is
site-specific. For example, for breast and thyroid cancer, the risk models use a combined
cohort from the LSS and medically irradiated groups that include Caucasians. The risk
models are combined to give a lifetime attributable risk (LAR) representing the probability
that an individual will develop (incidence) and may die (mortality) from cancer associated
with radiation exposure.
Based on these calculations, the BEIR VII Committee (NRC, 2006) finds that for the US
population, rates for all radiation attributable cancer incidence are about twice the rates
for mortality. This ratio varies significantly on a site-specific comparison. The highest
LAR for radiation induced cancer mortality in males and females is for the lung, based on
a population of mixed ages. For radiation induced cancer incidence, “other solid cancers”
have the highest LAR for males, while the lung, breast, and other solid cancers all have
relatively high LARs for females. For leukaemia, incidence LAR is approximately 30%
higher than mortality LAR for both males and females due to radiation exposure.
The overall LAR for cancer incidence and mortality attributable to radiation exposure av-
eraged over all ages is given in Table 2.1. Similar estimates (Wise, 2003) of lifetime risk for
incidence and mortality of solid cancer due to radiation exposure were calculated for the
Australian population based on LSS data to 1990 and Australian background cancer inci-
dence and mortality rates. However, more recent analyses have not been published.
Radiation induced cancer incidence and mortality are dependent on sex and age at expo-
sure. The BEIR VII Report (NRC, 2006) provides site-, age- and sex-dependent lifetime
risk estimates that can be applied to different exposure situations. Figure 2.2 shows over-
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Table 2.1: BEIR VII Committee’s preferred estimates of life-
time attributable risk (10−2 Gy−1) for solid cancer and leukaemia
incidence and mortality due to radiation exposure (NRC, 2006).
Exposed
Populationa
Solid Cancerb ,c Leukaemiab ,d
Incidence Mortality Incidence Mortality
Males 8.00 4.10 1.00 0.69
Females 13.1 6.10 0.72 0.52
a Estimates apply for a population of mixed ages.
b LAR is calculated from the weighted average of the relative and
absolute risk transport models.
c DDREF of 1.5 is applied.
d Estimates based on a linear-quadratic model.
all cancer incidence and mortality for males and females as a function of age at exposure.
This model shows an increased risk of cancer incidence and mortality for persons younger
than 30 years of age at exposure and for ages above 30 the difference is less distinct.
Children are considerably more radiosensitive than adults because their cells are not yet
mature and still developing and they have more years of remaining lifetime in which a
radiation induced cancer may appear. For example, the lifetime risk of radiation induced
fatal cancer resulting from radiation exposure of a girl aged 10 years is almost double the
risk due to the same radiation exposure of a woman at 30 years of age. However, a recent
study (Shuryak et al., 2010) suggests that the risks in middle age have potentially been
underestimated and this may warrant consideration in the future.
The ICRP (2007b) recommends the use of nominal risk coefficients for stochastic effects
after radiation exposure which are averaged over sex and age at exposure and based on
cancer incidence data, mainly from the LSS. Similar to the method applied by the BEIR
VII Committee (NRC, 2006), lifetime EAR and ERR are determined. In the case of the
ICRP, these are averaged across the sexes and then weighted to transfer risks across pop-
ulations. A DDREF of two is applied (except for leukaemia, which is again based on a
linear-quadratic model) and these risk estimates are then applied across a composite pop-
ulation baseline cancer rate computed by the ICRP. A radiation detriment is then applied
which takes into account lethality, loss of quality of life, and life impairment (number of
years lost) and is a sum of the site-specific detriments. The ICRP detriment-adjusted
nominal risk coefficients for all radiation induced cancers are given in Table 2.2. For the
whole population, these are averaged over age and sex, while adult specific coefficients
exclude children. The risk of heritable effects in the whole population associated with
gonad exposure is included in the total risk coefficient. The overall fatal risk coefficient
recommended for use by the ICRP is rounded to 5% per sievert (ICRP, 2007b).
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Figure 2.1: Excess relative risk of solid cancer due to radiation exposure based on data
from the Life Span Study. The inset shows the linear-quadratic fit for leukaemia (from
the BEIR VII Report (NRC, 2006)).
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Figure 2.2: Overall cancer incidence and mortality due to radiation exposure for all solid
cancers and leukaemia for males and for females (BEIR VII Report (NRC, 2006)).
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Table 2.2: Detriment adjusted nominal risk coefficients (10−2
Sv−1) for stochastic effects after exposure to radiation at a low
dose rate (ICRP, 2007b).
Exposed Populationa Cancer Heritable Effects Total
Whole 5.5 0.2 5.7
Adultb 4.1 0.1 4.2
a Estimates are averaged over age and sex.
b The adult population excludes children, which are included in the
whole population.
2.3 Radiation Exposure from CT
The cancer risk associated with radiation exposure due to medical diagnostic imaging
has been receiving considerable attention in recent years (Berrington de Gonzalez et al.,
2009; Brenner et al., 2001a; Brenner, 2002; Brenner and Hall, 2007; Einstein et al., 2007a;
Fazel et al., 2009; Frush et al., 2003; Giles, 2004; Hall and Brenner, 2008; Hammer et al.,
2011; Kleinerman, 2006; Smith-Bindman, 2010; Smith-Bindman et al., 2009; Wall et al.,
2006). In particular, discussion has focused on CT as a relatively high dose modality,
which is potentially over-utilised. Even deterministic effects, such as hair loss, have been
reported in incidents in the US from apparent erroneous over-doses due to CT brain
perfusion scans (FDA, 2009a,b, 2010a). These, and radiotherapy incidents covered in the
general news media, have led to US Congressional hearings, FDA initiatives regarding
medical equipment regulations (FDA, 2010b) and new legislation for medical radiation
safety (California Senate Bill No. 1237). However, this focus on CT exposure has only
been relatively recent, considering that CT has been in use for almost 40 years.
The first clinical CT images were published in 1973 by Godfrey Hounsfield and James
Ambrose (Ambrose, 1973a,b; Ambrose and Hounsfield, 1973; Ambrose, 1973c; Hounsfield,
1973). However, the theoretical basis for this type of imaging dates back to 1917 and
the research of mathematician Johann Radon (Carlton and Adler, 1996). Allan Cormack
published work in the mid-sixties on the theoretical basis of CT and Hounsfield, while
working for EMI Ltd (Hayes, Middlesex, UK), was the first to build a CT scanner in 1971
and realise its clinical applications. The Nobel Prize for Medicine was jointly awarded to
Cormack and Hounsfield in 1979.
CT uses the attenuation of X-rays by the patient’s body to produce a tomographic cross-
sectional image (or slice) of the body, which can be reformatted into three dimensional
reconstructions on some modern scanners. CT differs from conventional radiography
whereby the full three dimensional structure of the body is collapsed into a two dimen-
sional projection. A major disadvantage of radiography is the lack of spatial resolution in
the direction of the X-ray beam, which can be referred to as “depth scrambling” (Webb,
1988). Conversely, a CT image is formed by scanning a volume of tissue from all direc-
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tions, giving multiple projections through the object, and reconstructing an image of the
object from these projections. The resultant image appears as though a slice has been
physically removed from the body and overlying structures can be differentiated. Differ-
ent scanners operate on various geometries and utilise a range of technology, which have
evolved considerably over time. Appendix A provides background to the development of
CT scanner design and technology.
When first introduced CT had limited application and could only be used for brain scans,
where the patient’s head was immobilised by a water bag that accommodated the large
changes in flux adjacent to the head (Bushberg et al., 2001). Despite the increased ap-
plications available with advanced CT scanners, it was predicted that magnetic resonance
imaging (MRI) would eventually reduce the CT workload (Kalra et al., 2004a; Rehani and
Berry, 2000; Vock, 2005). However, with the introduction of multiple row detector CT
(MDCT) scanners and sub-second rotation times, the ease and speed of CT scanning has
ensured its viability. Furthermore, emerging CT technologies have also influenced the age
profile of CT usage (UNSCEAR, 2010a) as it becomes possible to perform more paedi-
atric imaging with newer, faster scanners. There is generally no longer the need to use a
general anaesthetic to keep the child still for the duration of the scan and hence there is
more likelihood for paediatric CT imaging to be used, where previously it may have been
avoided due to the anaesthetic risks.
An early Australian survey found that there were 334 CT scanners nationally, approxi-
mately 18 per million people in the mid-nineties (Thomson and Tingey, 1997). By 2007,
this number had increased by about 30% (UNSCEAR, 2010a). Similarly, worldwide sur-
veys conducted by UNSCEAR have also shown increases in other countries (Table 2.3),
with Japan having a considerably higher number of scanners relative to the population
(UNSCEAR, 2000, 2010a).
Table 2.3: Increase in the number of CT scanners per million population
by country (UNSCEAR, 2000, 2010a).
Country CT Scanners (per million population) Percentage
Increase1991-1996 1997-2007
Australia 18.8 24.5 30.3
Japan 63.7 92.6 45.4
New Zealand 8.2 12.0 46.3
UK 6.0 6.7 11.7
US 26.2 - -
In the UNSCEAR 2000 report (UNSCEAR, 2000) CT constituted approximately 6% of
all medical diagnostic procedures in countries with advanced health care systems (Level
I) (Table 2.4). In the more recent report (UNSCEAR, 2010a) published in 2010 this had
increased to 10%. The increase for other countries with less advanced health care is even
more significant. In the earlier survey (UNSCEAR, 2000), 34% of the annual global dose
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due to medical exposures was due to CT. For the period 1997-2007 this had risen to 43%
(UNSCEAR, 2010a).
Table 2.4: Contribution of CT to medical diagnostic imaging examinations and the
effective dose from these examinations (UNSCEAR, 2000, 2010a).
Health Care
Levela
Percentage contribution of
CT to total number of
medical examinations
Percentage contribution of
CT to dose from medical
examinations
1991-1996 1997-2007 1991-1996 1997-2007
I 6 10 41 46
II 1 2 5 15
III/IVb 0.4 15 2 65
Global average 5 7 34 43
a Health care levels are defined by the number of physicians per head of population. Level I has at
least 1 per 1,000; Level II has 1 per 1,000-3,000; Level III has 1 per 3,000-10,000; Level IV has 1
per >10,000.
b There is great uncertainty in the frequency and doses for health care level III/IV countries
(UNSCEAR, 2010a).
Similarly, data from the US (NCRP, 1989, 2009) shows that in 1980 CT accounted for
1.8-2.5% of all radiological examinations and delivered approximately 5% of the collective
dose for medical procedures. By 2001, CT accounted for 13% of procedures and 30% of the
collective dose (Nickoloff and Alderson, 2001) and results for 2006 show CT contributed
17% of all procedures (excluding dental) and 49% of the dose (Mettler et al., 2009, 2008).
In the UK, the collective dose from CT almost doubled over a ten year period (to 2002) to
account for 47% of the dose from all medical X-ray examinations (Hart and Wall, 2004),
whereas by 2003/2004 CT only accounted for 9% of all examinations (Shrimpton et al.,
2006). In the late nineties, Australian estimates show that medical exposures accounted
for 35% of the dose from all sources, while CT contributed 45% of the dose from these
medical sources (Webb et al., 1999; Wise and Thomson, 2004).
Although CT remains a small percentage of the total number of medical examinations, it
is evident that it contributes a significant proportion of the collective dose to the popula-
tion. For countries with advanced health care, the average dose per CT examination has
increased significantly since its inception in the seventies (UNSCEAR, 2010a) (Table 2.5).
Conversely, the average dose for a chest radiograph has been decreasing. In the earliest
results (1970-1979) only doses for CT head scans were included and hence the dramatic
increase in the survey for the following decade (1980-1990). However, using the average
dose as an indicator of CT dose levels may be misleading. A number of studies and surveys
(Moss and McLean, 2006; Muhogora et al., 2010; Shrimpton et al., 2006; Smith-Bindman
et al., 2009; Wallace et al., 2010) have found that substantial variation in dose for the
same type of CT examination is observed between sites.
Since children are more sensitive to radiation than adults, it is meaningful to analyse
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Table 2.5: Changes over time in the average dose for CT examinations
and chest radiographs for countries with advanced health care systems
(UNSCEAR, 2010a). Percentage increases on previous time period are
shown in brackets.
Year Average dose per CT
exam (mSv)
Average dose per chest
radiograph (mSv)
1970-1979 1.3 0.25
1980-1990 4.4 (238%) 0.14 (-44%)
1991-1996 8.8 (100%) 0.14 (0%)
1997-2007 7.4 (-16%) 0.07 (-50%)
paediatric CT doses and imaging trends. The more recent UNSCEAR survey results
(UNSCEAR, 2010a) provide a breakdown of CT trends for particular protocols by age
and sex. However, this data is relatively incomplete and lacks the detail necessary for
a meaningful global analysis. The only age groups provided are 0-15 years, 16-40 years
and over 40 years. At an UNSCEAR meeting in August 2010 it was agreed to commence
preliminary investigations that focus specifically on children (UNSCEAR, 2010b). There
are already some smaller scale surveys that have been conducted on paediatric CT utilisa-
tion rates (Blackwell et al., 2007; Dorfman et al., 2011; Larson et al., 2011; Mettler et al.,
2000; Townsend et al., 2010; Wiest et al., 2002) and the IAEA is assessing paediatric CT
utilisation in developing countries (Muhogora et al., 2010).
2.4 Children and CT
In February 2001 a series of three featured articles (Brenner et al., 2001a; Donnelly et al.,
2001; Paterson et al., 2001) and an editorial (Rogers, 2001) in the American Journal
of Roentgenology generated significant media coverage in the US regarding the dose to
children from CT scanning. The day that the articles were published the front page of the
newspaper USA Today carried a headline “CT scans in children linked to cancer later”
(Donnelly and Frush, 2001). This resulted in a strong public reaction, but also encouraged
the medical community to become more aware of paediatric CT dose. Interestingly, prior
to this, concerted efforts from CT manufacturers to reduce dose were limited (Donnelly,
2005). The first paper on paediatric CT dose reduction appeared as early as 1986 (Brenner
et al., 2001b; Robinson et al., 1986), but it was not until the publication of these articles
in 2001 that attention was properly drawn to the issue.
One of the important realisations was that CT protocols for adults were in some cases being
used on children. While early scanners did not allow adjustment of parameters, advanc-
ing technology provided operators with the ability to lower the dose for younger/smaller
patients although it appeared that this was not being utilised in some cases. A paediatric
hospital survey of CT examinations performed on children at outside institutions found
that no appreciable adjustment of parameters was being made based on the examination
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type or patient age (Paterson et al., 2001). To compound the problem, the number of
CT scans being performed on children appeared to be increasing (Blackwell et al., 2007;
Brenner et al., 2001a; Wiest et al., 2002). This growth in CT utilisation can be attributed
to advances in technology allowing faster scanning times and hence greater feasibility for
conducting scans on uncooperative, young and/or sick patients. Furthermore, the avail-
ability of CT scanners makes them readily accessible and it has become an expectation of
some patients or their families that CT imaging be performed.
The combination of using adult parameters and the higher radiation risk for children
compared with adults leads to a significantly higher attributable lifetime cancer mortality
rate in children (Brenner et al., 2001a). According to Brenner et al. (2001a), based
on 600,000 abdominal and head CT scans performed annually in the US on children
under the age of 15 years, approximately 500 of these children might ultimately die of
radiation induced cancer. These figures, used in isolation, may cause considerable concern
particularly for parents with children requiring a CT scan. However, it is important to
make a comparison with the background cancer rate from causes other than radiation.
Approximately 140,000 of the 600,000 children will eventually die from cancer from non-
radiation related causes and the radiation induced cancer risk increases this rate by only
0.35% (Brenner et al., 2001a).
Furthermore, the health benefit of the CT scans must also be considered. The radiation
attributable cancer rate, calculated by Brenner et al. (2001a), equates to about 1 in every
1,200 abdominal and head CT scans leading to a fatal cancer in the age group under 15
years. It is expected that a significant proportion, ideally all, of these examinations would
have a diagnostic benefit changing patient management and even have been life saving.
The risk to benefit ratio must be regarded in this context and is ultimately a decision
that the child’s clinician must make. Furthermore, the risks calculated by Brenner et al.
(2001a) are likely to be high, since they are based on the use of adult parameters. For a
properly optimised and clinically justified examination, these risks are lower.
The Society for Pediatric Radiology (SPR) responded (Pediatric Radiology, 2001) to the
press coverage of the articles as unbalanced and potentially dangerous and stated that the
benefits of CT imaging had not been highlighted. Brenner et al. (2001c) agreed that the
risks are almost always outweighed by the benefits, but when the risks are applied to such a
large population they become a public health issue. For an individual patient the benefits
are justified, but from a population perspective the risks must be considered.
The emphasis on risk is prevalent in the commentary surrounding CT paediatric dose.
Defining what is acceptable in terms of risk will always be a challenging question. Human
nature tends to lead us to overreact when presented with a small risk, while larger risks,
such as dying from lung cancer due to smoking are often disregarded (Picano, 2004).
Donnelly (2002) draws the parallel with the introduction of X-ray imaging in medicine
and the delay in realising its harmful effects. He cautions that over-utilisation can result
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from the successful introduction of new technology, without realising its unforseen dangers
which leads to belated optimisation of techniques and implementation of appropriate safety
and protection measures.
A symposium on dose reduction in the US held in 2002 concluded that the clinical value
of CT is unquestioned, but that further optimisation of the dose to children is necessary
(Linton and Mettler, 2003). A radiologist is quoted from the symposium keynote address
as remarking that “the truth is that we were asleep at the switch on the issue of CT
dose” (Linton and Mettler, 2003). Despite the known controversy regarding quantifying
the risk associated with low radiation doses, it was becoming apparent in the literature,
particularly from 2001 onwards, that dose reduction was needed for paediatric CT.
2.4.1 Dose Reduction Techniques
There are numerous ways of reducing and optimising the dose to the patient from CT ex-
posure. However, dose is inextricably linked to image quality and the factors contributing
to each must be balanced to ensure images are of diagnostic quality, while dose is min-
imised. Both image quality and dose also depend on patient size (Nickoloff, 2002; Nickoloff
et al., 2003; Siegel et al., 2004), which must be taken into account. Optimisation is not a
simple process and the danger exists that a diagnosis may be missed due to poor image
quality (Cohen, 2009) or that the dose is not as low as reasonably achievable. The aim
is to achieve acceptable, rather than optimal, image quality (Frush, 2009) with the least
dose.
Identifying an appropriate level of noise so that images are considered diagnostic is one of
the current challenges (Lewis, 2005). As highlighted in the 2001 articles (Brenner et al.,
2001a; Donnelly et al., 2001; Paterson et al., 2001) what is relevant for adults may not
necessarily apply equally to children. Children do not usually have the same fat planes
between tissues and organs as adults and therefore do not have the same inherent contrast
and tissue differentiation (ICRP, 2007a; McCollough et al., 2006; Nievelstein et al., 2010;
Vock, 2005). Additionally, details of interest are smaller in children and this translates
into a higher contrast to noise requirement. It follows that a constant level of noise across
adults and children is inadequate and that children will generally require a less noisy image
(McCollough et al., 2006; Nievelstein et al., 2010). There will be some clinical situations
that may tolerate more noise in areas of higher contrast such as the skeleton and lung
parenchyma (Frush, 2008).
Following the discussion generated from the articles in 2001, an Alliance for Radiation
Safety in Pediatric Imaging was formed in 2007 (including the SPR, American Soci-
ety of Radiological Technologists, American College of Radiology, American Association
of Physicists in Medicine and other medical organisations and agencies) (Goske et al.,
2008a,b). The Royal Australian and New Zealand College of Radiologists (RANZCR)
subsequently became a member (2010). The central message of the Alliance through their
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Image Gently campaign (http://www.pedrad.org/associations/5364/ig/) is to “child-size” CT
scans. The key recommendations are (Goske et al., 2008b; Strauss et al., 2010):
1. Reduce or child-size the amount of radiation used.
2. Scan only when necessary.
3. Scan only the indicated region.
4. Scan once: multiphase scanning is usually not necessary in children.
These simple messages in fact encompass the essence of dose reduction. Before examining
practical ways of reducing dose, the issue of justification of the CT scan deserves further
consideration. Clinically, the decision to request a scan is the first opportunity to mitigate
the dose if it is decided that the scan is not necessary at all.
Justification of the Scan
Eliminating unnecessary or inappropriate CT examinations is the most effective method
of reducing dose (Donnelly, 2005). A CT examination for an individual child is justified
if there is reasonable likelihood that it will produce a health benefit or inform patient
management, otherwise the child only receives the potential detrimental radiation effects.
The population is advantaged when the summed positive health benefits from those whose
management is positively influenced by the imaging are greater than the summed detri-
mental effects. The net positive health effects of the CT examination will be greater when
unnecessary studies are not performed and the studies performed are optimised for both
image quality and dose.
The principle of justification applied to medical exposure situations requires the medical
practitioner to weigh the benefits of the procedure against the risks of radiation detri-
ment due to the exposure to ensure that there is a net benefit (ICRP, 2007b,c). One
of the impediments to determining the risk-benefit ratio for diagnostic imaging is that
the indication for the examination is a current medical problem with the imaging poten-
tially providing an immediate benefit, while the radiation effects relate to possible future
risks. The ICRP (2007b; 2007c) defines three levels of justification that must be met when
considering medical exposures (Table 2.6).
Firstly, the use of radiation in medicine is well proven as being beneficial and doing more
good than harm. Hence, justification is taken for granted at this top tiered level. The
second level of justification applies to defined radiological practices (e.g. chest radiography
for the diagnosis of serious pulmonary conditions (ICRP, 2007c)). These procedures are
justified at a national or international level by professional bodies. The third level of jus-
tification relates to the individual patient procedure. In this case, the medical practitioner
should consider the objective of the exposure and also the individual involved. Alternative
procedures including initial physical examination and those that do not involve ionising
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radiation, such as magnetic resonance imaging (MRI) or ultrasound, should be considered.
Prior imaging for the individual should also be checked to see if the required diagnostic
information has been previously acquired.
Table 2.6: Levels of justification for medical exposures in the ICRP system of
radiation protection (ICRP, 2007b,c).
Level of
Justification
Description Responsible Person
Level 1 Use of radiation in medicine Justification is taken for granted
Level 2 Specified procedures with a spec-
ified objective
Decided by national and interna-
tional professional bodies
Level 3 Individual patient procedure Decided by medical practitioner
There are numerous reasons that unnecessary scans may be undertaken including defensive
medicine for fear of litigation from not performing a CT scan, pressure from the public
to use high end technical examinations and in some cases there is a financial incentive to
perform more CT examinations (Brenner and Hricak, 2010; Broder, 2008; Donnelly, 2005;
Hendee et al., 2010; Studdert et al., 2005). The medical practitioners peer review group
in Australia recently reported that CT scans were being initiated without appropriate
clinical justification (PSR, 2010). The report suggested that lack of knowledge about
particular imaging modalities and using imaging instead of undertaking adequate clinical
assessment may also be contributors to inappropriate CT use (PSR, 2010). Furthermore,
opportunities to educate referrers on inappropriate requests may be missed, leading to
over-utilisation of imaging (Hendee et al., 2010).
CT imaging should not be the default choice, particularly in the trauma setting. In a
retrospective review (Fenton et al., 2004) of the results in more than 2,000 trauma CT
scans of children (January 1999 to October 2003), it was found that more than 50% were
normal. CT “is wonderful, but not every time for every patient” (Linton and Mettler,
2003). An informal poll (Pediatric Radiology, 2002) of paediatric radiologists revealed
that approximately one third of requests are likely to be unnecessary. Recent Australian
media commentary (Margo, 12 March 2009) highlighted that the “rapid gratification” felt
by patients by receiving quick results from a CT scan seemed to imply that the small
and remote risk of cancer later on was outweighed. Furthermore, patients were pressuring
doctors to order CT scans, yet the doctors were “not always up to date” with the risks
associated with CT exposure and therefore unable to make an informed clinical decision
(Margo, 12 March 2009), especially about alternative imaging. However, the availability
of non-ionising imaging techniques (e.g. MRI and ultrasound) must also be sufficient so
that CT is not the easiest, default imaging option (Klig, 2006).
The ICRP state that justification is the shared responsibility of the requesting clinician and
the radiologist (ICRP, 2007a). Some authors have suggested that paediatric CT request
forms should be vetted by consultant radiologists (Paterson and Frush, 2007) or even
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informed consent obtained from the patient (de Campo and de Campo, 2010). However,
other authors comment on the difficulty in obtaining consent for procedures involving
radiation because the risk is age-dependent and cumulative (Brink et al., 2011; Goske and
Bulas, 2009) or because of the risk of a parent refusing a justified CT scan (Karsli et al.,
2009). Alternatively, consent above a certain dose level (Baerlocher and Detsky, 2010,
2011) may be warranted combined with a clear radiation risk communication strategy
such as the graphical depiction suggested by Picano (2004). Informed decision making
may provide a viable alternative to informed consent (Goske and Bulas, 2009) and would
educate the patient providing an opportunity for shared decision making (Merck et al.,
2011). One study (Larson et al., 2007) surveyed parents of children undergoing CT scans,
before and after providing a brochure on radiation safety and found that the level of
consenting to the CT scan did not change.
Other studies (Hadley et al., 2006; Kuppermann, 2008; Osmond et al., 2010) encour-
age the use of clinical decision rules and potentially incorporating these into software,
as long as they are simple, accurate and well-founded. An online tool called Diagnostic
Imaging Pathways (www.imagingpathways.health.wa.gov.au) has been developed in Australia
to support informed decision making. Furthermore, a consumer and referrer information
database called “InsideRadiology” (www.insideradiology.com.au) on medical imaging has been
established to encourage informed choice. The value of education should not be under-
estimated as one of the most important steps in changing trends in the ordering of CT
scans.
Recent discussions (Margo, 12 March 2009; Street et al., 2009) in Australia have also
highlighted the need for a central register of medical exposures. This would provide both
individuals and their doctors with information regarding their exposure history allowing
more information for justification of procedures. A study (Sodickson et al., 2009) covering
a US institution’s records for a period of 22 years found that 33% of patients underwent
five or more CT examinations and 5% had undergone between 22 and 132 examinations.
A US study (Dorfman et al., 2011) of medical imaging utilisation for children found that
over a three year period 45% of the cohort receiving CT imaging had two or more scans,
and 14% had three or more scans during that time. An Israeli study (Chodick et al., 2006)
over a five year period found that 15% of the cohort (0-18 years) had a prior CT scan
within that time frame and a Japanese survey (Ghotbi et al., 2006) found that almost a
quarter of children had repeat scans during a one year time period. It is conceivable that
some individuals have numerous CT examinations across different hospitals and practices
during their lifetime with no real knowledge of their cumulative radiation exposure.
One way to reduce the number of scans per individual is to ensure that imaging is not re-
peated unnecessarily after transfer between health care facilities (Bagg et al., 2008; Chwals
et al., 2008; Cook et al., 2010; Street et al., 2009). This is an issue that affects patients of
all ages. CT scans may be repeated if the outside images do not arrive with the patient,
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are in an unreadable format, or if the quality and outside protocol is questioned. Repeat
imaging should only be undertaken if there is a clinical indication for doing so.
Child-Size the Exposure
For the same exposure factors, the dose to a child or small adult will be greater than for
a larger person. Although the energy imparted is less in the child, the absorbed energy
is distributed in a smaller organ and hence dose to the organ (absorbed energy in the
mass) will in fact be higher (Brenner, 2002; Frush et al., 2003; Huda, 2002; McNitt-Gray,
2002; Paterson and Frush, 2007). Furthermore, when an organ is proximal to the X-ray
tube, an adult and a child will receive the same incident exposure from the X-ray beam.
When that organ is on the opposite side to the tube, the patient’s body will provide some
shielding to the organ. In a child, this self-shielding will be less, which results in a higher
dose to the organ (Brenner, 2002). These factors combined with the higher risk of related
cancer induction because of a child’s radiosensitivity and remaining length of life, are key
drivers for reducing the dose during CT scans of children.
A simple method of dose reduction is to minimise the overall exposure by decreasing
the area exposed and scanning only the indicated region (ICRP, 2007a; Vock, 2005).
Due to the shorter scan times in MDCT, there is a tendency to increase the scan region
(Campbell et al., 2005). This should be avoided and only the minimum length required for
diagnostic purposes should be included in the scan. Reducing the scan region in follow-
up CT examinations in patients with certain clinical indications (e.g. cystic fibrosis) is
also possible based on prior scanning of the patient (Jimenez et al., 2006). Furthermore,
whenever possible for helical scans, the scan length should be scanned in one large block
rather than two or more contiguous blocks because of the contribution to dose from over-
ranging due to data interpolation (Heggie et al., 2006).
Multi-phase (e.g. pre- and post-contrast) examinations should not be conducted for chil-
dren, or avoided unless absolutely necessary (ICRP, 2007a; Paterson and Frush, 2007;
Vock, 2005). For example, it rarely changes a child’s management when searching for a
calcification to conduct a pre-contrast scan in addition to the post-contrast study (Pater-
son and Frush, 2007). Another method is the use of shielding, such as bismuth shielding,
to limit dose to the breast, thyroid or eyes during the scan (Coursey et al., 2008; Fricke
et al., 2003; Heaney and Norvill, 2006; Hopper, 2002; Kim et al., 2010; Mukundan et al.,
2007; Parker et al., 2008). However, more recently, there has been debate as to whether
reducing the tube current instead of using bismuth shielding is a more effective measure
(Geleijns et al., 2010). Additionally, preparing the child psychologically for the CT scan
and/or having a parent or carer remain in the room during the scan if necessary, may assist
in acquiring an optimised examination (Nievelstein et al., 2010; Strauss et al., 2010).
Adjusting the parameters used for the examination is a more direct way of influencing dose
for a given protocol. The dose to a patient is proportional to the number of photons in
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the X-ray beam, which is quantified by the tube current in milliamperes (mA) multiplied
by the time for a single rotation of the X-ray tube in seconds (s) to give mAs. CT is a
quantum noise limited system (Huda et al., 2002), which means the image quality can be
improved by increasing mAs. Noise is inversely proportional to the square root of mAs
and hence an increase in the number of photons will provide better counting statistics,
lowering quantum noise, but increasing the dose to the patient. Beam collimation, slice
width and pitch will also affect dose and image quality, although changes in these individual
parameters typically improve image quality at the expense of increasing the dose.
Manufacturers have introduced automatic tube current modulation (see Section A.2, Ap-
pendix A), which is perhaps one of the most important dose saving tools available on
modern scanners (Kalra et al., 2004b; McCollough, 2008). The scanner software deter-
mines the necessary current required, based on the size of the patient, to achieve a setting
predefined by the user. In addition to this automated dose optimisation feature, the op-
erator (typically a radiographer) can also influence the techniques used. It should now be
standard practice to adjust parameters for children based on age, weight, size or a com-
bination of these and there is much literature addressing these techniques (Boone et al.,
2003; Donnelly et al., 2001; Haaga, 2001; Huda et al., 2000; Lucaya et al., 2000; Paterson
and Frush, 2007; Suess and Chen, 2002; Verdun et al., 2004). Paterson et al. (2007) pro-
vide an excellent review of some of the suggested protocols for children and manufacturers
now provide age- or weight-based technique charts that can be utilised.
Age can be a difficult parameter to use as a reference for technique selection. Children
vary significantly in size, particularly if they are sick and applying a protocol based on
general age groups may be insufficient. The exception may be for head protocols, as the
skull develops with age and is the main attenuator in the head (Ghotbi et al., 2006; ICRP,
2007a; Suess and Chen, 2002). Furthermore, the head shows rapid growth in the first two
years, but then gradually plateaus (Kleinman et al., 2010). Weight can be used (Ghotbi
et al., 2006; Kim and Newman, 2010; Singh et al., 2009), although patient diameter or
girth is more likely the most accurate measure as it directly correlates with the pathway
traversed by the beam (Boone et al., 2003; Haaga, 2001; Kleinman et al., 2010). The initial
scan projection radiograph can be used to take a measurement of the patient’s anatomy
on which to base the scan parameter selection. The clinical indication can also be used as
an input for protocol selection (Singh et al., 2009).
Donnelly et al. (2001) created a look-up table based on weight which they used for
their single-slice helical CT scanner (CT/I, GE Healthcare, Waukesha, Wisconsin, US).
In some rare instances they needed to increase the protocol defined current by 50 mA
to decrease noise in order to identify very small lesions (e.g. in the evaluation of an
immuno-compromised child for fungal liver disease). Boone et al. (2003) investigated
suitable parameters for children by assessing the dose, noise and contrast to noise ratio
(CNR) for a series of measurements on a 16 MDCT scanner (LightSpeed, GE Healthcare,
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Waukesha, Wisconsin, US) using cylindrical phantoms. They freely provide technique
charts in Excel (Microsoft Office) spreadsheet format that calculate the mAs required for
a paediatric exposure to maintain the same CNR as the equivalent adult CT scan for
abdominal and head examinations. The dose reduction factor is determined based on the
patient’s abdomen or head diameter.
Huda et al. (2000) tried a different approach and determined the mAs and voltage val-
ues required to achieve the same detector energy fluence as for specific adult protocol
parameters. Lucaya et al. (2000) found that there was no difference in the image quality
scores between 50 and 180 mAs for high resolution chest CT scans and that dose could be
dramatically decreased (72% reduction). Suess and Chen (2002) provide percentage reduc-
tions in mAs for head protocols and body protocols based on the child’s age and weight,
respectively. Verdun et al. (2004) proposed using a dose efficiency descriptor (defined as
noise reduction per unit dose) and determined dose values and a noise level for specific
weight classes. Brisse et al. (2009a) extended this concept to use relative low contrast
detectability to determine appropriate parameters based on patient diameter.
The Image Gently campaign (www.pedrad.org/associations/5364/ig) provides guidelines for
an alternative method for determining paediatric parameters. Baseline techniques are
established based on adult head and abdomen scans. This allows a correlation between all
types of scanners using the phantoms currently used for quality assurance tests. A table
of reduction factors is then provided to determine the paediatric parameters based on
posterior-anterior (PA) thickness. This method is based on existing American College of
Radiology (ACR) national CT accreditation dose recommendations for adult protocols and
may not be directly utilised by a dedicated paediatric institution, for example. More recent
ACR accreditation requirements include a dose recommendation for paediatric abdomen
examinations (ACR, 13 September 2010).
The voltage of the X-ray tube is a more difficult parameter to adjust as the effect on image
quality is more complex. Furthermore, the dose relationship is not simply explained as
it depends on the filtration of the beam (beam quality) and scanner geometry, which are
unique to individual machines. Huda and Slone (2003) have shown that an increase in
tube voltage from 80 to 140 kVp will increase the dose by a factor of five, while Nickoloff
(2002) shows that increasing from 120 to 140 kVp will increase the dose by about 30-45%.
Increasing the voltage, while keeping all other parameters constant, will degrade the low
contrast resolution, but simultaneously decrease noise due to more photons penetrating
the patient and the contrast to noise ratio may actually increase or be maintained.
With the range of protocols that can be applied, another issue that has been considered is
the ease of following the protocol in clinical practice where parameters need to be manually
adjusted depending on patient size. Frush et al. (2002) have shown that a colour coded
format based on weight was found to be strongly preferred by the CT scanner operator
because it was easier to use and/or understand. Although more sheets of paper were
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required (each weight category was presented on a separate sheet rather than in a single
table) it was found that this lead to less errors. It has been suggested (Saxena et al.,
2005) that software modifications should be made by manufacturers to allow the use of
pre-programmed weight based protocols. However, Frush et al. (2002) consider that
although a weight based system could be entered, the parameters often need changing
and hence there are grounds for maintaining a paper based system. Singh et al. (2009)
assessed compliance with weight based colour coded protocol selection determined by
clinical indication and found that non-compliance was typically due to patients being
older, heavier or larger in size. In their implementation of the colour coded scheme, the
protocols were programmed into the scanner for easy selection once the decision had been
made on which protocol to use.
Benchmarking and awareness of dose levels are essential to the process of dose optimisa-
tion. Diagnostic reference levels (DRLs) are becoming more common for medical imaging
modalities, especially CT. DRLs represent the lower bound of potentially unacceptable
practice, rather than being an upper limit not to be exceeded (Shrimpton and Wall,
2000). These can be set at a practice, regional and/or national level and are calculated
by surveying doses for standard patients across practices and generally established at the
third quartile value. Dose surveys can then be conducted at a practice level and compared
with national DRLs to determine when local practice should be reviewed, particularly
when the DRL is consistently exceeded. DRLs have been used for some time in Euro-
pean countries (Bongartz et al., 2004). A summary of DRLs relating to paediatric CT
procedures is provided in Table D.1 (Appendix D).
Education
The critical factors in any of the dose reduction techniques discussed are education and
collaboration. Without knowledge and understanding of the key issues affecting dose
and close cooperation between referrers, radiologists, radiographers, technologists and
physicists, the full potential of dose reduction will not be achieved. Furthermore, training
is an important step in the installation of any new scanner. Advances in technology do not
automatically translate to more skilled use of that technology (Chodick et al., 2009).
A survey (Arch and Frush, 2008) of SPR members has assessed the effectiveness of ed-
ucation on optimisation since the 2001 articles (Brenner et al., 2001a; Donnelly et al.,
2001; Paterson et al., 2001) and found that parameters for CT scans are being adjusted.
Despite a relatively high response rate of “unknown” for questions regarding protocols
(22%; 13/59) and current or voltage (49%; 29/59), of the respondents who did answer the
questions 98% reported that tube current was based on either patient weight (78%) or age
(20%). Only one respondent used the same tube current regardless. A lower percentage
of respondents selected “unknown” compared with a survey conducted five years earlier.
Similarly, reductions in voltage were found, with no respondents using more than 120 kVp
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for routine chest and abdomen scans.
Other evidence is emerging that demonstrates that the education campaign since 2001
has had a mixed effect on paediatric CT utilisation rates. A survey of North American
paediatric facilities found that the proportion of diagnostic imaging (including ultrasound,
MRI and CT imaging) that was attributable to CT had declined steadily since 2003
(Townsend et al., 2010). However, the study did not report absolute utilisation rates and
hence overall trends are less clear. Other evidence reveals that paediatric CT usage is
still increasing, particularly for pre-surgical diagnosis of appendicitis where it is replacing
ultrasound based primarily on availability after hours, cost and the high level of skill
required by the ultrasound operator (Brenner and Hall, 2007; Frush, 2008; Partrick et al.,
2003; Reed, 2008; Sivit, 2008; Wagner, 2002). A preliminary result from a US study has
demonstrated an apparent deceleration in growth for CT imaging of children, although
overall utilisation is still increasing (Wiest et al., 2002).
Explanation of radiation dose to a patient undergoing a CT scan or their family appears to
be provided in only some circumstances. A survey (Lee et al., 2004) conducted in the US
found that over a two week period in a hospital’s emergency department, 93% of patients
did not receive information about radiation exposure before undergoing a CT scan. A
recent Australian survey (Zhou et al., 2010) of medical students and interns found that
over half underestimated the dose from common examinations, while a quarter incorrectly
identified MRI as producing ionising radiation, a result repeated in another Australian
survey (Keijzers and Britton, 2010) of emergency department doctors. This survey found
that the clinical scenario was a determinant of whether a patient was informed of radiation
risk (Keijzers and Britton, 2010). Other surveys have also found the misconception that
MRI involves ionising radiation (Jacob et al., 2004; Soye and Paterson, 2008) and in
most radiation doses were underestimated (Quinn et al., 1997; Rice et al., 2007; Shiralkar
et al., 2002; Soye and Paterson, 2008). Interestingly, most surveys reveal a relatively low
proportion of the medical profession having any formal radiation safety training (Jacob
et al., 2004; Keijzers and Britton, 2010; Quinn et al., 1997; Soye and Paterson, 2008).
Education does not need to be restricted to the medical profession and users of CT. The Im-
age Gently alliance have released a campaign on their website (www.pedrad.org/associations/
5364/ig) to help inform parents. A medical record card can be used to track their child’s
exposure to ionising radiation and brochures explaining medical exposure are also pro-
vided. Online risk calculators for paediatric CT scans have also started to emerge (Alessio
and Phillips, 2010). In addition, the Image Gently concept has broadened to include Step
Lightly, which addresses dose issues in paediatric interventional radiology (Sidhu et al.,
2009) and the Image Wisely campaign (www.imagewisely.org) has been established which
focuses on adult radiation protection in medicine (Brink and Amis, 2010).
32
CHAPTER 2. MEDICAL RADIATION EXPOSURE
2.5 Conclusions
It is agreed that there is uncertainty in the extrapolation of risks from the LSS to the
lower doses typical of CT imaging and debate on this topic continues. However, the most
reasonable assumption for radiation protection purposes is that even low doses of ionising
radiation are potentially harmful, particularly for children. It will require large scale,
long-term epidemiological studies of patients who have undergone CT scans to quantify
the risk. These types of studies are inherently difficult in terms of obtaining sufficient
sample sizes and the extensive follow-up required to account for radiation induced cancer
latency. Although these studies are commencing, the results may take many years to
publish and may even then be equivocal.
In the past decade the risks associated with paediatric CT scanning have received increas-
ing attention. In the context of the growth in paediatric CT utilisation and the use of
parameters which were leading to higher than necessary radiation doses, the health risks
for the cohort of children undergoing CT scans are no longer considered to be negligible.
Therefore, the impetus is to decrease the population health risks by reducing unnecessary
imaging, educating and informing all those involved in the process from the referring clini-
cian to the patient and ensuring that when a CT scan is clinically indicated, it is performed
with an optimal technique. The exposure risks associated with diagnostic medical imaging
using ionising radiation are unavoidable, but the risks can be appropriately managed and
reduced.
2.6 Publications Arising from this Chapter
1. Brady, Z., Cain, T. M. and Johnston, P. N., Justifying referrals for paediatric CT,
Medical Journal of Australia, 2012 (accepted) (Brady et al., 2012a).
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Chapter 3
Experimental Dosimetry
3.1 Introduction
There has been much discussion and increasing awareness of the potential adverse popu-
lation health effects due to radiation exposure from paediatric CT scans (Brenner et al.,
2001a; Frush et al., 2003; Hall and Brenner, 2008). Quantifying the dose from these scans
is necessary for assessing potential risk and to enable optimisation. However, there are a
variety of dose measures and indicators that are used for CT dosimetry (see Appendix A.5
for a discussion of these) and it is often difficult to determine the most appropriate quan-
tity to use. Typically, a combination of these quantities is necessary to adequately describe
the exposure situation.
The organ or tissue absorbed dose is the most relevant quantity to assess radiation detri-
ment. This can be measured experimentally by placing dosemeters in an anthropomorphic
phantom, which mimics the human body in terms of the physical characteristics of size
and shape, but is also equivalent in terms of material properties that affect X-ray photon
interaction and dose deposition. The types of dosemeters generally employed for diag-
nostic radiology dosimetry include thermoluminescence dosemeters (TLDs) (Brisse et al.,
2009b; Chapple et al., 2002; Nishizawa et al., 2008) and, more recently, metal oxide semi-
conductor field effect transistors (MOSFETs) (Bower and Hintenlang, 1998; Mukundan
et al., 2007; Yoshizumi et al., 2007).
Both TLD and MOSFET dosimetry methods are time consuming. TLDs are particularly
labour intensive due to the additional steps of annealing and read out, compared with
MOSFETs which allow real time dose determination. However, both dosimetry methods
require careful calibration by reference to an ionisation chamber measurement. While
an ionisation chamber is considered the “gold standard” of radiation dosimetry, TLDs are
routinely used in medical dosimetry because of their reliability, small size and tissue equiv-
alence. A more detailed discussion of TLD dosimetry is provided in Appendix C.
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Measuring organ absorbed doses is also restricted by the number of dosemeters that can be
used for the dose assessment. This is particularly relevant for dispersed and large organs
and tissues such as the bone marrow, bone surface, muscle and skin. Furthermore, the
attenuation properties of different tissues needs to be taken into account, particularly at
the photon energies relevant to CT, and in some cases electronic equilibrium will not exist
(for example in marrow cavities). Due to the complexity and required time and resources,
experimental dosimetry in diagnostic radiology is infrequently performed in the clinical
setting.
There are only a limited number of studies where physical anthropomorphic phantoms
and dosemeters have been used to measure organ doses for paediatric CT. Chapple et al.
(2002) used a range of paediatric anthropomorphic phantoms (representing neonate, 1,
5, 10 and 15 year old children) and TLDs to measure CT organ absorbed doses for four
non-overlapping regions of the head, chest, abdomen and pelvis using fixed, non-clinical
scan parameters. However, the aim of the study was to develop a scanner-independent
dose conversion method for calculating effective dose for any of these anatomical regions
using the dose length product (DLP) and hence effective dose rather than organ doses are
reported.
Brisse et al. (2009b) also used a range of phantoms (representing newborn, 1, 5 and 10
year old children) with 69-74 high sensitivity LiF:Mg,Cu,P TLDs to assess the effect of
automatic tube current modulation on organ absorbed dose. This study was conducted
on an earlier four row multiple detector CT (MDCT) scanner and total body helical
examinations were performed for each phantom. Therefore, reported organ absorbed doses
do not demonstrate the effects of scattered radiation or over-ranging from standard clinical
scan lengths. The authors comment on the lack of measured organ absorbed dose data in
the literature for MDCT scanners.
Fujii et al. (2007; 2009) used an anthropomorphic phantom representing a six year old
Japanese child with 32 silicon spherical photodiodes to measure organ absorbed doses for
chest and abdominal CT examinations. Nishizawa et al. (2008) used the same phantom
and 160 BeO and CaSO4:Tm TLDs to assess organ absorbed dose for CT brain and chest
examinations. The Fujii et al. (2007; 2009) and Nishizawa et al. (2008) studies are
similar to work undertaken in this thesis, although they have been undertaken with a
phantom representing a younger child of Japanese nationality. Furthermore, the Fujii et
al. studies (2007; 2009) have been performed with a limited number of photodiodes. The
Nishizawa et al. study (2008) comments on the lower sensitivity of BeO TLDs and the
energy dependence of the CaSO4:Tm TLDs.
McDermott et al. (2009) used an anthropomorphic phantom representing a five year old
child and measured point doses for eight organ and tissue locations with TLDs for head
and chest CT protocols on a 64 MDCT scanner. The authors remark on the lack of
published information regarding measured paediatric CT organ doses. Again, this study
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is comparable to the current work, although undertaken on a smaller sized phantom and
with far fewer measurement locations.
Hollingsworth et al. (2007) used an anthropomorphic phantom of a five year old child and
20 MOSFET detectors to measure organ absorbed doses for cardiac-gated CT angiography.
Coursey et al. (2008) used the same anthropomorphic phantom and also 20 MOSFET
detectors placed in the chest region to assess the effect of bismuth breast shielding on
organ absorbed doses. Similarly, Mukundan et al. (2007) used the same phantom and
20 MOSFET detectors placed in the head region to assess the effect of bismuth shielding
on the dose to the eye for children. All of the MOSFET studies are limited by the small
number of dosemeters used and in the case of Coursey et al. (2008) and Mukundan et al.
(2007) only a small region of the body was assessed.
In this part of the thesis, absorbed dose to radiosensitive organs and tissues was directly
measured using 101 high sensitivity TLDs for typical CT examinations of the brain, chest
and abdomen/pelvis at a paediatric hospital (The Royal Children’s Hospital (RCH) Mel-
bourne). A subset of measurements was repeated with MOSFETs to compare with the
TLD measurements. The comparison of the two dosimetry techniques is discussed in Chap-
ter 4. In a later part of this thesis, the measured organ absorbed doses were compared
with computed doses, which is discussed in Chapter 5.
Due to the limitation of performing organ dosimetry regularly in the clinical setting,
effective dose is a single parameter that is often used as an estimate of radiation detriment.
It is not a directly measurable quantity, but a means of expressing a non-uniform, partial
body exposure in terms of an “effective” whole body dose (Christner et al., 2010; ICRP,
2007b; McCollough et al., 2010). This allows comparison of relative radiation risk between
different imaging modalities and even other sources of exposure. For example, it allows
comparison of the relative risk from a chest X-ray, a chest CT scan and a nuclear medicine
cardiac scan.
Effective dose is derived from the mean organ and tissue absorbed doses weighted for the
type of radiation and the organ or tissue radiosensitivity. A more complete discussion of
computing effective dose is given in Appendix B. Radiation and tissue weighting factors
are provided by the International Commission on Radiological Protection (ICRP) and the
factors are updated over time based on advances in the scientific understanding of the
effects of radiation on the human body. The most recent recommendations published in
2007 are contained in ICRP Publication 103 (ICRP 103) (ICRP, 2007b), which updated
ICRP Publication 60 (ICRP 60) (ICRP, 1991). In this thesis, the effective dose is de-
termined according to both the ICRP 60 and ICRP 103 definitions from the organ and
tissue absorbed doses measured using TLDs. The changes in the effective dose definition,
which are primarily due to altered tissue weighting factors, are investigated when applied
to paediatric CT scans.
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3.2 Methods
3.2.1 CT Examinations
Organ and tissue absorbed doses were measured using TLDs for typical CT examinations
undertaken at the RCH on a 16 MDCT scanner (Siemens Sensation 16, Erlangen, Ger-
many). The commonly performed CT protocols that were assessed included brain, chest
and abdomen/pelvis examinations. Depending on the type of examination, CT protocols
at the RCH are categorised into several age groups: 0-6 months, 6 months-3 years, 3-6
years (or under 5 years), 6-10 years (or 5-10 years) and over 10 years. In this thesis,
the currently used protocols at the RCH for a child aged over 10 years were assessed.
This selection was made by an experienced radiographer based on the size and represen-
tative age of the anthropomorphic phantom. The parameters used are summarised in
Table 3.1.
Table 3.1: Current CT protocols at the RCH for a child aged over 10 years.
Examination kVp Qref mAs
a Rotation
time (s)
Pitch Beam
Collimation
CT Brain 120 270 0.75 axial 12x1.5 mm
CT Chest 120 80 0.5 1 16x1.5 mm
CT Abdomen/Pelvis 120 60 0.5 1.25 16x1.5 mm
a Qref is the Imaging Quality Reference mAs, which is a Siemens specific setting used for
automatic tube current modulation (CARE Dose 4D), which is set by the user for each
protocol. This value is adjusted based on image quality requirements and the amount of
noise acceptable in the image. It is defined in terms of the effective mAs (actual mAs
divided by pitch).
The CT brain examination is undertaken in axial mode to allow angulation of the gantry
to reduce the dose to the lens of the eye, whereas both the chest and abdomen/pelvis
examinations are performed in helical mode with differing pitches. For both body exami-
nations the scanned volume is larger compared with the head examination and therefore
motion artefacts can become problematic, hence the need to use a faster helical scanning
protocol. A higher pitch value is used for abdomen/pelvis scans where contrast resolution,
rather than spatial resolution, has the higher priority. Higher values of pitch lead to a
faster scan, but also a spreading of the slice sensitivity profile and hence a decrease in
spatial resolution.
CT X-ray Spectra
The effective energy of the CT beam was calculated using IPEM Report No. 78 (Cranley
et al., 1997) and the associated program Spectrum Processor (Reilly and Sutton, 1997).
All CT protocols were performed at 120 kVp utilising either the inherent body or head
filter depending on the type of examination being performed. The half value layer (HVL)
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of the X-ray beam is 7.5±0.2 mm Al at 120 kVp with the head filter and 8.8±0.2 mm Al
at 120 kVp with the body filter (Siemens Manual). Typical X-ray photon spectra at
120 kVp for these filters are shown in Figure 3.1. The effective energy range at 120 kVp is
approximately 60-70 keV depending on the filter being used, which is similar to the value
used by other authors (Fujii et al., 2007; Nishizawa et al., 2008).
CTDI Measurements
The following tests were undertaken to determine the accuracy of alignment at the isocen-
tre of the scanner: agreement between the internal and external scan plane lights; co-
incidence of the internal scan plane lights and scan plane; and alignment of the coronal
and sagittal plane lights with the scan plane. CTDI measurements were performed with a
calibrated 3 cm3 Radcal ion chamber with 100 mm length, model 10X5-3CT and a model
9095E electrometer (Radcal Corp., Monrovia, California, US). For a discussion of CT
dosimetry formalism refer to Section A.5, Appendix A. Reproducibility of the beam output
was assessed using CTDI100 in air measurements at the isocentre. CTDIvol measurements
in both the body (32 cm diameter) and head (16 cm diameter) CT dosimetry phantoms
were also undertaken. Correct alignment of the ion chamber and dosimetry phantoms for
all measurements was assessed according to the ImPACT protocol (ImPACT, 1997).
3.2.2 Anthropomorphic Phantom
In paediatric diagnostic radiology applications, it is not feasible to conduct in vivo dosime-
try on real subjects. However, an anthropomorphic phantom which simulates the human
body can be used for this purpose. There are several commercially available anthropo-
morphic phantoms, including a paediatric range. In this thesis, a Computerized Imaging
Reference Systems (CIRS) anthropomorphic phantom of a 10 year old child was used
(Figure 3.2, Model 706-D, CIRS, Inc., Norfolk, Virginia, US).
CIRS manufacture five paediatric phantoms, each representative of an age bracket as
shown in Table 3.2. Organ dimensions for children within each bracket do not vary by
more than 15% and the phantoms are representative of ethnic variations and both sexes
(Varchena, 2002). For children, height is more indicative of body size than age, particularly
when considering children suffering from an illness who may be undergoing CT examina-
tions in a hospital. Hence, for dosimetry purposes, children falling within the height ranges
specified in Table 3.2 are best represented by the corresponding phantom. The phantom
used in this thesis represents children 124-156 cm tall, which broadly corresponds to 7 to
13 year olds.
The CIRS Model 706-D phantom used in this thesis consisted of 31 slab sections each
25 mm thick, which assemble to form the head and trunk of the body (legs and arms are
not included). The phantom is made from epoxy resins, with photon attenuation values
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Table 3.2: CIRS paediatric anthropomorphic phantom range
(Varchena, 2002).
Phantom Name Age Range (years) Height Range (cm)
Newborn 0-0.5 Up to 66
1 yo 0.5-3 66-95
5 yo 3-7 95-124
10 yo 7-13 124-156
15 yo 13-17 156-168
within 1% for bone and soft tissue and 3% for lung tissue at photon energies from 30 keV
to 20 MeV, as claimed by the manufacturer (CIRS, 2006; Varchena, 2002) (Figure 3.3).
The material specifications are shown in Table E.1 (Appendix E). The CIRS Model 706-D
phantom provides 214 locations for dosimetry devices in 19 inner organs (CIRS, 2006).
These are located by holes in the slabs which are plugged when not in use with tissue-,
bone-, and lung-equivalent material depending on their location.
For TLD measurements in this thesis, the plugs were halved and a small amount of plug
material removed so that a TLD chip could be inserted between the halves (CIRS, 2006;
Yoshizumi et al., 2007). The TLD chips were always handled with vacuum tweezers to
avoid contamination and damage of the TLDs (Figure 3.4).
3.2.3 Thermoluminescence Dosimetry
The paediatric CT organ and tissue absorbed doses to be measured in this thesis are in
the range of 10 µGy to 100 mGy. These are relatively low compared with radiotherapy
doses which routinely exceed 1 Gy. Therefore high sensitivity TLDs were used. These con-
sisted of 3.175x3.175x0.889 mm3 chips of lithium fluoride doped with magnesium, copper
and phosphorous (LiF:Mg,Cu,P) (TLD-100H, Thermo Scientific, Franklin, Massachusetts,
US), with a detection range of 1 µGy to 10 Gy (Thermo, 2007). The glow curve consists
of three low temperature peaks (70-160°C), a main dosimetry peak at about 220°C and a
high temperature peak at 300°C (Moscovitch and Horowitz, 2007). Appendix C provides
further information on thermoluminescence dosimetry.
TLD Annealing
The TLDs were annealed before each irradiation in an annealing tray with the lid re-
moved in a micro-processor controlled oven (Scientific Equipment Manufacturers (South
Australia) Pty Ltd, Adelaide, South Australia, Australia) located at the Peter MacCallum
Cancer Centre (East Melbourne, Victoria, Australia). The annealing cycle consisted of
three segments including a 19 minute heat up cycle to 240°C, 15 minutes maintained at
240°C and an oven cool down for five minutes. The TLDs were then left to cool in the
oven to ensure a consistent cooling rate and duration after each anneal.
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A recognised disadvantage of LiF:Mg,Cu,P is the potential for residual signals from peaks
above the main dosimetry peak which remain after the relatively low temperature anneal.
However, annealing the TLDs at a higher temperature is a destructive process, with the
TLDs irreversibly losing their sensitivity (Duggan et al., 2004). Recently, the manufacturer
has succeeded in reducing this residual signal to less than 1% after changes to the TLD
production stream (Ramlo et al., 2007).
TLD Read Out
TLDs were read out on a Model 5500 automatic thermoluminescent reader (Harshaw,
Thermo Electron Corporation, Ohio, US) located at the William Buckland Radiotherapy
Centre (WBRC, Melbourne, Victoria, Australia). The read out cycle included a preheat
segment at 155°C for eight seconds, an acquire phase for 26.7 seconds with a linear ramp
rate of 20°C/s to 240°C. A post anneal followed for 10 seconds at 240°C. The gain setting
for the reader was set to high. This temperature profile is similar to that used by others
for this type of TLD material (Bartolotta et al., 1995; Davis et al., 2003; Dong et al.,
2002; Duggan et al., 2004; Kron et al., 1996; Lupke et al., 2006; Moscovitch and Horowitz,
2007). The preheat is effective in removing the contribution of the low temperature peaks
(Moscovitch and Horowitz, 2007). All TLDs were read out within 24 hours of being
irradiated to limit effects of fading, although fading is considered negligible for this type
of TLD material (Dong et al., 2002; Duggan and Kron, 1999).
The annealing tray was specifically designed for these TLDs and was also used for storage.
The tray was cleaned in an ultrasound bath and heated multiple times before its first use.
Ten TLDs were initially placed in the tray for storage. These TLDs were irradiated and
read out and the process then repeated to confirm that no contaminants remained from
the manufacturing process of the tray. The mean difference in response between the two
read outs was ∼2%.
TLD Calibration
Individual calibration factors (CF ) for each TLD were derived from a series of three
calibration irradiations of 100 mGy each using a 6 megavoltage (MVp) photon beam. The
calibration factor is given by:
CF =
1
3
[
3∑
i=1
di
ri − bi
]
(3.1)
where di is the calibration dose relative to water at 6 MVp in milligray (mGy), ri is the
TLD reading in nanocoulombs (nC) after the calibration irradiation and bi is the mean
reading in nC for a batch of unirradiated TLDs. The calibration factor has units of
mGy·nC−1. The background reading was measured for the entire batch of TLDs after
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being prepared and treated in the same way as when the batch was calibrated. The same
mean background measurement was used for each calibration.
During measurements of CT doses, the measured dose relative to water (Di) at location i
for a TLD with calibration factor CF was calculated by:
Di = CF × (Ri −B) (3.2)
where Ri is the TLD reading in nC after the CT exposure and B is the mean reading in
nC for a set of unirradiated TLDs from the same batch.
The TLD set (106 TLDs) was irradiated for calibration using a 6 MVp 10x10 cm
2 X-
ray photon beam on a linear accelerator (linac). The TLDs were placed in a Perspex
holder with sufficient distance between adjacent TLDs to limit scattering effects (Fig-
ure 3.5).
Three different linacs located at WBRC were used for calibration of the TLDs. Before
each calibration the output of the linac was checked with a calibrated 0.6 cm3 Farmer-type
NE2581 ion chamber (NE Technology, Reading, UK) and Scanditronix Wellhofer Dose 1
electrometer (IBA Dosimetry, Louvain-la-Neuve, Belgium) with calibration traceable to a
national primary standard (Australian Radiation Protection and Nuclear Safety Agency,
Yallambie, Victoria, Australia) (Figure 3.6). Ion chambers are calibrated to cobalt-60 and
then corrected for linac energies. Temperature and pressure corrections were automatically
applied to the ion chamber reading and a correction factor was determined for each linac
output (range 0.992-1.008). Each batch of TLDs in the Perspex holder was placed 100 cm
from the source. Slabs of solid water with a total thickness of 5 cm were placed on the
TLDs and a dose of 100 mGy was used for each calibration. TLD readings that were not
reproducible to within 4% over the three calibration measurements were not used. This
left a batch of 101 out of 106 TLDs for use. The coefficient of variation of the calibration
factors for the batch of utilised TLDs was 4.2%.
The major advantages of calibrating the TLDs using a linac are reproducibility and unifor-
mity of output. This is possible with LiF:Mg,Cu,P compared with other TLD materials,
because it exhibits relatively linear energy and dose response (Duggan, 2002; Duggan
et al., 2004). Typically for measurement of CT dose using traditional LiF:Mg,Ti TLDs
(e.g. TLD-100), calibration is undertaken on a general X-ray unit with beam quality
matched to the CT beam using additional filtration (Brix et al., 2004; Cohnen et al., 2006;
Lechel et al., 2009; Nawfel et al., 2000; Yoshizumi et al., 2007). Alternative calibration
methods include using a CT scanner (Groves et al., 2004) or a superficial X-ray therapy
(SXRT) unit (Duggan et al., 2003; Smith et al., 1998).
A comparative calibration of the TLDs was also performed on an SXRT unit (Therapax
S3, Pantak, Branford, Connecticut, US) for a batch of 100 TLDs to compare calibration
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factors with those derived from the 6 MVp linac exposure. The desired CT beam quality
was 120 kVp with a half value layer (HVL) of 7.5±0.2 mm Al and/or 8.8±0.2 mm Al
(Siemens Sensation 16 CT Scanner HVL for head and body filters respectively (Siemens
Manual)). The closest beam quality match on the superficial unit was achieved with an
energy of 120 kVp and 1.1 mm Al and 0.3 mm Cu filters resulting in a HVL of 8.1 mm Al
and effective beam energy of 66 keV (Reilly and Sutton, 1997). The output of the SXRT
unit was checked with the same calibrated Farmer ion chamber used to verify the linac
output and a correction factor of 0.981 was subsequently used. The ion chamber output
measurements were made in air at a focus to detector distance (FDD) of 25 cm and a cone
steel applicator was attached to the X-ray tube head for a beam size of 10 cm diameter.
A cone applicator with FDD of 25 cm and beam diameter 15 cm was fixed to the X-ray
tube head for the TLD irradiations to ensure all TLDs were fully irradiated.
The TLD batches were placed in the same Perspex holder as used for the linac calibra-
tions and in contact with the cone applicator. A correction for the change in beam area
was applied to calculate the time required (0.11 min) to apply a dose of 100 mGy to the
TLDs. The TLDs were read out using the same methodology as for the 6 MVp linac cali-
bration exposures and individual calibration factors for each TLD (dose to water divided
by background corrected TLD reading) were derived. The calibration factors from the
6 MVp calibration, including an energy correction for the TLD energy response based on
Duggan et al. (2004), were compared with the calibration factors derived from the SXRT
calibration. On average the SXRT derived calibration factors were 4.2% higher than the
6 MVp derived calibration factors.
TLD Measurement Uncertainty
The calculation of uncertainty for TLD measurements was based on the International
Organization for Standardization (ISO) Guide to the Expression of Uncertainty in Mea-
surement (Bentley, 2005; ISO, 1993 (corrected & reprinted, 1995)) and the UK Institute
of Physical Sciences in Medicine (IPSM) analysis of TLD uncertainties for patient dose
measurements (IPSM, 1992). The treatment of uncertainties took into account random
(Type A) and systematic (Type B) errors (Table 3.3).
Table 3.3: Random and systematic uncertainties for TLD calibration and mea-
surement (IPSM, 1992).
Random (Type A) Uncertainties Systematic (Type B) Uncertainties
TLD calibration reading Dose meter calibration
TLD background reading (calibration) TLD energy response
Calibration dose TLD dose linearity
TLD measurement reading TLD signal fading
TLD background reading (measurement) Temporal variation of TLD reader
Referring to equation (3.1), the uncertainty in the background reading (bi) and the cali-
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bration dose (di) are considered negligible compared with the variation in the TLD reading
(ri). Hence, the random error in the calibration factor (CF ) for a single TLD is simply
the standard deviation in the calibration factor (σCF ) for the three irradiations given
by:
σCF =
[
1
3
3∑
i=1
(CFi − CF )2
]1/2
(3.3)
The dose (Di) at TLD measurement location i in the anthropomorphic phantom for a CT
examination is given by equation (3.2). The total random error in the dose measurement
(σDi) using propagation of errors is given by:
σDi =
[(
∂Di
∂Ri
)2
σ2Ri +
(
∂Di
∂B
)2
σ2B +
(
∂Di
∂CF
)2
σ2CF
]1/2
σDi =
[
CF 2σ2Ri + CF
2σ2B + (Ri −B)2σ2CF
]1/2
σDi = Di ×
[
σ2Ri
+σ2B
(Ri−B)2 +
σ2CF
CF 2
]1/2 (3.4)
where σB is the standard deviation in the background readings of the unirradiated batch
of TLDs and σRi is zero since there is only one measurement. Multiple TLDs were placed
in each organ of the anthropomorphic phantom. Random errors for the organ doses were
combined using propagation of errors.
The systematic errors identified for the measurements are given in Table 3.4. The total
systematic error was ±4% (two standard deviations). This is lower than a similar analysis
conducted by Broadhead et al. (1997) for the use of TLD-100 (LiF:Mg,Ti) which found
the total non-random uncertainty to be ±9%. The overall uncertainty is calculated by
combining the random and systematic uncertainties in quadrature. This typically ranged
from 4% to 10% for this batch of TLDs.
Absorbed Dose to Tissue
For each CT examination assessed in this thesis, the TLDs were irradiated three times
using an identical protocol before being read out to improve counting statistics and increase
the dose to be measured. The resultant measured dose was divided by three to calculate
the organ or tissue absorbed dose per examination. This method has been used in other
studies (Geleijns et al., 1994; Groves et al., 2004; Hunold et al., 2003).
The TLDs were calibrated at an energy of 6 MVp (effective energy 2 MeV (Kron et al.,
1998)) on a linac. Although the energy response for the high sensitivity TLDs is more linear
than the energy response of LiF:Mg,Ti (Figure C.1, Appendix C), a CT spectrum weighted
energy correction factor for keV energies (CkeV (E)) was applied based on published energy
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Table 3.4: Values for systematic uncertainties (two standard deviations) in TLD
measurements.
Systematic (Type B)
Uncertainties
Value Reference
Dose meter calibration ±1% ARPANSA Calibration Certificatea
TLD energy response ±1% Duggan et al. (2004), Kron et al. (1998)
TLD dose linearityb ±1% Harris et al. (1997)
TLD signal fadingb ±1% Moscovitch and Horowitz (2007)
Temporal variation of TLD reader ±4% Calculated from experimentc
a Calibrated by ARPANSA to a traceable national standard.
b Negligible.
c Standard deviation of mean readings for the light response checks carried out on the TLD
reader across calibration and measurement readings. The temporal response of the reader
was more consistent at the commencement of the experimental work and it is expected that
the increased variation and hence relatively high uncertainty in the above table is due to
either drift in the system or an accumulation of dirt on the photomultiplier tube lens. After
servicing of the system, this variation appears to have been corrected.
response modelling which provides a dose response ratio when normalised to high photon
energy radiation (Figure C.1, Appendix C) (Duggan et al., 2004; Kron et al., 1998). The
correction takes into account the response of the TLDs at the CT energy compared with
the linac calibration energy, although the correction is close to unity (Duggan et al.,
2004). The energy correction factor (CkeV (E)) was calculated to be 1.03 using an energy
spectrum weighting (averaged over the CT spectra for the head and body filter given in
Section 3.2.1). Beam hardening changes due to tissue, muscle and bone attenuation were
considered and the change to the energy correction factor was negligible. Therefore, the
energy correction factor does not include changes in the beam spectrum due to attenuation
by the phantom or scattering within the phantom. The changes in the beam spectrum
due to attenuation have been considered for the systematic uncertainty in the TLD energy
response.
Furthermore, an energy dependent tissue conversion factor (fT (E)) was used to estimate
the dose relative to tissue from the calculated organ absorbed doses relative to water,
given by:
fT (E) =
[
µen
ρ (E)
]
T[
µen
ρ (E)
]
W
(3.5)
where [µen/ρ (E)]T is the mass energy absorption coefficient for tissue at photon energy E
and [µen/ρ (E)]W is the mass energy absorption coefficient for water at photon energy E.
The ratio of mass energy absorption coefficients for tissue to water using the same spectrum
weighting applied for the energy correction factor gives a tissue conversion factor of 1.02
(Hubbell and Seltzer, 2004; ICRU, 1989; Johns and Cunningham, 1983). Mass energy
absorption coefficients were used from Report No. 44 from the International Commission
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on Radiation Units and Measurements (ICRU, 1989) as made available in tabulated form
by the US National Institute of Standards and Technology (NIST) (Hubbell and Seltzer,
2004). Both the energy correction factor (CkeV (E)) and tissue conversion factor (fT (E))
were also applied to the calculated uncertainties.
The absorbed dose to tissue (DT,i) in milligray (mGy) at location i in the anthropomorphic
phantom measured with TLD j is then given by:
DT,i = [CFj · CkeV (E) · fT (E)]× (Ri,j −B) (3.6)
where Ri,j is the reading on TLD j in nC after the exposure and B is the mean background
reading in nC for a set of unirradiated TLDs from the same batch.
Further correction for differences in mass energy absorption coefficients were taken into
account for organs and tissues where the ratio of mass energy absorption coefficients
relative to tissue weighted over the CT spectrum differed from that of soft tissue. The
corrected organ or tissue absorbed doses Dorg,i at location i were calculated by:
Dorg,i = DT,i ×
[
µen
ρ (E)
]
org[
µen
ρ (E)
]
T
(3.7)
where DT,i is the dose to tissue at location i given by equation (3.6), [µen/ρ (E)]org is
the mass energy absorption coefficient for the organ or tissue of interest at photon en-
ergy E and [µen/ρ (E)]T is the mass energy absorption coefficient for tissue at photon
energy E. Table 3.5 shows the organs/tissues for which a correction factor was applied.
The corrections applied for the dose to the bone surface are addressed separately below
(Section 3.2.4).
Table 3.5: Ratio of photon mass energy absorption
coefficients for various organs and tissues relative to
soft tissue weighted over the CT spectrum (Hubbell
and Seltzer, 2004; ICRU, 1989).
Organ/Tissue (org) [µen/ρ (E)]org / [µen/ρ (E)]T
Brain 1.01
Lung 1.01
Testes 0.99
Eye lens 0.93
Red bone marrow 0.90
Breast 0.88
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3.2.4 Measurement of Organ and Tissue Absorbed Dose
For large or extended organs and tissues, the average absorbed dose is challenging to
measure. Ideally, a large number of TLDs should be placed at all available locations in
the phantom. Furthermore, multiple TLDs at each location improves the accuracy of
measurement. Scalzetti et al. (2008) recommend a system involving 187 measurement
locations to properly obtain average organ absorbed dose in a phantom of an adult male.
Studies (Groves et al., 2004; Hollingsworth et al., 2007; Hunold et al., 2003; Hurwitz et al.,
2007b; Kawaura et al., 2006; Scalzetti et al., 2008) using TLDs and/or MOSFETs for
assessment of effective dose in CT have used a varying number of measurement locations
ranging from 20 to 66 (Table F.1, Appendix F).
In this thesis 90 measurement locations have been used, mainly limited by the number
of TLDs available. The TLDs were placed in organs and tissues identified in the recent
ICRP 103 Recommendations (ICRP, 2007b), which provides the most extensive list to
date (refer to Table B.2, in Appendix B). The selection of these points was based on a
methodology similar to Scalzetti et al. (2008) where the number of locations was guided
by organ size and the relative importance for dosimetry purposes based on the ICRP 103
tissue weighting factors (ICRP, 2007b). The TLD measurement locations used are shown
in Figure F.1 (Appendix F).
One option considered was to place more TLDs in the area of the phantom exposed to
the primary X-ray beam based on the protocol used (i.e. brain, chest or abdomen/pelvis).
However, it was decided that for consistency, TLDs would be used in the same location
independent of the examination type. The one exception was for TLDs used to measure
skin dose. Six TLDs were used for this purpose and all were placed in the primary beam.
The bone marrow, bone surface, skin, lung and liver were considered to be large organs
or tissues and therefore a higher number of TLDs were placed in these areas. The bone
surface dose was calculated from the bone marrow dose, necessitating only one group of
TLDs for these measurements.
Effective dose using the ICRP 60 and ICRP 103 definitions was calculated from the mea-
sured organ and tissue absorbed doses according the formalism in Appendix B. Further
detail regarding specific organ absorbed dose estimates is provided below.
Dose Variation within an Organ and Reproducibility
A preliminary measurement was undertaken with a smaller batch of calibrated TLD-100H
chips to investigate the variation in dose within large organs and the reproducibility of
TLD measurements. Seven TLD measurement locations were selected in both the lung
and in the liver (total of 14 TLDs) in the anthropomorphic phantom of a 10 year old child
(Figure 3.7). A CT chest examination was performed and repeated three times using
an identical protocol without removing the TLDs to improve counting statistics. This
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procedure was then repeated three times with three different sets of 14 TLDs to assess
measurement reproducibility.
It was found that the absorbed dose varied by up to 21% within each organ (where the
range of measured absorbed doses for the organ has been expressed as a percentage of
the mean measured absorbed dose for the organ). This variation in dose highlighted
the necessity to use multiple measurement locations in organs and tissues, particularly
those that are large, in order to determine the mean organ or tissue absorbed dose. The
ICRP recommends averaging the absorbed dose over an organ or tissue to take account of
the heterogeneity of exposure and states that the mean organ or tissue absorbed dose is
associated with the radiation detriment due to stochastic effects with adequate accuracy
(ICRP, 2007b). The ICRP also observes that averaging of the absorbed dose across an
organ relies on a linear dose-response relationship (ICRP, 1991). The 21% variation in
point dose measurements was expected based on the size of the organs and the partial
exposure. For the repeated measurements, it was found that the absorbed doses measured
at each location were reproducible on average to within 3.4% (two standard deviations;
range 0.5%-8.0%).
Mean Absorbed Dose
For an organ or tissue with multiple TLDs the mean absorbed dose to the organ or tissue
(Dorg) was calculated with an equal weighting for each TLD, as follows:
Dorg =
1
n
n∑
i=1
Dorg,i (3.8)
where Dorg,i is given by equation (3.7), Dorg,i = DT,i for soft tissue, and n is the number
of TLDs placed in that organ or tissue. The locations of TLDs in large organs and tissues
were selected to ensure that the dose measurement was representative of the dose across
the entire organ or tissue.
Gonads Absorbed Dose
The gonads absorbed dose (Dgonads) was calculated from the equally weighted average of
the absorbed dose to the testes (Dtestes) and ovaries (Dovaries), given by (ICRP, 1991,
2007b):
Dgonads =
Dtestes +Dovaries
2
(3.9)
Equivalent dose was calculated from the averaged gonad absorbed dose using the sex-
averaged tissue weighting factor. However, the separate testes and ovaries organ absorbed
doses have been reported separately, where applicable.
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Substituted Organ Absorbed Doses
For the oral mucosa and salivary glands, the absorbed dose to the mandible was used
as no specific location is provided in the anthropomorphic phantom for these tissues.
Similarly, the heart is not specified in the anthropomorphic phantom and instead a point
identified as the oesophagus was used as a surrogate. The measurement for this TLD
was used for the heart absorbed dose and was also combined with the other oesophageal
TLD measurements to calculate the average oesophagus absorbed dose. The extrathoracic
(ET) region was approximated by the thyroid absorbed dose and the lymphatic nodes by
the muscle absorbed dose. These approximations are also used by the ImPACT group
(ImPACT, 2011).
TLDs were also placed at the lens of the eye, which is not specified in the organs and
tissues at risk of stochastic effects by the ICRP. The dose to the eye was measured in
order to assess deterministic effects.
Colon Absorbed Dose
The ICRP 103 Recommendations (ICRP, 2007b) specify that the absorbed dose to the
colon is calculated as the mass-weighted mean of the absorbed dose to the upper large
intestine (DULI) and lower large intestine (DLLI). The upper large intestine was listed
as a remainder organ in ICRP 60 and the lower large intestine absorbed dose was used
for the colon absorbed dose, although this definition was revised in ICRP Publication 69
(ICRP, 1995). The original ICRP 60 definition has been used for the colon equivalent
dose calculation in this thesis, although the difference to the effective dose calculation is
negligible (<1.5%).
The organ masses for a 10 year old child given in ICRP Publication 89 (ICRP, 2002) and
the mass weightings used for the ICRP 103 method are given in Table 3.6. The absorbed
dose to the ULI is the mass-weighted average of the absorbed dose to the ascending (Dasc)
and transverse colon (Dtrans) and the absorbed dose to the LLI is the mass-weighted aver-
age of the absorbed dose to the descending (Ddesc) and rectosigmoid colon (Drecto).
Table 3.6: Upper and lower large intestine organ masses and per-
centages (mass weightings) for a 10 year old (ICRP, 2002).
Organ Organ Mass (g) Mass Weighting (%)
Ascending (inc caecum) 51 43
Transverse 68 57
ULI 119 57
Descending 51 56
Rectosigmoid 40 44
LLI 91 43
Colon 210 100
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Therefore, for a 10 year old the colon absorbed dose (Dcolon) according to ICRP 103 is
calculated by:
Dcolon = 0.57DULI+0.43DLLI = 0.57 (0.43Dasc + 0.57Dtrans)+0.43 (0.56Ddesc + 0.44Drecto)
(3.10)
Red Bone Marrow Absorbed Dose
Bone tissue consists of an outer continuous hard layer of cortical (compact) bone and an
underlying layer of trabecular (cancellous or spongiosa) bone. The shafts of long bones
and the outer layers of short, flat and irregular bones consist of cortical bone. Trabecular
bone, found in the ends of long bones and throughout the interior of flat bones, is a lattice
of bone structures called trabeculae. Red bone marrow (RBM) fills the spaces between
trabeculae and is involved in red blood cell production and is therefore considered active
marrow. A fatty yellow inactive marrow fills lumen in the cortical bone. At birth, all bone
marrow is predominantly red marrow. With age and depending on the site of the bone,
red marrow gradually transforms to yellow marrow with only about a third of marrow
being active by adulthood (ICRP, 2002).
The absorbed dose to the RBM is included in the calculation of effective dose, because of
the red marrow radiosensitivity and in particular, the risk of leukaemia induction as a result
of exposure. The bone marrow measurement locations in the anthropomorphic phantom
were selected based on the six highest bone marrow fractions for a 10 year old (Cristy,
1981; Cristy and Eckerman, 1987) as shown in Table G.1 (Appendix G). Weight fractions
for an adult (40 years of age) have been included for comparison. It was considered
that the extremities (arms and legs) would receive a negligible dose since they are not in
the primary X-ray beam. Furthermore, they are not included on the anthropomorphic
phantom and hence could not be used for a bone marrow measurement. Only the clavicles
and upper spine skeletal regions were not allocated any TLD measurement locations. The
bone marrow in these regions accounts for less than 3% of the total bone marrow and
hence will have an insignificant contribution to the total bone marrow dose.
Photoelectrons produced in the ionisation process may have a longer range than the small-
est dimension of the cavities containing RBM (Johns and Cunningham, 1983). Hence,
electrons produced in the RBM are likely to leave it without depositing all their energy
and electrons produced in the adjacent bone will likely contribute energy to the RBM.
The number of electrons produced in the bone will be much higher because of the high
atomic number and hence increased probability of photoelectric interactions. Therefore,
secondary electron equilibrium in the RBM cannot be assumed. To correct for this an
energy dependent dose enhancement factor (fde,b (E)) derived by King and Spiers (King
and Spiers, 1985) is applied for different types of bone. Considering equation (3.7), for
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the dose to the RBM at location i in a type of bone b, (DRBM,i,b), this becomes:
DRBM,i,b = DT,i ×
[
µen
ρ (E)
]
RBM[
µen
ρ (E)
]
T
× (1 + fde,b (E)) (3.11)
where DT,i is the dose relative to tissue at location i, as given by equation (3.6), and the
ratio of mass energy absorption coefficients is given in Table 3.5. The dose enhancement
factor depends on the bone (b) for which the bone marrow dose is being determined (King
and Spiers, 1985).
The dose enhancement factors for different bone types provided by King and Spiers (1985)
were matched to the bone measurement locations used in this thesis according to the
method of Eckerman and Stabin (2000). The bone matching is shown in Table G.2 (Ap-
pendix G). The dose enhancement factor is energy dependent, with a maximum for all
types of bone at 50 keV. Therefore, it is insufficient to use a monoenergetic dose enhance-
ment factor based on the effective energy of the CT beam, which is close to the energy at
which the maximum dose enhancement occurs. For example, the dose enhancement factor
for an effective energy of 60 keV would overestimate the dose by approximately 15% in
all bones compared with using a dose enhancement factor based on the CT photon energy
spectrum. Therefore, the dose enhancement factors were calculated by weighting over the
CT spectrum (attenuation by the phantom neglected) and are summarised in Table G.2
(Appendix G).
The red marrow absorbed dose in the bone must then be summed to derive the total red
bone marrow absorbed dose. A weighted sum was applied using the bone marrow weight
fractions for a child shown in Table G.1 (Appendix G) (Kawaura et al., 2006; Nishizawa
et al., 2008; Yoshizumi, 12-13 June 2009). The total red bone marrow absorbed dose
(DRBM ) was calculated according to:
DRBM =
∑
b,i
[
DRBM,i,b ×
(
MRBM,b
MRBM
)]
(3.12)
where DRBM,i,b is given in equation (3.11) and measured at each of the locations selected
for bone marrow measurements and the second term is the mass weight fraction of bone
marrow at each of those locations (mass of red bone barrow in bone b, MRBM,b, divided
by total mass of red bone marrow in the skeleton MRBM ) (Table G.1, Appendix G).
Various methods can be used for calculating the absorbed dose to the RBM (Caracappa
et al., 2009; Eckerman and Stabin, 2000; Kramer et al., 2003; Lee et al., 2006b). Each
provides an approximation that attempts to model the complex structure of the bone and
energy deposition. The disequilibrium of energy deposition in bone marrow and the dis-
tribution of red bone marrow in the body for a child have been considered in the approach
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used in this thesis. However, a recognised limitation is that only six locations for bone
marrow measurement were selected.
Bone Surface Absorbed Dose
The endosteal tissue (or bone surface) is the layer of tissue covering trabeculae surfaces in
regions of trabecular spongiosa and the cortical surfaces of the medullary cavities of the
shafts of all long bones (ICRP, 2009). In adults, the medullary endosteum contributes
approximately 1% to the total endosteum massi. Assuming similar proportions in chil-
dren, the dose to the medullary endosteal will be negligible compared with the dose to the
endosteal tissue of the spongiosa and therefore can be discarded (Lee et al., 2006b). Simi-
lar to the bone marrow calculation, secondary electron equilibrium cannot be assumed in
the absorbed dose measurement and calculation for the bone surface. However, the depth
defining the bone surface has recently been reconsideredii and new dose enhancement fac-
tors are not yet availablei. In previous studies, the absorbed dose to the homogeneous
skeletal tissue has been used as a conservative estimate of the absorbed dose to the bone
surface (Kramer et al., 2003; Lee et al., 2006b). In this thesis, the average absorbed dose
to the spongiosa has been substituted for the absorbed dose to the endosteum (Schlattl
et al., 2007)i.
Spongiosa bone consists of trabeculae and active and inactive bone marrow. The mass
of each depends on the bone and varies with age. The percentage of active marrow in
bones for a 10 year old are known from Cristy and Eckerman (1987) and for inactive
marrow and trabecular bone from Eckerman and Stabin (2000) (Table G.3, Appendix G).
The total mass of each in the skeleton is provided in ICRP Publication 89 (ICRP, 2002)
and hence the mass of active and inactive marrow and trabecular bone for a 10 year old
can be calculated using the percentage mass distributions (Table G.4, Appendix G). The
resulting percentage distributions of active and inactive marrow and trabecular bone in
the spongiosa bone for different skeletal regions in a 10 year old are given in Table G.5
(Appendix G). There is a large amount of variation in the composition of the spongiosa in
different bones. Furthermore, the overall composition for a 10 year old is different from an
adult (37%, 37%, 27% active marrow, inactive marrow and trabecular bone respectively in
total spongiosa in the skeleton compared with 33%, 33%, 33% for adults (ICRU, 1992)).
Therefore, it is warranted to consider the spongiosa composition in each bone in the
calculation of the absorbed dose to the spongiosa. Hence, the dose to the bone surface
(Dbs) is approximated by the average dose to the spongiosa (Dspongiosa):
iJ Jansen [UK Health Protection Agency] 2011, pers. comm., 17 January.
iiIn contrast to previous assumptions, recent studies have indicated that the cells at risk for bone cancer
induction are localised out to 50 µm (previously assumed: 10 µm) from both the trabecular surfaces and
interior cortical surfaces of the medullary cavities, but not within the Haversian canals of cortical bone
(Bolch et al., 2007; ICRP, 2009).
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Dbs ≈ Dspongiosa =
∑
b,i
DT,i ×

[
µen
ρ (E)
]
spongiosa[
µen
ρ (E)
]
T
× (Mspongiosa,b
Mspongiosa
) (3.13)
where DT,i is the dose relative to tissue at location i, as given by equation (3.6), and
measured at each of the locations selected for bone marrow measurements in bone b, the
second term is the ratio of mass energy absorption coefficients for spongiosa in bone b
relative to soft tissue, and the last term is the mass weight fraction of spongiosa at each
location (mass of spongiosa in bone b, Mspongiosa,b, divided by total mass of spongiosa in
the skeleton Mspongiosa as given in Table G.6, Appendix G).
Based on the selected measurement locations, the dose to approximately 52% of the spon-
giosa will be determined. However, 44% of the remaining spongiosa is in the arms and
legs and therefore will have a negligible dose since they are not directly in the X-ray
beam. The clavicles and upper spine were the only other skeletal regions not allocated
any TLD measurement locations, as for the bone marrow measurements. The spongiosa
in these regions accounts for 4% of the total spongiosa and hence will have an insignificant
contribution to the total bone surface absorbed dose.
The mass energy absorption coefficient for spongiosa depends on the bone and is a weighted
summation for the proportion of active and inactive marrow and trabecular bone for that
bone. The spongiosa to tissue ratio of mass energy absorption coefficients for each bone
considered in this thesis are also given in Table G.6, Appendix G. The spongiosa mass
energy absorption coefficients were determined from ICRU Report 46 (ICRU, 1992) using
the energy dependent coefficients for adult red marrow, adult yellow marrow and cortical
bone for a 10 year old childiii.
Skin Absorbed Dose
Skin absorbed dose was measured using TLDs placed on the anterior, posterior and left
and right lateral surfaces of the phantom. The TLDs were placed in the scan region to
ensure that they were irradiated by the primary X-ray beam. The average absorbed dose
measured by n TLDs was scaled by the ratio of the irradiated area to the overall phantom
surface area (PSA). This method was used as ICRP 60 assumes that the risk of skin
cancer is proportional to the irradiated skin area (ICRP, 1991). The skin surface area
proportions for a 10 year old are summarised in Table 3.7. The proportion of surface area
irradiated for each CT protocol assessed is shown in Table 3.8. Other authors (Fujii et al.,
2007; Kawaura et al., 2006; Nishizawa et al., 2008) have used a similar method. Nishizawa
et al. (2008) calculated that the exposed area for a CT chest examination for an anthro-
pomorphic phantom of a six year old child was 17.5%, and 25% for an abdominal-pelvic
iiiIn ICRU Report 46, spongiosa is a composition of cortical bone, red and yellow marrow (ICRU, 1992).
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examination, which are similar to the irradiated surface area proportions used in this
thesis.
Therefore, the absorbed dose to the skin (Dskin) was calculated by:
Dskin =
PSA
n
n∑
i
DT,i (3.14)
where DT,i is the absorbed dose to tissue at location i as given in equation (3.6).
Table 3.7: Skin surface area proportions for 10 year
old (ICRP, 2002).
Region Skin surface area proportion
Head 10.9%
Trunk 33.6%
Upper extremities 19.4%
Lower extremities 36.2%
Table 3.8: Irradiated proportion of skin surface area for 10 year
old for specific CT examinations.
Examination Area irradiated Irradiated skin surface
area proportion (PSA)
CT Brain 67% of head area 7.19%
CT Chest 50% of trunk 16.8%
CT Abdomen/Pelvis 60% of trunk 20.2%
Muscle Absorbed Dose
The muscle absorbed dose was calculated from an approximation of the absorbed dose to
all soft tissue measured by the TLDs. It was assumed that muscle is uniformly distributed
in the head and trunk. The average absorbed dose directly in the beam and outside of
the beam to the head and trunk was calculated for all TLD locations that were classified
as soft tissue (TLD locations inside bone, lens of the eye and on the skin surface were
excluded). The total average absorbed dose to soft tissue in the head and the trunk was
then calculated by weighting the average absorbed dose inside and outside of the beam
by the volume of the head or trunk directly and indirectly irradiated, respectively. The
total muscle absorbed dose was determined by weighting the head and trunk total average
soft tissue absorbed doses by the muscle mass ratio for that region to the whole body
muscle mass based on adult ratios (ICRP, 2009; Na et al., 2010), assuming that the ratios
are similar between children and adults. From these ratios, 3% of muscle mass is in the
head and 51% in the trunk. The remainder is in the extremities, which were considered
to receive a negligible exposure. Some authors (Fujii et al., 2007) exclude the muscle
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absorbed dose calculation as part of the remainder organ absorbed dose based on the
difficulty in deriving a value for this tissue.
3.3 Results
Alignment of the laser lights with the X-ray scan planes was first assessed. The laser lights
are used to position a patient at the isocentre of the scanner. In the State of Victoria in
Australia, it is required that agreement must be within ±2 mm (DoH, 2007). External
laser lights, at a small distance from the centre of the gantry, are provided in the axial,
coronal and sagittal scan planes to more easily align a patient. Internal laser lights are
also provided in the axial plane only. It was found that the external laser light was not
co-incident with the internal laser light in the axial plane (difference of 4-5 mm). It was
confirmed that the internal laser light was co-incident with the scan plane (estimated
deviation less than 0.75 mm) and therefore the internal laser light was used for alignment
in this plane. The normalised measured CTDIvol values and displayed values are given in
Table 3.9 and demonstrate good agreement, even for the tilted gantry.
Table 3.9: Values of normalised CTDIvol displayed on the console and
measured. The percentage difference between the values is also provided.
Filter kVp Beam
Collimation
(mm)
Normalised CTDIvol
(mGy/100 mAs)
Percentage
Difference
Console Measured
Head 120 10 16.8 16.9 1%
120 18a 19.2 18.0 -6%
Body 120 10 6.3 6.0 -5%
a Performed with a tilted gantry to simulate experimental measurements.
Automatic tube current modulation was used on all CT examinations undertaken. The
average current (mA), CTDIvol, DLP and scan length values for each CT examination
performed on the TLD loaded phantom are summarised in Tables 3.10 and 3.11.
The TLD measured organ and tissue absorbed doses for the three paediatric CT exami-
nations assessed in this thesis are shown in Table 3.12 and Figure I.1 (Appendix I). The
highest average absorbed dose is to the brain (33.6 mGy) and eye lens (19.3 mGy) for the
brain examination. The highest mean absorbed dose for the chest examination is for the
thyroid and ET region (10.9 mGy) and for the abdomen/pelvis examination is the stom-
ach (8.9 mGy). The range of measured absorbed doses and mAs and CTDIvol normalised
absorbed doses have also been provided in Tables I.1 to I.3 (Appendix I). Organs on the
periphery of the scan volume can have a significant variation in absorbed dose across
the organ due to partial irradiation. For example, the measurement points in the kidney
for the chest examination resulted in doses of 2.8, 1.7 and 0.9 mGy (cranial to caudal).
For the brain and abdomen/pelvis examinations where the kidney was either completely
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Table 3.10: Values of tube current (mA) and rotation time product (mAs) for
the phantom CT examinations.
Examination Average mA
(min, max)a
Average
Actual
mAsb
Average
Effective
mAsc
Qref
Effective
mAsd
CT Brain 345 (102, 379) 259 259 270
CT Chest 155 (112, 199) 78 78 80
CT Abdomen/Pelvis 160 (114, 175) 80 64 60
a The average current was derived from a single CT examination performed on a TLD loaded
CIRS anthropomorphic phantom of a 10 year old child by averaging the mA values for each
single rotation.
b The average actual mAs was calculated by multiplying the average current (mA) by the
rotation time (sec).
c The average effective mAs was calculated by dividing the average actual mAs by the pitch.
d Qref is the Imaging Quality Reference mAs, which is a Siemens specific setting used for
automatic tube current modulation (CARE Dose 4D), which is set by the user for each
protocol. This value is adjusted based on image quality requirements and the amount of
noise acceptable in the image. It is defined in terms of the effective mAs (actual mAs
divided by pitch).
outside the scanned volume or located directly within it, the absorbed doses were more
consistent.
The absorbed dose to soft tissue for the colon, red bone marrow and bone surface mea-
surement locations are shown in Table 3.13. The absorbed doses for these organs and
tissues are not based on the simple average of multiple TLDs in each organ (as detailed
in the Methods Section) and have therefore been provided individually. As expected,
the colon absorbed doses are all negligible for the brain examination. They are slightly
higher for the CT chest examination, particularly for the transverse colon in the upper
large intestine which is closest to the scanned volume for a chest scan. The measured
colon absorbed doses are all higher for the abdomen/pelvis examination where the colon
is directly irradiated. The measured absorbed doses vary considerably for the locations
selected for the red bone marrow and bone surface calculations. This is expected since
these locations range from the skull to the pelvis and therefore may be directly irradiated,
partially irradiated or completely outside of the scanned volume. This is evident in the
range of measured absorbed doses for all examinations, although it can be most readily
seen in the brain examination where the absorbed dose to the skull measurement locations
is 41 mGy, while all other locations are less than 1 mGy.
A further comparison of individual TLD measured absorbed doses from all three CT
examinations is shown in Figure 3.8. These graphs show the individual TLD measurements
from the top of the phantom (cranial, slab 1) to the base (caudal, slab 31). Out-of-field
doses demonstrated a gradual reduction in dose with distance from the scanned volume
for each examination, as expected. The extent of over-ranging for the helical examinations
has also been indicated on these graphs.
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Table 3.11: Average values of CTDIvol, DLP and scan length for the phantom CT
examinations.
Examination Average CTDIvol
a ,b
(mGy)
Average DLPa ,b
(mGy·cm)
Average Scan
Lengtha ,c (cm)
CT Brain 40.0±0.3 640±5 16.006±0.005b
CT Chest 5.72±0.08 152±10 26.6±1.5
CT Abdomen/Pelvis 4.56 168±3 36.9±0.7
a The average CTDIvol, DLP and scan length were calculated from a series of three CT
examinations using identical protocols performed on a TLD loaded CIRS anthropomorphic
phantom of a 10 year old child. The range is two standard deviations calculated from the series
of three examinations.
b Dose indicators for the CT brain examination were displayed on the CT scanner in terms of the
16 cm diameter phantom and in terms of the 32 cm diameter phantom for the CT chest and
abdomen/pelvis examinations.
c The scan length for the tilted brain scan on the CT scanner is taken as the length perpendicular
to the beam axis. This is not the actual length scanned on the patient.
The effective doses calculated from the measured absorbed doses using the ICRP 60
and ICRP 103 formalisms are shown in Table 3.14. The effective dose computed us-
ing ICRP 103 was 22% lower for the CT brain examination, 16% higher for the CT chest
examination and only 4% lower for the CT abdomen/pelvis examination when compared
with the effective dose computed using ICRP 60. The differences are predominantly due
to revision of the tissue weighting factors.
3.4 Discussion
3.4.1 Comparison of Organ and Tissue Absorbed Doses
Table 3.12 and Figure I.1 (Appendix I) provide a comparison of mean organ and tissue
absorbed doses from the TLD measurements for the three CT examinations assessed.
Without taking into account the relative radiosensitivities of the organs and tissues, the
highest absorbed doses are to the bone surface, brain and eye lenses for the CT brain
examination. Despite the angling of the gantry, the eye lenses still receive a significant
dose. The highest thyroid absorbed dose is from the CT chest examination and this is
dependent on each individual scan and the selection of collimation as the thyroid may or
may not be within the scan volume. Even when it is outside the scan volume it is likely
to receive a dose from scattered radiation, over-beaming and over-ranging in the case of
helical examinations when the chest is being imaged. As expected, organs within the scan
volume receive higher absorbed doses than those outside the scan volume.
Lens Absorbed Dose
The lens of the eye does not need to be considered for stochastic effects. However, it is
useful to consider the deterministic effects, such as cataracts, which have a threshold of
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Table 3.12: TLD measured organ and tissue absorbed doses in an
anthropomorphic phantom of a 10 year old child for different CT exam-
inations.
Organ/Tissue Absorbed Dose (mGy)a
Mean±2σ
CT Brain CT Chest CT Abdomen/Pelvis
Bone Marrow 6.1±0.3 2.4±0.1 3.2±0.1
Colon 0.026±0.001 0.52±0.03 8.0±0.4
Lung 0.46±0.02 9.9±0.4 4.1±0.2
Stomach 0.068±0.003 4.8±0.2 8.9±0.4
Breast 0.27±0.01 9.1±0.4 1.29±0.06
Gonads 0.0127±0.0006 0.080±0.004 3.7±0.2
Bladder 0.0111±0.0006 0.080±0.004 6.9±0.3
Oesophagus 0.48±0.02 9.2±0.4 3.3±0.1
Liver 0.118±0.005 10.5±0.5 8.5±0.4
Thyroid 1.67±0.07 10.9±0.5 0.24±0.01
Bone Surface 5.0±0.2 3.4±0.2 3.6±0.2
Brain 33.6±1.4 0.22±0.01 0.033±0.001
Salivary Glands 2.7±0.1 1.32±0.06 0.117±0.005
Skin 2.0±0.3 1.38±0.09 1.7±0.1
Total Remainder 0.49±0.02 4.4±0.2 4.9±0.2
Adrenals 0.094±0.005 5.1±0.3 6.9±0.3
ET Region 1.67±0.07 10.9±0.5 0.24±0.01
Gall Bladder 0.054±0.003 2.7±0.2 8.6±0.5
Heart 0.51±0.02 8.6±0.4 1.02±0.05
Kidney 0.064±0.003 1.80±0.09 8.3±0.4
Lymph Nodes 0.53±0.02 2.5±0.1 2.8±0.1
Muscle 0.53±0.02 2.5±0.1 2.8±0.1
Oral Mucosa 2.7±0.1 1.32±0.06 0.117±0.005
Pancreas 0.084±0.004 6.4±0.3 8.7±0.4
Prostate 0.0087±0.0007 0.057±0.005 5.8±0.4
Small Intestine 0.023±0.001 0.36±0.02 8.5±0.4
Spleen 0.156±0.007 9.2±0.4 7.9±0.4
Thymus 0.47±0.02 9.3±0.4 0.81±0.04
Uterus/Cervix 0.0126±0.0009 0.115±0.008 6.6±0.4
Eye Lenses 19.3±0.9 0.191±0.009 0.040±0.002
Testes 0.0115±0.0007 0.029±0.003 0.99±0.05
Ovaries 0.0139±0.0008 0.131±0.007 6.4±0.3
a Errors are expressed as two standard deviations of the combined random and
systematic errors.
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Table 3.13: TLD measured absorbed doses to soft tissue in the colon consist-
ing of the upper large intestine (ULI) and lower large intestine (LLI) and the
bone locations for the red bone marrow (RBM) and bone surface (BS) mea-
surements in an anthropomorphic phantom of a 10 year old child for different
CT examinations.
Organ/Tissue Absorbed Dose to Soft Tissue (mGy)
CT Brain CT Chest CT Abdomen/Pelvis
Ascending colon (ULI) 0.03 0.34 8.50
Transverse colon (ULI) 0.03 1.04 8.28
Descending colon (LLI) 0.03 0.33 8.63
Rectosigmoid colon (LLI) 0.01 0.12 6.04
Pelvis (RBM/BS) 0.01 0.10 6.06
Ribs (RBM/BS) 0.49 9.09 4.66
Skull (RBM/BS) 41.09 0.14 0.03
Spine – middle (RBM/BS) 0.16 7.73 4.52
Spine – lower (RBM/BS) 0.02 0.32 5.59
Scapulae (RBM/BS) 0.55 8.05 0.59
Table 3.14: Values of effective dose for standard paediatric CT examina-
tions calculated from TLD measurements of absorbed dose using the ICRP 60
(ETLD,60) and ICRP 103 (ETLD,103) formalisms. The percentage difference be-
tween the values is also provided.
Examination ETLD,60 (mSv) ETLD,103 (mSv) (ETLD,103-E60)/E60
CT Brain 1.8 1.4 -22%
CT Chest 4.3 5.0 16%
CT Abdomen/Pelvis 5.0 4.8 -4%
about 0.5 Gy (ICRP, 2011). The TLD measured absorbed dose to the lens was 19 mGy
for the CT brain examination. This is similar to the absorbed dose (15±2 mGy) mea-
sured in another study (Heaney and Norvill, 2006) for adult CT head examinations with
gantry angulation. Despite angling the gantry as a dose saving technique, the lens dose
remains relatively high although well below the deterministic threshold. This dose may
have resulted from scattered radiation or over-beaming, where the penumbral region of
the X-ray beam is not used for image formation. This ensures uniform exposure of the
MDCT detectors, but results in exposure of the patient that does not contribute to the
data acquisition. The portion of the beam missing the detectors is greater for smaller
collimations as was the case for the brain examination.
Directly Irradiated Organs
Measured absorbed doses for multiple TLDs located in directly irradiated large organs
varied throughout the organ volume. This is due to differences in photon attenuation for
measurement locations that are superficial compared with those that are deeper within
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an organ and/or relative to the body and other structures (e.g. bony) within it. The
individual measured absorbed doses in the brain for the scan of the head region ranged
from 25.9 to 41.2 mGy. This variation in dose is also attributable to non-uniformity in
the exposure because of gantry angulation. The range of absorbed doses in the lung
for the chest examination was 8.4 to 11.4 mGy and in the liver was 7.3 to 9.8 mGy for
the abdomen/pelvis examination. It is therefore necessary to use multiple measurement
locations across larger organs, so that the mean absorbed dose adequately reflects the
heterogeneity in dose deposition.
Partially Irradiated Organs
Organs on the periphery of the scan volume can have a significant variation in absorbed
dose across the organ due to partial irradiation. For example, as already discussed, the
measurement points in the kidney for the chest examination resulted in absorbed doses of
2.8, 1.7 and 0.9 mGy (cranial to caudal). For the brain and abdomen/pelvis examinations
where the kidney was either completely outside the scanned volume or located directly
within it, the absorbed doses were more consistent. For the brain examination the three
kidney measurement points were all 0.1 mGy and, cranial to caudal, the kidney absorbed
doses were 8.3, 8.2 and 8.4 mGy for the abdomen/pelvis examination. Averaging of
multiple measurement points is necessary for organs which are partially irradiated.
Selecting the location of an organ or tissue can have a considerable effect on the measured
absorbed dose when the organ or tissue is located on the edge of the scan volume. The
thyroid is on the periphery of the scan range for the chest examination and therefore may or
may not be directly exposed depending on operator technique. For the chest examination
performed on the anthropomorphic phantom, the dose to the thyroid (10.9 mGy) appears
to indicate that it is in the primary beam. However, this dose may also be due to over-
beaming and/or over-ranging.
It is clear from Figure 3.8 that absorbed doses of equivalent magnitude to those in the
directly irradiated scanned volume were measured outside of the imaged range. The dotted
lines on these figures represent the estimated additional scan length due to over-ranging
(van der Molen and Geleijns, 2007) necessary for data interpolation in helical scans. The
additional length at the beginning and end of the imaged volume correlates well with
absorbed doses measured beyond the imaged volume. Over-ranging is greater for larger
beam collimation and higher pitch, which may reduce scan times, but at the cost of
increased dose in the over-ranging region (Fujii et al., 2009).
The extrathoracic (ET) region is included as a remainder organ in ICRP 103. It was dif-
ficult to determine a location in the anthropomorphic phantom for this tissue and instead
the thyroid absorbed dose was used as a substitute. This may be a poor approximation
when the scan volume is adjacent to this region since the thyroid may be in the scan
range, while the ET region is not, but it will still be allocated a dose as though it were ex-
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posed to the primary beam. This is a recognised limitation of substituting organ absorbed
doses.
Out-of-Field Doses
Out-of-field doses have been measured for tissues and organs outside the scanned volume
for all three CT examinations (Figure 3.8). There is a gradual reduction in dose with
distance from the scanned volume for each examination. The extent of out-of-field doses
is greatest for the brain examination where the mAs (current exposure time product) is
more than three times higher than either body examination and where the gantry was
angled towards the body for the examination. It is interesting to note that organs and
tissues outside of the scanned volume for the brain examination, such as the lung, breast,
oesophagus, thymus, heart and liver, have all received a small absorbed dose. This may
result from the uncertainty in measurement for the TLDs at low doses or may arise from
scattered radiation. The increased photon flux and/or gantry angulation may have resulted
in a higher scattered radiation dose to distant organs for this examination. Alternatively,
since the brain is located at a distal part of the body, there is greater body length for the
scattered dose to be deposited and hence measured, compared with an examination of the
chest or abdomen/pelvis.
3.4.2 ICRP 60 versus ICRP 103 Effective Dose
The ICRP defines effective dose as a parameter for expressing stochastic risk from radiation
exposure and recommends its use only for radiation protection purposes (ICRP, 2007b).
However, effective dose has found widespread application in evaluating doses from medical
exposure due to its effectiveness in condensing a complex set of parameters for any exposure
situation into a single quantity (McCollough et al., 2010). It is routinely used to compare
doses resulting from variations in protocols or from different modalities. However, while
taking into account the nature of the exposure, characteristics of a specific individual
are not considered. Hence, effective dose provides a broad, generic estimate and is an
indication only of the typical dose. Although it should not be applied to the individual, it
is often used for incident dose assessments and other situations involving specific patients
to express a “relative” risk. Despite its use when inappropriate, effective dose is a useful
parameter for expressing risk.
Over time the definition of effective dose has changed, as the effects of radiation on different
organs and tissues is continually revised in accordance with scientific knowledge. These
changes are primarily due to tissue weighting factors, although the inclusion of additional
organs and tissues to be considered for stochastic risk has also occurred. Effective dose
is derived from the mean organ and tissue absorbed doses and any changes to tissue
weighting factors will not affect the absorbed dose. Therefore, it is useful to measure
organ and tissue absorbed doses and from these effective dose may be computed using
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various ICRP definitions.
The measurements undertaken using the TLD loaded anthropomorphic phantom were used
to derive effective dose based on both the ICRP 60 and ICRP 103 formalisms (ETLD,60 and
ETLD,103 respectively). A comparison of these values show that the ICRP 103 definition
leads to a lower effective dose for a CT brain examination, a higher value for a CT chest
examination and approximately the same value for a CT abdomen/pelvis examination
(Table 3.14). It is expected that the effective dose for examinations involving the brain
will decrease using the ICRP 103 definition. Since the brain is directly irradiated the
tissue weighting factor according to ICRP 60 is 0.025 (remainder splitting rule), whereas
for ICRP 103 the brain is identified as a primary organ with a weighting factor of 0.01,
accounting for the decrease in effective dose. Similarly, Christner et al. (2010) found a
39% reduction for CT brain examinations for adults.
However, there are other studies (Deak et al., 2010; Huda et al., 2011) that show an increase
in the effective dose estimate for CT brain examinations based on the ICRP 103 definition,
when compared with the ICRP 60 definition. The ICRP 60 effective dose estimates made
by Deak et al. (2010) for CT brain examinations appear to apply a tissue weighting factor
of 0.005, rather than 0.025, for the brain dose and consequently underestimate the ICRP
60 effective dose. Therefore, Deak et al. (2010) conclude that the ICRP 103 effective dose
estimate for brain examinations increases relative to the ICRP 60 estimate, which does
not agree with the findings of this thesis.
The study by Huda et al. (2011) similarly reports an increase in effective dose estimates for
CT head examinations for adults according to ICRP 103, when compared with ICRP 60
effective dose estimates. They have made use of the ImPACT CT Patient Dosimetry Calcu-
lator (version 1.0) for effective dose estimates according to either ICRP 60 or ICRP 103.
ImPACT does employ the ICRP splitting rule for ICRP 60 effective dose calculations.
However, the effective dose estimates in ImPACT are based on Monte Carlo simulations,
which use a mathematical anthropomorphic phantom. Not all of the organs and tissues
specified in the ICRP 103 effective dose estimate were included in the Monte Carlo cal-
culations and the method of substituting known organ absorbed doses has been used by
ImPACT. For example, the salivary glands and oral mucosa in ImPACT have been al-
located the brain absorbed dose. Since the brain absorbed dose is relatively high when
directly irradiated in a CT brain examination, the salivary glands and oral mucosa are
allocated this same absorbed dose, even though it is most likely that they would not be
directly irradiated in this type of scan. Therefore, the ICRP 103 effective dose estimates
in ImPACT are higher relative to the ICRP 60 effective dose estimates for a brain exam-
ination due to the inappropriately high absorbed doses allocated to these tissues, which
are only included in the ICRP 103 effective dose estimate and not the ICRP 60 effective
dose. These differences are discussed further in Chapter 5.
One of the significant changes to tissue weighting factors in ICRP 103 was the increase
62
CHAPTER 3. EXPERIMENTAL DOSIMETRY
from 0.05 to 0.12 for the breast weighting factor. This is demonstrated by a 16% increase
in the effective dose using ICRP 103 tissue weighting factors for a CT chest examination,
which reflects the increased radiosensitivity attributed to the breast. Li et al. (2011a) also
found a 16% increase and Fujii et al. (2009) a 19% increase in effective dose for paediatric
CT chest examinations when using ICRP 103 instead of ICRP 60.
The tissue weighting factor for the gonads also changed significantly, decreasing from 0.20
to 0.08 in ICRP 103. However, the effective dose for a CT abdomen/pelvis examination
using ICRP 103 is only 4% lower than the ICRP 60 value. In this case, the reduction in
the gonad tissue weighting factor is balanced by an increase in the weighting factor for
the remainder organs from 0.05 to 0.12. Fujii et al. (2009) also found a 4% decrease in
the ICRP 103 effective dose for CT abdomen/pelvis examinations (Fujii et al., 2009). For
adults, Christner et al. (2010) similarly found a 14% increase for CT chest examinations
and 7% decrease for CT abdomen/pelvis examinations.
3.5 Conclusions
Organ and tissue absorbed doses have been measured for CT brain, chest and abdomen/
pelvis examinations using high sensitivity TLDs loaded in an anthropomorphic phantom
of a 10 year old child and for currently used protocols on the RCH CT scanner. When
considering stochastic effects, the highest measured absorbed dose was to the brain as a
result of radiation exposure from a CT brain examination. However, a lower absorbed
dose to a more radiosensitive organ may in fact lead to a greater stochastic risk. The
relative radiosensitivities of the organs and tissues have only broadly been taken into
account in the present analysis using the averaged tissue weighting factors intended for
adults. Chapter 8 provides a detailed assessment of the radiation induced cancer incidence
and mortality risks associated with the measured organ absorbed doses, using age-specific
organ risk factors.
The TLD measurements demonstrated some of the issues in estimating average absorbed
dose to an organ or tissue. Directly and fully irradiated organs and tissues lead to more
consistent dose measurements throughout their volume. Organs and tissues on the pe-
riphery of the scan volume had a range of dose measurements and were also affected by
over-ranging in helical scanning. Even organs distant from the scanned volume had a
small amount of radiation exposure, likely due to scattered radiation.
From the measured absorbed doses, effective doses have been derived based on ICRP 60
and ICRP 103 formalisms. Effective dose is not a physical quantity but an estimate of
biological detriment reflecting the risk from radiation exposure. It is a useful generic quan-
tity that can be used for optimisation in diagnostic radiology. However, differences arise
in the effective dose for paediatric CT depending on whether the ICRP 60 or ICRP 103
formalism is used. These changes reflect the lower weighting now applied to the brain for
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direct irradiation, the increased assessed radiosensitivity of the breast and the remainder
organs collectively and the decrease in assessed radiosensitivity for the gonads.
3.6 Publications Arising from this Chapter
1. Brady, Z., Cain, T. M. and Johnston, P. N., Differences in using the International
Commission on Radiological Protection’s Publications 60 and 103 for determining
effective dose in paediatric CT examinations, Radiation Measurements, 2011, 55:132-
142 (Brady et al., 2011e).
2. Brady, Z., Cain, T. M. and Johnston, P. N., Effective dose calculation in CT using
high sensitivity TLDs (EPSM ABEC 2010 Conference Proceedings), Australasian
Physical & Engineering Sciences in Medicine, 2011, 34(1):111 (Brady et al., 2011b).
3. Brady, Z., Cain, T. M. and Johnston, P. N., Calculations of effective dose for
paediatric CT examinations presented at the 16th International Conference on Solid
State Dosimetry, 2010, Sydney, Australia (Brady et al., 2010b).
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Figure 3.1: X-ray photon spectra at 120 kVp for the Siemens Sensation 16 CT scanner
using the head filter (7.5 mm Al HVL [input parameter: 7 mm Al filtration], mean photon
energy 63 keV) and body filter (8.7 mm Al HVL [input parameter: 11.1 mm Al filtration],
mean photon energy 66 keV) (Reilly and Sutton, 1997).
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a) b)
c) d)
Figure 3.2: CIRS anthropomorphic phantoms a) examples of phantoms of a male adult,
female adult and baby, b) RCH CIRS phantom of a 10 year old child assembled (without
assembly frame), c) RCH CIRS phantom of a 10 year old child’s head showing some slab
sections removed, d) with head slab sections disassembled.
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Figure 3.3: Anterior-posterior and lateral views of the anthropomorphic phantom of a
10 year old child, with 3D reconstruction of the skeleton shown on the left.
Figure 3.4: Slab from phantom with TLDs being loaded from storage and annealing
tray using vacuum tweezers. Each plug was halved with the TLDs placed between the two
halves.
Figure 3.5: TLD-100H chips (x25) placed in Perspex holder for calibration irradiations.
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Figure 3.6: Linac output check prior to calibration of the set of TLDs. Solid water
blocks were used and a 0.6 cm3 Farmer ion chamber was placed at 100 cm from the focus
with 5 cm of solid water between the source and ion chamber.
a) b)
c) d)
Figure 3.7: TLD measurement locations in the anthropomorphic phantom of a 10 year
old child in the lung (circled in images a and b) and in the liver (circled in images c and
d). The phantom slab numbers are a) 13, b) 15, c) 17 and d) 18.
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Figure 3.8: Individual absorbed dose to soft tissue measurements for various CT ex-
aminations of the TLD loaded anthropomorphic phantom of a 10 year old child. The
horizontal axis corresponds to the slab number of the phantom (slabs 1-31), where a sin-
gle slab may be loaded with multiple TLDs. a) CT brain examination: the axial scan
range was from above the head and because of the tilt of the gantry only fully irradiated
down to slab 3 (solid vertical line), and partially irradiated down to slab 7 (dotted line).
b) CT chest examination: the scan range included the entire thorax anatomy from slab 10
(first solid vertical line) to half way through the liver, slab 18 (second solid vertical line).
The dotted lines represent the extent of over-ranging for the helical scan (van der Molen
and Geleijns, 2007). c) CT abdomen/pelvis examination: the scan range was from just
above the diaphragm, slab 16 (first solid vertical line) to symphysis pubis, slab 28 (second
solid vertical line). The dotted lines represent the extent of over-ranging for the helical
scan (van der Molen and Geleijns, 2007).
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Chapter 4
MOSFET Dosimetry
Comparison
4.1 Introduction
A measurement device that is finding increased application in the diagnostic imaging field
(Bower and Hintenlang, 1998; Dong et al., 2002; Frush and Yoshizumi, 2006; Hollingsworth
et al., 2007; Hurwitz et al., 2007a,b, 2009; Jones et al., 2005; Miksys et al., 2010; Mukundan
et al., 2007; Peet and Pryor, 1999; Sessions et al., 2002; Wang et al., 2005; Yoshizumi et al.,
2007, 2003) is the metal oxide semiconductor field effect transistor (MOSFET) (Figure 4.1).
A MOSFET consists of a silicon n-type substrate, with a polysilicon conducting gate
electrode mounted on a silicon dioxide (SiO2) layer grown on the substrate. Doped (p
+)
source and drain terminals are separated by the gate region.
When a negative voltage is applied to the gate, holes (positively charged) are attracted
to the gate electrode and are trapped at the substrate-SiO2 interface. When there is
an accumulation of charge a conduction channel (p-channel) is formed. The required
voltage to generate the conduction channel is called the threshold voltage. When ionising
radiation is incident on the MOSFET and passes through the SiO2 layer, electron-hole
pairs are created which changes the charge carrier trapping within the device. Holes move
towards the substrate-SiO2 interface where they become trapped, while electrons move
away from the gate. The overall effect is to change the threshold voltage required to
initiate the conduction channel. It is the shift in threshold voltage which is measured
(before and after irradiation by ionising radiation) which is proportional to the radiation
dose.
The major advantage of MOSFETs is that they are real time. However, there are other
factors, such as angular and energy dependence, that must be taken into consideration
when using MOSFETs instead of TLDs. MOSFETs were used in this thesis with the
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anthropomorphic phantom of a 10 year old child to repeat a limited number of the TLD
measurements. This allowed a comparison between the two dosimetry methods. The
MOSFETs used were a trial set on loan to the RCH from Best Medical Canada (Ottawa,
Ontario, Canada).
4.2 Methods
High sensitivity MOSFET dosemeters (TN-1002RD, Best Medical Canada, Ottawa, On-
tario, Canada) were used to repeat some of the measurements undertaken with the TLD-
100H chips. Five individual MOSFETs were connected to each bias module, which trans-
ferred data wirelessly to a laptop. Two bias modules with 10 high sensitivity MOSFETs
were calibrated and used (Figure 4.2).
The MOSFETs were calibrated using a general radiography X-ray tube (Optimus 80,
Philips Healthcare, Andover, Massachusetts, US) matched to the CT scanner beam quality
to be used during the measurements. This was achieved on the general X-ray tube by using
125 kVp and adding 1 mm Al and 0.2 mm Cu filters. This model of X-ray tube is limited to
selection of 117 kVp and 125 kVp at higher kVp, hence 120 kVp could not be used. When
measured with a calibrated Unfors Xi solid state detector (Unfors, Billdal, Sweden), the
HVL of the beam was 8.1 mm Al. For calibration, each set of five MOSFETs connected
to a bias module was placed adjacent to a 6 cm3 Model 10X6-6 ion chamber connected to
a Radcal 9095E electrometer (Radcal, Monrovia, California, US) and a calibrated Unfors
Xi solid state detector (Figure 4.3).
Each MOSFET wire was colour coded and connected to the same terminal in the same
bias reader for calibration and subsequent measurements. Three exposures were made
at approximately 10 mGy and millivolt to centrigray (mV/cGy) conversion factors were
computed using the MOSFET software (DXPOSURE Software, Version 2.2, Best Medical
Canada, Ottawa, Ontario, Canada). All MOSFET measurements were read out immedi-
ately after exposure to avoid any additional charge build up. Figure 4.4 shows differences
in conversion factors for different beam qualities with HVL ranging from 3-8 mm Al (mea-
sured by the Unfors Xi). The values are consistent and hence a single conversion factor
was used.
The CIRS anthropomorphic phantom of a 10 year old child used for TLD measurements
was also used for the MOSFET measurements. When using MOSFETs all portions of
the plug were removed from the phantom slab and the MOSFET and wire were inserted
into the hole. Electrical tape was used to cushion the MOSFET wires between the slabs
(Yoshizumi et al., 2007). The combination of the MOSFET wire and tape resulted in a
small gap between adjacent phantom slabs. Care was taken when moving the phantom
for the experimental set up as the MOSFET wires protruded when the phantom was fully
assembled (Figure 4.5).
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Figure 4.1: Schematic of a metal oxide semiconductor field effect transistor (MOSFET)
(Hallil, 12-13 June 2009).
Figure 4.2: Two Mobile MOSFET bias modules with five high sensitivity MOSFETs
connected to each module. The wires of each MOSFET are colour coded for easy identi-
fication. In the photograph, protective casings are around the individual MOSFETs.
Figure 4.3: MOSFET calibration configuration.
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Figure 4.4: MOSFET sensitivity for different beam qualities. Error bars are two standard
deviations based on three measurements at each beam quality.
Figure 4.5: MOSFET wires protrude when the phantom is fully assembled.
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For measurements of absorbed dose for CT examinations, the MOSFETs were placed
inside the liver and lung within the anthropomorphic phantom. The tissue absorbed dose
(DT ) was calculated from the measurement of absorbed dose in air (Dair), taking into
account the mass energy absorption coefficient (µen/ρ) of the MOSFET oxide coating
(Sessions et al., 2002), by:
DT [Gy] = Dair
[
µen/ρ
]
T[
µen/ρ
]
air
= X [R]× 0.00876
[
J
kg
R−1
] [µen/ρ]
oxide[
µen/ρ
]
air
[
µen/ρ
]
T[
µen/ρ
]
oxide
(4.1)
The conversion factor calculated for each MOSFET relative to the Unfors dose measure-
ment already takes into account the conversion from roentgen to gray (0.00876 Gy per R).
The ratio of mass energy absorption coefficients (tissue to air) at 60 keV (effective energy
of the CT beam, Figure 3.1) for soft tissue is 1.07 and for the lung is 1.08 (Hubbell and
Seltzer, 2004). These were applied when calculating the absorbed dose for the relevant
tissues.
4.3 Results
The ratio of MOSFET to TLD measured absorbed doses for seven locations in the liver
and lung are shown in Figure 4.6. These were obtained using the protocol for a CT chest
examination for children aged over 10 years (Table 3.1). The MOSFET measurements
are on average 9% higher than the TLD measurements.
4.4 Discussion
TLDs have traditionally been the gold standard for medical dosimetry. However, they are
not easy to use and require careful, reproducible preparation and calibration. Furthermore,
they are passive dosemeters and do not provide a real time result. MOSFETs are finding
increased application as a potential dosimetry tool for medical exposures. Although they
have not yet gained widespread acceptance, there are numerous studies based on MOSFET
measurements for diagnostic radiology (Bower and Hintenlang, 1998; Dong et al., 2002;
Ehringfeld et al., 2005; Frush and Yoshizumi, 2006; Hurwitz et al., 2007a,b, 2009; Jones
et al., 2005; Miksys et al., 2010; Peet and Pryor, 1999; Yoshizumi et al., 2007), including
articles assessing paediatric CT doses (Coursey et al., 2008; Hollingsworth et al., 2007;
Mukundan et al., 2007).
Some of the known limitations of MOSFETs are the energy and angular dependence,
particularly for lower energies encountered in diagnostic radiology (Dong et al., 2002;
Ehringfeld et al., 2005; Jones et al., 2005; Wang et al., 2005). However, these may be
addressed to some extent with consistent positioning and appropriate correction factors.
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Dong et al. (2002) have demonstrated an increased sensitivity of high sensitivity MOS-
FETs at low doses (below about 5 mGy) compared with TLD-100H chips which varied
less than 3% over the same dose range suggesting that TLDs may be more suitable at the
very low doses typical of plain radiography.
In this thesis, the absorbed doses measured with the MOSFETs were within reasonable
agreement (on average within 9%) of the TLD measurements (Figure 4.6). Yoshizumi et
al. (2007) compared the same high sensitivity MOSFETs against TLD-100 chips for CT
examinations in an adult anthropomorphic phantom. They found the difference between
the dosimetry methods ranged from 1% to 27% in the scanned volume (Yoshizumi et al.,
2007). The disparity was much greater for organs outside of the field of view, due to
the lower limit of detection for MOSFETs (1.4 mGy compared with 0.20 mGy for TLDs)
(Yoshizumi et al., 2003). Of the individual TLD measured absorbed doses for CT brain,
chest and abdomen/pelvis examinations (Chapter 3), only 48% of the measured doses were
greater than 1.4 mGy. This was for all TLDs, including those placed distant from the
scanned volume (e.g. testes for a CT brain examination). However, for the TLDs placed
in the directly irradiated volume, the measured absorbed doses were predominantly above
5 mGy (Figure 3.8). Therefore, MOSFETs appear to be a reasonable alternative to TLDs
for measuring CT organ absorbed doses in the scanned volume.
The main advantage of MOSFETs is the ability to make an immediate measurement.
They can be placed in the same locations as TLDs, hence making real time organ and
tissue dosimetry plausible. This benefit may even outweigh any limitations, since real
time measurement will facilitate optimisation of protocols and simplify dosimetry in the
clinical environment. For example, in Chapter 3 TLDs were used to measure organ and
tissue doses in an anthropomorphic phantom for typical CT examinations including the
initial topogram dose. The measured dose was attributable to both the topogram and scan
doses. Using the MOSFETs it was quickly verified that for the measurement positions in
the liver and the lung the topogram absorbed dose was on average only 2% (maximum
4%) of the total absorbed dose from the examination. This was not readily undertaken
with the TLDs.
4.5 Conclusions
MOSFETs offer an alternative dosimetry method that is fast and easy to use. However,
they do require initial calibration and conversion factors must be derived for all beam
qualities and energies that are to be used. This is performed at acceptance and is labour
intensive. Further studies are required to assess the necessary frequency of calibration,
both over time and relative to the cumulative dose that each MOSFET receives. Fur-
thermore, MOSFETs have a lifetime related to cumulative exposure and hence must be
replaced on a semi-regular basis. TLDs also require labour intensive calibration, although
TLD-100H material has the advantage of a relatively linear energy response. Both TLDs
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and MOSFETs are small, fragile and require careful handling. TLDs remain the gold
standard and are the more accurate method for undertaking dosimetry. However, con-
sidering that effective dose is intended to be a broad estimate of typical dose, the real
time nature of MOSFETs may lead to the acceptance of some of these limitations. In the
future, MOSFETs may become indispensable to medical imaging clinical dosimetry.
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Figure 4.6: Ratio of MOSFET to TLD measured doses for the liver and lung. The num-
ber after the organ (e.g. Liver 103) refers to the position number in the anthropomorphic
phantom. Errors are two standard deviations calculated from the combined errors from a
series of three MOSFET and TLD measurements.
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Chapter 5
Computational Dosimetry
5.1 Introduction
Estimates of organ absorbed dose and effective dose are frequently required for CT ex-
aminations in order to assess stochastic risk or to assist in the process of optimisation.
Experimental dosimetry measurements, for example with thermoluminescence dosemeters
(TLDs) or metal oxide semiconductor field effect transistors (MOSFETs) placed in an
anthropomorphic phantom, are difficult to implement in the diagnostic radiology clinical
environment. These methods require significant resources in terms of equipment, time and
skilled staff, which often prevent radiology practices from performing experimental dosime-
try. Therefore, it is necessary to have alternative, indirect or computational methods for
determining CT dose.
Existing dose computational methods for medical exposure situations are predominantly
based on Monte Carlo radiation transport simulations. For exposures from CT exami-
nations there are various Monte Carlo-based dose calculators available (ImPACT, 2011;
Kalender et al., 1999; Le Heron, 1993; Stamm and Nagel, 2011b). These are dependent
on the type of CT scanner used and provide estimates of organ and tissue absorbed dose
for a reference person of a standardised size and shape. More recent methods using Monte
Carlo simulations for CT exposures provide a technique for estimating organ and tissue
absorbed doses that is specific to the size of the patient and is independent of the CT
scanner (Li et al., 2011a; Turner et al., 2011).
Currently there is no definitive method for undertaking CT dosimetry and multiple ex-
perimental and computational approaches exist. The choice between dosimetry methods
is often more difficult when considering children, since the dose estimates need to be
age-specific or reflect the range of ages necessary to accurately represent the paediatric
population. Furthermore, with a wide variety of methods available, there is potential for
doses to differ. Since organ and tissue absorbed doses are used for risk assessment and
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effective dose for radiation protection purposes, it is important to assess the extent of the
variability between different methods. There are only a limited number of studies com-
paring CT doses using experimental and/or computational techniques (Brix et al., 2004;
Geleijns et al., 1994; Groves et al., 2004; Kim et al., 2011; Lechel et al., 2009; Lee et al.,
2011), particularly for paediatric CT imaging (Deak et al., 2008; Li et al., 2011c).
The objective of this part of the thesis was to compare different computational methods for
paediatric CT organ dosimetry and effective dose estimation to assess their reliability for
clinical implementation. The types of anthropomorphic phantoms and categories of CT
computational methods that can be used to assess medical exposures are reviewed in the
background section. Several of the available computational dose methods for paediatric CT
examinations were investigated using standard clinical protocols. The computed absorbed
doses were compared with absorbed doses measured using TLDs placed in a physical
anthropomorphic phantom representing a 10 year old child (Chapter 3). Different methods
of determining effective dose were also assessed and compared with the effective doses
calculated from the measured organ and tissue absorbed doses.
5.2 Background
5.2.1 Computational Anthropomorphic Phantoms
For most computational organ dosimetry methods, the patient must be modelled by an
anthropomorphic phantom, which represents an idealised form of human anatomy (Lee
and Bolch, 2006; Martin, 2007; Xu and Eckerman, 2010). The first type of computational
phantom (1960s to 2000s) is often referred to as a stylised or mathematical phantom (Xu
and Eckerman, 2010) and was originally developed by the Oak Ridge National Laboratory
(ORNL) for the Medical Internal Radiation Dosimetry (MIRD) Committee (Snyder et al.,
1969). This phantom represented a hermaphrodite adult and anatomical structures were
defined by solid geometrical objects such as elliptical cylinders and cones. An independent
set of ORNL phantoms, including children, were later developed by Cristy and Eckerman
(Cristy, 1980; Cristy and Eckerman, 1987). The German National Research Centre for
Environment and Health (GSF) also used the initial hermaphrodite adult phantom to
develop an adult male and adult female for external dosimetry (Kramer et al., 1982).
The next class or generation (1980s to 2000s) of computational phantom is referred to as
a voxel phantom (Xu and Eckerman, 2010). These phantoms were constructed by voxel
segmentation from CT and magnetic resonance imaging (MRI) cross-sectional images of
humans (Caon et al., 1999; Fill et al., 2004; Kramer et al., 2003; Lee et al., 2006a,c;
Petoussi-Henss et al., 2002; Saito et al., 2001; Zankl et al., 1988). More recently a third
generation of hybrid phantoms (2000s to present) have emerged (Xu and Eckerman, 2010),
which use boundary representation (BREP) where exterior surfaces are defined by non-
uniform rational B-splines (NURBS) and polygon mesh (PM) surfaces (Lee et al., 2007b,
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2008a, 2010; Li et al., 2008, 2011a,b,c; Segars et al., 2008; Xu et al., 2007). The BREP
modelling technique provides more anatomically realistic models that also allow deforma-
tion of surfaces, which is useful for organ motion or sizing (Xu and Eckerman, 2010) and
scaling for different body morphometrics (Lee et al., 2010). Both voxel and hybrid phan-
toms are patient-specific, based on the images that were initially captured. Therefore, the
standard technique is to scale the organs to match ICRP recommended reference organ
masses (ICRP, 2002, 2006).
5.2.2 CT Scanner-Dependent Computational Methods
There are two main Monte Carlo data sets of normalised organ absorbed doses from
CT exposures. These were generated by the UK National Radiological Protection Board
(NRPB, now the Health Protection Agency, HPA) (Jones and Shrimpton, 1993, 1991) and
the GSF (Zankl et al., 1991, 1993). These data sets provide organ absorbed dose data
normalised to the CTDI measured in air at the isocentre (CTDIair) of the CT scanner and
are dependent on the type of scanner modelled in the Monte Carlo simulation. The NRPB
data set is used via an Excel (Microsoft Office) interface in the “CT Patient Dosimetry
Calculator” provided by the UK ImPACT group (ImPACT, 2011) and similarly the GSF
data set is used via an Excel interface in the commercially available “CT-Expo” calculator
(Stamm and Nagel, 2011b). Other calculators are also available (CTDOSE (Le Heron,
1993), CT-Dose, ImpactDose (formerly WinDose (Kalender et al., 1999)).
The design and specifications of the CT scanner are predictably proprietary information
and as a result, Monte Carlo models generally simulate only a limited number of CT
scanners. There are 23 data sets from the NRPB, modelling 27 scanners from Siemens,
Picker, CGR, GE, and Philips that were clinically operational in the late eighties to early
nineties (Jones and Shrimpton, 1993; Shrimpton and Edyvean, 1998). Notably, these are
all single detector CT (SDCT) scanners. The GSF data set models the Siemens Somatom
DRH scanner (Brix et al., 2004; Zankl et al., 1991), which was also included in the NRPB
data set.
Since the data sets were generated for older scanners their relevance to new CT technology
is potentially limited. However, the ImPACT group have addressed this by using an Im-
PACT Factor which matches new CT scanners to the existing NRPB Monte Carlo data sets
using output dependent conversion factors (Lewis et al., 2000). The GSF data set similarly
utilises the ImPACT method for matching new scanners to a set of scanner-specific correc-
tion factors which are related to the single scanner that was originally modelled (Nagel,
2002; Shrimpton and Edyvean, 1998). The scanner matching technique is a recognised
limitation of using the existing data sets (Christner et al., 2010; Shrimpton, 2004).
The ImPACT dose calculator uses Monte Carlo data generated from simulating an expo-
sure of a single hermaphrodite adult mathematical phantom (Jones and Shrimpton, 1993,
1991), while CT-Expo uses data for adult male and adult female mathematical phantoms
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(Kramer et al., 1982; Zankl et al., 1991) and baby and child voxel phantoms (Veit et al.,
1989; Zankl et al., 1993, 1995).
In addition to these traditional CT dose calculators, it is expected that a CT dose calcula-
tor using Monte Carlo data sets based on the University of Florida (UF) family of hybrid
phantoms (Lee et al., 2010) will be available in the futurei. Another research group at
Duke University are investigating segmenting a range of clinical images for patients of all
ages and weight percentiles to produce a library of Monte Carlo dose estimates using the
patient-specific hybrid phantoms allowing patient-specific dose estimation by matching a
patient’s characteristics to one in the database (Li et al., 2008, 2011a,b,c).
5.2.3 CT Scanner-Independent Computational Methods
Shrimpton (2004) was first to propose a method of estimating organ absorbed dose using
coefficients normalised to the weighted CTDI (CTDIw), which takes into account the
scanner output characteristics and the impact on dose deposition in standardised dosimetry
phantoms. Measurements are made in a polymethyl methacrylate (PMMA) homogeneous,
cylindrical phantom and CTDIw is calculated from a weighted average of measurements
at the centre and periphery, which includes the effects of the scanner beam shaping filter
on dose. The standard phantoms used for CT dosimetry are a 32 cm diameter phantom
representing an adult’s body and a 16 cm diameter phantom representing the head of an
adult or child, or in some cases a child’s body.
Normalising doses to a quantity, such as CTDIw, which takes account of the influence
of the scanner design on dose deposition in a patient (standardised phantom), removes
some of the scanner dependence which was a feature of the original Monte Carlo CT dose
data sets which were normalised to CTDIair. The feasibility of this method was demon-
strated by normalising effective dose across different age groups for three types of scanners
(Shrimpton, 2004). The variability in the effective dose coefficients normalised to CTDIw
for each age group and examination type was less than 10% (Shrimpton, 2004).
Turner et al. (2010) further demonstrated the viability of this method using Monte Carlo
simulations for four modern multi-detector CT (MDCT) scanners and one of the GSF voxel
phantoms (Fill et al., 2004; Petoussi-Henss et al., 2002). Organ and effective doses were
normalised to the volumetric CTDI (CTDIvol), which is calculated by dividing the CTDIw
by the pitch for helical scans. The mean variance across scanners for all organs was 5.2%
and only 4.2% for effective dose (Turner et al., 2010). Turner et al. (2011) further assessed
estimating scanner-independent organ absorbed doses for CT abdominal examinations
across a range of GSF computational phantoms (Fill et al., 2004; Petoussi-Henss et al.,
2002) to take into account varying patient size, including children. They concluded that
the method was feasible for fully irradiated organs and showed a dependence on patient
iC Lee [US National Cancer Institute] 2011, pers. comm., 18 May.
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size (Turner et al., 2011). The method was more variable for partially irradiated organs
due to the organ size, proximity to the scan region and relative organ position between
different phantoms (Turner et al., 2011).
Li et al. (2008; 2011a) have shown a similar correlation between organ absorbed dose and
patient size for CT chest examinations using Monte Carlo modelling for a single MDCT
scanner and multiple patient-specific hybrid phantoms developed from paediatric patient
clinical images. They demonstrated that changes in beam collimation, pitch and tube
voltage had little effect (<7%) on CTDIvol-normalised lung doses for CT chest examina-
tions and they predict that this may also apply to other centrally located organs in the
scan volume (Li et al., 2011a).
Traditional DLP to effective dose conversion methods (Chapple et al., 2002; Khursheed
et al., 2002; Shrimpton and Wall, 2000; Shrimpton et al., 2006; Shrimpton, 2004) utilise
the same principle. Since the DLP is based on the CTDIvol, these conversion methods
also provide a generic approach for estimating effective dose across different scanners.
Similarly, these methods all demonstrate a dependence on the size of the patient and in
the past have predominantly been defined relative to the age of the patient. Conversion
coefficients are readily utilised and easily understood in the clinical setting and are useful
for providing a sufficiently precise estimate of effective dose (Shrimpton and Wall, 2009),
considering the uncertainty in the value for a reference patient is about ±40% (Martin,
2007).
5.3 Methods
Twelve methods for determining CT doses have been evaluated using three clinical pae-
diatric CT protocols. One method was experimental and based on dose measurements
(Chapter 3), while the remainder were computational. The methods are summarised in
Table 5.1 and detailed further below. The clinical protocols were all designed for use on
a Siemens Sensation 16 MDCT scanner (Siemens, Erlangen, Germany) using automatic
tube current modulation (CARE Dose 4D). The standard parameters for the CT protocols
used when scanning a 10 year old patient are given in Tables 3.1 and 3.10 and these were
used as input parameters for the various computational methods. In the experimental
method, the CT brain examination was performed with a tilted gantry to minimise dose
to the lens of the eye. It was not possible to simulate this in many of the computational
methods and instead the dose estimates were made with the axis of rotation parallel to
the long axis of the phantom where necessary.
The scan lengths for all examinations were defined by matching the anatomical regions
exposed on the physical phantom with the same regions on the computational phantoms
(Table 5.2). The inferior slice of the brain examination extended between the supraorbital
ridge and first cervical vertebra and the scan continued to just beyond the vertex, the
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chest examination included the entire thorax and half of the liver and the abdomen/pelvis
examination began slightly superior to the diaphragm and ended at the symphysis pubis.
Each of the phantoms is shown in Figure J.1 (Appendix J) with scan regions indicated for
the three CT examinations. The reference patient considered in the dose estimates was a
10 year old child, or the next closest age where this was not available.
Method 1: Experimental Method - TLD Measurements
Organ and tissue absorbed doses were measured and reported in Chapter 3 using TLDs
placed in a physical anthropomorphic phantom representing a 10 year old child. All
experimental measurements were undertaken at the Royal Children’s Hospital (RCH)
Melbourne on a Siemens Sensation 16 MDCT scanner. Effective dose was estimated from
the absorbed dose measurements as described in Chapter 3 using both ICRP 60 and
ICRP 103 tissue weighting factors.
Methods 2 and 3: ImPACT and CT-Expo - CT Dose Calculators
Organ and tissue absorbed doses and effective doses were derived using ImPACT (Im-
PACT, 2011) and CT-Expo (Stamm and Nagel, 2011b). Since the NRPB data set utilised
by ImPACT was generated using a mathematical phantom representing an adult, paedi-
atric modifying factors (Khursheed et al., 2002) derived from Monte Carlo modelling using
the ORNL Cristy and Eckerman (1987) mathematical phantoms representing children were
applied when calculating effective dose. The paediatric modifying factors only apply to
the effective dose and hence the organ and tissue absorbed doses were determined from
the adult phantom, although paediatric factors for the kilovoltage, tube current and rota-
tion time were used. In CT-Expo organ and tissue absorbed doses and gender-averaged
effective dose were calculated using the GSF voxel phantom representing the seven year
old child (Veit et al., 1989; Zankl et al., 1993, 1995). Both ImPACT and CT-Expo provide
effective dose estimates using the ICRP 60 and ICRP 103 Recommendations.
Method 4: PCXMC - Radiography Dose Calculator
A dose calculator called PCXMC Dose Calculations (STUK, 2008) designed for two-
dimensional (2D) radiography and fluoroscopy applications (Tapiovaara and Siiskonen,
2008) was used to simulate the CT examinations using multiple 2D projections. PCXMC
is a PC-based program, which runs a Monte Carlo simulation based on an X-ray beam
projection and other user specified examination conditions, including the X-ray spectrum,
to calculate organ and tissue absorbed doses and effective dose. Twenty projection angles
using a beam collimation equivalent to the total CT scan region were summed to simulate
a 360 degree rotational CT scan. A large focal to source distance was used to produce uni-
directional photons, allowing greater control over the defined scan volume. The beam was
angled to simulate the tilted gantry for the CT brain examination. PCXMC runs Monte
84
CHAPTER 5. COMPUTATIONAL DOSIMETRY
Table 5.1: Summary of organ and effective dose derivation methods and quantities
compared in this thesis.
Method Toola Phantom ICRP
Publicationc
Quantity
Typeb Representative
Age
Measurementd TLD Physical 10 yo ICRP 60 ETLD,60
ICRP 103 ETLD,103
ImPACTe ,f MC Stylised ORNL Adult ICRP 60 EImPACT,60
ICRP 103 EImPACT,103
CT-Expoe ,g MC Voxel GSF 7 yo ICRP 60 EEXPO,60
ICRP 103 EEXPO,103
PCXMCe ,h MC Stylised ORNL 10 yo ICRP 60 EPCXMC,60
ICRP 103 EPCXMC,103
Lee et al.e ,i MC Stylised ORNL 10 yo ICRP 60 EORNL,60
Voxel UF 11 yo ICRP 60 EUF,60
Li et al.e ,j MC Hybrid Patient specific ICRP 103 ELi,103
Turner et al.e ,k MC Voxel GSF Patient specific NAf NAf
k coefficiente ,l MC Stylised ORNL 10 yo ICRP 60 EDLP,60
Deak et al.e ,m MC Stylised ORNL 10 yo ICRP 60 EDEAK,60
ICRP 103 EDEAK,103
Chapple et al.e ,n TLD Physical 10 yo ICRP 60 ECHAPPLE,60
kw coefficient
e ,o MC Stylised ORNL 10 yo ICRP 60 ECTDI,60
a Tool used for dose calculation: either thermoluminescence dosemeters (TLD) or Monte Carlo (MC)
modelling.
b Phantom types including physical or stylised (mathematical), voxel and hybrid computational
phantoms developed by various groups including the Oak Ridge National Laboratory (ORNL)
(Cristy and Eckerman, 1987), German National Research Centre for Environment and Health
(GSF) (Veit et al., 1989; Zankl et al., 1993, 1995), and University of Florida (UF) (Lee et al.,
2006c).
c The ICRP Publication used for calculation of effective dose.
d Experimental method.
e Computational methods.
f ImPACT Dose Calculator (ImPACT, 2011).
g CT-Expo Dose Calculator (Stamm and Nagel, 2011b).
h PCXMC Dose Calculator (STUK, 2008).
i Lee et al. (2007a).
j Li et al. (2011a).
k Turner et al. (2011) provide a method for organ dose estimation only, not effective dose.
l Shrimpton et al.(2006).
m Deak et al. (2010).
n Chapple et al. (2002).
o Shrimpton (2004).
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Table 5.2: Scan length parameters for the computational and physical phantoms.
Examination CT-Expoa ImPACTa PCXMC TLDb
Start End Length
(cm)
Start End Length
(cm)
Length
(cm)
Length
(cm)
CT Brain 48.0 63.0 15.0 80.0 94.0 14.0 13.0 16.0c
CT Chest 24.0 43.0 19.0 37.5 69.5 32.0 25.0 26.6
CT
Abdomen/Pelvis
4.00 30.0 26.0 6.00 46.0 40.0 30.0 36.9
a Start and End scan length parameters for CT-Expo and ImPACT are input parameters specific
to these CT dose calculators.
b The average scan length was calculated from a series of three CT examinations using identical
protocols performed on the TLD loaded physical anthropomorphic phantom representing a 10
year old child (see Table 3.11).
c The scan length for the tilted brain scan on the CT scanner is taken as the length perpendicular
to the beam axis. This is not the actual length scanned on the patient.
Carlo simulations using mathematical hermaphrodite phantoms based on the ORNL Cristy
and Eckerman phantoms (1987), with some modifications that improve the head and neck
modelling, correct the thyroid location and model organs and tissues specified in ICRP
103 (Tapiovaara and Siiskonen, 2008). Absorbed doses were calculated using the phantom
representing a 10 year old child. PCXMC provides effective dose estimates using both
ICRP 60 and ICRP 103 definitions.
Methods 5 and 6: Lee et al. (2007a) ORNL 10 yo and UF 11 yo mAs-
Normalised Doses
Lee et al. (2007a) provide mAs-normalised organ and tissue absorbed doses and effective
dose for several types of CT examinations based on Monte Carlo simulations using a
range of ORNL mathematical (Cristy and Eckerman, 1987) and the University of Florida
(UF) patient-specific voxel phantoms (Lee et al., 2006c). The computed doses used for the
assessment in this thesis were based on simulations using the ORNL phantom representing
a 10 year old child and the UF phantom representing a male 11 year old child (Table K.1,
Appendix K). The same CT scanner and kVp considered in this thesis were used in the
simulations by Lee et al. (2007a). The beam collimations for the current protocols were
wider (18 mm for brain examinations and 24 mm for body examinations), compared with
the simulated 12 mm beam in the other study. However, Lee et al. (2007a) concluded
that organ and effective dose did not vary significantly for different beam collimations.
Li et al. (2011a) also support this finding for organ absorbed doses in the scan volume,
although they also observe that collimation can have an effect on organs located at the
edge of scan, likely due to over-ranging for helical scans. Effective dose was calculated by
Lee et al. (2007a) using the ICRP 60 formalism, modified to produce a gender-specific
estimate according to the methodology of Zankl et al. (2002).
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Method 7: Li et al. (2011a) CTDIvol-Normalised, Size-Specific Doses
Organ and tissue absorbed doses for the CT chest examination were calculated according
to a relationship suggested by Li et al. (2011a) derived from Monte Carlo modelling
using multiple patient-specific hybrid phantoms (Li et al., 2011b,c). They found that the
CTDIvol-normalised organ and tissue absorbed dose (in terms of the 16 cm dosimetry
phantom) (nHT (dchest)) is given by (Li et al., 2011a):
nHT (dchest) =
e(αT dchest+βT )
12.19
(5.1)
where αT and βT are organ specific fitting parameters provided in Table K.2 (Appendix K)
and dchest is the average chest diameter between the lung apex and base. For the calculated
absorbed doses in this thesis, the chest diameter of the physical phantom (21 cm) from the
experimental method was used. Equation (5.1) was used to calculate the absorbed dose for
all organs specified by Li et al. (2011a), although it is recognised that the correlation with
chest diameter is only strong for large organs (e.g. lung) and centrally located tubular
organs (e.g. oesophagus) inside the scan volume. The correlation is weaker for small
organs inside the scan volume (e.g. thyroid and breast) and organs on the periphery or
outside the scan volume (e.g. liver and small intestine) and distributed organs (e.g. bone
surface and red bone marrow).
Effective dose normalised to DLP (k) as a function of the average chest diameter (dchest)
was calculated according to (Li et al., 2011a):
k (dchest) = e
(αkdchest+βk) (5.2)
where αk = −0.093 cm−1 and βk = −2.01. This conversion coefficient is based on effective
dose calculated according to the ICRP 103 definition.
Method 8: Turner et al. (2011) CTDIvol-Normalised, Size-Specific Doses
Organ absorbed doses were calculated for fully irradiated organs in the CT abdomen/pelvis
examination using the size-corrected, scanner-independent organ absorbed dose estimates
provided by Turner et al. (2011). They found through Monte Carlo simulations using
a range of computational anthropomorphic phantoms and different scanner models that
the CTDIvol-normalised organ absorbed dose (in terms of the 32 cm dosimetry phantom)
averaged over different scanner models
(
nD¯P,O
)
can be given by (Turner et al., 2011):
nD¯P,O = A0e
(B0×perimeter) (5.3)
where P refers to the phantom model, O to the organ and the perimeter (in cm) is defined
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at the central slice for the abdomen component of the scan. The parameters A0 and B0
are given in Table K.3 (Appendix K). The abdomen perimeter for the physical phantom
used in this thesis was 59 cm. The method by Turner et al. (2011) does not provide an
estimate of effective dose.
Methods 9-11: DLP to Effective Dose Conversion Coefficients
The effective dose (E) for each examination was estimated from the DLP (Table 3.11) us-
ing anatomy- and age-dependent conversion coefficients, k (mSv·mGy−1·cm−1), according
to:
E = k ·DLP (5.4)
Three different sets of conversion coefficients were utilised. Firstly, the widely employed
conversion coefficients (Khursheed et al., 2002; Shrimpton et al., 2006) derived using Monte
Carlo dose estimates based on the Cristy and Eckerman (1987) paediatric mathematical
phantoms were used (Table K.4, Appendix K). These conversion coefficients are applicable
to effective dose estimates according to ICRP 60 only.
Secondly, Deak et al. (2010) have recently provided sex- and age-specific conversion coef-
ficients as a function of X-ray tube voltage for effective dose estimates for both ICRP 60
and ICRP 103 definitions. The coefficients for estimating effective dose for a 10 year
old child undergoing CT examinations at 120 kVp (Table K.5, Appendix K) have been
utilised in this thesis. These coefficients were derived from Monte Carlo modelling of an
MDCT scanner and the ORNL Cristy and Eckerman (1987) mathematical phantoms with
modifications to incorporate organs and tissues specified in ICRP 103. It should be noted
that Deak et al. (2010) were not recommending the replacement of existing conversion
coefficients, but aimed to provide information regarding voltage-, age- and sex-dependency
using modelling of a specific CT scanner.
Finally, Chapple et al. (2002) proposed a size dependent equation for determining DLP
conversion coefficients (k) for children undergoing CT examinations, given by:
k = y0 +A1e
−x/t1 (5.5)
where y0, A1 and t1 are fitting parameters given in Table K.6 (Appendix K) and x is the
height of the patient for head examinations or equivalent diameter of the region being
scanned for body examinations. The equivalent diameter is calculated from both height
and weight and therefore takes into account density, which may provide a better corre-
lation with energy imparted than the perimeter (Lindskoug, 1992). For the calculated
effective doses in this thesis, the dimensions of the physical phantom from the experi-
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mental method were used. The height of the physical phantom was 140 cm (including
legs, which were not physically present on the phantom) and the equivalent diameter was
17 cm (calculated using a height of 140 cm and weight of 32 kg). Equation (5.5) was
derived from TLD measurements made in a range of physical paediatric anthropomorphic
phantoms (representing neonate, 1, 5, 10 and 15 year old children). This effective dose
estimate is based on the ICRP 60 definition.
Method 12: CTDIw to Effective Dose Conversion Coefficients
An alternative method proposed by Shrimpton (2004) for estimating the effective dose for
axial scans from CTDIw rather than DLP was also used. In this model, the effective dose
(E) using the ICRP 60 formalism is calculated according to (Shrimpton, 2004):
E = kw · CTDIw (5.6)
where kw is a conversion coefficient with units mSv·mGy
−1 as given in Table K.7 (Ap-
pendix K). It follows for helical scans that since the dose is inversely proportional to pitch
(Goldman, 2008; McCollough and Zink, 1999), effective dose may be calculated using equa-
tion (5.6) and substituting CTDIvol for CTDIw since CTDIvol is calculated by dividing
CTDIw by the helical pitch.
5.4 Results
The mean organ and tissue absorbed doses measured with TLDs have previously been
presented in Table 3.12. Comparison of the measured and computed organ and tissue
absorbed doses are provided in Figure 5.1 for a paediatric CT brain examination, Figure 5.2
for a paediatric CT chest examination and Figure 5.3 for a paediatric CT abdomen/pelvis
examination. The largest disparities between the measured and computed absorbed doses
were for the salivary glands and oral mucosa resulting from the CT brain examination
(up to a 15-fold difference). This was also found for the same tissues for the CT chest
examination, although the difference was smaller (up to a 4-fold difference). For the
CT abdomen/pelvis examination the computed absorbed doses to the testes showed the
greatest variation from the measured absorbed doses (up to a 7-fold difference).
Overall, computed absorbed doses to organs and tissues fully and directly irradiated on all
phantoms demonstrated the best agreement with the measured absorbed doses. For the
CT brain examination the maximum variation of the computed absorbed dose to the brain
from the measured absorbed dose was 31% resulting from the CT-Expo calculation. For
the CT chest examination the maximum variation from the measurements was 18% for
the lung (PCXMC), 14% for the thymus (PCXMC and Li 2011), 24% for the oesophagus
(UF 11 yo), 32% for the heart (Li 2011) and 31% for the breast (PCXMC).
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The CT abdomen/pelvis examination included several fully and directly irradiated organs
in the scan volume. The greatest variation in the calculated absorbed doses compared
with the measured absorbed doses was 26% for the liver (ORNL 10 yo), 19% for the spleen
(ORNL 10 yo), 24% for the stomach (ORNL 10 yo), 14% for the gall bladder (ImPACT),
26% for the adrenals (Turner 2011), 32% for the pancreas (ORNL 10 yo), 16% for the
kidneys (ORNL 10 yo), 49% for the small intestine (ORNL 10 yo), 45% for the colon
(UF 11 yo), 19% for the uterus (CT-Expo), 25% for the ovaries (CT-Expo), 18% for the
bladder (ImPACT) and 38% for the prostate (CT-Expo). The largest differences between
measured and computed absorbed doses were mainly seen in the calculations using the
ORNL 10 year old phantom.
Absorbed doses to organs and tissues that were partially irradiated on the edge of the
scan volume showed larger variation between the methods. For example, the maximum
variation from the measured absorbed dose was 190% for the lens of the eye computed
absorbed dose for the CT brain examination (CT-Expo), 84% for the thyroid computed
absorbed dose for the CT chest examination (PCXMC) and 77% for the lung computed
absorbed dose for the CT abdomen/pelvis examination (PCXMC). Similarly, extended
tissues, such as the skin, muscle, bone marrow and bone surface, demonstrated larger
variance in dose. For example, the greatest deviation in the computed skin absorbed dose
from the measured value was 125% for the CT brain examination and 118% for both the
CT chest and abdomen/pelvis examinations. The maximum variation in skin absorbed
dose was due to the CT-Expo calculation for all three types of CT examination.
The values of effective dose estimated from the experimental and computational methods
are given in Table 5.3. The effective dose according to ICRP 60 ranged from 1.5-2.5 mSv for
the CT brain examination, 3.0-4.7 mSv for the CT chest examination and 4.3-5.7 mSv for
the CT abdomen/pelvis examination (excluding the adult ImPACT doses). The effective
dose according to ICRP 103 ranged from 1.4-2.3 mSv for the CT brain examination,
3.6-6.2 mSv for the CT chest examination and 3.9-5.4 mSv for the CT abdomen/pelvis
examination (excluding the adult ImPACT dose). The range of effective dose values is
shown in Figure 5.4.
The values of effective dose using the ICRP 60 methodology were normalised to ETLD,60
and are shown in Figure 5.5. Similarly, the calculated ICRP 103 effective dose values
relative to ETLD,103 are shown in Figure 5.6. For the ICRP 60 formalism, the effective doses
estimated from the computational methods varied from the effective doses determined from
the absorbed dose measurements by -30% to 35% and for the ICRP 103 methodology the
variation was -29% to 41%. Table 5.4 gives the DLP to effective dose conversion coefficients
calculated by dividing the computed effective dose by the DLP values given in Table 3.11
for all methods investigated.
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Table 5.3: Values of effective dose from the experimental and com-
putational methods investigated.
Quantity Effective Dose (mSv)
CT Brain CT Chest CT Abdomen/Pelvis
ETLD,60 1.8 4.3 5.0
EImPACT,60 1.6 (1.9-2.1)
a 3.3 (3.6-4.6)a 3.8 (4.6-5.7)a
EEXPO,60 2.5 4.7 5.3
EPCXMC,60 1.8 4.4 4.6
EORNL,60 2.0 3.4 4.8
EUF,60 1.9 3.0 4.9
EDLP,60 2.0 4.1 5.3
EDEAK,60 1.5 3.3 4.5
ECHAPPLE,60 2.3 3.6 4.7
ECTDI,60 1.7 3.1 4.3
ETLD,103 1.4 5.0 4.8
EImPACT,103 1.8 (2.2-2.3)
a 4.0 (4.4-5.6)a 3.6 (4.3-5.4)a
EEXPO,103 2.0 5.3 5.1
EPCXMC,103 1.4 5.3 4.1
ELi,103 - 6.2 -
EDEAK,103 1.7 3.6 3.9
a ImPACT recommends scaling the effective dose calculated for the adult by
paediatric scaling factors derived by Khursheed et al. (2002). A range is
provided for the recommended factors and the bracketed terms in the Table
above represent the lower and upper limits of this range for a 10 year old
child.
5.5 Discussion
For medical exposures, the risk to an individual is assessed from the mean absorbed dose
to radiosensitive organs and tissues, since the probability of cancer induction depends
on the anatomy exposed, the level of exposure and the age and gender of the individual
(ICRP, 2007c). The homogeneity of absorbed dose in an organ or tissue depends on the
exposure situation and also the size or physical distribution of that organ or tissue. For CT
examinations, the exposure is a partial irradiation of the body which leads to heterogeneity
of the absorbed dose distribution in some organs and tissues, particularly those that are
not completely located within the scan volume. Furthermore, distributed tissues such as
the skin and bone marrow will always exhibit a varying absorbed dose distribution for CT
examinations due to the nature of the exposure. These factors contribute to the difficulty
and variability in CT organ dosimetry.
The exposure risk will also depend on the type of radiation, expressed by the equivalent
dose (ICRP, 2007b), although for CT examinations this is numerically equal to the ab-
sorbed dose. The effective dose reflects the combined detriment from the risk of stochastic
effects in different organs and tissues averaged over all ages and both sexes. The ICRP
makes recommendations regarding radiation and tissue weighting factors, which are re-
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Table 5.4: Calculated DLP to effective dose conversion coefficients.
k (mSv/mGy·cm)a CT Brain CT Chest CT Abdomen/Pelvis
ETLD,60/DLP 0.0029 0.014 0.014
EImPACT,60/DLP 0.0025 (0.0030-0.0033)
b 0.010 (0.011-0.015)b 0.011 (0.013-0.016)b
EEXPO,60/DLP 0.0039 0.015 0.015
EPCXMC,60/DLP 0.0028 0.014 0.013
EORNL,60/DLP 0.0031 0.011 0.014
EUF,60/DLP 0.0030 0.009 0.014
EDLP,60/DLP 0.0032 0.013 0.015
EDEAK,60/DLP 0.0023 0.010 0.013
ECHAPPLE,60/DLP 0.0036 0.011 0.013
ECTDI,60/DLP 0.0026 0.010 0.012
ETLD,103/DLP 0.0022 0.016 0.014
EImPACT,103/DLP 0.0028 (0.0034-0.0037)
b 0.013 (0.014-0.018)b 0.010 (0.012-0.015)b
EEXPO,103/DLP 0.0031 0.017 0.014
EPCXMC,103/DLP 0.0022 0.017 0.012
ELi,103/DLP - 0.020 -
EDEAK,103/DLP 0.0027 0.011 0.011
a The conversion factors (k) were calculated by dividing the effective dose by the dose length product
(DLP) obtained from the CT examinations using the physical phantom representing a 10 year old
child. The DLP values were 640 mGy·cm, 317 mGy·cm and 350 mGy·cm for the CT brain, chest and
abdomen/pelvis examinations respectively. These DLP values are all relative to the 16 cm dosimetry
phantom. The conversion coefficients can be multiplied by a factor of approximately 2 to give
coefficients relative to the 32 cm dosimetry phantom for the body examinations.
b ImPACT recommended paediatric scaling factors (Khursheed et al., 2002) used and range is shown in
brackets.
vised to take account of new scientific information regarding the biological effectiveness of
radiation and tissue and organ radiosensitivity. Recommendations in ICRP Publication
60 (ICRP, 1991) have been in use for about 20 years and these have been recently revised
in ICRP Publication 103 (ICRP, 2007b).
In the diagnostic radiology clinical environment, it is beneficial to estimate both absorbed
dose and effective dose from CT examinations for assessment of risk and to reduce dose.
Furthermore, the BEIR VII Report (NRC, 2006) has highlighted the need for epidemiolog-
ical research studies, especially to follow-up children receiving CT scans. Several studies
investigating the effects of low dose radiation have commenced (Bernier et al., 2012; Brady
et al., 2011f; Hricak et al., 2011; Pearce et al., 2011) and these require reconstruction of
paediatric CT doses. Therefore, CT dose calculation methods that are applicable to chil-
dren are required in both the clinical and research contexts.
Several methods of estimating CT dose have been investigated in this thesis. Actual
clinical scenarios have been evaluated by using typical CT protocols that a 10 year old
child may undergo at a children’s hospital. As the tools assessed here are often used for
dose assessment, it is useful to examine the extent of the differences between the methods
when calculating paediatric CT doses. There are several important influencing factors on
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the measured and calculated absorbed doses that need to be considered. These include
the models used to represent the organs and their position in the body, the type/model of
CT scanner being used and/or modelled in the calculation and the scan parameters used
in simulating the X-ray exposure. It should be noted that the clinical conditions could
not be matched exactly in the computational methods and therefore, various assumptions
and approximations had to be made. Consequently, the variables associated with each
method could not be strictly controlled, but rather the conditions that have been used for
each method provide the best match to the clinical scenario.
5.5.1 Patient Modelling
The most significant difference between the various methods is due to the phantom used
to model the patient. The PCXMC computational phantom is the closest model in age
and size to the physical phantom used for the experimental measurements. However,
the elemental compositions of these phantoms differ and are shown in Figure E.1 and
Table E.2 (Appendix E). The dimensions of the PCXMC and CT-Expo child phantoms
are compared in Table E.3 (Appendix E) with dimensions of the physical phantom used
for TLD measurements. In addition to the differences in composition and overall size
between the phantoms, there are other internal disparities such as the location of organs
that will also affect dose estimates.
Organ Positioning
Differences between phantoms in terms of organ depth, the exterior shape of the trunk of
the phantom and diameter relative to the incoming radiation beam will affect the dose (Lee
et al., 2007a; Zankl et al., 2005). As summarised in Table 5.1, the methods investigated
utilise physical, stylised (or mathematical), voxel and hybrid phantoms representing 7-11
year old children and an adult to which paediatric scaling factors were applied. Even
for the voxel and hybrid phantoms where the organ masses are scaled to represent a
reference person, some of the organ topology of the individual whose images were originally
segmented to construct the phantom will remain (ICRP, 2009). Therefore, it is expected
that some variation in the calculated doses will be evident and, in fact, unavoidable across
the different methods.
The thyroid and ET region absorbed doses for the CT chest examination demonstrate a
wide variation between the dosimetry methods. Lee et al. (2011) have previously identified
that the vertical placement of the thyroid can lead to significant differences in absorbed
dose estimates. In the mathematical phantoms the thyroid is located in the neck region,
whereas for other phantoms including the physical and UF phantoms, it is partially in
the upper trunk region. In this more realistic anatomy, the thyroid will also receive some
shielding from the clavicles and scapulae (Lee et al., 2007a), but may also be directly
irradiated in a chest examination leading to variations in the dose calculation.
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Abdominal organs such as the adrenals, pancreas and kidneys are typically positioned
higher in the earlier phantom models (Lee et al., 2011). Therefore, for the CT chest
examination (Figure 5.2), the computed absorbed doses to these organs using the earlier
mathematical phantoms tend to be higher compared with the other methods. For this
exposure situation when these organs are located higher within the phantom model, they
are closer to the direct scan volume or are even positioned partially within it leading to
the higher absorbed doses.
The location of the testes can also lead to a difference in absorbed dose, which is evident
in Figure 5.3 for the CT abdomen/pelvis examination. The testes location can vary
between phantoms relative to the mid-femoral neck (Lee et al., 2011). Therefore, if the
scan extends to the mid-femoral neck anatomical landmark, the testes may be fully or
partially irradiated or even outside the scan region depending on the phantom. Lee et al.
(2007a) also comment that the depth of the testes between the legs can lead to a greater
shielding effect for lateral projections in some phantoms. This shielding is observed in
the lower absorbed dose to the testes in the UF 11 year old phantom compared with
the ORNL 10 year old phantom where the scan length extended to mid-testes on both
phantoms (Figure 5.3). For the other methods, the testes are predominantly outside of
the scan volume.
In addition, the overall size of a phantom will affect the absorbed dose to organs outside of
the scan volume. In smaller phantoms, such as the one used in CT-Expo which represents
a seven year old child, the closer relative proximity of organs to the scanned volume will
increase doses. On the other hand, for an adult phantom, as in ImPACT, these organs will
be further away from the directly irradiated area (see for example the kidney absorbed
doses in Figure 5.2).
Organ Absorbed Dose Substitution
Some of the phantoms do not model all organs and tissues listed in ICRP 60 and ICRP 103
and often other organ absorbed doses are used as a substitute to approximate these doses.
For example, for measurements made in the physical phantom, the thyroid absorbed dose
approximated the absorbed dose to the ET region. An example in ImPACT is for the
salivary gland and oral mucosa absorbed doses, which are approximated by the brain
absorbed dose (ImPACT, 2011). In CT-Expo the absorbed dose to the heart is not cal-
culated or included in the effective dose calculation as conversion factors are not available
for determining the absorbed dose to this organ for the child phantomii.
The effect of organ absorbed dose substitution can be seen in Figure 5.1 in the high
absorbed doses assigned to the salivary glands and oral mucosa in the ImPACT calculations
for the CT brain examination. As the experimental method demonstrates, the absorbed
iiG.Stamm [Institute of Diagnostic and Interventional Radiology, Germany] 2011, pers. comm., 29
September.
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dose to these tissues is in fact considerably less than the brain absorbed dose. This will
also influence the effective dose estimate.
For all dosimetry methods, except for ImPACT and Deak et al. (2010), the effective
dose for a CT brain examination using ICRP 103 tissue weighting factors is lower than
the estimate using the ICRP 60 tissue weighting factors. This is due to the lower tissue
weighting factor allocated to the brain using ICRP 103. However, by substituting the
brain absorbed dose for the salivary glands and oral mucosa absorbed doses in ImPACT,
the ICRP 103 effective dose for a CT brain examination is incorrectly higher than the
ICRP 60 effective dose. This is because the inappropriately high absorbed doses allocated
to these tissues are only included in the ICRP 103 effective dose estimate and not the
ICRP 60 effective dose.
The effective dose for a CT brain examination derived using the Deak et al. (2010)
conversion factors also demonstrates an increase between the ICRP 60 effective dose and
ICRP 103 effective dose. However, for the ICRP 60 effective dose calculation it appears
that the remainder splitting rule has not been applied and hence the brain has been
considered a remainder organ when it should have been allocated a tissue weighting factor
of 0.025 rather than 0.005. This consequently underestimates the ICRP 60 effective dose
for the CT brain examination. A more detailed discussion of the effects of the changed
tissue weighting factors in ICRP 103 on paediatric CT doses is given in Section 3.4.2
(Chapter 3).
5.5.2 CT Scanner Modelling
Another significant difference, which applies to the scanner dependent methods assessed in
this thesis, is the type of CT scanner that was modelled in the dose calculations. ImPACT
and CT-Expo both use methods of scanner matching to allow dose estimates for scanners
which were not modelled in the original Monte Carlo data sets. PCXMC is not designed
for CT dose estimates and therefore it was necessary to simulate the CT X-ray spectra
using appropriate filtration. However, this did not take into account the shaped beam filter
used in most modern scanners, which likely led to the wider variation in organ absorbed
doses calculated with PCXMC.
The CT scanner used for the TLD measurements in this thesis has a Straton X-ray tube
(Siemens, Erlangen, Germany). The ImPACT dose calculator demonstrates that the out-
put in air at the isocentre using the body filter is 12% higher at 120 kVp and 24 mm
beam collimation for the Straton tube compared with earlier Siemens X-ray tubes (Im-
PACT, 2011). The CTDIw is 9% higher for the Straton tube using the same exposure
conditions. Although the dose conversion coefficients provided by Lee et al. (2007a) are
based on Monte Carlo simulations with the same type of CT scanner as used for the TLD
measurements in this thesis, it is not clear whether a Straton X-ray tube was used. Simi-
larly, CT-Expo does not explicitly mention the Straton tube and therefore it is not clear
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whether it has been considered.
Geleijns et al. (1994) have previously compared the NRPB (ImPACT) and GSF (CT-
Expo) data sets and found that only the NRPB data set models the shaped beam filters
typically used in CT scanners. This leads to significant differences in the organ absorbed
dose conversion factors between the two data sets. In CT-Expo a further scanner specific
correction factor (kCT ) is applied to the GSF data set conversion factors to take into
account differences in scanner geometry, beam filtration and beam-shaping (Brix et al.,
2004; Nagel, 2002). For the Siemens Sensation 16 CT scanner, this correction factor is 0.9
(Brix et al., 2004; Nagel, 2002; Stamm and Nagel, 2011b).
The modelling provided by Li et al. (2011a) and the conversion coefficients produced by
Deak et al. (2010) are both derived from Monte Carlo modelling of 64 MDCT scanners.
The other DLP and CTDI conversion methods (Chapple et al., 2002; Shrimpton et al.,
2006; Shrimpton, 2004) attempt to provide more generic conversion coefficients by aver-
aging over several scanners. Turner et al. (2011) investigated the feasibility of scanner
independent conversion factors, although these are currently limited to organs in the scan
region for an abdominal examination.
To assess differences resulting from the CT scanner modelling, the output of the scanners in
the CT dose calculators ImPACT and CT-Expo were compared with the output measured
on the CT scanner used for the TLD measurements. Measurements of CTDI100 were
made in air (CTDI100,air) at the isocentre with a calibrated 3 cm
3 Radcal ion chamber
with 100 mm length, model 10X5-3CT and a model 9095E electrometer (Radcal Corp.,
Monrovia, California, US) for various beam collimations and utilising both the inherent
head and body filters. The ImPACT CTDI100,air values are available for all scanners
included in the dose calculator. A correction factor for beam collimation is provided to
calculate CTDI100,air values relative to those for a 10 mm beam collimation.
The CTDI100,air values are not as readily accessible in CT-Expo, although they can be
calculated from the normalised CTDIw values which are provided with respect to the head
(H) and body (B) CT dosimetry phantoms (nCTDIw,H/B), as follows (Brix et al., 2004;
Nagel, 2002):
nCTDI100,air =
nCTDIw,H/B
PH/B
(5.7)
where PH/B represents “phantom factors” defined by the above CTDI ratio. A reference
value is used in the CT-Expo dose calculator (nCTDIw,H/B,ref) and corrections applied
for different slice collimations (kOB) and voltages (U) from the reference conditions. The
reference conditions for the Siemens Sensation 16 scanner are 120 kVp and 24 mm beam
collimation (Brix et al., 2004; Nagel, 2002; Stamm and Nagel, 2011b). For any other
combination of parameters, the weighted CTDI is defined as (Brix et al., 2004):
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nCTDIw,H/B = nCTDIw,H/B,ref · kOB ·
(
U
Uref
)2.5
(5.8)
The slice collimation factor (kOB) corrects for both differences in the collimation and
for over-beaming effects. Therefore, equations (5.7) and (5.8) can be used to calculate
nCTDIair.
A comparison of the ImPACT and CT-Expo CTDI100,air values with the measured values
is given in Table 5.5. For the CT chest and abdomen/pelvis examinations assessed in this
thesis, a 24 mm beam collimation was used. However, this collimation is only available
in helical mode and therefore could not be replicated in axial mode for the CTDI100,air
measurement. The next widest collimation width was assessed (18 mm). For ImPACT
there is better agreement for the 10 mm collimation over all voltages than for the other
collimation widths. The 10 mm collimation is the reference condition in ImPACT. For
the wider beam collimations used for the examinations in this thesis, it does appear that
the ImPACT CTDI100,air values will be slightly higher. The converse is true for CT-Expo.
There is better agreement with the measurements for the wider collimations. For CT-Expo
the reference condition is 24 mm. However, it is interesting to note that for the measured
values and ImPACT the CTDI100,air values increased with changing beam collimation from
10 mm to 18 mm while the voltage remained constant, whereas CT-Expo demonstrated a
decrease in CTDI100,air for these beam collimations.
Table 5.5: Comparison of measured CTDI100 values with ImPACT and CT-
Expo for various kVp and beam collimations.
Filter kVp Beam Collimation
(mm)
CTDI100 in Air (mGy/100 mAs)
Measured ImPACTa CT-Expoa,b
Head 120 10 23.3 24.3 (4%) 28.1 (21%)
120 18 25.8 28.4 (10%) 25.2 (-2%)
Body 80 10 5.5 5.7 (4%) 7.2 (30%)
100 10 10.6 10.9 (3%) 12.5 (18%)
120 10 16.5 17.2 (4%) 19.7 (20%)
120 18 18.2 20.1 (11%) 17.7 (-3%)
120 24 - 19.1 17.0
a Percentage difference from the measured values is shown in brackets.
b The kOB factors are 1.16, 1.04 and 1.00 for 10 mm, 18 mm and 24 mm beam
collimations, respectively. The phantom factor (PH/B) is 0.76 for the head filter and
0.77 for the body filter for examinations on a child (Stamm and Nagel, 2011b).
Values for the normalised CTDIw calculated from the dose indicators displayed on the CT
scanner for the TLD measurements and provided in ImPACT and CT-Expo are given in
Table 5.6 for the three types of paediatric CT examinations investigated. ImPACT displays
CTDIw values, but uses only CTDIair to calculate organ and effective dose. The CTDIw
value is used to calculate the DLP, which ImPACT also displays for information, although
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it is not used in the dose calculations. CT-Expo uses CTDIw for organ and effective dose
calculations. The differences in the CTDIw values for the CT brain examination may be
due to the tilted gantry, which is not simulated in ImPACT or CT-Expo. For the body CT
examinations of the chest and abdomen/pelvis, the CT scanner and ImPACT normalised
CTDIw are both relative to the 32 cm dosimetry phantom, whereas the CT-Expo values
are relative to the 16 cm dosimetry phantom. The CT-Expo values have been divided
by a factor of two to allow comparison. All CTDIw values for the body examinations are
within 10% of the scanner displayed values. The ImPACT values are slightly higher, while
the CT-Expo values are slightly lower.
Table 5.6: Comparison of CTDIw values from the CT examinations performed on the
physical phantom with ImPACT and CT-Expo values for the same examinations.
Examination CTDIw (mGy/100 mAs)
CT Scannera ImPACTb CT-Expob Scaled CT-Expob ,c
CT Brain 15.4 19.9 (29%) 19.1 (24%) -
CT Chest 7.3 7.8 (7%) 13.1 (79%) 6.6 (-10%)
CT Abdomen/Pelvis 7.1 7.8 (10%) 13.1 (85%) 6.6 (-8%)
a The CT scanner CTDIw values were calculated from CTDIvol·pitch and the mAs displayed during
the CT examinations on the TLD loaded physical phantom representing a 10 year old child. Note
that CTDIvol and mAs values displayed on the CT scanner are an average for the examination
since tube current modulation was employed for each scan.
b Percentage difference from the CT scanner values is shown in brackets.
c The CT-Expo CTDIw values for body examinations on children are relative to the 16 cm
dosimetry phantom. These have been scaled by 0.5 to allow comparison with the scanner
displayed values and ImPACT which are both relative to the 32 cm dosimetry phantom.
The method of matching CT scanners in ImPACT using an ImPACT Factor (ImF ) was
also assessed. The factor is defined by (ImPACT, 2011):
ImF = a
CTDIc
CTDIair
+ b
CTDIp
CTDIair
+ c (5.9)
where the centre and periphery CTDI values (CTDIc, CTDIp) are measured in the CT
dosimetry phantoms at a particular tube voltage and a = 0.4738, b = 0.8045 and c =
0.0752 using a 10 mm beam collimation. The ImF is then matched to the closest ImF
for a scanner in the original Monte Carlo data set. The CTDI values and the matched
data sets are shown in Table 5.7. It is evident that the scanner matching is dependent
on the CTDI values and variations between measurement and ImPACT values which are
averaged values will invariably exist. For this case, different data sets would have been
selected depending on whether measurements on the specific scanner or ImPACT averaged
values were used.
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Table 5.7: Calculation of the ImPACT Factor to enable scanner matching.
Region Method CTDIair CTDIc CTDIp ImPACT
Factor (ImF)
Matched
Data Set(mGy/100 mAs)
Head Measured 23.3 15.5 17.5 0.993 14
ImPACT 24.3 15.6 17.7 0.965 17
Body Measured 16.5 3.6 7.2 0.529 10
ImPACT 17.2 4.3 8.4 0.587 16
5.5.3 Scan Parameters
Tube Current
The scan parameters used to simulate the exposure situation are a further source of vari-
ation between the different methods assessed. For all computational methods a constant
tube current was assumed, whereas the CT examinations on the physical phantom utilised
a range of current values varied during the examination to reduce dose to the patient
while maintaining adequate image quality (Appendix H). For the experimental method,
the ranges of tube current values were 102-379 mA, 112-199 mA and 114-175 mA for the
CT brain, chest and abdomen/pelvis examinations respectively. Using a physical phan-
tom representing a 10 year old child, Brisse et al. (2009b) have shown that modulating
the tube current in the z-direction decreases the absorbed dose to organs in areas of low
attenuation, such as the lungs, but increases the absorbed dose to organs such as the
bladder and ovaries due to the high density pelvic bones. In this thesis, x-y-z tube current
modulation was used, but the effects on organ absorbed doses are likely to be similar to
those noted by Brisse et al. (2009b).
Scan Length
Scan length was another parameter that varied between each of the methods assessed
(Table 5.2). In ImPACT, CT-Expo and PCXMC the scan volume was determined by
matching the anatomy scanned on the physical phantom, rather than using the actual scan
length. This was necessary, in particular for ImPACT where the adult phantom differed
considerably in size to the child physical phantom. Matching anatomy will also lead to
differences in the scan length due to the different placement of some organs between the
various phantoms, as previously discussed. Furthermore, identifying the matching start
and end locations on the mathematical and voxel phantoms in the dose calculators was not
straightforward as many organs are not clearly described for the phantom models. For the
other computational methods used, the scan length was predetermined by the modelling
undertaken in each study and therefore could not be influenced by any selections made in
this thesis. This is likely to have the greatest effect on the dose to organs at the edge of
a scan volume.
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The effect of varying the scan length is best demonstrated by the absorbed dose to the
thyroid from the CT chest examination (Figure 5.2) and the absorbed dose to the testes
from the CT abdomen/pelvis examination (Figure 5.3). The thyroid has been directly
irradiated in the experimental method and in the computational methods using CT-Expo
and based on Li et al. (2011a) and therefore the absorbed doses from these methods are
much higher. Similarly, the CT abdomen/pelvis examination in Lee et al. (2007a) partially
included the testes, resulting in the higher absorbed doses than calculated or measured
in the other methods. Therefore, both the organ placement in a phantom and the scan
length will affect the absorbed dose to organs at the periphery of the imaging. Lechel et
al. (2009) had similar findings regarding organs on the border or partly inside the scan
volume, recommending that organ absorbed dose comparisons between different methods
could only be reliably made for those organs completely irradiated in all phantoms. Li et
al. (2011a) and Turner et al. (2011) confirmed this finding for CT chest and abdomen
examinations respectively.
Over-Ranging
Another important factor that affects the absorbed dose to organs at the start and end
of a scan volume is the additional length included for data interpolation for helical exam-
inations. The “exposed” length is longer than the “imaged” length and depends on the
pitch, beam collimation and reconstruction algorithm (van der Molen and Geleijns, 2007).
For the CT scanner used for the experimental method, the over-ranging length for a pitch
of 1-1.25 is approximately 5-6 cm (van der Molen and Geleijns, 2007), with half of this
length added to each end of the scan. CT-Expo can optionally apply a correction for over-
ranging in helical examinations and for the helical CT protocols assessed in this thesis,
the CT-Expo over-ranging length was 4.8 cm for the chest examination and 5.5 cm for the
abdomen/pelvis examination which had a higher pitch. Figure 3.8 clearly demonstrates
the effects of over-ranging for the helical examinations, where the TLD measurements
show the additional dose outside of the “imaged” scan length. The user can allow for
over-ranging by including additional length in the dose calculation. However, determining
the extra length is complex and currently not displayed on the CT scanner. In PCXMC,
helical examinations could not be simulated and an adjustment was made to the scanner
output to account for the pitch. However, this incorrectly assumed that the scan volume
was uniformly irradiated from all directions by a beam with constant output.
5.5.4 Which Method(s) is Best?
Organ Dosimetry
There are many factors affecting the derivation of organ and tissue absorbed doses and
it was anticipated that differences would exist between the dosimetry methods. However,
these differences should not be considered limitations. Rather, the variation demonstrates
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the non-uniform nature of the human body (the uniqueness of each individual) and the
difficulty in specifying phantoms to be representative of broad populations. Although
reference phantoms are designed to reflect ICRP organ reference masses, the placement of
the organ within the body and the proximity relative to other organs are not standardised
and have an important influence on dose estimates. Furthermore, while in this thesis
computed absorbed doses have been assessed against measured absorbed doses, these
may not equate to the “true” absorbed dose. There is uncertainty associated with the
TLD measurements, limitations due to the number of TLDs used and the design of the
physical anthropomorphic phantom will affect the measured result. In addition, the clinical
conditions such as a tilted gantry, tube current modulation and over-ranging were not
necessarily incorporated into the computational tools. Therefore, the measured absorbed
doses serve as a reference point for comparing the wide range of methods assessed.
In this thesis it was found that there was less variation in the absorbed doses to organs that
are directly and fully irradiated, whereas for organs on the periphery of the scan volume
the dose variation was more pronounced. For the CT brain examination, the brain was
the only directly irradiated organ and the measured and computed absorbed doses were all
within approximately 30%. For the CT chest examination, the calculated absorbed doses
for directly irradiated organs were similarly within approximately 30% of the measured
absorbed doses for all methods. There was slightly more variation in the absorbed doses
for directly irradiated organs and tissues for the CT abdomen/pelvis examination. The
majority of computed absorbed doses were within approximately 30% of the measured
values, except for the absorbed dose to the small intestine, colon and prostate which were
all within 50%. Therefore, for directly irradiated organs all computational methods were
considered suitable for dose estimation.
Although limited to organs that were directly irradiated for a CT abdomen/pelvis exami-
nation only, the scanner-independent CTDIvol-normalised organ absorbed doses provided
by Turner et al. (2011) demonstrated the best correlation with the measured absorbed
doses. These were all within 7% of the measured absorbed doses, except for the adrenals
absorbed dose, which was 26% higher than the measured absorbed dose. Expressing the
measured organ absorbed doses from this thesis as CTDIvol-normalised organ absorbed
doses (in mGy to tissue per mGy of CTDIvol for the 16 cm dosimetry phantom) for
the brain was 0.8 mGy/mGy for the CT brain examination and 0.7-0.9 mGy/mGy for
directly irradiated organs for both the CT chest and abdomen/pelvis examinations (Ta-
bles I.1 to I.3, Appendix I). It may be worthwhile expressing absorbed doses in this way
in the future when comparing different dose estimates.
For absorbed doses to organs and tissues on the periphery of the scanned volume, the
variation in doses was significant. These differences are predominantly due to the notable
variation in organ positioning between phantoms, although the defined scan length also
contributed to the differences in dose. Overall, CT-Expo provided estimates of absorbed
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dose that were closest to the measured values for organs that were located in the neck
and chest regions and on the periphery of the scan volume. This may be due to the
incorporation of the over-ranging length for helical scans in the CT-Expo calculation,
which a user may opt to do manually on other software. Interestingly, for organs located
in the abdomen/pelvis region that were partially irradiated, no one method was better
than the others. This may reflect the influence that organ depth has on dose variability,
since this region can be thicker than other parts of the body and hence organs will be
shielded to a different extent between the phantoms.
For distributed tissues, such as the bone marrow, bone surface, skin, lymph nodes and mus-
cle, there was a wide variability in absorbed dose. Some computational methods provided
estimates that were in good agreement with the measured absorbed doses, although there
was no single method that demonstrated consistently good agreement for all distributed
tissues for a particular type of examination or for a single distributed tissue across the
different examinations. For organs and tissues that were distant to the scan region, there
were also large dose differences. However, the necessity of calculating absorbed doses for
organs that will receive distant scattered radiation exposure should be considered as these
doses are generally very low and in fact negligible when assessing potential stochastic
effects. The ability to reliably calculate these doses is most likely inconsequential.
Effective Dose
The effective dose estimates that were in best agreement with the values derived from the
experimental method across all CT examinations for both ICRP 60 and ICRP 103 defini-
tions of effective dose were those calculated using PCXMC. This was unexpected as the
tool was designed to simulate 2D radiography exposures and does not model various as-
pects of the CT scanner geometry and design. However, it should be noted that the organ
and tissue absorbed doses calculated with PCXMC did not demonstrate the same corre-
lation with the measured absorbed doses. It is likely that the over- and under-estimation
of organ absorbed doses have balanced to provide a reasonably good approximation of
effective dose when compared with measurement. This arises from the weighting applied
to equivalent doses when deriving the effective dose, which means that each organ or tis-
sue absorbed dose only has a partial contribution to the total effective dose. Hence, the
weighted sum used to calculate effective dose to some extent compensates for errors in
organ absorbed dose estimates.
Overall, some of the computational methods overestimated the TLD derived effective
dose and some underestimated the dose. For the body examinations, the computational
methods were more likely to underestimate the dose. Geleijns et al. (1994) found that
calculated effective doses for body examinations on adults were about 40% lower than
effective doses derived from measurement, while Groves et al. (2004) found that the
doses calculated from Monte Carlo modelling were 18% lower. Brix et al. (2004) also
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demonstrated a consistent underestimation of effective dose on MDCT scanners using an
earlier version of CT-Expo compared with effective dose derived from measurement. They
suggested that this was due to the effects of over-ranging which were not incorporated
in most of the dose calculations considered here, but were included in the measurements.
The results in this thesis tend to support this, since CT-Expo effective dose estimates
(which now incorporate over-ranging) for body examinations are in close agreement with
the values derived from measurement. When calculating doses due to helical CT scans,
an estimated additional length should be included to allow for over-ranging when defining
the start and end positions of the scan.
The experimental method employed here is impractical to use routinely in the clinical en-
vironment and some of the computational methods, such as PCXMC, are also not readily
applied as they are time intensive. Overall, the CT dose calculators which were assessed
(ImPACT and CT-Expo) were the most user-friendly and comprehensive methods for cal-
culating CT doses. The simplest, quickest method and the one used most regularly in
radiology practices is the DLP conversion method (Shrimpton et al., 2006). DLP conver-
sion coefficients have been derived from all of the effective doses calculated in this thesis
(Table 5.4). It is not the intention that any of these replace existing values, particu-
larly since they are derived from effective doses calculated for a single examination with
set parameters and the associated value of DLP, but they provide a useful overview and
demonstrate the variable range that may arise depending on the dose calculation method-
ology used. Generally, all of the methods assessed provided an estimate of effective dose
that was within a reasonable range (40%) of the value derived from measurement.
5.6 Conclusions
In this part of the thesis, eleven computational CT dose calculation methods were assessed
and compared with experimental measurements for paediatric CT clinical protocols for a
10 year old patient. Often the clinical scenario is difficult to simulate in the available dose
calculation methodologies and it is useful to assess the reliability of the available tools given
this significant limitation. There was a greater level of consistency between absorbed
doses calculated for organs and tissues completely and directly irradiated in the scan
volume. The greatest disparities were between doses to those organs and tissues partially
irradiated on the periphery of the scan volume. The variation between doses for distributed
organs was found to be lower than expected. Overall, the organ and tissue absorbed doses
demonstrated greater variation than the estimated effective doses. All computational
methods investigated provided an effective dose estimate within approximately 40% of the
effective dose derived from absorbed dose measurements.
Size-dependent functions providing CTDIvol-normalised organ absorbed doses appear to
be one of the most promising calculation methods, particularly as these are scanner inde-
pendent. It will be interesting to see in the future if these methods can be modified to
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apply equally well to organs and tissues that are partially irradiated or distributed through
the body and whether the effects of tube current modulation and an angled gantry can be
accommodated.
5.7 Publications Arising from this Chapter
1. Brady, Z., Cain, T. M. and Johnston, P. N., Comparison of organ dosimetry meth-
ods and effective dose calculation methods for paediatric CT, Australasian Physical
& Engineering Sciences in Medicine, 2012 (published online 11 April 2012) (Brady
et al., 2012b).
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Figure 5.1: Organ and tissue absorbed doses in milligray (mGy) for a paediatric CT brain
examination measured with TLDs placed in a physical phantom representing a 10 year
old child and calculated using ImPACT (ImPACT, 2011), CT-Expo (Stamm and Nagel,
2011b), PCXMC (Tapiovaara and Siiskonen, 2008) and organ conversion coefficients for
the ORNL 10 year old phantom and the UF 11 year old phantom as described by Lee et
al. (2007a). The absorbed dose to the remainder organs and tissues as defined in ICRP
103 is also shown.
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Figure 5.2: Organ and tissue absorbed doses in milligray (mGy) for a paediatric CT
chest examination measured with TLDs placed in a physical phantom representing a 10
year old child and calculated using ImPACT (ImPACT, 2011), CT-Expo (Stamm and
Nagel, 2011b), PCXMC (Tapiovaara and Siiskonen, 2008), organ conversion coefficients
for the ORNL 10 year old phantom and the UF 11 year old phantom as described by Lee
et al. (2007a) and size-specific conversion coefficients provided by Li et al. (2011a). The
absorbed dose to the remainder organs and tissues as defined in ICRP 103 is also shown.
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Figure 5.3: Organ and tissue absorbed doses in milligray (mGy) for a paediatric CT
abdomen/pelvis examination measured with TLDs placed in a physical phantom repre-
senting a 10 year old child and calculated using ImPACT (ImPACT, 2011), CT-Expo
(Stamm and Nagel, 2011b), PCXMC (Tapiovaara and Siiskonen, 2008), organ conversion
coefficients for the ORNL 10 year old phantom and the UF 11 year old phantom as de-
scribed by Lee et al. (2007a) and size-specific conversion coefficients provided by Turner
et al. (2011). The absorbed dose to the remainder organs and tissues as defined in ICRP
103 is also shown.
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Figure 5.4: The range of effective dose values for all measurement and theoretical meth-
ods investigated (excluding adult ImPACT doses) according to ICRP 60 and ICRP 103
methods.
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Figure 5.5: Ratio of various effective dose values based on ICRP 60 calculated from
computational methods to the effective dose based on ICRP 60 estimated from TLD mea-
surements (ETLD,60) in a physical phantom representing a 10 year old child for paediatric
CT brain, chest and abdomen/pelvis examinations.
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Figure 5.6: Ratio of various effective dose values based on ICRP 103 calculated from
computational methods to the effective dose based on ICRP 103 estimated from TLD mea-
surements (ETLD,103) in a physical phantom representing a 10 year old child for paediatric
CT brain, chest and abdomen/pelvis examinations.
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Chapter 6
Survey of Patient Doses in
Paediatric CT to Establish Local
DRLs at RCH
6.1 Introduction
In the internationally adopted system of radiation protection, a medical procedure involv-
ing the exposure of a patient to ionising radiation must be both justified and optimised
(ICRP, 2007c). A dose limit or constraint is not applicable in these situations, as the ex-
posure will depend on the medical question being investigated and a higher radiation risk
may be warranted in cases where there is potential for greater clinical gain. A procedure
involving exposure to radiation will result in net patient benefit if undertaken according
to appropriate clinical guidance which incorporates the radiation protection principles of
justification and optimisation. However, a number of surveys (Dougeni et al., 2012; Moss
and McLean, 2006; Muhogora et al., 2010; Shrimpton et al., 2006; Smith-Bindman et al.,
2009; Wallace et al., 2010) of doses from CT examinations have observed substantial dif-
ferences between practices for the same type of examination, suggesting that exposures
may not be suitably optimised. The extent of the variation indicates these differences
are not solely attributable to patient factors, such as size and shape, but must also be
a result of the exposure parameters and protocols used. Therefore, optimisation of CT
protocols is essential, particularly for children who are more radiosensitive than adults
(NRC, 2006).
The ICRP introduced diagnostic reference levels (DRLs) as an optimisation tool for man-
aging dose from medical imaging procedures (ICRP, 1991, 1996a, 2001, 2007c). DRLs are
defined for common diagnostic examinations as the typical dose level for groups of standard
sized patients or standard phantoms for broadly defined types of equipment (ARPANSA,
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2008b; IPEM, 2004). A DRL is not a static quantity and it is the regular update, review
and assessment of dose trends, rather than the precise value, that is of importance to the
optimisation process (Oestmann, 1998). As the contribution of medical imaging to col-
lective population dose continues to grow (UNSCEAR, 2010a), there is greater awareness
and utilisation of tools such as DRLs to reduce and manage dose.
Modality and exam specific DRLs are typically set by regulatory authorities at a national
level, at the third quartile value of the dose distribution from a substantive survey of
patient doses (Bongartz et al., 2004; ICRP, 2001; IPEM, 2004; Shrimpton et al., 2005).
One objective of establishing DRLs and reviewing the values is to improve the dose dis-
tribution for a type of examination over time (ICRP, 2007c). Ultimately a narrow range
of values representing good practice may be derived (ICRP, 2007c). Furthermore, it is
conceivable that a lower level may also be relevant to indicate a value below which im-
age quality is questionable (ICRP, 2001). Both image quality and dose are factors that
must be considered for optimisation, although currently the focus of DRLs is as a dose
indicator.
In Australia, the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA)
has issued a Code of Practice regarding radiation protection in medicine (ARPANSA,
2008b). The new requirements make it necessary to implement a dose monitoring pro-
gram at a practice level to facilitate comparison with DRLs (ARPANSA, 2008b). It is the
intention that DRLs are not used as a constraint, but rather a level, which if consistently
exceeded warrants investigation (ICRP, 1996a). By periodically undertaking patient dose
surveys, a facility can determine if local levels of exposure are acceptable in terms of
Australian practice (ARPANSA, 2008a). National DRLs have yet to be established, al-
though ARPANSA have commenced a survey to determine values for CT (ARPANSA,
2011).
The new Australian requirements also recommend that local DRLs (LDRLs) be estab-
lished with regard to national values where these exist (ARPANSA, 2008a). In practices
in which the LDRL is significantly lower than the national DRL, it is preferable that the
lower level be utilised in order to encourage optimisation. Furthermore, it may be relevant
for a practice to have an LDRL that is higher than the national DRL (e.g. specific trauma
imaging), although these protocols must be clearly justified and regularly reviewed. The
Institute of Physicists and Engineers in Medicine (IPEM) in the United Kingdom (UK)
originally discouraged the use of LDRLs due to the lack of statistical significance in the
small sample sizes available within a single institution (George et al., 2004). However,
later guidelines recommend that LDRLs may be calculated from the mean of the dose
distribution, rather than the third quartile (IPEM, 2004). Establishing the value at the
third quartile incorrectly conveys that 25% of patient doses are always at a level war-
ranting investigation. Therefore, the mean value LDRL represents the typical dose level
for a protocol at that institution, reflecting the local situation. These values should be
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reviewed more frequently than national DRLs, allowing greater local control and increased
opportunity for management and optimisation of doses.
The aim of this part of the thesis was to conduct a survey of CT doses for typical exam-
inations performed at the Royal Children’s Hospital (RCH) in Melbourne, Australia. As
the hospital is currently being redeveloped and the CT scanner will be decommissioned,
this survey will provide a useful baseline for comparison of doses after installation of a
new scanner. The dose levels were compared with other Australian published data and
international DRLs to facilitate benchmarking.
6.2 Methods
A retrospective audit of patient records at the RCH for CT brain, chest and abdomen/pelvis
examinations was undertaken. Approval was gained from the institutional Human Re-
search Ethics Committee to access this data. The RCH is a major Australian specialist
paediatric hospital and the only dedicated paediatric hospital in both Victoria and Tasma-
nia. It was established in 1870 and in the 2007-2008 financial year treated approximately
35,000 inpatients, 130,000 outpatients and had 68,000 emergency department attendances
(RCH, 2008). The RCH performed 3,685 CT examinations in 2008.
All CT scans included in this survey were performed on a Sensation 16 multidetector CT
(MDCT) scanner with a Straton X-ray tube (Siemens, Erlangen, Germany) utilising au-
tomatic tube current modulation (CARE Dose4D). This is the only CT scanner located
at the RCH. The gender, age, parameters used (kVp, time per rotation, detector configu-
ration, beam collimation, pitch, effective mAs) and dose indicators, volumetric computed
tomography dose index (CTDIvol) and dose length product (DLP) were recorded for each
patient (see Section A.5, Appendix A for a discussion of CT dosimetry terms).
In clinical practice at the RCH, the protocol to be used for an individual patient is typically
selected based on the age of the patient for head examinations and the weight of the patient
for body examinations. However, all protocols are programmed into the RCH CT scanner
in terms of patient age and are given in Table L.1 (Appendix L). Depending on the type
of examination, the RCH CT protocols are categorised into several age groups including
0-6 months, 6 months-3 years, 3-6 years (or under 5 years), 6-10 years (or 5-10 years) and
over 10 years. Body weight is not a parameter that is recorded at the RCH and since this
survey was retrospective, the age of the patient was used to group the surveyed records.
It is recommended that when assessing doses from a patient survey at a practice level,
the sample should consist of at least 10 patients (Bongartz et al., 2004; IPEM, 2004). In
this survey, samples of 20 patients were selected for each age group in each of the three
study protocols. The CT protocols were not changed during the survey period. Only
those patient examinations where there were no obvious indicators that the examination
was atypical were sampled. For example, patients with metal implants were excluded. For
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CT examinations of the brain, only those performed without contrast were included in the
survey. CT examinations of the chest and abdomen/pelvis were included whether they
were performed with or without intravenous contrast, as all post-contrast examinations
were single phase only and the same protocol was used. Consecutive patient records were
included in the survey if they met the inclusion criteria. The patient records were sampled
from 2009 to early 2011. When 20 patient records were accumulated for an examination
type and age category, then no earlier records were required.
On most modern CT scanners, the CTDIvol and DLP values are displayed as projected
values following the CT localiser radiograph (also called the scout/surview/topogram/
scanogram) and the itemised values resulting from each individual part of the examination
and total values are displayed at the conclusion of an examination based on the scan
parameters used. At RCH this final dose screen is recorded for each patient so that
these values could readily be collected for use in the survey. The CTDIvol values represent
standardised dose measurements made in two different polymethyl methacrylate (PMMA)
homogenous, cylindrical phantoms. The measurements are made at the periphery and
centre of the cylinder and weighted accordingly to take into account the varying dose
distribution with depth in the phantom during a CT scan. Typically, a 16 cm diameter
dosimetry phantom is used to represent the head of an adult or child (or child’s body) and
a 32 cm diameter dosimetry phantom to represent an adult’s body. Some jurisdictions
now require the phantom size for the CTDIvol and DLP calculations to be displayed on
the final dose screen, although this was not a feature of the RCH scanner.
It was found from TLD measurements earlier in this thesis that there were limitations in
using the dose indicators displayed on the CT scanner console after an examination (Chap-
ter 3, Chapter 5). The displayed dose indicators on the RCH scanner for paediatric body
examinations were based on the 32 cm dosimetry phantom. This displayed dose consider-
ably underestimated the dose measured with TLDs and supports the recommendation by
Shrimpton and Wall (2000) that all CT dose indicators should be expressed in terms of the
16 cm dosimetry phantom for children regardless of age or scan location. Displayed dose
indicators for head examinations were expressed in terms of the 16 cm dosimetry phan-
tom, which more closely reflected TLD measurements. To distinguish between the values,
CTDIvol,16 and DLP16 will be used for doses relative to the 16 cm dosimetry phantom and
CTDIvol,32 and DLP32 for doses relative to the 32 cm dosimetry phantom.
Since this study relates to children, doses expressed in terms of the 32 cm dosimetry
phantom were converted to doses relative to the 16 cm dosimetry phantom following the
methodology of Huda et al. (2010) taking into account the X-ray beam filtration used
for the scan. This is necessary since the 16 cm dosimetry phantom is generally reserved
for head imaging and therefore the head, rather than the body, filter is used on the CT
scanner. Using the ImPACT CT Dosimetry Tool (ImPACT, 2011) and the methodology
of Huda et al. (2010), a conversion factor of 2.08 was determined to convert body doses in
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terms of CTDIvol,32 and DLP32 into CTDIvol,16 and DLP16, respectively. The UK National
Radiological Protection Board (NRPB, now the Health Protection Agency) use a factor
of “about two” when deriving DRLs for paediatric CT to convert from the 32 cm to the
16 cm dosimetry phantom dose (Shrimpton et al., 2005). Siegel et al. (2004) also found a
similar dose ratio between the two phantoms.
The DLP is calculated by multiplying the CTDIvol by the scan length. For helical scans,
this represents the imaged length, rather than the exposed length as it does not take into
account the additional over-ranging length required for helical data interpolation on many
CT scanners (van der Molen and Geleijns, 2007). The imaged scan length was calculated
from the recorded CTDIvol and DLP values for each patient in the survey.
Recommendations were made regarding establishing LDRLs in terms of CTDIvol and DLP
for the RCH based on mean dose values from the survey. These dose indicators do not take
into account the relative radiosensitivity of the organs and tissues exposed or the amount
of the body directly irradiated and therefore effective dose was estimated. Effective dose
is designed to provide a measure of overall radiation detriment due to stochastic effects
and is to be used for prospective dose assessment to facilitate planning and optimisation
(ICRP, 2007b). While not intended for retrospective use for estimation of doses to indi-
viduals, it is utilised here as an optimisation tool that will allow comparison with similar
procedures undertaken at different hospitals. The surveyed median DLP values were used
with published (Shrimpton et al., 2006) age- and region-specific conversion coefficients
(Table K.4, Appendix K) to calculate effective dose according to the 1990 Recommenda-
tions of the ICRP (ICRP 60 (ICRP, 1991)). These conversion coefficients were matched
to the age groups used in this survey to estimate effective dose. Where some age groups
included a range of ages incorporating two different conversion coefficients, these values
were averaged.
Conversion coefficients derived earlier in this thesis based on TLD measurements (Chap-
ter 5) and the 2007 Recommendations of the ICRP (ICRP 103 (ICRP, 2007b)) were also
used to convert DLP values to effective dose. These conversion coefficients were derived
from measurements made in a physical phantom representing a 10 year old child. The
values were scaled for all other age groups according to the relative ratios of the published
ICRP 60 conversion coefficients (Shrimpton et al., 2006). This method is approximate,
but suitable for the purpose of providing broad estimates of effective dose using the two
different ICRP Recommendations (ICRP, 1991, 2007b). These conversion coefficients are
compared with other published ICRP 103 paediatric conversion coefficients in Table 6.1.
Deak et al. (2010) provide conversion coefficients specific to a 64 MDCT scanner and
Alessio and Phillips (2010) derive conversion coefficients based on adult effective doses,
adjusted for paediatric sizes. It is evident that a wide range of values currently exists
in the literature. The conversion coefficients based on earlier TLD measurements (Chap-
ter 3) were used for effective dose estimates in this thesis because they are specific to this
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scanner and calculated directly from a paediatric anthropomorphic phantom, rather than
an adult phantom.
6.3 Results
The age and gender distribution of patients included in the survey are shown in Table M.1
(Appendix M). For the three types of examination, overall more records for males than
females were recorded. For CT chest examinations for children aged 5-10 years, there were
very few female patient records (15%) that met the study inclusion criteria in the time
period surveyed. The parameters set in the age-dependent standard, pre-programmed
protocols are given in Table L.1 (Appendix L). In addition, the mean value of the tube
current, scan length and the dose indicators from the patient records survey are also
provided in Table L.1 (Appendix L).
Figure 6.1 shows CTDIvol,16 values plotted against DLP16 for all age groups, with a linear
fit and zero y-intercept. The gradient of each line gives the average scan length of the
pooled data. Values of DLP16, CTDIvol,16 and scan length as a function of patient age are
shown in Figure 6.2. The CTDIvol increased with age for all types of examination, regard-
less of whether the examination was of the body or head region. The DLP increased with
age for each type of examination, although the increase was less for brain examinations
than for body examinations. Scan length did not substantially change with age for CT
brain examinations, while for body examinations it increased with age, particularly for
the youngest age groups.
The range and median values for CTDIvol,16, DLP16, mAs and scan length are shown
for each age group in Figure 6.3. These graphs demonstrate the wider range of scan
lengths for body examinations compared with head examinations. The bottom panel of
Figure 6.3 shows a graph of CTDIvol,16 normalised to 100 mAs for each age group and each
examination. Since this quantity is independent of both the examination mAs and the scan
length, it reflects the influence on dose of the protocol parameters initially selected.
Recommended LDRLs in terms of both CTDIvol and DLP are given in Table 6.2 based on
the survey results. These are rounded values of the mean of the age group for each type
of examination. The values have been provided in terms of both the 16 cm and 32 cm
dosimetry phantoms for the body examinations. Effective dose according to ICRP 60 and
ICRP 103 definitions was calculated using the median DLP value and age- and site-specific
conversion factors. The values of effective dose are given in Table 6.3.
6.4 Discussion
Repeat surveys conducted in the UK have shown that DRLs assist in reducing radiation
doses over time (Shrimpton et al., 2005). DRLs for paediatric CT examinations were
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Table 6.1: Dose length product (DLP) to effective dose (E) conversion coefficients.
Examination Age Groupa E/DLP Conversion Coefficient
(mSv·mGy−1·cm−1)b
ICRP 60c ICRP 103d ICRP 103e ICRP 103f
CT Brain 0-6 m [0 y] 0.011 0.0076 0.0085 0.013
6 m-3 y [1 y] 0.0067 0.0046 0.0053 0.008
3-6 y [5 y] 0.0040 0.0028 0.0035 0.005
6-10 y [10 y] 0.0032 0.0022 0.0027 0.004
>10 y [Adult] 0.0021 0.0014 0.0019 0.002
CT Chest <5 y [1 y] 0.026 0.032 0.026 0.038
5-10 y [5, 10 y] 0.016 0.019 0.014 0.023
>10 y [10 y] 0.013
(0.014)
0.016
(0.017)
0.012
(0.015)
0.019
(0.020)
CT
Abdomen/
pelvis
<5 y [1, 5 y] 0.025 0.023 0.022 0.026
5-10 y [5, 10 y] 0.018 0.016 0.014 0.018
>10 y [10 y] 0.015
(0.015)
0.014
(0.014)
0.012
(0.014)
0.015
(0.015)
a Age groups are defined in terms of months (m) or years (y). The age groups used in the survey were
based on the categorisations used for RCH CT protocols. Since conversion coefficients are generally
defined for a specific age, these were matched to the age groups used in the survey. The age specific
to the conversion coefficients is shown in square brackets in this column. For example, for the 0-6
month age group for CT brain examinations in this survey, the age-specific conversion coefficient for
0 year olds has been used. In some cases an average of conversion coefficients was used based on the
distribution of ages in the survey and for these, two ages have been listed in the square brackets.
b All values of the conversion coefficients are relative to the 16 cm dosimetry phantom, except those
shown in round brackets, which are relative to the 32 cm dosimetry phantom and are for adults.
Some of the patients in the >10 year age group will be closer in size to an adult rather than a child.
c ICRP 60 conversion coefficients provided by Shrimpton et al. (2006), which are age-specific. These
values have been used to calculate the ICRP 60 effective doses given in Table 6.3.
d These conversion coefficients were derived from the measurements made in Chapter 3. These values
have been used to calculate the ICRP 103 effective doses given in Table 6.3.
e ICRP 103 conversion coefficients provided by Deak et al. (2010), which are age-specific and
kV-specific. The kV for each protocol is given in Table L.1 (Appendix L). All body conversion
coefficients in Deak et al. (2010) have been provided relative to the 32 cm dosimetry phantom and
therefore have been divided by two to be expressed relative to the 16 cm dosimetry phantom, except
for the values in rounded brackets. Deak et al. (2010) provide separate conversion coefficients for
the abdomen and the pelvis. For the CT abdomen/pelvis examinations in the Table above the
conversion coefficients for these two regions have been averaged.
f ICRP 103 conversion coefficients provided by Alessio and Phillips (2010), which are age-specific.
The conversion coefficients given in the Table above for the CT abdomen/pelvis examinations for
Alessio and Phillips (2010) relate to the abdomen only.
117
CHAPTER 6. SURVEY OF PATIENT DOSES IN PAEDIATRIC CT TO ESTABLISH
LOCAL DRLS AT RCH
y = 14.95x 
R² = 0.95 
y = 33.86x 
R² = 0.95 
y = 44.68x 
R² = 0.95 
0
200
400
600
800
1000
1200
1400
0 20 40 60
D
L
P
1
6
 (
m
G
y
.c
m
) 
CTDIvol,16 (mGy) 
CT Brain
CT Chest
CT Abdomen/Pelvis
CT Brain linear fit
CT Chest linear fit
CT Abdomen/Pelvis linear fit
Figure 6.1: DLP16 as a function of CTDIvol,16 for CT brain, chest and abdomen/pelvis
examinations from the RCH paediatric dose survey. A linear fit is shown for each exami-
nation with a y-intercept of zero.
Table 6.2: Recommended local diagnostic reference levels (LDRLs) at the RCH for
typical paediatric CT examinations.
Examination Age Groupa LDRL (Mean Value)b
CTDIvol,32
(mGy)c
DLP32
(mGy·cm)d
CTDIvol,16
(mGy)c
DLP16
(mGy·cm)d
CT Brain 0-6 m - - 18 250
6 m-3 y - - 20 300
3-6 y - - 30 450
6-10 y - - 40 650
>10 y - - 45 700
CT Chest <5 y 2 50 3 100
5-10 y 5 150 11 300
>10 y 12 400 23 800
CT Abdomen/Pelvis <5 y 2 100 4 150
5-10 y 5 200 10 400
>10 y 8 350 15 750
a Age groups are defined in terms of months (m) or years (y).
b Dose indicators for CT chest and abdomen/pelvis examinations were displayed on the CT scanner
as CTDIvol,32 and DLP32. These have been multiplied by a factor of 2.08 according to the
methodology of Huda et al. (2010), prior to rounding, to give CTDIvol,16 and DLP16. The dose
indicators for the CT brain examinations were already displayed in terms of CTDIvol,16 and DLP16
and therefore did not require correction.
c CTDIvol values in milligray (mGy) have been rounded up to the nearest whole number.
d DLP values have been rounded up to the nearest 50 mGy·cm.
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Figure 6.2: a) CTDIvol,16, b) DLP16 and c) scan length versus patient age for CT brain,
chest and abdomen/pelvis examinations from the RCH paediatric dose survey.
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including the median value, for different age groups for typical CT brain, chest and ab-
domen/pelvis examinations from the RCH paediatric dose survey. The bottom panel
shows normalised median CTDIvol,16 values.
120
CHAPTER 6. SURVEY OF PATIENT DOSES IN PAEDIATRIC CT TO ESTABLISH
LOCAL DRLS AT RCH
Table 6.3: Summary of estimated effective doses for typical paediatric CT ex-
aminations at the RCH.
Examination Age Groupa Median
DLPb
(mGy·cm)
Effective
Dose
ICRP 60c
(mSv)
Effective
Dose
ICRP 103d
(mSv)
CT Brain 0-6 m 221 2.4 1.7
6 m-3 y 283 1.9 1.3
3-6 y 423 1.7 1.2
6-10 y 597 1.9 1.3
>10 y 675 1.4 1.0
CT Chest <5 y 60 1.6 1.9
5-10 y 296 4.6 5.6
>10 y 755 (363)e 9.8 (5.1)f 12 (6.3)f
CT Abdomen/Pelvis <5 y 99 2.5 2.3
5-10 y 380 6.6 6.2
>10 y 729 (351)e 11 (5.3)f 10 (4.9)f
a Age groups are defined in terms of months (m) or years (y).
b DLP for CT chest and abdomen/pelvis examinations were displayed on the CT scanner as
DLP32. These have been multiplied by a factor of 2.08 according to the methodology of
Huda et al. (2010), prior to rounding, to give DLP16. The dose indicators for the CT
brain examinations were already displayed in terms of DLP16 and therefore did not
require correction.
c The effective dose is calculated from the median DLP16 using age- and region-specific
published conversion factors (Shrimpton et al., 2006) (Table K.4, Appendix K).
d The effective dose is calculated from the median DLP16 using age- and region-specific
conversion factors derived earlier in this thesis (Chapter 5).
e The value in brackets is the DLP32 value, which is displayed on the scanner. This has
been included for comparison as some of the patients in this age group will be closer to an
adult size rather than a child size.
f The effective dose in brackets is calculated from the median DLP32 using adult
region-specific published conversion factors for ICRP 60 (Shrimpton et al., 2006)
(Table K.4, Appendix K) or conversion coefficients derived from TLD measurements for
ICRP 103.
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10-40% lower when comparing surveys at five year intervals (Shrimpton and Wall, 2000;
Shrimpton et al., 2005). With an established and widely adopted DRL program, it is
envisaged that at some point doses may become relatively constant and DRLs will then
be important to protect against unnecessary dose increases. In Australia, there will be a
significant initial opportunity for optimisation when national DRLs are established.
At the local level, dose surveys can be undertaken to establish LDRLs which can be
compared with national DRLs where these are available. It is useful to conduct surveys
based on real patients, which can be repeated at regular intervals to assess CT practice at
an institution. Using the dose indicators on the CT display (CTDIvol and DLP) ensures
that results will be comparable between different scanners, sites and countries, as long as
the dosimetry phantom is specified. Furthermore, Heggie (2005) argues that dose surveys
are also an essential tool for understanding local practice when commissioning a new CT
scanner to ensure that optimisation is undertaken. Therefore, LDRLs are useful to gauge
changes in local practice and techniques and the impact of new imaging technology.
Establishing typical dose levels for children is more challenging than deriving these values
for adults. Parameters and hence doses vary considerably with size and age for children.
Multiple reference values for a particular examination may be appropriate to account for
the variation in size across age ranges. It has been suggested that age may not be an
appropriate indicator of size in children and a method for deriving a representative “age”
from a size measurement of the patient has been developed (Hart et al., 2000; IPEM,
2004). The diameter of the patient directly correlates with the distance that the X-ray
beam travels in the patient and hence is a more direct determinant of dose (Boone et al.,
2003; Haaga, 2001; Hart et al., 2000; IPEM, 2004; Kleinman et al., 2010). However,
in this survey, dose records were grouped for children based on age and not size. This
allowed investigation of the range of doses that may be encountered in a particular age
bracket.
6.4.1 Scan Parameters and Patient Age
The results of the patient dose survey undertaken show that the dose indicators, CTDIvol
and DLP, increased with patient age (Figure 6.3). Furthermore, the range of these values
is widest in the older patients for all types of examinations. This is due to the consider-
able variation in patient size in the eldest cohort, which spans children aged 10 years to
adolescents aged 18 years.
Normalising the CTDIvol values with respect to mAs provides a better indication of the
dose dependence on the programmed scan parameters, as it quantifies the intensity of the
X-ray beam and reflects the effects of tube voltage, beam collimation and pitch on the dose
to the patient, regardless of the patient size. The slight variation in normalised values for
protocols using the same parameters evident in the results from this thesis is due to the
limitations of using average mAs for this calculation (see for example normalised values
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for CT brain examinations in the bottom panel of Figure 6.3). For a fixed tube current
these values would be identical.
CT brain examinations had the highest value of normalised CTDIvol (Figure 6.3). This is
partly attributable to the narrower beam collimation compared with body examinations,
which incurs a greater dose penalty due to over-beaming, where the unused penumbral
region of the X-ray beam is proportionally higher for narrower collimations. Furthermore,
less filtration is used for head scanning, which leads to a greater dose compared with a
more filtered beam with higher beam quality for body examinations (Huda et al., 2010).
Since the kVp, beam collimation and pitch did not change for the different age groups for
brain examinations, the normalised CTDIvol remained constant.
The beam collimation and pitch also remained constant between the age groups for the
body examinations, although the kVp increased over the three age groups. This is observed
in the increasing normalised CTDIvol values in Figure 6.3. The chest and abdomen/pelvis
normalised values for the same age groups differ only by the pitch. It is interesting that
the values are similar as the two body regions have quite different attenuation and contrast
characteristics. It may be expected that the CTDIvol values which reflect the patient dose
may be lower for the chest than for the abdomen/pelvis due to the reduced attenuation
from the air in the lungs and the increased inherent contrast in this area allowing for lower
dose settings. However, this was not always the case, particularly for the oldest age group
(Figure 6.3).
Tube Current Modulation
In all examinations assessed, the tube current modulation dose reduction tool was used
(CARE Dose4D). This requires a user-defined reference mAs valuei, which is set at a level
to achieve the desired image quality. The tube current is modulated based on the size
of the patient being scanned relative to the standard sized patient (defined as weighing
20 kg or five years of age for this scanner). Therefore, for very young/small patients it is
expected that the range of mAs values for the examination will be less than the reference
value and for older/large patients, the mAs will exceed the reference mAs value. This
was found to be true in the patient records survey results. For a four day old patient
undergoing a CT chest examination the average value for the examination was 49 mAs
compared with a reference value of 65 mAs. For a 14 year old adolescent undergoing a
CT chest examination the average was 124 mAs and the reference was 80 mAs.
For the brain examinations which were undertaken with a tilted gantry, the average tube
current was lower than the reference value for all age groups. Some sections of the scan had
a very low tube current where the transmission length through the brain was quite small
(e.g. top of the head). Overall, the mAs for the brain examinations increased significantly
iIn this context Siemens use an effective mAs, which is defined as the actual mAs divided by the pitch.
This quantity is referred to as Qref .
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with age, reflecting the higher reference mAs required to achieve the same image quality
in older patients with a more radio-dense skull.
For the body examinations, the change in examination mAs reflected both the reference
mAs values and/or the increasing size of the older patients. For example, for chest ex-
aminations the increase between the younger groups was due to the increasing reference
value and/or the increasing size of the patient, whereas the increase in the oldest group
was due only to larger patient size since the reference value remained constant. For ab-
domen/pelvis examinations the patients in the oldest group were larger, which would
increase the examination mAs, but this was offset by a lower reference mAs and hence the
median examination mAs was the same for the two oldest age groups.
Scan Length
The change of body size as children develop is clearly evident in the longer scan lengths
for the body examinations in older children (Figure 6.1c). As expected, variation in scan
length is not as readily evident for scans of the head, except in perhaps the youngest
patients. The average scan length for brain examinations increased between the two
youngest age groups (up to three years old), but was then fairly consistent (Table L.1,
Appendix L). This correlates well with the rapid growth of the head in the first two years
(Kleinman et al., 2010).
Generally, the greatest change in scan length in body examinations occurred in the first
five years. The length of the scan for abdomen/pelvis examinations was 11-13 cm longer
on average than for examinations of the chest for all age groups (Table L.1, Appendix L).
For children under five years, the average chest scan length was 40% shorter than the
abdomen/pelvis scan length, whereas in the older age groups it was only 25% shorter. Re-
gardless of age, the anatomical borders of the scan seldom change. For chest examinations,
the entire thorax anatomy and half of the liver are routinely included. For abdomen/pelvis
examinations the typical scan range is from just above the diaphragm to symphysis pubis.
Hence, it is most likely that anatomical changes as children develop lead to differences in
the comparative sizes of the chest and abdomen/pelvis in different age groups, which is
reflected in the relative scan lengths from this survey.
For all scans in helical mode, the operator’s planned length defines the mid-position of
the first and last image to be reconstructed and the length of the table movement for a
single rotation (which varies with pitch) is automatically added to this planned length.
This additional half-rotation width at each end is part of the imaged length and included
in the DLP calculation. An additional scan length due to over-ranging for helical data
interpolation is not included in the DLP and van der Molen and Geleijns (2007) have shown
that for this scanner with a pitch of 1-1.25, the over-ranging length is 5-6 cm. Therefore,
the scan lengths calculated here represent the imaged length and underestimate the total
length exposed and consequently the effective dose.
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Effective Dose
It is important to distinguish the values of CTDIvol and DLP from the actual dose to
the patient. These quantities are measures of dose in a CT dosimetry phantom, whereas
effective dose reflects the stochastic risk to the patient from the radiation exposure. Es-
timates of effective dose have been given in Table 6.3. In the eldest age category, both
DLP16 and DLP32 may be applicable for the range of patient sizes in this age group and
hence both values have been reported. A comparison between ICRP 103 and ICRP 60
effective dose estimates for paediatric CT examinations is provided earlier in this thesis
(see Section 3.4.2, Chapter 3).
The effective dose estimates for this survey are similar to those found in a multicentre
study in Belgium, although these largely related to single detector CT scanners (Pages
et al., 2003). A recent study by Thomas and Wang (2008) reported effective doses based
on a similar paediatric patient dose survey for an 8 MDCT scanner without tube current
modulation. The effective doses in their study were calculated using ICRP 60 conversion
coefficients. The ICRP 60 effective dose estimates reported in the current survey are
predominantly lower, except for imaging of the chest in the older age groups. This appears
to be due to two factors. Firstly, in the other study a higher pitch (1.375) is used, which
will reduce dose. Secondly, the mAs was lower than the present survey. However, the
earlier study reports that dose ranges within an age group for an examination can be large
(Thomas and Wang, 2008).
6.4.2 Comparison with Physical Phantom
In an earlier part of this thesis (Chapter 3), measurements were undertaken using a physical
anthropomorphic phantom representing a 10 year old child. The phantom was scanned
on the RCH CT scanner using the protocols for a child aged over 10 years (Table 3.1),
which were selected by an experienced radiographer. Table 6.4 provides the displayed
dose indicators compared with those collected in the survey for a real patient in each
examination category who was 10 years of age.
The normalised values of CTDIvol are similar between the phantom and patient for all
three types of examination. Since normalised CTDIvol is independent of the patient, it
was expected that for any patient or phantom these values would be in agreement. There
is a slight variation in the CTDIvol values, which is due to the limitations of using the
average mAs from the scan for this calculation.
Parameters for the CT brain examination were similar between the phantom and the
patient demonstrating that the size of the head and attenuation properties were well
matched. However, for the body examinations some variation was evident due to body size.
For the CT chest examination, the mAs was considerably lower (47%) for the examination
of the physical phantom and consequently the CTDIvol was also lower. The mAs was 28%
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Table 6.4: Displayed dose indicators for CT examinations of a physical phantom rep-
resenting a 10 year old child compared with the dose indicators for CT examinations
of 10 year old patients at the RCH.
Parameter CT Braina CT Chestb CT Abdomen/Pelvisb
Phantom Patientc Phantom Patientc Phantom Patientc
Effective mAs 231 230 80 150 65 90
Scan length (cm) 16.0 15.6 26.6 28.4 36.9 46.6
CTDIvol (mGy) 40.0 40.8 5.72 10.5 4.60 6.33
DLP (mGy·cm) 640 637 152 298 168 295
Norm. CTDIvol
(mGy/100 mAs)
17.3 17.7 7.15 7.00 5.66 5.63
a Dose indicators for the CT brain examination are CTDIvol,16 and DLP16.
b Dose indicators for the CT chest and abdomen/pelvis examinations are CTDIvol,32 and DLP32.
c A patient was selected from the survey data for each examination based on age to match the
phantom.
lower and the scan length was 21% shorter for the CT abdomen/pelvis examination of
the phantom when compared with the sampled 10 year old patient. The differences in
these parameters suggest that the size of the phantom body was smaller than the 10 year
old patients sampled in the survey. However, it is noted that this comparison is based
on a single patient for each examination who may or may not be representative of the
population.
6.4.3 Optimisation in Australian Paediatric CT Practice
An assessment of dose optimisation at the RCH can be made by comparing the examination
parameters and dose indicators from this thesis with other published Australian values.
For paediatric CT this includes data from an Australian multi-site survey by Moss and
McLean (2006), a project coordinated by the Royal Australian and New Zealand College
of Radiologists (RANZCR) under the Quality Use of Diagnostic Imaging (QUDI) Program
(Wallace et al., 2007a,b) and paediatric DRLs established at the Royal Children’s Hospital
Brisbane (RCHB) (Watson and Coakley, 2010).
Australian Survey Data
Table 6.5 provides a comparison of values from the current survey with those published
in an earlier Australian survey (Moss and McLean, 2006) in which a range of practices
in New South Wales participated during 2001-2002. In the earlier survey, 52 practices
responded, including both hospital-based and private sites. Four dedicated paediatric
centres participated in the survey, while other respondents returned data if they carried
out paediatric CT scans (for most centres this was two or less per month). Two-thirds
of the CT scanners for which data was submitted were single slice. All scanners were
capable of helical scanning. Although the RCH was not included in the earlier survey, the
comparison is still useful to gauge the current practices at RCH.
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Table 6.5: Comparison of mean (and maximum) values of RCH examination parameters
from the current paediatric dose survey with those collected in an earlier Australian survey
(Moss and McLean, 2006).
Examination Age
Group
kVp mAs Pitch CTDIvol
(mGy)
nCTDIw nCTDIvol
(mGy/100 mAs)
CT Brain 8 week 120 (140) 157 (480) 1.03 (1.50) 28.3 (153) 18.1 18.0
0-6 m 120 (120) 91 (120) axial 17.1 (22.6) 18.8 18.8
5-7 y 125 (140) 226 (411) 1.03 (1.67) 42.0 (139) 18.7 18.6
3-6 y 120 (120) 159 (189) axial 30.0 (33.5) 18.9 18.9
6-10 y 120 (120) 212 (228) axial 39.8 (42.7) 18.8 18.8
CT Chest 8 week 117 (135) 63 (195) 1.37 (2.00) 10.0 (42.3) 19.7 15.7
<5 y 80 (80) 65 (90) 1 (1) 1.4 (2.0) 2.2 2.2
5-7 y 121 (140) 99 (200) 1.35 (2.00) 16.9 (43.4) 20.9 17.1
5-10 y 100 (100) 109 (145) 1 (1) 5.0 (6.5) 4.5 4.5
CT
Abdomen/
pelvis
8 week 118 (130) 67 (195) 1.41 (2.00) 10.8 (42.3) 21.3 15.9
<5 y 80 (80) 90 (136) 1.25 (1.25) 1.6 (2.4) 2.2 1.8
5-7 y 121 (140) 123 (400) 1.29 (2.00) 20.6 (52.1) 20.0 16.7
5-10 y 100 (100) 128 (158) 1.25 (1.25) 4.6 (5.7) 4.5 3.6
a Shaded rows are values from the earlier Australian survey (Moss and McLean, 2006). White rows
are from the current paediatric dose survey (2010-2011). Age categories have been matched as
closely as possible.
b Values in brackets are maximum values, while all other values are mean values.
c CTDIw and CTDIvol values from the previous Australian survey have been normalised in terms of
mAs for comparison with this survey. CTDIw and CTDIvol for the current survey are in terms of
the 16 cm dosimetry phantom for the brain examinations and the 32 cm dosimetry phantom for the
body examinations. The size of the phantom has not been specified in the earlier survey (Moss and
McLean, 2006).
d Since the same protocol was used within each age group in the current survey the values of kVp and
pitch do not vary within an age group.
e Age groups are defined in terms of weeks, months (m) or years (y).
Comparison of the present RCH survey with the earlier results shows that there are some
differences in practice. CT brain examinations are not performed at 140 kVp at the RCH,
while some sites had previously used this value. However, the mean value for CT brain
scans (120 kVp) for earlier practices does not differ from current practice at the RCH.
Examinations of the chest and abdomen/pelvis are currently performed at a lower kVp at
the RCH, which is a recognised dose saving technique in recent years. The dose reduction
is reflected in the normalised CTDI values. This decrease in dose will only be achieved
if changes in other parameters, such as the mAs, do not offset the dose saving. This is
observed in the CTDIvol values, which are up to seven times lower at the RCH for body
examinations.
For all CT brain examinations the average mAs for the RCH patients is less than the
average from the previous survey. Furthermore, the maximum values are considerably
lower than those reported several years ago. This is also observed for examinations of the
chest and abdomen/pelvis where maximum mAs values in all age groups were substantially
higher in the earlier survey. This may be a consequence of the number of sites involved in
the first survey, which included practices where adult imaging was more common. Hence,
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the maximum values may be attributable to sites at which adult parameters were not
changed when scanning children and hence were quite high.
For the body examinations, the average values for mAs at the RCH are comparable or
higher than the earlier survey values. For the youngest age group this may be due to
the difference in the age groupings. The earlier survey values are based on an eight week
old baby, whereas the RCH values are derived from a sample of patients aged 0-5 years.
Again, the age range is broader for the older children in the RCH evaluation (5-10 years
compared with 5-7 years). Furthermore, the mAs may not provide a direct correlation
with changes in dose for these examinations, since the kVp has also varied. The influence
of the change in parameters on dose must be considered in the context of all parameters,
rather than any one parameter in isolation. Normalised CTDI values provide information
on the protocol settings, independent of mAs, while CTDI values reflect the total dose
for the examination taking into account the size of the patient and the mAs required to
produce a diagnostic image based on the other protocol settings used.
Based on the normalised CTDI values, current protocol settings for CT brain examinations
at RCH are commensurate with Australian practice in 2001-2002. Overall, doses from
brain scanning have decreased since this time based on the lower mAs now utilised, which
is reflected in the lower CTDIvol values. The CTDI values have decreased considerably
for body examinations, predominantly due to the lower kVp values now used. Although
some of the dose saving achieved by reducing the kVp has been offset by lower pitch values
and higher mAs values, overall the CTDIvol values demonstrate that the dose reduction
in current practice is substantial.
The other contributing factor to dose is the volume scanned. An indication of the dose
as a result of scan length is given by the DLP. This data was not provided in the earlier
Australian study and hence a comparison cannot be made. In general, it appears that
current protocols at the RCH will lead to reduced doses to children from CT examinations
compared with typical practices in 2001-2002 in Australia.
QUDI Optimisation Project
The issue of paediatric CT dose optimisation in Australia was assessed in 2006 and 2007
in a pilot project funded by the Australian Department of Health and Ageing under the
QUDI Program (Wallace et al., 2007a,b). A survey of standard protocols for a five year
old patient across Australian paediatric institutions aimed to determine typical doses in
terms of DLP. This was followed by optimisation workshops and then a re-assessment of the
typical DLPs. The standard parameters for each protocol were entered into the dosimetry
tool CT-Expo (Stamm and Nagel, 2011b) to calculate DLP, rather than using real patient
data. It should be noted that these DLPs will include the additional scan length for over-
ranging due to helical scanning, which is not included in the RCH reported DLPs for the
survey conducted in this thesis. The RCH participated in the QUDI project.
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In the initial survey conducted in 2006, it was found that doses varied between sites by more
than 11-fold. This variation reduced for some protocols when the sites were re-surveyed in
2007. However, interestingly, some protocols showed an increase in dose disparity. In the
QUDI project, DRLs were proposed based on the sixth highest ranked DLP. Almost all
DRLs reduced in the second survey, some substantially. This demonstrated the benefits
of training and feedback in the optimisation process.
From the second, post-optimisation survey, the QUDI DRL for head examinations (for
varying clinical indications) ranged from about 200-500 mGy·cm. The mean DLP in the 3-
6 year age category for the current RCH survey based on patient records was 435 mGy·cm.
This is within the DRL range suggested in the QUDI study, although at the higher end. It
is comparable with the QUDI DRL values for head imaging for trauma or space occupying
lesions, which are likely to be the most common types of imaging performed at the RCH.
Therefore, the RCH brain imaging protocols in this age group appear appropriate when
compared with the QUDI DRLs.
For the body examinations, the dosimetry phantom is not specified in the QUDI project,
although it is assumed that it is in terms of the 16 cm phantom as CT-Expo applies this
phantom for all paediatric calculations (Stamm and Nagel, 2011b). The chest DRLs are
all just above 100 mGy·cm in the QUDI survey. The mean DLP values from the RCH
survey for chest examinations were 57 mGy·cm and 296 mGy·cm for the under 5 years and
5-10 year age categories, respectively. While the youngest age group is in line with the
QUDI DRL, the next age category significantly exceeds the value. This may be due to the
age range being wider for this thesis and the influence of using real patient data.
The UK experience has shown that there can be a wide variation in doses when sites are
requested to submit their standard protocols on a questionnaire compared with a sample
of actual patient dose records (Shrimpton et al., 2005). They concluded that for some
sites, the standard protocols may not reflect general practice. The QUDI project is based
on a questionnaire of standard protocols, rather than patient dose surveys and this may
also impact on the QUDI DRLs. A practice’s standard protocol may be overly optimistic,
in terms of dose, compared to what happens in actual practice. Alternatively, this result
may suggest that the RCH can review optimisation for their CT chest protocols in the
middle age group.
For imaging of the abdomen the QUDI DRL values range from about 300-500 mGy·cm,
depending on the clinical indication. It is not clear whether the pelvis is included in
this imaging. The mean DLP values from the RCH survey for CT abdomen/pelvis ex-
aminations were 107 mGy·cm and 384 mGy·cm for the under 5 years and 5-10 year age
categories, respectively. These compare favourably with the QUDI DRL values.
The QUDI project is a valuable tool for paediatric CT dose optimisation in Australia. It
provides a useful opportunity to benchmark against current Australian practice. Further-
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more, for sites that more commonly scan adults, the QUDI DRLs provide an indication
of best practice at paediatric hospitals. It would be beneficial to expand this study design
to other paediatric age groups to enable a more comprehensive overview of paediatric CT
doses in Australia. This may be achieved when national DRLs are established in Australia
(ARPANSA, 2011).
Royal Children’s Hospital Brisbane
A comprehensive single-site Australian survey was recently undertaken by Watson and
Coakley (2010) at the Royal Children’s Hospital Brisbane (referred to as RCHB to dis-
tinguish it from the Royal Children’s Hospital (RCH) Melbourne) based on paediatric
protocols on a 64 MDCT scanner. A comparison with the current survey (Table 6.6)
shows that the majority of CTDIvol and DLP values in the Watson and Coakley study
are significantly lower. The dose reduction may be attributable to changes in technology
between the 16 MDCT scanner used in this thesis and the newer 64 MDCT scanner of
their survey. However, it may also be due to optimisation of protocols as some of the
dose saving appears to be due to lower mAs values. In particular, the examinations of
the brain at RCHB demonstrate a significant reduction in mAs compared with the RCH
examinations.
It is not completely clear in the Watson and Coakley paper (2010) whether the CTDIvol
values are expressed in terms of the 16 cm or 32 cm dosimetry phantom. For example, for
the same subset of patients in the 11-25 kg weight range (average age 4.8 years) undergoing
CT chest examinations, the CTDIvol values with the 16 cm and 32 cm dosimetry phantoms
as the reference are both 3 mGy. However, it is clear that the DLP values are relative to
the 16 cm phantom. Therefore, in Table 6.6 CTDIvol values for body imaging should be
compared with caution.
For CT chest imaging, the RCH values are comparable with the RCHB values in the
youngest age group. It would be useful to compare normalised CTDIvol values, although
this data is not available. For the youngest children, the RCH protocol parameters using
a lower kVp (80 kVp versus 120 kVp) and higher pitch (1 versus 0.828) would suggest
that the RCH doses will be lower than RCHB doses. However, the CTDIvol values are
the same, which appears to indicate that higher mAs values are offsetting any dose saving
made with the selection of kVp and pitch.
In the 5-10 year age category the DLPs for body imaging at RCH are considerably higher
than any of the corresponding groups in the RCHB survey, particularly for chest imaging.
For example, the mean DLP at RCH in the 5-10 year age group at RCH is 296 mGy·cm,
whereas the DLP for the group with average age 9.9 years at RCHB is 152 mGy·cm. One
of the significant benefits of the Watson and Coakley study (2010) is that they have access
to patient weight and have reported dose values in terms of both age and weight.
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Table 6.6: Comparison of examination parameters from the current paediatric dose
survey at RCH Melbourne with those collected in an earlier study at RCH Brisbane
(Watson and Coakley, 2010).
Examination Weight
Range
(kg)
Average
Age or
Range
(y)
kVp mAs Pitch CTDIvol,16
(mGy)
DLP16 (mGy·cm)
Mean Range
CT Brain 0-9 1.1 120 60 axial 7 106 76-188
- 0-0.5 120 91 axial 17 217 152-292
9-19 2.4 120 75 axial 7 171 70-422
- 0.5-3 120 105 axial 19 281 227-340
- 3-6 120 159 axial 30 435 365-532
>19 9.6 120 125 axial 13 337 155-449
- 6-10 120 212 axial 40 608 518-712
- >10 120 235 axial 44 679 506-807
CT Chest 0-10 0.7 100 - 0.828 3 55 17-100
- <5 80 65 1 3 57 29-104
11-25 4.8 120 - 0.828 3 83 33-163
- 5-10 100 109 1 10 296 189-379
26-40 9.9 120 - 0.828 5 152 94-328
- >10 120 157 1 23 799 472-1159
41-60 13.3 120 - 0.828 14b 328 184-592
61-75 14.7 120 - 0.828 18b 461 280-716
>75 14.4 120 - 0.828 32b 779 384-950
CT
Abdomen/
pelvis
0-10 0.6 120 - 0.828 3 67 33-122
- <5 80 91 1.25 3 107 67-204
11-25 4.5 120 - 0.828 5 153 72-220
- 5-10 100 128 1.25 10 384 237-549
26-40 10.4 120 - 0.828 5 313 176-504
- >10 120 129 1.25 15 702 406-851
41-60 13.4 120 - 0.828 8 502 192-976
61-75 14.5 120 - 0.828 35b 1485 1238-1732
a Shaded rows are values from the RCHB (2006-2008) (Watson and Coakley, 2010). White rows are
from the current paediatric dose survey at RCH (2010-2011).
b These values were only given relative to the 32 cm dosimetry phantom and therefore have been
multiplied by a factor of two so that all CTDI and DLP values are expressed relative to the 16 cm
dosimetry phantom.
6.4.4 International Paediatric CT DRLs
A number of countries have established or proposed DRLs for paediatric CT examina-
tions. The international values have been summarised in Table D.1 (Appendix D). DRLs
for children are most commonly provided for the head, chest and abdomen. The mean
values of CTDIvol and DLP from the patient dose survey conducted at the RCH in this
thesis have been compared with the corresponding international DRL values in Figure 6.4
(where they are quantified in a similar way, e.g. in terms of the same dosimetry phantom,
similar age group and examination). The national values established in the other countries
were based on surveys that included a range of single detector CT scanners and MDCT
scanners in clinical practice at the time. All of the other surveys included the 16 MDCT
scanner assessed in this study. For a local dose survey, the mean value is used to represent
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the typical dose for a type of examination. DRLs on the other hand generally represent
the 75th percentile of a substantive dose survey or measurements made using phantoms
and standard protocols. Hence, for this inter-comparison, if the local mean value signif-
icantly exceeds a corresponding DRL, this may indicate that further investigation and
optimisation is warranted locally.
Germany
The German study (Galanski et al., 2007) was based on a nation-wide survey of paedi-
atric CT practice conducted during 2005-2006 where a questionnaire was used to collect
standard protocol settings from facilities that performed more than 100 paediatric CT
examinations per year. Forty-two institutions participated in the survey.
The proposed DRLs were calculated using the third quartile values for adults (equiva-
lent to the above 15 years age category used in the survey) for brain examinations and
abdomen/pelvis examinations. The adult chest DRLs were based on two-thirds of the
abdomen/pelvis value, as the chest values surveyed were considered unnecessarily high.
A moderate, rather than strong, adaptation was then made to these values for patient
age and weight to calculate the set of proposed paediatric CT DRLs. Therefore, the Ger-
man DRLs to some extent represent desired practice rather than the results of the survey.
Comparison with the third quartile values from the survey reveal that the derived DRLs
are comparable, but overall slightly lower than the third quartile survey results. Further-
more, over-ranging effects have been taken into account for the DLP calculation, which
were negligible for the brain examinations, but increased the DLP on average by 10-20%
for the body examinations. The German study is unique in this respect, as it is more
common to use the DLP displayed on the scanner which does not include the effects of
over-ranging. For a DRL to be practical, it should reflect the dose quantity used clinically.
However, to give a true indication of total dose, effects such as over-ranging need to be
included. Either way, as with the size of the phantom, it is essential to define the factors
on which the DRLs are based.
The German survey establishes DRLs for the same examinations considered in this thesis:
brain, chest and abdomen (including pelvis). There are more age groups defined in the
German study including newborn, up to one year, 1-5 years, 6-10 years, 11-15 years and
above 15 years, whom were considered adults. The newborn DRLs were not used for
comparison. All other age groups matched those used in this thesis fairly well, with the
11-15 year group being matched to the >10 year category in this thesis. One exception
was made for chest imaging, since the majority of the group in the >10 year category were
in fact 15 years or older in the present survey. Therefore, the above 15 years DRL from
the German study was used for chest imaging when comparing to the >10 year group in
this thesis.
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Figure 6.4: Comparison of a) mean CTDIvol values and b) mean DLP values for different
age groups for common CT examinations from the paediatric dose survey undertaken in
this thesis (RCH 2011) with international DRLs (Germany 2006 (Galanski et al., 2007),
Switzerland 2005 (Verdun et al., 2008) and UK 2003 (Shrimpton et al., 2005)). The year
indicates the last year of data collection in each of the studies. All values are relative to
the mean RCH values from this thesis. All values are relative to the 16 cm dosimetry
phantom (CTDIvol,16, DLP16) except for the chest and abdomen/pelvis examinations in
the >10 year age category, which are relative to the 32 cm dosimetry phantom (CTDIvol,32,
DLP32).
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Switzerland
For the Swiss study (Verdun et al., 2008) undertaken in 2005, dedicated paediatric CT
practices submitted standard protocol settings and displayed doses on a questionnaire.
This survey method also did not collect data relating to examinations conducted on specific
patients. A scaling factor of 1.25 was used to calculate the suggested DRL from the mean
survey value. This method has also been used by others to provide a dose level comparable
with the third quartile when a dose distribution is not available (Aroua et al., 2004). In
this survey the sample size was only small, consisting of eight facilities. It appears that the
DLP displayed on the scanner was used to derive the DRLs and hence over-ranging has
not been taken into account, as it was in the German study (Galanski et al., 2007).
The CT examinations surveyed in the Swiss study include the clinical indication for the
scan. These were trauma for the brain examinations and detection of malignancy for scans
of the chest or abdomen. It is not clear whether the pelvis was included in the abdominal
scanning and this may have varied between the sites included in the survey. The groups
were separated in terms of age and/or weight into <1 year or 10 kg, 1-5 years or 10-20 kg,
5-10 years or 20-35 kg and 10-15 years or >35 kg. This matched closely the age groups
used in this thesis.
UK
Paediatric CT DRLs were reported from a UK survey undertaken in 2003 (Shrimpton et al.,
2005). This survey collected information on standard protocols, as well as data from scans
undertaken on individual patients for a sample of ideally at least 10 patients. For paediatric
head imaging, approximately 50 standard protocols were submitted and for paediatric
chest imaging approximately 20 different protocols were sampled. Abdomen imaging was
not assessed for children in this survey. The UK survey differs from other studies through
the collection and analysis of patient data. However, for children, the sample sizes were
relatively small. For all head imaging, 56 patient data sets were submitted across all
paediatric age groups and for chest imaging only 16 patient records were included. The
standard examination protocol data was used to establish DRLs based on rounded third
quartile values. Although the effects of over-ranging are acknowledged, the additional
scan length is not consistently incorporated as in the German study, due to more limited
knowledge regarding this effect at the time of this survey.
Collection of data in the UK study for the paediatric head and chest imaging was based
on clinical indications. These were trauma including non-accidental injury for the head
imaging of both the posterior fossa or cerebrum and detection of malignancy for the chest
examinations. Recommendations for DRLs were provided for 0-1 year olds, five year olds
and 10 year olds. This differed from this thesis and the German and Swiss surveys which
used age ranges. The 0-1 year old category was matched to the same category for brain
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imaging in this thesis. The five year old DRL was compared with the 1-5 year group for
brain scans and the <5 year age category for chest and abdominal examinations. The 10
year old age group was matched to the 5-10 year age brackets from this thesis and UK
adult DRLs were used for comparison with the >10 year age category of this thesis. This
may result in the UK values being at the upper limit for each category.
Dosimetry Phantom
A meaningful comparison of international DRLs for paediatric CT examinations can only
be made when the dose indicators are defined in terms of the same CT dosimetry phantom.
For adults, it is generally accepted practice to use the 16 cm dosimetry phantom for head
examinations and the 32 cm dosimetry phantom for body examinations. Although, even
for adults there are some body regions where selection of the relevant phantom is not
straightforward, including examinations of the cervical spine, sinuses or the whole body
in a single scan (Huda et al., 2010). In these cases it is also important that for adult
examinations the phantom is specified. For children, there is little consistency in the
choice of phantom used for the dose indicators.
For body examinations, it has been shown that for children the dose indicator should be
defined in terms of the 16 cm phantom (Shrimpton and Wall, 2000). The CT scanner
at the RCH uses the 32 cm phantom and therefore an adjustment was made to convert
CTDIvol and DLP values to be in terms of the 16 cm phantom (Huda et al., 2010). The
UK survey also defines DRLs in terms of the 16 cm phantom (Shrimpton et al., 2005).
The German study provides values in terms of both dosimetry phantoms where relevant
(Galanski et al., 2007). The Swiss study is less clear, as the phantom size is not defined
(Verdun et al., 2008). However, in the Swiss study comparisons are made with the UK
and German studies, and based on the values of the DRLs derived, it appears that these
are also in terms of the smaller dosimetry phantom.
For children or adolescents aged over 10 years, and in particular over 15 years, it may
be considered that they are approaching an adult size and the larger 32 cm dosimetry
phantom is applicable for expressing the dose for body examinations. The German study
provides DRLs for body examinations for 11 years and above only in terms of the 32 cm
dosimetry phantom (Galanski et al., 2007). For the comparisons made in this thesis all
body doses for chest and abdomen/pelvis imaging in the age group >10 years have been
expressed in terms of the 32 cm dosimetry phantom. The exception is the values for the
Swiss study, as it is unclear which phantom was originally used.
Brain Examinations
For CT examinations of the brain, the 16 cm dosimetry phantom is consistently used for
children and adults ensuring that when inter-comparisons are conducted the same quantity
will be evaluated. Figure 6.4a shows that in all age groups for brain examinations the RCH
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mean CTDIvol values are equal to or lower than international values. This implies that
the protocol settings for brain scans at the RCH are well optimised and reflect current
international practice.
In some age groups the mean DLP values at the RCH are slightly higher (<10%) than the
corresponding international DRLs (Figure 6.4b). This suggests that the scan lengths may
be slightly longer at the RCH. Furthermore, the dose saving evident in the CTDIvol values
for the RCH has reduced when comparing the DLPs, conveying that the scan lengths
at RCH may on average be slightly longer, offsetting the dose reduction achieved in the
parameter selection for the protocols.
It must be noted, there are other contributing factors that may result in a numerical
difference in the dose indicators, but not the actual dose to the patient. For axial brain
examinations there may be a small component of the scan that extends beyond the top
of the skull and scans only air to ensure that the complete region of clinical interest is
included in the scan range. For the protocol settings used at the RCH, this will be up
to a maximum of a single beam collimation, or 18 mm, of extended scan length which
does not directly expose the patient, but increases the DLP and, hence this may account
for the observed differences in DLP values. Additionally, the definition of scan length for
examinations performed with a tilted gantry will also directly affect the DLP. For example,
on this scanner the scan length is measured parallel to the patient’s long axis, whereas
measurement of the scan length parallel to the axis of rotation would reduce the length by
approximately 10%. Therefore, the actual dose to the patient has not changed, but the
DLP has, depending on the scan length used. Overall, the RCH values are comparable, if
not lower than international values for CT head examinations. It is evident from Figure 6.4
that parameters and doses for CT brain examinations are fairly consistent.
Body Examinations
For body imaging, the RCH mean values are considerably lower than international DRLs
in terms of both CTDIvol and DLP in the <5 years age group (Figure 6.4). This is most
likely due to the low kVp (80 kVp) employed at the RCH, which leads to a considerable
dose reduction. For example, the UK survey found that almost 80% of sites conducted
chest imaging in this age group at 120 kVp, with only 5% using 80 kVp (Shrimpton et al.,
2005). This may also explain why the UK DRL is higher than the other values in the 5-10
year age group. Again, 120 kVp is typically used in the UK, while at the RCH 100 kVp is
used in this age group. The German survey found that in younger patients it was more
likely that a lower kVp would be used for chest imaging than for abdomen/pelvis scans,
although in the 2-5 year age group low kVp chest imaging accounted for just over 30% of
the examinations (Galanski et al., 2007).
The German CTDIvol DRLs are up to 15% lower than the mean values at the RCH in the
two older age groups for chest imaging (Figure 6.4a). However, it should be noted that
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the German survey data resulted in values which they concluded were unnecessarily high
for chest imaging when compared with abdomen imaging and therefore the DRLs were
modified (decreased), apparently with the intention of encouraging optimisation. The
mean values at the RCH are in fact comparable with the third quartile values for chest
imaging from the German survey.
The German DRLs in terms of DLP are also lower than the RCH mean values in the two
older age groups for chest imaging (Figure 6.4b). As previously discussed, the German
chest DRLs are lower than the third quartile values found in their survey and therefore
may underestimate current German practice. However, the DLP values in the German
study also include the over-ranging length in the helical scans, which was not included
in the RCH DLPs. Therefore, it was expected that the German DLP DRLs would be
higher than the RCH mean values which do not include this additional length. The third
quartile value for the scan length, including over-ranging, in the age group 6-10 years in
the German study was 22.7 cm. The mean scan length in the RCH survey for 5-10 year
olds was 28.7 cm. Clearly, the RCH scan length is extended. Similarly, the Swiss DLP
is lower than the RCH value in the 5-10 year age group. The average scan length for
5-10 year olds in the Swiss study (Verdun et al., 2008) was 23 cm, again shorter than the
lengths found at the RCH.
All RCH mean values for abdomen/pelvis examinations across all age groups are equal
to or lower than the international DRLs. In the two older age groups, the dose saving
achieved through the selection of parameters, evident in the CTDIvol values at the RCH,
appears to be offset to some extent by a longer scan length when assessing the DLP values.
In particular, the third quartile values in the German survey, which should be longer due
to the inclusion of the over-ranging scan length are in fact several centimetres shorter.
In the 5-10 year age group the mean RCH scan length was 39.6 cm, while the German
survey third quartile value was 31.6 cm. Similarly in the over 10 year category the RCH
mean length was 46.9 cm and the German third quartile value was 40.0 cm. Again, there
appears to be an opportunity for dose reduction by reviewing the scan length for the RCH
examinations. However, overall the RCH average dose values for abdomen/pelvis imaging
are lower in comparison.
6.5 Conclusions
Conducting a CT dose survey within a facility is essential for understanding and analysing
local practice. The mean values from these surveys are also useful for comparison with na-
tional or even international DRLs to facilitate benchmarking and ultimately optimisation
of both dose and image quality. A comparison of the average dose values at the RCH with
international DRLs for common paediatric CT examinations has shown that the RCH
values are typically comparable or lower. In particular, the use of 80 kVp for both chest
and abdomen/pelvis imaging in children under five years of age leads to a significant dose
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saving. There is potential for dose optimisation at the RCH by reducing scan lengths for
body examinations for children over five years of age. In the short term, a review of these
protocols should be undertaken to determine if there is appropriate justification for the
extended scan lengths.
In the future, it may be worthwhile deriving LDRLs at the RCH for common protocols
based on clinical indication. This may result in narrower ranges for the scan lengths and
allow more directed LDRLs. The comparison undertaken in this thesis has shown that
it is not simple to compare a practice’s dose values against published DRLs. There are
many factors that need to be considered and the dose indicators need to be properly
defined in terms of the CT dosimetry phantom used and the type of examination. For
a more thorough comparison it is essential to also consider the scan length and where
possible the normalised CTDIvol values. Using several quantities enables optimisation of
protocol parameters, as well as operator technique by isolating the influence of each factor
on dose.
It was found in this thesis that comparison of the normalised CTDI values was beneficial
as the dependency on mAs was removed. With tube current modulation becoming a
common feature of CT scanners today, it is useful to have a quantity that is not influenced
by a factor that constantly changes throughout the scan. Furthermore, it is necessary to
have a quantity that reflects the parameters, such as kVp, beam collimation and pitch
that are defined when originally establishing protocols. The normalised CTDI values are
useful for other sites to consider when assessing parameter choice for common paediatric
CT protocols. These values will also provide a point of comparison for the RCH when
replacing the current CT scanner.
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Chapter 7
Assessment of Australian
Paediatric CT Imaging Trends
7.1 Introduction
In Australia in 1996, CT imaging was the largest source of radiation exposure from diag-
nostic radiology procedures, accounting for about 50% of the total dose (Webb et al., 1999).
The annual per capita dose from CT examinations was approximately 0.39 millisieverts
(mSv) compared with 0.83 mSv from all medical diagnostic exposures (Webb et al., 1999;
Wise and Thomson, 2004). CT imaging contributed approximately 17% of the average
total annual dose of 2.3 mSv from all natural and non-natural radiation sources. Hence,
CT was recognised as a major source of radiation exposure in Australia even more than a
decade ago.
There have been several Australian studies investigating CT imaging trends and radiation
dose (McLean et al., 2003; Moss and McLean, 2006; Thomson and Tingey, 1997; Wise and
Thomson, 2004). The most comprehensive, in terms of the number of sites surveyed, was
conducted by the Australian Radiation Laboratory (ARL, now the Australian Radiation
Protection and Nuclear Safety Agency, ARPANSA) in 1994/95 (Thomson and Tingey,
1997). The authors estimated that the exposure from CT imaging induced about 280
fatal cancers per year; one in every 4,000 CT examinations. This estimate was based on a
mean dose of 6.6 mSv per exam, the linear no-threshold hypothesis and a nominal fatality
risk coefficient of 4% per Sv for a population of working age (ICRP, 1991).
Another Australian study provided an assessment of the change in CT radiation doses
from 1994 to 2002 (Wise and Thomson, 2004). The authors found that the number of
procedures had increased by 60% and that the mean dose per procedure increased from
8.3 to 11.7 mSv over this period, raising the annual per capita dose to 0.9 mSv in 2002
(Wise and Thomson, 2004).
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Other Australian studies have surveyed a smaller number of local sites to assess CT radi-
ation dose (McLean et al., 2003; Moss and McLean, 2006). McLean et al. (2003) surveyed
nine radiology departments in 2003 regarding paediatric protocols for an 8 week old baby
and 7 year old child and made an estimation of effective dose levels using Monte Carlo
dose simulations. They found that for chest and abdomen procedures there was a wide
range in doses across the different sites, with the specialist paediatric departments having
lower doses and a narrower dose range. The average dose was found to be less than 10 mSv
with a range of 1-20 mSv.
A wider survey was conducted by Moss and McLean (2006) who included all sites in
New South Wales licensed to possess CT scanners in 2001/02. This survey assessed scan-
ning protocols and radiation dose for both adults and children; the latter were based on
protocols for 8 week old and 5-7 year old patients. They again found a wide range of
doses between sites for comparable examinations. Doses for paediatric head examinations
ranged from 1.3-2.0 mSv and for adult head examinations 1.6-2.7 mSv. Chest protocols
ranged from 1.9-7.9 mSv for children and 4.9-7.8 mSv for adults, while abdomen imaging
resulted in doses of 4.4-14.1 mSv for children and 7.7-13.3 mSv for adults.
This thesis provides an analysis of current paediatric CT imaging trends in Australia for
the age range 0-18 years based on examinations that have been billed to Medicare, the
universal health care system of the Australian Government. Medicare is administered by
the Department of Health and Ageing who are responsible for ensuring that Medicare
Benefits Schedule (MBS) payments are made for eligible health services provided to Aus-
tralian residents by eligible health care providers. Services provided to public patients in
a public hospital form the largest group of medical services funded outside the Medicare
Benefits Schedule and are not captured in the Medicare data. It has previously been es-
timated that 24% of CT examinations are non-Medicare funded (Thomson and Tingey,
1997). However, it is not clear if this figure is representative of the situation for paediatric
patients. Therefore, in view of the higher risks from radiation exposure in children, this
thesis analysed the imaging rate in a major Australian children’s hospital for comparison
with data from Medicare.
7.2 Methods
A selection of diagnostic imaging services data are made publicly available by Medicare.
The information is limited in its completeness for assessing overall imaging rates as it
excludes procedures not funded by Medicare. Although care is needed when extrapolating
to the total number of medical imaging procedures undertaken, Medicare data are the best
currently available resource for describing trends in medical imaging in Australia.
The data relating to imaging services assessed in this thesis were accessed via the statis-
tical reporting function on the Medicare website (www.medicareaustralia.gov.au). The data
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retrieved relate to the total number of services, including age and gender distributions, for
calendar years from 1994 to 2010. CT services correspond to MBS item codes and may
incorporate multiple scans undertaken on a patient during a single visit. The Medicare
data is provided in age bands which included 0-4 years, then 10 year age bands to 84 years
and a single age band for 85 years and above. Additional data including the total num-
ber of services and patients and other de-identified population demographic information
including single year of age for patients aged 0-18 years were provided by the Department
of Health and Ageing for CT examinations performed from 1986 to 2008. The Medicare
definition of a CT service has changed over the last two decades and therefore, where
possible, the number of CT patients has been used.
Data on the Australian population were obtained from the Australian Bureau of Statistics
in order to calculate imaging rates (ABS, 2008a, June 2009). The Estimated Resident
Population (ERP) at the midpoint of each reference year was used. The ERP data was
available either by single year of age or in five year age bands and these were combined
to match the available Medicare age bands. Imaging rates are expressed as the number
of services or patients per 1,000 persons of the ERP in each year corresponding to the
Medicare age bands. Indexed rates based on a reference year were calculated to assist
in interpreting changes in the data over time. The indexed rate for all other years was
calculated by determining the ratio of the comparison period value to the reference period
value.
To determine if the Medicare CT data accurately reflects the imaging trends for chil-
dren and young people aged 0-18 years, CT imaging data was extracted from the Royal
Children’s Hospital (RCH) Melbourne radiology information system (RMS, Kestral, Aus-
tralia). The RCH is a major Australian specialist paediatric hospital and the only dedi-
cated paediatric hospital in both Victoria and Tasmania. It was established in 1870 and in
the 2007-2008 financial year treated approximately 35,000 inpatients, 130,000 outpatients
and had 68,000 emergency department attendances (RCH, 2008). Approval was gained
from the RCH Human Research Ethics Committee to retrospectively access this data.
Information on the type of CT procedure, date of procedure, and age and gender of the
patient was obtained from 1986 to 2008 and the billing code was included for procedures
performed from 1999 onwards. Approximate scaling factors were derived from the RCH
data to adjust Medicare data for those CT services that are not billed to Medicare.
Data from the RCH were used to calculate the CT imaging trends for patients aged 0-18
years. Each patient visit was counted individually and referred to as CT patients hereafter.
The RCH imaging rate was compared with the paediatric data based on number of CT
patients over the same time period obtained from Medicare.
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7.3 Results
Approximately two million CT services across all age groups were billed to Medicare in
Australia in 2010 (Figure 7.1). The annual growth rate in the number of CT services has
ranged from 6.3% to 13.3% over the last 16 years, with the only decrease seen in the last
year at 3.5%. The recent decrease is promising, but it is too early to be confirmed as an
ongoing trend. There was an average annual increase of 7.8% over the last 16 years. Taking
population growth into account, the number of CT services per 1,000 persons (imaging
rate) has increased by an average of 7.1% per year, or almost tripled in the last 15 years
(1994-2009) based on the number of services billed to Medicare (Table 7.1).
Table 7.1: Number of CT services and imaging rate in Australia for services billed to
Medicare in 1994 and 2009.
Age at
Scan
(years)
No. CT Services (%)a CT Imaging Rate (No.
services per 1,000 personsb)
1994 2009 1994 2009
0-4 2,827 (0.5) 2,410 (0.1) 2 2
5-14 17,982 (2.9) 26,890 (1.3) 7 10
15-24 45,813 (7.5) 103,503 (5.0) 17 34
25-34 72,003 (11.8) 157,397 (7.5) 25 51
35-44 96,766 (15.8) 253,374 (12.1) 36 81
45-54 110,155 (18.0) 355,599 (17.0) 52 118
55-64 104,240 (17.0) 433,670 (20.8) 70 175
65-74 100,370 (16.4) 402,426 (19.3) 79 259
75-84 52,748 (8.6) 285,556 (13.7) 80 292
≥ 85 9,533 (1.6) 65,385 (3.1) 53 171
Total 612,437 (100.0) 2,086,210 (100.0) 34 95
a CT services billed to Medicare.
b Annual imaging rate calculated by dividing the number of CT services billed to Medicare in that year
by the Estimated Resident Population at the midpoint of the year, multiplied by 1,000 (ABS, 2008a,
June 2009). Note that this does not include non-Medicare funded CT services.
The number of patients for whom CT services were billed to Medicare in the 0-18 year
age bracket has more than tripled over the 22 year period from 1986 to 2008, increasing
from approximately 17,500 to 58,200 (Figure 7.2). The number of patients undergoing CT
examinations at the RCH also demonstrated an increase over this time. In 1986 about
1,500 patients underwent CT examinations at the RCH and by 2008 this had more than
doubled to over 3,600 CT patients. For comparison with the annual growth rate of CT
services for the entire population over the past 15 years of 8.5%, the average annual change
in the number of CT patients aged 0-18 years whose services were billed to Medicare is
4.5% and for RCH CT patients is 5.6% over the same 15 year period.
The age and gender distribution of CT services billed to Medicare compared with the
Australian population for 2009 are shown in Figures 7.3 and 7.4. Based on Medicare data,
only a small percentage (0.10%) of CT scans are carried out for the very young (0-4 years),
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Figure 7.1: Number of MRI (white) and CT (dark grey) services for the Australian pop-
ulation billed to Medicare Australia from 1994 to 2010 and the number of CT procedures
(light grey) performed in the United States from 1994 to 2006 (NCRP, 2009).
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Figure 7.2: Number of patients aged 0 to 18 years for whom CT services were billed to
Medicare in Australia from 1986 to 2008 (data provided by the Australian Department of
Health and Ageing).
143
CHAPTER 7. ASSESSMENT OF AUSTRALIAN PAEDIATRIC CT IMAGING
TRENDS
with the bulk of examinations occurring for those aged between 45-74 years (Figure 7.3).
A greater percentage of scanning is performed for women aged 15-64 or over 85 years
(Figure 7.4). In the youngest age group (0-4 years) the distribution is almost equal and
in the group 5-14 years, a slightly higher proportion of males are scanned. Trends in
the CT imaging rate for males and females have been similar since 1986 (Figure 7.5).
More CT examinations are performed on males aged 0-14 years than on females, while for
adolescents aged 15-18 years the imaging rate is similar for both sexes.
There are certain time points where trends in the change in the CT imaging rate are similar
between all age groups (circled in Figure 7.6). Figure 7.7 focuses on the CT imaging rate
for the 0-18 year age range relative to 1986. The 0-4 and 5-9 year age groups show a
decrease in the last five years, while the older age groups show an overall increase in CT
imaging rate. This data does not include those services not billed to Medicare.
Data is available from Medicare for other diagnostic modalities from 1994, although the
age grouping is limited to 0-4, 5-14 and 15-24 years. Figure 7.8 shows an indexed rate
representing the relative change in the CT imaging rate relative to the year 2000 for each
modality. The increase in the CT imaging rate in the 0-24 year age group is comparable to
increases in the ultrasound imaging rate over the past 15 years. In contrast, diagnostic ra-
diology services (including plain X-ray imaging, fluoroscopy and interventional radiology)
have remained fairly constant, while nuclear medicine services have declined. The greatest
increase in imaging rate is observed for MRI services, which were first billed to Medicare
in 1998 and have seen a dramatic increase since that time. Approximately 2.6 million
diagnostic imaging services were billed to Medicare for the 0-24 year age group in 2009.
As a proportion of this total number, CT represents 5% of funded services, while nuclear
medicine accounts for 1%, MRI 2%, ultrasound 26% and diagnostic radiology 66%.
Billing trends at the RCH were assessed to calculate the percentage of paediatric CT
imaging performed that is captured by Medicare data. In 1999, 42% of all CT procedures
at the RCH were billed to Medicare and this had decreased to 31% by 2008. The 0-
4 year age group had the lowest percentage of Medicare funded procedures performed,
dropping to a minimum in 2000 of 19%. Since 1999, CT procedures not billed to Medicare
included public in-patients (56%), Transport Accident Commission patients (5%), patients
not charged (3%), international patients (1%), and inter-hospital and Work Cover patients
(<0.1%). The remaining 35% of patients were captured in Medicare data via billing to
Medicare, either directly or through their private health fund.
Approximate scaling factors for children that can be applied to Medicare data to account
for those examinations not billed through Medicare are given in Table 7.2. These are
calculated from the last seven years of RCH billing data from 2002 to 2008. Other ded-
icated paediatric hospitals across Australia vary in the number of CT patients billed to
Medicare. For the financial year 2008/09 these ranged from 7% in Western Australia,
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Figure 7.3: Comparison between age distribution for CT services billed to Medicare (di-
amonds) and of the Australian population (squares) in 2009 (ABS, June 2009; Medicare).
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Figure 7.4: Age and gender distribution of the CT imaging rate (number of CT services
billed to Medicare Australia per 1,000 people) in 2009 in Australia (ABS, 2008a, June
2009; Medicare).
145
CHAPTER 7. ASSESSMENT OF AUSTRALIAN PAEDIATRIC CT IMAGING
TRENDS
C
T
 s
e
rv
ic
e
 p
e
r 
1
,0
0
0
 p
e
rs
o
n
s
 
0
5
10
15
20
25
30
35
40
C
T
 s
e
rv
ic
e
 p
e
r 
1
,0
0
0
 p
e
rs
o
n
s
 
Year 
0-4 males
0-4 females
5-14 males
5-14 females
15-24 males
15-24 females
Figure 7.5: CT imaging rates (number of CT services billed to Medicare Australia per
1,000 persons) for males (blue) and females (red) in the younger age ranges (ABS, 2008a,
June 2009; Medicare).
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2008a, June 2009; Medicare).
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Figure 7.8: Indexed rate of the number of services for different diagnostic imaging modal-
ities per 1,000 persons aged 0 to 24 years billed to Medicare in Australia from 1994 to
2009 relative to the imaging rate in 2000 (base of each index is the number of services per
1,000 persons in the year 2000) [CT = Computed Tomography, US = Ultrasound, MRI
= Magnetic Resonance Imaging, NM = Nuclear Medicine, DR = Diagnostic Radiology]
(ABS, 2008a, June 2009; Medicare).
147
CHAPTER 7. ASSESSMENT OF AUSTRALIAN PAEDIATRIC CT IMAGING
TRENDS
24% in South Australia, 27% in Queensland, to 44% in New South Walesi. This varia-
tion highlights the challenges of assessing imaging trends and reinforces the importance of
qualifying estimates of non-Medicare imaging statistics.
Table 7.2: Gender and age distribution for paediatric CT imaging
in Australia in 2008.
Category No. CT
Patientsa(%)
Scaling
Factorb
CT Imaging Rate
(No. patients per
1,000 persons)c
0-18 y 58,183 (100) 2.7-3.3 30-36
Sex
0-18 y, male 31,115 (53) 2.7-3.6 31-41
0-18 y, female 27,068 (47) 2.6-3.2 27-33
Age
0-4 y 1,919 (3) 3.8-4.9 5-7
5-9 y 6,725 (12) 2.4-2.9 12-15
10-14 y 18,563 (32) 2.4-3.2 32-42
15-18 y 30,976 (53) 1.3d 34
a Patients for whom CT services were billed to Medicare in 2008 (data
provided by the Australian Department of Health and Ageing).
b Scaling factor derived from billing data at the RCH from 2002 to 2008 to
adjust the Medicare number of patients for those CT services that are not
billed to Medicare. The range represents the mean ± 2*standard deviation.
The scaling factor is calculated as 1+X/(100-X) where X is the percentage of
patients not billed to Medicare. Using the scaling factor the actual number
of patients aged 0-18 years having a CT scan in 2008 is closer to three times
58,183 or about 175,000.
c Annual imaging rate calculated by dividing the number of CT patients billed
to Medicare in 2008 (adjusted by the scaling factor) by the Estimated
Resident Population at the midpoint of 2008, multiplied by 1,000 (ABS,
2008a, June 2009). The adjustment is made to include non-Medicare funded
CT services.
d The published adult scaling factor has been used for the 15 to 18 year age
range (Thomson and Tingey, 1997).
The CT usage profile for 2008 differs between Medicare and RCH data and neither matches
the age distribution of the Australian population in the 0-18 year age group. Figure 7.9
shows the number of CT patients by year of age at the RCH as a percentage of all CT
patients at RCH for 2008. Similarly, the percentage age distribution is shown for those
CT patients billed to Medicare by all practices in Victoria. The largest percentage of
CT imaging is performed at the RCH for patients less than one year old, while the older
patients (15-18 years) constitute a greater proportion of the Medicare-billed CT services
in Victoria. The Victorian population distribution is reasonably consistent across the 0-18
year age range.
Table 7.3 compares the average annual change in the CT imaging rate over the last 22 years
with the change in the imaging rate in the last five years based on the RCH and Medicare
data sources. The average annual change has been provided for both time periods to
iTM Cain [Royal Children’s Hospital Melbourne] 2009, pers. comm., 13 April.
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demonstrate the changing trend in recent years in some age groups.
7.4 Discussion
As Brenner and Hall (2007) state, the risk to the individual from diagnostic radiation
exposure is small and in most cases for a properly justified procedure, the benefit to
the individual will outweigh any risk. However, with increasing rates of CT usage the
application of small levels of risk to a large population produces a health concern. Based
on CT usage in 2007, it is estimated that 1.5% to 2.0% of all cancers in the US may be
caused by CT imaging (Brenner and Hall, 2007). The total number of CT scans in the US
has increased annually by 8% to 15% over the last seven to 10 years (Figure 7.1), which is a
greater rate than population growth (Mettler et al., 2009, 2008; NCRP, 2009) and similar
trends are seen in the UK (Hall and Brenner, 2008). This thesis shows that although the
rate of increase is not as high as in the US (Figure 7.1), the use of CT imaging in Australia
is increasing and at a much faster rate than population growth.
There have been expectations (Kalra et al., 2004a; Mettler et al., 2000; Rehani and Berry,
2000; Vock, 2005) that magnetic resonance imaging (MRI) may begin to lighten the work-
load in CT. In Australia, the Medicare data show that both MRI and CT services are
increasing (Figure 7.1). However, over the past ten years MRI has only slowly increased
from 15% to 20% of the total number of services. This slower than expected uptake may
primarily be due to the restricted access, continued high cost and limited Medicare rebates
for MRI scans.
Figure 7.3 demonstrates that the CT usage profile (Medicare) does not match the age
distribution of the Australian population (ABS, June Quarter 2008). A greater percentage
of CT scans are performed in an older, smaller percentage of the population. This is in
agreement with recent demographic data from the US (Mettler et al., 2008). The New
Zealand National Radiation Laboratory conducts a survey every ten years of CT usage.
The most recent survey was conducted in 2007 (Stirling and Cotterill, 2008) and also
demonstrates similar trends to the Australian data.
Furthermore, CT imaging rates for boys consistently exceed those for girls in the youngest
age groups (0-14 years) (Figure 7.5). A similar trend was found in a US study of more
than 300,000 health care records for children under the age of 18 years (Dorfman et al.,
2011). CT was used more frequently for boys except in the 15-17 year age group. For
Australia, over the larger age range from 15-64 years, women are scanned more than men
(Figure 7.4). This could reflect that boys are more likely to require a CT scan than girls
due to the activities being undertaken. From late adolescence onwards, it may be more
likely for women to seek medical advice than men and therefore higher CT rates are seen
in women. A recent study in Northern England found that the CT imaging rate was higher
in males than females in all age groups up to 22 years of age, except infants (<1 year)
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Table 7.3: The average annual change in the Australian CT imag-
ing rate since 1987 and since 2004 for persons aged 0 to 18 years.
Age at
Scan
(years)
Average annual change in CT imaging
rate (patients per 1,000 persons)a
1987-2009 2004-2009
RCHb
(%)
Australiac
(%)
RCHb
(%)
Australiac
(%)
0 4.6 -1.6 3.9 -8.2
1 4.4 -1.5 5.5 -6.6
2 7.1 -1.1 8.5 -5.4
3 3.7 1.0 4.7 -4.9
4 5.8 2.4 3.4 -1.4
5 3.5 2.5 -5.0 -2.4
6 3.7 3.7 -0.3 -3.4
7 3.0 4.0 -1.1 -2.7
8 4.2 4.0 5.7 -1.7
9 5.6 3.9 1.6 -2.3
10 6.1 4.0 0.8 -2.1
11 7.6 4.6 3.8 0.3
12 7.7 5.4 4.6 0.4
13 6.5 5.9 5.6 2.2
14 8.3 6.2 8.7 2.9
15 10.1 6.4 9.5 3.4
16 8.4 6.7 2.6 3.9
17 7.0 7.0 8.0 3.9
18 6.3 6.8 7.3 4.5
0-18 4.3 5.2 2.8 1.8
a Annual imaging rate calculated by dividing the number of patients
undergoing CT procedures in that year by the Estimated Resident
Population (ABS, 2008a, June 2009) in Victoria (for the RCH
calculations) or Australia (for the Australia calculations) at the midpoint
of the year, multiplied by 1,000.
b Number of patients undergoing CT examinations at the RCH.
c Number of patients undergoing CT examinations billed to Medicare in
Australia (data provided by the Australian Department of Health and
Ageing).
d Bolded and italicised figures represent those which the author believes
best represent the actual situation in paediatric CT imaging trends.
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(Pearce et al., 2011). Similarly, a large US trauma hospital also showed that imaging
in children from infants to the mid-teen years was slightly more common in males and
significantly higher for males aged 17 to 40 years (Boone and Brunberg, 2008).
Table 7.2 provides the scaled paediatric CT imaging rates for Australia in 2008. For every
1,000 persons aged 0-18 years, approximately 30-36 CT scans are performed annually.
Based on Medicare billing alone, there are about 11 CT scans performed per 1,000 persons
aged 0-18 years. Although there is little easily accessed published data on paediatric
imaging rates to make comparisons, Ono et al. (2011b) have tabulated imaging rates for
several countries for persons aged 0-15 years based on government department reports.
For example, Ono et al. (2011b) quote the number of CT procedures per 1,000 persons
(0-15 years) as being 10 for Sweden (in 2005), 7.6 for the UK (in 2006), 76-94 for the
US (in 2006) and 32-34 for Japan (in 2006). The Australian paediatric CT imaging rate
calculated in this thesis for 2008 compares favourably based on the Medicare data alone.
The scaled paediatric imaging rate for Australia, which may better reflect actual practice,
is lower than the US rate, comparable with the rate in Japan, but three times higher
than imaging rates in the UK or Sweden. The CT imaging rate for the whole population
in Australia for 2009 was estimated to be 95 CT services per 1,000 persons based on
Medicare data. The CT imaging rate for the US population was 223 procedures per 1,000
population (Mettler et al., 2009; NCRP, 2009). For both children and the population as a
whole, the Australian CT imaging rate appears to be much lower than the rate of imaging
in the US.
Assessing the change in the CT imaging rate showed increased growth for all age groups
in 1998 (Figure 7.6). This may coincide with the full introduction of helical scanning in
Australia. Alternatively, it may be a result of bulk billing only being available for CT
examinations conducted on scanners less than ten years oldii. If multiple sites replaced
scanners at the same time, this could account for an increase in the number of services
billed through Medicare. The Northern England study found that the CT imaging rate
for young people 22 years and under increased dramatically between 1997 and 2000, which
may also coincide with the introduction of helical scanning (Pearce et al., 2011). In this
thesis, there is another apparent growth period in imaging rates for all age groups in
2001 which may reflect the wider availability of MDCT scanners in Australia at this time
(Heggie, 2007). Furthermore, there is a decline in imaging rates in 2004, most significantly
in the 0-4 year age group with a 16.6% decrease on the previous year and in the 5-15 year
age group exhibiting a 7.6% decrease. This may be indicative of the heightened awareness
at this time in the international community regarding the radiation risks of CT scanning,
particularly in children. Since the turn of the century the 75-84 year age group have
consistently had the highest imaging growth rate.
The paediatric CT imaging trends in Australia are more difficult to assess than adult
iiS Goergen [Southern Health] 2009, pers. comm., 14 April.
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trends. This is because of the relatively small percentage of examinations included in the
national health care system database. A survey of CT facilities in Australia found that on
average 24% of CT examinations were non-Medicare funded for the Australian population
(Thomson and Tingey, 1997). In this thesis, the CT imaging rates at a dedicated paediatric
hospital were assessed and it was found that on average 65% of paediatric procedures were
not billed to Medicare.
When averaged over the last 10 years, the percentage of non-Medicare funded procedures
at the RCH was found to be higher in the youngest age group: 77% for the 0-4 year age
group; 60% for the 5-14 year age group; and 57% for the 15-18 year age group. This
implies that more children in the 0-4 year age group are imaged as public patients.
The distribution of CT services billed to Medicare across the age range 0-18 years demon-
strates that the majority of funded services are performed on older adolescents (Figure 7.9).
Conversely, at the RCH a greater percentage of CT patients are either very young (0-4
years) or early adolescents (10-15 years). More CT patients are less than one year old
than any other age at the RCH. The reasons for this include that the RCH has a dispro-
portionate number of very young sick patients; very young children may have a CT scan
without general anaesthetic rather than an MRI scan with general anaesthetic when either
modality could be used for diagnosis; and older patients who are able to tolerate an MRI
scan without general anaesthetic are less likely to have a CT scan. Furthermore, older
adolescents aged 17-18 years are more easily imaged at adult hospitals and less likely to
attend a children’s hospital. These trends in the younger age groups are reflected in data
for a large Israeli health service (Chodick et al., 2006).
Due to the small number of paediatric CT examinations billed to Medicare, caution
must be exercised when deriving imaging trends from Medicare data, particularly in the
youngest age group. Therefore, in this thesis, data from a dedicated paediatric hospital
was assessed and compared with the Medicare data. It was observed that trends differed
between the data sets and were in fact opposite for some ages (Table 7.3).
In 2008, 57% of CT services for the 0-4 year age group billed to Medicare in Victoria were
performed at the RCH compared to 12% for 5-14 year olds. Since only a small percentage
of RCH services were billed to Medicare, the overall number of patients at the hospital
undergoing CT examinations exceeded the number in the Medicare Victorian data for
each single year of age in the 0-4 year range. Therefore, when assessing imaging trends it
was considered justified to rely on the RCH data for trends in the 0-4 year age range and
on national Medicare data for the older ages, 5-18 years (bolded and italicised figures in
Table 7.3).
Using this premise, Table 7.3 shows that the average annual growth over the past 22 years
in the CT imaging rate for single year of age in the range 0-18 years has varied from
2.5% to 7.1%, with an average of 5.1% per year (calculated using the data from RCH for
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0-4 year olds and Medicare data for 5-18 year olds for the period 1987-2008). Although
the CT imaging rate in this age group shows growth, it does not appear to be increasing
at the same rate as the CT imaging rate in the overall Australian population. Studies
from US institutions found that the average annual increase in CT imaging for 0-17 year
olds was 8.2% (Wachtel et al., 2009) and the average annual increase in the percentage
of emergency department visits that included CT imaging for 0-18 year olds was 12.7%
(Wiest et al., 2002). A more recent study of nationwide trends in the US calculated an
annual growth rate of 13.2% from 1995 to 2008 in the number of paediatric visits to the
emergency department including a CT examination (Larson et al., 2011).
Interestingly, an assessment of the CT imaging rate for children and young people in the
last five years shows that the trend of continuous growth is beginning to change. Over the
past five years, the annual change in the CT imaging rate for paediatric age groups has
ranged from -3.4% to 8.5% for single year of age and therefore has included some year-
on-year decrease in usage (bolded and italicised figures in Table 7.3 for 2004 to 2008). A
recent US study (Townsend et al., 2010) based on a survey of North American paediatric
institutions similarly found that the utilisation of CT had decreased as a percentage of
MRI, ultrasound and CT imaging between 2003 and 2007. From Table 7.3, the average
change in CT imaging rate from 2004 to 2008 has now reduced to 1.7% per year for the
age range 0-18 years (calculated using the data from RCH for 0-4 year olds and Medicare
data for 5-18 year olds for the period 2004-2008).
Table 7.3 shows that for the 0-4 year age group, the annual growth in the CT imaging rate
in recent years does not differ considerably from the average annual growth over the past
22 years based on RCH data. One reason for the continued increase in the imaging rate
for the very young is the ability of new CT technology to perform CT angiography studies,
particularly for infants less than one year old to assess for vascular abnormalities of the
pulmonary veins and great vessels associated with congenital heart disease. Furthermore,
faster scans allow CT scans of the brain in the case of trauma to be performed without
general anaesthetic where previously the infant may have had an MRI scan or be placed
under observation.
Based on the Medicare data in Table 7.3, the 11-18 year age range demonstrates slower
growth over recent years and a decrease in the imaging rate is evident for 5-10 year olds.
This may be indicative of a heightened awareness internationally of the potential radiation
risks of CT scanning, particularly in children, and is similar to the trend found in a recent
US study (Townsend et al., 2010). The series of articles in 2001 focussed attention on
the incorrect use of adult parameters when scanning children and the increased radiation
induced cancer risk that results (Brenner et al., 2001a; Donnelly et al., 2001; Paterson
et al., 2001). The decrease in imaging rate in the 5-10 year age range and the slower
growth for 11-18 years might suggest a reduction in non-essential or unjustified imaging
in these age groups and/or an increased preference for MR imaging.
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A preliminary result from a US study also demonstrated an apparent deceleration in
growth for CT imaging of children (Wiest et al., 2002). Similar reductions in imaging
in the 0-4 year age group have not been observed in this thesis. CT imaging for the
youngest children may already have been more conservatively justified and hence the
same magnitude of decrease is not observed in that age range.
7.5 Conclusions
This thesis significantly extends current knowledge of paediatric CT scanning trends in
Australia. As stated by Pearce (2011) in an editorial on this work “it is a welcome and
important addition to the sparse literature”. It was found that the number of CT services
provided in Australia is clearly increasing and is exceeding population growth. When
analysing CT imaging rates using Medicare data, consideration must be given to the
number of services not billed to this system. From this thesis it is evident that this is a
significant percentage for 0-18 year olds. Based on combined data from Medicare and a
dedicated paediatric hospital it appears that the rate of paediatric CT imaging growth has
slowed in recent years and even demonstrates a reduction in some age brackets. Whilst it
is encouraging that the imaging rate for children and young people is lower than that for
adults, overall the imaging rate continues to increase. Some increase may be warranted
due to improvements in the diagnostic power of CT. However, it is essential that every
CT examination is justified and is of net benefit to the individual.
7.6 Publications Arising from this Chapter
1. Brady, Z., Cain, T. M. and Johnston, P. N., Paediatric CT imaging trends in
Australia, Journal of Medical Imaging and Radiation Oncology, 2011, 55:132-142
(Brady et al., 2011d).
(a) The above paper led to a request for interview and citations in several media
forums (Collins, 20 April 2011; Corderoy, 17 May 2011; Nafziger, 21 April 2011,
Gastroenterology Update, 27 April 2011).
(b) The editorial (Pearce, 2011) of the issue of the Journal of Medical Imaging and
Radiation Oncology that this paper appeared in was dedicated to a discussion
of the issues raised.
2. Brady, Z., Cain, T. M. and Johnston, P. N., Paediatric CT in Australia - trends
and risk (EPSM ABEC 2010 Conference Proceedings), Australasian Physical & En-
gineering Sciences in Medicine, 2011, 34(1):110 (Brady et al., 2011a).
3. Brady, Z., Cain, T. M. and Johnston, P. N., Computed tomography - are we imaging
more or less? presented at the RANZCR/AIR/FRO/ACPSEM Combined Scientific
Meeting, 2009, Brisbane, Australia (Invited Speaker) (Brady et al., 2009).
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Figure 7.9: Percentage age distribution of computed tomography (CT) patients from 0
to 18 years billed to Medicare in Victoria (MBS VIC) and at the Royal Children’s Hospital
Melbourne (RCH) in 2008 (data provided by the Australian Department of Health and
Ageing and the RCH). The percentage age distribution of the Victorian population in
these age groups is also shown (ABS, 2008a, June 2009).
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Chapter 8
Projected Cancer Risks for
Paediatric CT in Australia
8.1 Introduction
Despite the prevalence of CT as a diagnostic imaging tool in hospitals today, the typical
doses and associated radiation risks are not well understood. Primarily this is because the
doses are not accurately known or easily calculated (see Chapter 5). Furthermore, there
are large uncertainties, in addition to a lack of consensus, regarding the risk from radia-
tion exposure at low doses. The United States National Research Council of the National
Academies regularly reviews the available epidemiological and experimental research on
the biological effects of ionising radiation (BEIR) and provides a framework for estimat-
ing cancer risk due to radiation exposure. The latest report, BEIR VII (NRC, 2006),
was delivered in 2006 and provides age-, sex- and site-specific estimates of the lifetime
attributable risk (LAR) associated with radiation exposure.
The Life Span Study (LSS) of the atomic bomb survivors is the principal source of data
considered by the BEIR VII Committee along with medical and occupational radiation
studies. The BEIR VII Report supports the linear no threshold (LNT) model as the
best descriptor of the relationship between solid cancer incidence and low dose radiation
exposure (NRC, 2006). A linear-quadratic model is used for leukaemia as it was found
to provide substantially better agreement than the LNT model with the observed risk
from exposure. The LNT theory is widely accepted (Brenner et al., 2003) as the most
plausible model for radiation induced cancers for low dose exposures and is also adopted
by the International Commission on Radiological Protection (ICRP) as the basis of the
international system of radiation protection (ICRP, 2007b).
Cancer risk estimation based on BEIR VII modelling is limited by the uncertainties that
exist from using the LSS data to derive radiation induced cancer risk. The sources of
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uncertainty arise from transporting the cancer incidence and mortality from the Japanese
atomic bomb survivors to a Western population. Furthermore, the LSS data is extrapo-
lated to low dose and dose rate exposure situations. The risk modelling of BEIR VII is
also affected by sampling variability in the model parameter estimates for the LSS data.
Despite these inherent uncertainties, one of the most useful applications of the BEIR VII
radiation risk models is for estimating the detriment from exposure situations where doses
differ substantially across the body. Exposure from CT examinations falls within this
scope. Other studies have also applied the BEIR VII attributable cancer risks to CT
exposures on the basis that it is the best method currently available (Berrington de Gon-
zalez et al., 2009; Brenner et al., 2001a; Brenner and Hall, 2007; Einstein et al., 2007a;
Smith-Bindman et al., 2009).
The aim of this part of the thesis was to assess the lifetime cancer incidence and mortality
risks for Australian children attributable to radiation exposure from CT. By applying the
BEIR VII risk models based on cancer incidence and mortality to the doses measured in
this thesis, projected cancer risk estimates can be made.
8.2 Methods
The organ and tissue absorbed doses for CT brain, chest and abdomen/pelvis examina-
tions were measured by thermoluminescence dosimetry (TLD) in a physical anthropomor-
phic phantom representing a 10 year old child (Chapter 3). These measurements were
undertaken for typical CT protocols performed at the Royal Children’s Hospital (RCH)
Melbourne. The absorbed doses for organs and tissues for those malignancies identified in
BEIR VII are given in Table 8.1. The BEIR VII lifetime incidence and mortality risks for
males and females are provided in Table 8.2 for radiation exposure at 10 years of age.
Table 8.1: Organ and tissue absorbed doses measured by TLD for
a 10 year old child.
Organ/Tissue Absorbed Dose (mGy)
CT Brain CT Chest CT Abdomen/Pelvis
Stomach 0.07 4.8 8.9
Colon 0.03 0.52 8.0
Liver 0.12 10 8.5
Lung 0.46 9.9 4.1
Breast (Females) 0.27 9.1 1.3
Uterus (Females) 0.01 0.12 6.6
Ovary (Females 0.01 0.13 6.5
Prostate (Males) 0.01 0.06 5.8
Bladder 0.01 0.08 6.9
Other (Females) 2.7 5.2 3.7
Other (Males) 2.2 4.3 3.2
Bone Marrow 6.1 2.4 3.2
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Table 8.2: Lifetime attributable risk (LAR) of site-specific solid cancer
and leukaemia mortality for males and females for exposure at 10 years
of age (NRC, 2006).
Cancer Site Incidencea Mortalitya
Males
% per Gy
Females
% per Gy
Males
% per Gy
Females
% per Gy
Stomach 0.0055 0.0072 0.0030 0.0041
Colon 0.0241 0.0158 0.0117 0.0073
Liver 0.0043 0.0020 0.0031 0.0017
Lung 0.0216 0.0504 0.0219 0.0442
Breast - 0.0712 - 0.0167
Uterus - 0.0036 - 0.0008
Ovary - 0.0073 - 0.0039
Prostate 0.0067 - 0.0012 -
Bladder 0.0150 0.0152 0.0032 0.0043
Other 0.0503 0.0523 0.0200 0.0220
Thyroid 0.0050 0.0275 - -
All Solidb 0.1325 0.2525 0.0641 0.1051
Leukaemia 0.0120 0.0086 0.0071 0.0053
All Cancersc 0.1445 0.2611 0.0712 0.1104
a These estimates are obtained as combined estimates based on relative and
absolute risk transport adjusted by a dose and dose rate effectiveness factor
(DDREF) of 1.5 except for leukaemia, which is based on a linear-quadratic
model (NRC, 2006).
b The category of all solid cancers includes all cancer sites except for leukaemia.
c The category of all cancers includes all solid cancers and leukaemia.
The absorbed dose to the bone marrow was used for leukaemia risk projections (NRC,
2006). BEIR VII uses the absorbed dose to the colon to determine the risk for the “other”
cancers category, based on the same principle used in the LSS. In this thesis the absorbed
dose used for the “other cancers” category is based on the methodology of Brenner et al.
(2001c), where the doses are summed over radiosensitive organs and tissues not explicitly
listed in the BEIR VII list and weighted according to ICRP 103 tissue weighting factors.
A similar method is used in PCXMC risk assessments (Tapiovaara and Siiskonen, 2008).
Therefore, the “other” organ and tissue absorbed dose (Dother) was calculated according
to:
Dother =
∑
T wTDT∑
T wT
(8.1)
where wT is the ICRP 103 tissue weighting factor and DT is the organ or tissue absorbed
dose. These organs and tissues include the oesophagus, bone surface, brain, salivary
glands, skin, adrenals, extrathoracic (ET) region, gall bladder, heart, kidney, lymph nodes,
muscle, oral mucosa, pancreas, small intestine, spleen, thymus and testes (males).
The organ absorbed doses measured in this thesis were compared with absorbed doses mea-
sured in comparable studies. The absorbed doses were then multiplied by the BEIR VII
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sex- and site-specific LARs for cancer mortality and incidence for radiation exposure at
10 years of age. Calculated site-specific lifetime attributable cancer risks were summed
over the radiosensitive organs and tissues to give a total lifetime radiation-attributable
cancer risk resulting from each type of CT examination assessed. These were compared
with natural cancer incidence and mortality for the Australian population and as pro-
vided in ICRP 103 for a Euro-American population. The lifetime attributable risks for
each CT examination calculated in this thesis are equivalent to the concept of “effective
risk” proposed by Brenner (2008) or renamed “risk index” by Li et al. (2011a).
The calculated incidence and mortality risks for CT brain, chest and abdomen/pelvis
examinations were then multiplied by the number of children aged 10 years undergoing
these types of CT examinations in 2008 in Australia. The number of CT examinations
was calculated from Medicare data supplied by the Australian Department of Health and
Ageing, adjusted by previously derived (Chapter 7) scaling factors to account for the
number of services not billed to Medicare. This provided a more realistic range of the
actual number of patients undergoing CT examinations annually in Australia.
The calculated incidence and mortality risks for these types of CT examinations were also
applied to the entire 0-18 year age group. The risks will be underestimated for infants,
while overestimated for adolescents and hence will provide an intermediate estimate of
the level of risk for the entire cohort. In addition to reduced CT parameters for younger,
smaller children and higher site-specific radiation risk coefficients for younger children,
there can also be variations in different organs with age. For example, almost all bone
marrow is active (red bone marrow) at birth and with age gradually becomes inactive,
with only about a third remaining active in adulthood (ICRP, 2002). Therefore, the bone
marrow absorbed dose which directly correlates with leukaemia incidence will vary with
age, particularly in childhood. The radiation risks calculated for a CT scan undertaken
on a 10 year old child provide a reasonable benchmark for the average risk across the
0-18 year age band. Therefore, these calculated risks were applied to the number of CT
examinations performed for the relevant body regions at the RCH in 2008 across the 0-18
year age range and more broadly to the Australian population aged 0-18 years undergoing
CT scans (number of patients billed to Medicare in 2008 adjusted for the number not
billed).
8.3 Results
There are a limited number of studies in the literature detailing organ and tissue absorbed
doses for CT examinations on children (Brenner et al., 2001a; Brenner and Hall, 2007;
Coursey et al., 2008; Fujii et al., 2007). This is due to the complexity of undertaking
these types of measurements and the lack of resources and time for performing dosimetry
experiments in the clinical environment. Furthermore, where studies exist, it is often
difficult to make direct comparisons due to the number of differing variables that have
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considerable effect on dose. These include the type of experimental or computational
method, the representative age and type of anthropomorphic phantom used, the modelling
of the CT scanner, if applicable, and/or the CT examination parameters (e.g. kVp, mAs,
collimation, pitch and scan length).
A comparison of the organ and tissue absorbed doses measured in this thesis with those
from the literature is given in Table N.1 (Appendix N). The most regularly quoted risk
estimates for paediatric CT are those calculated by Brenner et al. (2001a; 2007). The
absorbed doses used in their first study (Brenner et al., 2001a) are considerably higher than
those measured in this thesis. One of the assumptions of their initial study was that adult
CT parameters were being used on children (Paterson et al., 2001) and the organ absorbed
dose estimates were made accordingly. For a 10 year old, they calculated the brain dose
to be 50 mGy from a CT head examination. This was decreased to 35 mGy in their
subsequent study (Brenner and Hall, 2007), which is very close to the value measured in
this thesis for a CT brain examination (34 mGy). Similarly, for a CT abdomen examination
the absorbed doses to the stomach and liver were 30 and 28 mGy respectively (Brenner
et al., 2001a), decreasing to 18 and 16 mGy in the second study (Brenner and Hall,
2007). However, these are approximately twice as high as the stomach and liver absorbed
doses measured for the CT abdomen/pelvis examinations in this thesis (8.9 and 8.5 mGy,
respectively).
Fujii et al. (2007) measured the organ absorbed doses in an anthropomorphic phantom
representing a younger child (6 years) on the same type of scanner for a CT chest ex-
amination with slightly different parameters. Absorbed doses are comparable with those
measured in this thesis except for the liver and stomach, which are lower. This is due to
the increased scan length for the CT chest examination in this thesis, which would have
included more of the liver and stomach in the scan volume. Coursey et al. (2008) also
provided organ absorbed dose measurements for a CT chest examination in a phantom
representing a younger child (5 years), which are comparable to this thesis. The breast
absorbed dose is lower, which is most likely due to the age difference of the phantoms and
the lower tube current used.
Using the organ absorbed doses measured in this thesis and the BEIR VII age-, sex- and
site-specific LARs, the lifetime cancer incidence and mortality risks for a 10 year old child
for a CT brain, chest or abdomen/pelvis examination were calculated and are given in
Table O.1 (Appendix O). Natural site-specific cancer incidence and mortality risks for the
Australian population (AIHW, 2009) and for a Euro-American population (ICRP, 2007b)
are also provided for comparison. The site-specific lifetime cancer incidence and mortality
risks are also shown in Figures 8.1 and 8.2. The overall lifetime attributable cancer risks for
all solid cancers and leukaemia are shown in Figure 8.3 for males and females undergoing
a CT examination at 10 years of age.
Another way of expressing the lifetime radiation induced cancer mortality risks is that
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the risk of exposure for a CT head examination of a male 10 year old child is one in
10,100 (Table O.2, Appendix O). Similarly, the radiation risk for the same child from a
CT chest examination is one in 2,700 and from a CT abdomen/pelvis examination is one
in 2,800. The risk of exposure to a female child of the same age is one in 8,500 from a
CT head examination, one in 1,300 for a CT chest examination and one in 2,100 for a CT
abdomen/pelvis examination.
The potential number of fatal and non-fatal radiation induced cancers can be predicted by
multiplying the calculated site- and sex-specific cancer incidence and mortality estimates
by the number of paediatric CT examinations undertaken in Australia. Table 8.3 shows
the predicted number of radiation induced malignancies from one year of CT scanning
(based on 2008 figures) in Australia in the 0-18 year age range.
Table 8.3: Predicted number of radiation induced non-fatal and
fatal cancers from CT brain, chest and abdomen/pelvis examinations
undertaken on 0-18 year olds in Australia in 2008.
Examination No. Incident Cancers No. Fatal Cancers
CT Brain ∼15 <10
CT Chest ∼20 ∼10
CT Abdomen/Pelvis ∼15 <10
a Calculations based on the number of patients for whom CT services were
billed to Medicare in 2008 (data provided by the Australian Department of
Health and Ageing). This number was adjusted by a scaling factor derived
in Chapter 7 to take into account non-Medicare funded CT services.
b The number of CT examinations was multiplied by the LAR for “all
cancers” calculated in this thesis based on site-specific organ absorbed doses
measured with TLDs (Chapter 3) multiplied by the site- and sex-specific
BEIR VII LARs for exposure at 10 years of age (NRC, 2006).
c Cancer risk projections detailed in this thesis should be considered with
regard to the considerable and multi-faceted uncertainties involved in these
types of estimates. However, albeit simplified, this is the best approach
currently available.
8.4 Discussion
8.4.1 Limitations of Risk Modelling
Large uncertainties exist in the BEIR VII estimated cancer incidence and mortality lifetime
risks attributable to radiation exposure. These risks predominantly rely on analyses of
the cancer incidence and mortality in Japanese atomic bomb survivors who were exposed
to intermediate radiation doses from gamma ray and neutron exposure. Uncertainties
arise when extrapolating to the lower doses and dose rates typical of CT low energy X-
ray photon exposures, from transporting these risks to a different population and from
sampling variability in the model estimates based on the Life Span Study data.
The subjective confidence intervals for the LARs in BEIR VII cover at least an order of
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Figure 8.1: Site-specific lifetime attributable cancer incidence risks for a 10 year old
undergoing a CT brain, chest or abdomen/pelvis examination for a) males and b) females.
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Figure 8.2: Site-specific lifetime attributable cancer mortality risks for a 10 year old
undergoing a CT brain, chest or abdomen/pelvis examination for a) males and b) females.
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magnitude and for site-specific risks can differ by a factor of two or more (NRC, 2006).
These uncertainties are combined with the uncertainties in organ absorbed dose mea-
surement when determining cancer risk estimates. Therefore, the cancer risk projections
detailed in this thesis should be considered with regard to the considerable and multi-
faceted uncertainties involved.
Shuryak et al. (2010) have recently postulated that the risk modelling in BEIR VII is
inconsistent with the observed relative risks of radiation induced cancer in the atomic
bomb survivors in the Life Span Study. By modelling radiation initiation effects, as
considered in BEIR VII, as well as radiation promotion of pre-existing premalignant cells,
they show that relative radiation risk may in fact be underestimated in middle age. The
proposed risk model still demonstrates a higher risk in the young, but it is somewhat
lower than the risks estimated in BEIR VII. Overall, the risk of radiation induced cancer
incidence is 37% lower for exposure at 10 years of age with the Shuryak et al. (2010) model.
Furthermore, site-specific risks vary considerably with age. Colon cancer risk is higher in
older age groups, while breast cancer risk decreases with increasing age. For exposure at
10 years of age, the initiation and promotion model estimates a decrease in cancer risk
compared with an initiation only model of 78% for the colon, 59% for the stomach, 44%
for the breast, 42% for the bladder, 37% for the liver and 14% for the lung. In terms of
applying risk factors to patient populations undergoing CT examinations, they comment
that the risk-benefit assessment will not be substantially affected even if the estimated
risks are increased by a factor of two (Shuryak et al., 2010). This is based on the premise
that the diagnostic benefit from a CT examination will far outweigh any small associated
radiation risk (Brenner and Hall, 2007).
8.4.2 Comparison of Risks from CT Examinations
For the three types of CT examination considered for a 10 year old in this thesis, the
greatest risk of death is from lung cancer in females from a chest examination (one in
2,300). This is a factor of two higher than the lung cancer mortality risk in males, which
is the next highest risk (Figure 8.2). This reflects the LARs for cancer mortality for the
lung, which are higher than any other site-specific mortality LAR for both males and
females (Table 8.2). A relatively high breast cancer mortality LAR for females coupled
with a high absorbed dose to this tissue from chest examinations places the breast in the
high risk category.
For some radiation induced cancers, such as lung cancer, there is a poor prognosis and a
greater likelihood that radiation induced cancer at this site will lead to death. However, for
some radiation induced cancers, the lethality fraction is comparatively low, with relatively
good survival for radiation induced cancer at these sites. It is more pertinent to discuss the
incident cancers for these sites. An example is radiation induced thyroid cancer, which is
rarely fatal (NRC, 2006). Considering the examinations on a 10 year old child, the highest
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incident risk for thyroid cancer is for females undergoing a CT chest examination (one in
3,300). The risk of non-fatal breast cancer is also relatively high and combined with the
high absorbed dose to the breast for a CT chest examination, the incidence risk of breast
cancer is one in 1,500 for females.
Interestingly, due to the high radiation induced lung cancer mortality risks, even the CT
brain examinations lead to some risk of dying from lung cancer due to the small absorbed
dose measured for the lung for this examination. Although the lung absorbed dose mea-
surement with the TLDs was low (0.46 mGy) it was confirmed by a CT-Expo (Stamm
and Nagel, 2011b) calculation (0.48 mGy) and is considered to be a dose arising from
scattered radiation. Overall, the CT brain examination risks are greatest from “other”
malignancies, which are dominated by the absorbed dose to the brain. Leukaemia is the
next highest fatal risk from CT brain examinations due to the amount of active bone
marrow in the skull of children and the high absorbed dose to this region.
The estimated lifetime mortality risks are somewhat greater for females than for males,
particularly for CT chest examinations (Figure 8.3). This is because of the substantially
greater risks from the exposure of the lung in females compared with males (Table 8.2).
The difference in lifetime mortality risks between sexes is less evident for the CT brain
examination, as the risks for “other” cancers, which dominate the risk for this type of direct
exposure of the brain, are quite similar between the sexes. The risk of fatal leukaemia is
a relatively small component of the total cancer risk for all types of CT examination for
both males and females.
The mortality risk from all cancers is about half the risk of cancer incidence. However,
the site-specific risks are quite different and this explains why for males the highest cancer
incidence is from CT abdomen/pelvis examinations, yet the highest cancer mortality is
due to CT chest examinations (Figure 8.3). Comparing the number of site-specific induced
cancers in males which progress to malignancy shows that more males potentially “die”
from lung cancer than actually “have” lung cancer (Figure 8.4). This disparity is due to
inherent uncertainties in the BEIR VII risk estimates. Figure 8.4 also shows that radiation
induced lung cancer is the most likely type of cancer to progress to death for both males
and females, followed by cancer of the liver.
8.4.3 Comparison of Calculated and Published Risks
Studies are beginning to emerge which use the BEIR V (Brenner et al., 2001a; Brenner
and Hall, 2007) or BEIR VII (Berrington de Gonzalez et al., 2009; Smith-Bindman et al.,
2009) cancer risk models to estimate the radiation induced cancer mortality for children
and/or young adults from medical imaging. Tables 8.4 and 8.5 provide a summary of
comparable results from this thesis and other studies for paediatric CT imaging.
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Figure 8.3: Lifetime attributable solid cancer and leukaemia risks for a 10 year old
undergoing a CT brain, chest or abdomen/pelvis examination.
0%
20%
40%
60%
80%
100%
120%
P
e
rc
e
n
ta
g
e
 o
f 
in
c
id
e
n
t 
c
a
n
c
e
rs
 p
ro
g
re
s
s
in
g
 t
o
 
d
e
a
th
 
Cancer Site 
Males
Females
Figure 8.4: Percentage of site-specific radiation induced cancers progressing to cause
death for males (black) and females (grey).
167
CHAPTER 8. PROJECTED CANCER RISKS FOR PAEDIATRIC CT IN
AUSTRALIA
This thesis found that the radiation induced cancer mortality risk from CT brain exami-
nations for a 10 year old child is lower than the risk estimated in two studies by Brenner
et al. (2001a; 2007). In both studies, they found the risk to be about one in 4,000. The
difference is readily explained by comparing the risk factors from the earlier BEIR V re-
port (NRC, 1990) used by Brenner et al. (2001a; 2007) with the risks given in the current
BEIR VII report (NRC, 2006) used in this thesis. For example, the sex-averaged lifetime
mortality estimates for “other” cancers are lower by a factor of two in BEIR VII. Since
this category of cancers are the highest contributor to radiation induced mortality for CT
brain examinations due to the absorbed dose to the brain, the estimates from Brenner
et al. (2001a; 2007) appear comparable with those from this thesis. The higher brain
absorbed dose used by Brenner et al. (2001a) in their first study, which reflected the use
of adult CT parameters on children, does not have a large effect on the total risk. This
is because the brain absorbed dose is only one contributing organ amongst many to the
category of “other” cancers and is not given a site-specific cancer risk.
The gender-averaged mortality risk from CT abdomen/pelvis examinations was found in
this thesis to be about one in 2,450. Brenner et al. (2001a) found the risk for abdominal
(excluding the pelvis) examinations to be about one in 800 based on the use of higher
adult CT parameters (Paterson et al., 2001) and about one in 1,250 using lower organ
absorbed doses (Brenner and Hall, 2007). The absorbed doses used were higher than
those measured in this thesis (Table N.1, Appendix N), which when combined with the
mostly higher risk factors in BEIR V leads to the conclusion that the risk estimates are
fairly comparable with those from this thesis.
Two recent comprehensive studies (Berrington de Gonzalez et al., 2009; Smith-Bindman
et al., 2009) estimate the age- and sex-specific cancer incidence risks attributable to CT
radiation exposure in the US population applying BEIR VII risk factors (Table 8.5). The
risks calculated in the current thesis for body examinations are considerably lower than
those calculated for the US population. This is surprising since the risks calculated in this
thesis are for a younger patient population in which the risks are expected to be higher
due to increased radiosensitivity compared with adults, even young adults. Since the
converse is true when comparing these studies, this may reflect the more optimised scan
parameters used at the RCH, resulting in lower organ absorbed doses and consequently
reduced overall risk.
The Smith-Bindman et al. (2009) study found the risk for females to be higher than
for males from CT brain examinations although this was not found in the Berrington
de Gonzalez et al. (2009) results. This was also an interesting finding of this thesis
arising from the small lung dose measured from the CT brain examination. This dose
combined with the high risk of radiation induced lung cancer in females, contributed to
the disparity in overall risk between males and females. In general, the radiation induced
cancer incidence risks from CT brain examinations calculated in this thesis were lower
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than the US results for 15 year olds (Berrington de Gonzalez et al., 2009), but higher than
the risks for 20 year olds (Smith-Bindman et al., 2009).
8.4.4 Projected Cancer Risks
The site- and sex-specific cancer incidence and mortality risks estimated in this thesis
can be applied to the number of paediatric CT examinations undertaken in Australia
to assess the potential number of fatal and non-fatal cancers induced (Table 8.3). The
proportion of CT examinations conducted on children aged 5 to 14 years billed to Medicare
in 2008 for the brain, chest and abdomen/pelvis are approximately 35%, 5-10% and 5-10%
respectively (Medicare). This does not include examinations which combine any of these
regions (for example chest/abdomen/pelvis). This breakdown of examinations is reflected
in the RCH data for 2008 for children aged 10 years. The RCH data shows that a large
percentage of the remaining examinations are conducted on extremities.
Other studies based on distributions of adult CT examinations have found that the pro-
portion of head examinations is 30-40% (Berrington de Gonzalez et al., 2009; Brenner
et al., 2001a; NCRP, 2009; Thomson and Tingey, 1997), chest examinations is 8-20%
(Berrington de Gonzalez et al., 2009; NCRP, 2009; Thomson and Tingey, 1997) and ab-
domen/pelvis examinations is 20-32% (Berrington de Gonzalez et al., 2009; Brenner et al.,
2001a). A recent assessment of a sample of children’s health care records in the US, found
that almost one-third of CT examinations were of the head (Dorfman et al., 2011). Ab-
domen and pelvis CT examinations were performed separately and therefore cannot be
directly correlated with this thesis, although they accounted for 30% of the CT imaging
(Dorfman et al., 2011). Chest CT examinations accounted for about 4% of all CT imaging
(Dorfman et al., 2011).
A study of CT records in Northern England for patients under 22 years showed a much
higher percentage of head and/or neck examinations (73%) although the cohort assessed
was for an earlier time period (1993-2002) (Pearce et al., 2011). Chest imaging and
abdomen/pelvis imaging each contributed to approximately 10% of all CT imaging (Pearce
et al., 2011). Ono et al. (2011a) found 68% head imaging and 17% body imaging based
on a Japanese survey of CT scanning in children. In Israel, about 55% of CT imaging
was of the head in 0-18 year olds, and approximately 25% of the body, including pelvis,
spine, chest and abdomen (Chodick et al., 2006). In this thesis, the following examination
distribution for children has been used: 35% for head examinations and 10%i each for
chest and abdomen/pelvis examinations.
In Australia, the total number of CT examinations undertaken on children aged 0-18 years
billed to Medicare was 58,183 (males 31,115; females 27,068). These examinations need
iThe upper values of these ranges have been used as these are still likely to underestimate the actual
volume of CT examinations performed on these regions of the body. These examinations are often combined
with other body regions and are difficult to categorise into this type of breakdown.
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to be scaled by a factor of 3 (range 2.7 to 3.3) to account for those examinations not
billed to Medicare (Chapter 7). Projected cancer risk estimates were then made based
on this range, the breakdown of examinations according to body region in this age group
and gender-averaged cancer incidence and mortality risks calculated for a 10 year old
from organ absorbed doses measured in this thesis (Table 8.3). Due to the latency period
for cancer to become apparent, these cancers will only be evident years after the CT
examinations have been performed and hence will not be easily linked to the CT radiation
exposure.
Despite the risk being lower from CT brain examinations than from body examinations,
CT brain scans lead to an almost equivalent number of cancers in the Australian population
as produced by each type of body scan. This is because of the much larger number of brain
examinations performed in this age group in Australia. Overall, CT chest examinations
lead to the greatest number of fatal radiation induced cancers.
Applying the same assumptions and risk estimates to the number of CT examinations
performed at the RCH reveals that it would take more than one year of scanning to
induce a fatal cancer from a single type of any of the examinations considered here. For all
CT brain examinations currently performed at the RCH, one fatal cancer will be caused
due to about seven years of CT scanning. It would take about five years of CT chest
examinations to lead to one fatal cancer and about seven years of CT abdomen/pelvis
examinations to result in one fatal cancer. These estimates assume the same CT imaging
rates as performed at the RCH in 2008 and the same organ and tissue absorbed doses as
measured in 2010 from standard protocols used on the RCH CT scanner.
The projected risks calculated in this thesis from CT scanning are much lower than the
natural site-specific cancer mortality rates in Australia (Tables O.1 and O.2, Appendix O).
For a 10 year old male undergoing CT examinations of the brain, chest or abdomen/pelvis
the projected risks of radiation induced fatal cancer are about 2,020, 540 and 560 times
lower respectively than the natural cancer mortality rate of one in five in Australia. For
a 10 year old female the fatal cancer risks are about 1,420, 220 and 350 times lower from
CT brain, chest and abdomen/pelvis examinations respectively than the natural cancer
mortality rate of one in six in Australia.
The risk estimates provided in this thesis for the total number of CT examinations per-
formed in the 0-18 year age group for Australia and at the RCH are based only on brain,
chest and abdomen/pelvis examinations. It is assumed that these account for about 55%
of all examinations in this age group (excluding those examinations that are combinations
of these). To provide a very approximate estimate of the total predicted number of fatal
cancers from one year of CT examinations, the risks can be assumed to be generally the
same for the remaining 45% of examinations. Based on this assumption, it is predicted
that up to 50 fatal cancers will be attributable to each year of paediatric CT scanning
in Australia (based on current Australian trends and doses at the RCH) in addition to
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the number of natural fatal cancers in this same group of children, which would be ex-
pected to be about 28,000-34,000ii over their lifetime. Similarly using this assumption
and combining the risks from each type of examination, it is expected that each year of
CT scanning of children aged 0-18 years at the RCH will lead to one fatal cancer. The
number of natural fatal cancers for this cohort of children would be about 650. Overall,
the estimated projected number of fatal cancers is only a very small (0.14%) percentage
increase over the natural background rate.
8.4.5 Risks in Perspective
To put the risks from CT examinations in perspective, Table 8.6 shows the lifetime risk of
dying from different causes in Australia. The mortality risk from a single CT examination
at the age of 10 years is considerably lower than any of the other causes of death considered.
The risks from CT examinations are only comparable when assessing causes of death in
a narrow age range. For example, the risk of death from a CT chest or abdomen/pelvis
examination for a 10 year old boy over his lifetime is roughly equivalent to half the risk of
death from all other causes while he is aged 10-14 years. However, considering the boy’s
risk of death over his lifetime (to age 74 years) from all causes, the risk from the CT body
examination is more than 700 times lower.
For a 10 year old girl, the risk of death from a CT chest examination over her lifetime
is roughly equivalent to double the risk of death from all other causes while she is aged
10-14 years. It is noted that girls are at a much lower risk of dying in this age group than
boys, yet their risk of radiation induced cancer is higher than boys undergoing the same
CT examination. The girl’s risk of death over her lifetime from a CT chest examination
is more than 200 times lower than the risk of death (to age 74 years) from all other
causes.
8.5 Conclusions
Based on current CT scanning rates and radiation doses, this thesis has shown that the
radiation risks account for only a very small percentage increase over the natural cancer
rate. The risks for the individual patient are small, particularly for a well optimised,
justified examination. These risk estimates are based on absorbed doses measured at
the RCH, which is a dedicated paediatric hospital. Therefore, it is expected that doses
at this institution arise from best clinical practice and are already well optimised, hence
presenting a best case scenario for risk projections. When considering the potentially
wide variation in doses across Australia, these risks could in fact be much higher. In that
case, when the risks are applied to the population there is the potential for a detrimental
health impact to arise. It would be extremely challenging to detect this increased level
iiThis range is based on the estimated range for the number of CT examinations performed on 0-18
year olds in Australia.
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of risk in the population due to the high natural incidence of cancer and the sometimes
lengthy latency period for radiation induced cancers to become evident. However, there
are some epidemiological studies (Giles, 2004) commencing, including one in Australia
(Brady et al., 2011f; Mathews and Chesson, 18 February 2009), which will be important
in assessing current theoretical risk models at low radiation doses.
It is important to acknowledge the considerable uncertainties involved in projections of
risk from radiation exposure and any use of these risk estimates must take these into
account. It has been assumed that even at low doses of radiation there is a small (and
theoretical) risk of cancer induction. The mechanistic risk model (NRC, 2006) on which
these estimates are based considers that radiation risk decreases with increasing age, which
may be inconsistent with models taking into account competing biological radiation effects
such as cancer promotion (Shuryak et al., 2010). A further limitation of the estimates made
here is that the risks for a 10 year old have been applied across the 0-18 year age range,
which will underestimate the risk in the younger age groups and overestimate the risk in
the older age groups. However, considering the assumptions and uncertainties involved in
these risk estimates, this will give an adequate, albeit limited, indication of the paediatric
risks.
Providing a better understanding of the lifetime attributable radiation risks for children
undergoing CT examinations will hopefully lead to better justification for scans in the
future. Furthermore, it will be a driver for undertaking dose optimisation at institutions
where the doses are much higher. Overall, the risk due to radiation exposure for an
appropriately justified and well optimised CT scan for an ill child hospitalised at the
RCH, for example, will almost always be much lower than the risk associated with not
performing the scan. The risk projections in this thesis must be considered in the context of
the substantial diagnostic and/or treatment benefit gained from a justified and optimised
CT scan.
8.6 Publications Arising from this Chapter
1. Brady, Z., Doses and risks in paediatric imaging in Australia, presented at the
Siemens Low Dose Academy, 2012, Sydney, Australia (Invited Speaker) (Brady,
2012a).
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Table 8.4: Comparison of sex-averaged paediatric cancer mortality risks
for CT brain and abdomen/pelvis examinations. Risk is expressed in terms
of the number of patients undergoing CT examinations (in Australia for this
study and in the US for the Brenner et al. studies (2001a; 2007)) that would
lead to the development of one radiation-induced cancer.
This Studya Brenner et
al. (2001a)b
Brenner et
al. (2007)c
Age at exposure (years): 10 10 10
Examination
CT Brain 9,300 4,000 4,000
CT Abdomen/Pelvis 2,450 800d 1,250d
a Cancer mortality risks for this thesis were calculated based on site-specific organ
absorbed doses measured with TLDs (Chapter 3) multiplied by the site- and
sex-specific BEIR VII LAR for exposure at 10 years of age (NRC, 2006).
b Brenner et al. (2001a) obtained paediatric organ absorbed doses by scaling adult
organ absorbed doses reported in a 1989 British survey (Shrimpton et al., 1991) by
relative age-dependent changes in effective dose estimated by Huda et al. (1997).
These age-dependent organ absorbed doses were multiplied by the age-specific BEIR
V LAR (NRC, 1990).
c Brenner et al. (2007) used paediatric organ absorbed doses from a 2000 US survey
(CRCPD, 2006). These age-dependent organ absorbed doses were multiplied by the
age-specific BEIR V LAR (NRC, 1990).
d These values are for abdomen examinations only (i.e. they do not include the
pelvis).
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Table 8.5: Comparison of male and female paediatric cancer incidence risks from CT
brain, chest and abdomen/pelvis examinations. Risk is expressed in terms of the number
of patients undergoing CT examinations (in Australia for this study and in the US for the
Berrington de Gonzalez et al. (2009) and Smith-Bindman (2009) studies) that would lead
to the development of one radiation-induced cancer.
This Study Berrington de
Gonzalez et al.a
Smith-Bindman
et al.b
Gender: Females Males Females Males Females Males
Age at exposure (years): 10 10 15 15 20 20
CT Examination
CT Brain 3,500 4,900 2,500 2,000 4,360 7,350
CT Chest 600 1,700 350 1,100 390 1,040
CT Abdomen/Pelvis 1,100 1,400 500 500 500 660
a Berrington de Gonzalez et al. (2009).
b Smith-Bindman et al. (2009).
c Cancer mortality risks for this thesis were calculated based on site-specific organ absorbed doses
measured with TLDs multiplied by the site- and sex-specific BEIR VII LAR for exposure at 10 years
of age (NRC, 2006).
d Berrington de Gonzalez et al. (2009) provide risk estimates for a range of ages, the younger age
groups being 3 years and 15 years. The risk estimates for 15 year olds are provided in the Table
above. The organ absorbed doses are calculated from technical parameters taken from a 2000 US
survey (CRCPD, 2006) and input into CT-Expo (Stamm and Nagel, 2011b). The BEIR VII risk
models were then applied, with minor modifications, and additional models were developed for sites
not covered by BEIR VII.
e Smith-Bindman et al. (2009) conducted a retrospective patient dose survey and calculated effective
dose using the dose length product (DLP) conversion method (Shrimpton et al., 2006). They
confirmed the effective doses for a small subset of patients with the ImPACT CT Dosimetry Tool
(ImPACT, 2011). The calculated effective dose was multiplied by the “all cancer” BEIR VII LAR.
The youngest age that risk estimates are provided for is 20 years and these risks are given in the
Table above.
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Table 8.6: Lifetime risk of dying for the Australian population from various causes.
Cause of Death Males Females Persons
CT brain examination at 10 years of agea 0.010% 0.012% 0.011%
CT chest examination at 10 years of agea 0.037% 0.076% 0.056%
CT abdomen/pelvis examination at 10 years of agea 0.035% 0.047% 0.041%
All causes combinedb ,c 25% 17% 25%
0-19 y 1.0% 0.72% 0.86%
0-4 y 0.63% 0.50% 0.56%
5-9 y 0.055% 0.049% 0.052%
10-14 y 0.063% 0.035% 0.049%
15-19 y 0.26% 0.13% 0.20%
60-64 y 4.2% 2.5% 3.3%
All neoplasmsb ,d 13% 8.3% 11%
Diseases of the circulatory systemb ,e 7.7% 3.6% 5.6%
External Causesb ,f 3.2% 1.1% 2.2%
0-19 y 0.30% 0.13% 0.22%
0-4 y 0.056% 0.032% 0.044%
5-9 y 0.023% 0.012% 0.018%
10-14 y 0.032% 0.012% 0.022%
15-19 y 0.19% 0.08% 0.14%
60-64 y 0.23% 0.09% 0.16%
Diseases of the respiratory systemb ,g 1.9% 1.3% 1.6%
Endocrine, metabolic and nutritional diseasesb ,h 1.2% 0.76% 1.0%
Diseases of the digestive systemb ,i 1.3% 0.62% 0.93%
Diseases of the nervous systemb ,j 0.90% 0.66% 0.78%
Infectious and parasitic diseasesb ,k 0.49% 0.27% 0.38%
Diseases of the genitourinary systemb ,l 0.37% 0.29% 0.33%
Diseases of muscoskeletal system and connective tissueb ,m 0.12% 0.19% 0.16%
a Cause of death from CT examinations is radiation induced cancer. Cancer mortality risks were
calculated based on site-specific organ doses measured with TLDs (Chapter 3) multiplied by the site-
and sex-specific BEIR VII Lifetime Attributable Risks (LAR) for exposure at 10 years (NRC, 2006).
b Risk of dying approximates the risk of contracting and dying of a disease if the risks at the time
of estimation (2006) remain throughout the specified period and age range (0 to 74 years). Risk is
expressed as a percent chance of dying from the disease (AIHW, 2008b). Causes of death are defined
in terms of the International Classification of Diseases (ICD) Codes (WHO, 2004).
c All causes combined, ICD10. Age breakdowns for this category have also been given. For example, the
risk of dying from all causes in the age group 0-19 years. The age group 60-64 years has been provided
to allow comparison with an older age group. d All neoplasms, ICD10 C00-D48. e Diseases of the
circulatory system, ICD10 I00-I99. For example, ischaemic heart diseases, pulmonary heart diseases,
hypertensive diseases, etc. f External causes, ICD10 V01-Y98. For example, transport accident,
drowning, assault, suicide, etc. Age breakdowns for this category have also been given. For example,
the risk of dying from external causes in the age group 0-19 years. The age group 60-64 years has
been provided for comparison with an older age group. g Diseases of the respiratory system, ICD10
J00-J99. For example, influenza, pneumonia, lung diseases due to external agents, etc. h Endocrine,
metabolic and nutritional diseases, ICD10 E00-E90. For example, diseases of the thyroid gland, obesity,
etc. i Diseases of the digestive system, ICD10 K00-K93. For example, diseases of the liver, appendix,
stomach, etc. j Diseases of the nervous system, ICD10 G00-G99. For example, inflammatory diseases of
the central nervous system, degenerative diseases of the nervous system, cerebral palsy, etc. k Infectious
and parasitic diseases, ICD10 A00-B99. For example, intestinal infectious diseases, HIV, tuberculosis,
etc. l Diseases of the genitourinary system, ICD10 N00-N99. For example, renal failure, diseases of
the male and female genital organs and urinary system, etc. m Diseases of the muscoskeletal system
and connective tissue, ICD10 M00-M99.
n All risks are quoted to two significant figures.
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Conclusions
The aim of this thesis was to assess the medical radiation exposure of children in Australia
from CT examinations. Radiation risk coefficients that are specific to the site of cancer
induction, the age at exposure and gender are made available in the BEIR VII Report
(NRC, 2006). These risks are applied to organ absorbed doses in order to assess site-,
age- and gender-specific radiation detriment. However, determining organ absorbed doses
for CT exposure is complex, which is evidenced by the large number of, mostly indirect,
methods currently available. Furthermore, few publications addressed experimental organ
dosimetry methods in paediatric CT or the magnitude of organ absorbed doses for clinically
used protocols. To provide a thorough assessment of the risks from paediatric CT in
Australia, it was also necessary to use imaging rates to project radiation induced cancer
risks for the population. However, there was no comprehensive analysis of paediatric CT
imaging frequency in Australia.
This thesis addressed these objectives by:
1. Developing and implementing a method of organ dosimetry for paediatric CT expo-
sures using a physical anthropomorphic phantom and high sensitivity TLDs.
2. Quantifying organ absorbed doses for typical paediatric CT examinations of the
brain, chest and abdomen/pelvis for clinically used protocols.
3. Critically comparing computational dosimetry methods using TLD measured ab-
sorbed doses to assess their reliability for paediatric CT organ dosimetry feasible for
clinical implementation.
4. Benchmarking CT doses at the RCH both nationally and internationally and devel-
oping an optimisation method for assessing CT parameter selection.
5. Identifying CT imaging frequencies and trends for the Australian paediatric popu-
lation.
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6. Projecting cancer risks for the population due to paediatric CT examinations based
on measured organ absorbed doses, radiation risk coefficients and Australian imaging
frequency.
There are few publications describing a methodology for TLD dosimetry for calculating
mean organ absorbed doses and estimating effective dose for diagnostic radiology applica-
tions, particularly in the paediatric setting. This is perhaps due to the much lower doses
typical of diagnostic imaging compared with radiotherapy and the lack of TLD dosimetry
equipment and anthropomorphic phantoms in radiology departments. Even for this thesis
it was necessary to draw upon resources from multiple sites, including radiotherapy cen-
tres, to undertake the TLD measurements. Furthermore, assessing organ absorbed doses
in children instead of adults has additional considerations. Red bone marrow, as well
as cortical and trabecular bone distributions vary with age. It is important to account
for these variations when assessing the risk of leukaemia which depends on the absorbed
dose to the red bone marrow and bone surfaces. In addition, experimental dosimetry in
the low energy range typical of CT exposures is inherently difficult. Differences in mass
energy absorption coefficients for different tissues must be considered and secondary elec-
tron equilibrium cannot be assumed for very small cavities, such as those containing bone
marrow.
Another challenge was to identify a material or device with sufficient sensitivity to detect
the low radiation doses encountered in paediatric CT. A relatively new, highly sensitive
TLD material, which has yet to achieve broad implementation in diagnostic radiology
dosimetry was selected. It was therefore necessary to develop a method for calibrating
and using this TLD material in the diagnostic energy range. Due to the relatively linear
energy and dose response of these TLDs it was possible to perform calibrations on a
linear accelerator ensuring uniformity and reproducibility of output. This is a significant
advantage associated with using these TLDs and a major improvement, which reduces
the overall uncertainty typical in TLD dosimetry in the low energy and low dose range.
MOSFETs were also investigated and found to be in reasonable agreement with TLDs,
but overall offered a less accurate, although more practical, alternative for regular use in
the clinical environment.
A systematic approach to TLD organ absorbed dose measurement and calculation was
developed and employed for the three typical CT examinations of the brain, chest and
abdomen/pelvis that were assessed in this thesis using clinical protocols at the RCH. A
method for obtaining average organ absorbed dose measurements in an anthropomorphic
phantom representing a child has been described. All organs and tissues considered to be
at risk of stochastic radiation effects as defined in ICRP 103 have been considered. The
highest measured organ absorbed doses were to the brain (33.6 mGy) for the CT brain
examination, to the thyroid and ET region (10.9 mGy) for the CT chest examination
and to the stomach (8.9 mGy) for the CT abdomen/pelvis examination. Furthermore,
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absorbed doses were found to be more consistent for directly and fully irradiated organs,
while organs on the periphery of the scan volume had a greater range of measured absorbed
doses. These organs were also affected by the over-ranging length in helical scanning. For
the organ absorbed doses derived from the TLD measurements, the CTDIvol-normalised
organ doses (in mGy to tissue per mGy of CTDIvol for the 16 cm dosimetry phantom)
were 0.8 mGy/mGy for the brain for the CT brain examination and 0.7-0.9 mGy/mGy for
directly irradiated organs for both the CT chest and abdomen/pelvis examinations.
The effective doses estimated from the TLD measured organ absorbed doses according to
ICRP 103 were 1.4 mSv, 5.0 mSv and 4.8 mSv for the CT brain, chest and abdomen/pelvis
examinations respectively. The ICRP 103 estimated effective dose was 22% lower for the
CT brain examination, 16% higher for the CT chest examination and 4% lower for the CT
abdomen/pelvis examination than the ICRP 60 estimated effective dose. This reflected
the changes to the tissue weighting factors in ICRP 103 which are now lower for the brain
when directly irradiated, higher for the breast and remainder organs and lower for the
gonads.
Experimental dosimetry is not often a practical option in radiology clinical environments
and a readily applied, indirect method of estimating organ absorbed doses is necessary for
any type of risk assessment. Furthermore, it is useful to reliably estimate effective dose
for planning and optimisation, particularly for CT protocol design. Therefore, several
computational dosimetry methods were compared with the TLD measurements made in
this thesis. There are only limited assessments in the literature of different CT dose
calculation methods and these are mainly for adults, using theoretical, controlled exposure
situations. For directly irradiated organs it was found that the computational methods
varied by up to 31% from the measured organ absorbed doses for the CT brain and chest
examinations and up to 49% for the abdomen/pelvis examination. Effective dose estimates
using the ICRP 60 formalism using the various computational methods differed by -30%
to 35% from the TLD derived effective doses. For ICRP 103 calculated effective doses,
the variation ranged from -29% to 41% from the TLD doses. One of the key reasons
for differences in dose calculations is due to the phantom used for either experimental
dosimetry or Monte Carlo modelling. Children are more problematic to model than adults
and several phantoms are required to adequately simulate anatomical differences over the
age groups from newborn to adolescent. It was found that placement of the organs relative
to other organs and also relative to the surface of the phantom had a significant effect on
the absorbed dose.
A retrospective patient dose survey was also conducted to derive local diagnostic reference
levels (DRLs) at the RCH for typical CT examinations in all paediatric age groups and to
verify the measurements made in the anthropomorphic phantom with real patient data.
The mean dose values from the patient dose survey were compared with national and
international dose levels to identify areas of optimisation and to assess changes in CT doses
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in Australia. The RCH DRLs were typically comparable to or lower than international
values. In particular, the use of 80 kVp for both chest and abdomen/pelvis imaging in
young children lead to a significant dose saving. Scan lengths for body imaging is one area
that can be reviewed for potential optimisation. Comparison of the RCH values with a
2001-2002 survey of Australian hospitals demonstrated that there were considerable dose
reductions as a result of new technology and optimised protocols at the RCH. However,
comparison with a more recent survey at another Australian hospital with a more advanced
CT scanner showed that further dose reduction is achievable. The method of assessing
patient CT doses described in this thesis will be useful to other practices undertaking
similar retrospective audits. Furthermore, in the future it will allow evaluation of protocols
on the new scanner to be installed at the RCH and ensure that the opportunity is used to
further optimise dose.
A review of the literature revealed that there was little information regarding the number
of CT examinations performed in Australia on children. There was a clear need for
research to be conducted in this area. A comprehensive analysis of Australian Medicare
and RCH records was undertaken in order to determine CT imaging rates in Australia
that reflected current usage. Medicare is the best available resource for assessing imaging
trends, although a major limitation is that it only captures CT services funded through
the national health care system. It was found through analysis of RCH records that in
the 0-18 year age range only one third of CT examinations are captured by Medicare.
To address this shortcoming, scaling factors have been derived in this thesis in order to
adjust Medicare data to take account of non-funded services. Overall, it was found that
the growth in CT imaging of Australians of all ages is exceeding population growth at a
significant rate. The average annual increase in the CT imaging rate for 0-18 year olds is
estimated to be 5.1%. However, in recent years, growth in the imaging rate for 11-18 year
olds has slowed, while for 5-10 year olds the imaging rate has declined.
Finally, by combining the measured organ absorbed doses and Australian CT imaging
frequency, it was possible to make estimates of the number of cancers induced from the
radiation exposure of children undergoing CT examinations. These risks were found to
be much lower than similar estimates based on the US population and CT practice. One
of the reasons for this is the much lower absorbed doses attributed to CT practice at the
RCH and it also seems likely that there is a lower utilisation of CT imaging for children
in Australia. Overall, it was found that there was only a very small percentage increase
(approximately 0.14%) over the background natural cancer rate due to radiation induced
cancers from CT imaging in the 0-18 year old Australian population.
There is sometimes an unreasonable level of anxiety associated with radiation exposure
and its risks. This anxiety is understandably even greater for parents whose children are
undergoing CT examinations. Often this concern will arise from a lack of awareness of
the risks. This originates from misinformation, or even a knowledge deficit, in the medi-
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cal profession regarding doses and risks and hence an inability to convey the appropriate
information to patients. To some extent, this is because the information is not easily and
readily available or is not directly applicable to their circumstances. For children’s hospi-
tals and other sites undertaking paediatric imaging in Australia there is little guidance on
specific dose requirements.
This thesis significantly extends the knowledge base and methodology for assessing pae-
diatric CT doses, risks and imaging trends in the Australian context. The trio of articles
(Brenner et al., 2001a; Donnelly et al., 2001; Paterson et al., 2001) published in 2001
resulted in an increased awareness and focus on issues relating to children and CT. It
is hoped that by conducting research in this area in Australia and developing a more
in-depth understanding of paediatric CT dose, that it will similarly stimulate discussion
and ultimately lead to dose reduction. Furthermore, it provides a useful basis for organ
dosimetry that may be utilised in the epidemiological study assessing the effects of low
doses of radiation to children from CT examinations that has commenced in Australia
(Brady et al., 2011f; Mathews and Chesson, 18 February 2009).
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Appendix A
Overview of CT Scanner Design,
Technology and Dosimetry
A.1 CT X-ray Production and Detection
X-ray Tube Components and X-ray Production
The basic components of an X-ray tube consist of two electrodes: a filament (cathode)
and target (anode), in a vacuum maintained typically by a glass housing (Figure A.1).
Electrons are produced by the filament through thermionic emission when a current is
applied. The electrons are accelerated towards the anode with the application of a high
voltage (20-150 kVp) across the electrodes. For CT, this is generally in the range 80-
140 kVp at discrete 20 kVp intervals, although 120 kVp is the most commonly used voltage
in the clinical setting.
A focusing cup is placed around the filament to ensure that electrons are focused on the
positive anode, rather than being attracted back to the gradually more positive filament,
or dispersing due to repulsive forces between the electrons (space charge effect).
When an electron interacts with an atom in the anode, kinetic energy of the electron can
be transferred to an orbiting atomic electron. This will cause excitation of the atom, or
if the energy exceeds the binding energy of an orbital electron, ionisation may also occur.
Electrons which have been excited to higher energy levels within an atom will drop back
to the lower energy, ground state and in doing so emit characteristic photon radiation
typically in the visible light to ultraviolet range. Where there is sufficient incident energy
to ionise the atom, an electron is ejected usually from the inner K-shell leaving an electron
hole or vacancy. One of the outer orbital electrons will quickly fill the vacancy and emit a
characteristic X-ray photon with energy equal to the difference between the shells in the
process. These emissions are dependent on the type of atom and the energy difference
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between electron shells, hence the term “characteristic” radiation. The emitted radiation
is at discrete energies and is readily evident in an X-ray spectrum as peaks.
When excess energy from the transition of an outer orbital electron to the inner shell
vacancy is transferred to another atomic electron, this electron may be emitted from the
atom as an Auger electron. The kinetic energy of the Auger electron will correspond to
the difference between the energy available from filling the inner orbital vacancy and the
Auger electron’s binding energy.
Another inelastic scattering process produces bremsstrahlung or braking radiation. The
nuclear electrostatic force causes the accelerated electrons to slow down or brake, and
change direction. In doing so, they lose some of their kinetic energy in the form of X-ray
photons. These photons have a full spectrum of energy from zero (the electron loses all of
its energy) up to the maximum energy of the incident electrons (equivalent to the potential
difference between the anode and cathode, i.e. the applied voltage). The energy of the
photons is measured in electron volts (eV) which is a unit of energy equal to the amount
of energy gained by an electron when accelerated across a potential difference of one volt
(V).
Additional aluminium or copper filtration is added to the CT beam to filter out the low
energy portion of the beam, which contributes to patient dose, but not to the image. Bow-
tie filters are also used to shape the beam to account for beam hardening at the centre
of the patient. For example, GE Healthcare (Waukesha, Wisconsin, US) scanners use
different body and head filters depending on the body part being scanned (Toth, 2002).
The bow-tie filters provide greater attenuation of the beam at the edges of the patient,
which are thinner and therefore do not require a beam with the same penetrability needed
for the more central thicker portion of a patient. The pre-patient filters will define the
dose profile of the X-ray beam.
Figure A.2 demonstrates emission spectra for an X-ray tube operated at 120 kVp, typical
of CT scanners. Curve 1 shows that even without additional filtration, the tube aperture
filters the softest (lowest energy) X-ray photons in the beam to a small extent. Curve 2
is a typical emission spectrum for a diagnostic X-ray unit and curve 3 for a CT scanner,
with a more heavily filtered beam. It is also evident that the average effective energy of
an X-ray beam is significantly less than the peak energy. The effective energy is much
higher in CT applications compared with general radiography due to the additional beam
filtration used.
The efficiency of X-ray production is relatively low and more than 99% of the incident
electron energy is converted to heat. Therefore, X-ray tubes must have sufficient heat
dissipation properties, particularly in the case of CT where there are high tube loadings.
The anode must have a high melting point and its heat capacity will be a limiting factor
for continuous operation and parameter selection when in use. The focal track of the
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Figure A.1: Components of an X-ray tube (http://openlearn.open.ac.uk).
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Figure A.2: Calculated X-ray emission spectra from a tungsten target produced at
120 kVp. Maximum energy of emitted photons is 120 keV. All curves include inherent
filtration from the tube aperture. Curve 1 is the typical spectrum with no additional
filtration, curve 2 includes 2.5 mm aluminium additional filtration (typical general X-ray
tube) and curve 3 shows the effect of 7 mm aluminium additional filtration (typical CT
tube) (Reilly and Sutton, 1997).
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anode is typically made of tungsten-rhenium for CT, as well as for general radiography
applications. However, the metal focal track is usually brazed or deposited onto graphite
for CT applications, which provides a higher heat capacity than a molybdenum body used
in general X-ray tubes (Hsieh, 2003). Oil or water cooling can also be used in CT scanners
to improve heat removal. Anodes will deteriorate over time with cracking and pitting
occurring from electron bombardment and a disadvantage of the graphite based anode is
an increased potential for these particles (Hsieh, 2003).
Two unique X-ray tube designs include the Straton tube (Schardt et al., 2004) (Siemens,
Erlangen, Germany) and the liquid spiral groove bearing (Schmidt and Behling, 2000)
(Philips Healthcare, Andover, Massachusetts, US). The Straton tube rotates the entire
vacuum vessel containing both the anode and cathode, compared with a conventional de-
sign that rotates the anode only. This allows bearings to be placed outside the vacuum,
which can then be lubricated. It also facilitates greater cooling of the anode by direct con-
ductive cooling via an oil stream on the back anode surface (Kalendar, 2005). The Philips
design replaces conventional ball bearings with a spiral groove, which use liquid metal
lubrication. This anode is directly cooled by the bearing, increasing heat capacity.
CT Detectors
Very early scanners utilised monolithic sodium iodide crystal scintillators doped with thal-
lium [NaI(Tl)] coupled with a photomultiplier tube (PMT). In these solid state detectors
X-ray photons hit the scintillator material causing excitation and ionisation. During de-
excitation, the atoms emit visible light (fluorescence) which is detected by the photocath-
ode of the PMT. Interaction of the light photons results in the ejection of electrons, which
are accelerated between dynodes creating an avalanche detected by the anode of the PMT.
This amplified signal is proportional to the energy of ionising radiation incident on the
detector. The scintillator material can be doped with an activator such as thallium to
increase the probability of light emission (conversion efficiency).
Sodium iodide detectors in the early scanners intercepted the entire beam and therefore
were very efficient (approximately 100% efficiency along the z-axis). However, they exhib-
ited poor temporal response and suffered from afterglow from phosphorescence (delayed
emission of light). These detectors were not suitable for later scanners which required
large numbers of detector banks. Any drift in calibration or fault in a single detector
would be propagated in the image as a ring artefact.
To overcome this problem, gaseous detectors were introduced in which a long metal cham-
ber was subdivided into smaller chambers by septa to form a detector array across the
patient. Each chamber was filled with xenon gas at a high pressure (10-30 atmospheres)
and the septa enclosing each volume formed electrodes. As these were highly directional,
scatter rejection was excellent (Bushberg et al., 2001). The interaction of X-ray photons
with the gas causes ionisation and in the presence of a low applied voltage (200-350 V)
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migration of the charges occurs before recombination can take place. The applied volt-
age also prevents secondary ionisations and the resulting current is measured with an
electrometer.
As CT scanner design advanced, more flexibility in the design of the detector was needed
than could be achieved by xenon detectors with their limited angular detection and bulk-
iness. Modern scanners have returned to scintillator material and now generally use solid
state detectors, which exhibit improved detection efficiency and are capable of detection
over a wider angle. Furthermore, ease of production is a necessity as modern scanners can
have more than 800 detector elements in an array (across the patient in the scan plane)
with multiple arrays and some scanners, with an entire ring of detectors, can exceed 4,800
individual detectors circling the patient (Bushberg et al., 2001).
Solid state detectors have a much higher density than gaseous detectors, making them
more compact with higher detection efficiency. Detectors used in modern CT scanners
consist of a ceramic or crystal scintillator coupled with photodiodes. The scintillator
materials used today have much higher conversion efficiency than NaI used in the earlier
detectors allowing PMTs to be replaced by photodiodes. These semiconductor diodes
are reverse biased and do not amplify the light signal in the way that PMTs do. No
electrical current flows in the diode until exposed to light, whereby the interaction of
photons causes the production of electron-hole pairs, resulting in a current proportional
to the light intensity.
Crystal scintillation detectors currently used include caesium iodide (CsI) and cadmium
tungstate (CdWO4), although ceramic scintillator solid state detectors, such as gadolinium
oxysulfide (Gd2O2S) or yttrium gadolinium oxide (YGO) are preferred. Propriety names
such as “ultra fast ceramic” (UFC) detector have been used for the Gd2O2S detector
(Siemens, Erlangen, Germany). The disadvantages of the materials vary. For example,
CdWO4 is susceptible to radiation damage and CsI can have considerable afterglow (Fuchs
et al., 2000). Furthermore, solid state detectors can lead to a ring artefact in the image
when a detector element fails, whereas gas detectors are less susceptible to this effect.
The overall efficiency of a detector is the product of the quantum detection efficiency
(QDE) and geometric detection efficiency (GDE). This represents the effectiveness of the
detector in converting incident X-ray energy into a signal. It follows that an ideal detector
will have an efficiency of one and utilise the entire incident beam, which will also optimise
the dose to the patient. However, the detector efficiency does not equate to the overall
dose efficiency of the system, which also requires the proportion of the beam actually used
in the imaging process to be taken into account (discussed further in Section A.2).
The QDE or intrinsic efficiency of the detector is its ability to absorb and detect an incident
photon and hence is the product of the absorption efficiency and conversion efficiency. For
a detector with low QDE, photons will pass through without detection. The detection
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efficiency is dependent on the linear attenuation coefficient of the detector and the detector
thickness (Hsieh, 2003). Increasing the thickness or the linear attenuation coefficient of
the material will increase the QDE. However, other factors, such as spatial resolution,
will be affected by thicker detectors and hence must be taken into consideration in the
design.
The GDE is a measure of the actual active area of the detector. Septa between detectors
in both the scan plane and along the z-axis will subtract from the total active detection
area. In addition, any post-patient collimators such as anti-scatter grids that are placed
in front of the detector will partially block some of the primary X-ray beam. The GDE
can be expressed as:
Geometric detection efficiency (GDE) =
Active detector area
Total detector area
(A.1)
Conversely, some advantages of the septa between detector elements and post-patient
collimators are to reduce cross-talk and increase scatter detection. In modern scanners
which have multiple rows of detector arrays, there is an increase in the number of septa due
to the larger number of detector elements which are in both the x-y and z-direction. This
results in a decrease in detector efficiency compared with earlier scanners that consisted
of a single detector array. Table A.1 lists properties of some common CT detectors. GE
Healthcare (Waukesha, Wisconsin, US) have developed a new detector with a scintillator
material consisting of a garnet gemstone and rare earth phosphor (∼1%). They claim that
it has less afterglow by a factor of four and is 100 times faster than Gd2O2S.
Table A.1: Comparison of CT detector properties (from Heggie et al.
(1997)).
Property Solid State Xenon
Crystal CdWO4 Ceramic 30 atm
Quantum detection efficiency (QDE) 95-100% 94-98% 50-60%
Geometric detection efficiency (GDE) 80% 80% >90%
QDE x GDE 76-80% 75-78% 45-55%
Afterglow ∼0 <1% ∼0
A.2 CT Scanner Design
CT technology has rapidly advanced since the first scanner was installed at the Atkinson-
Morley Hospital in Wimbledon, United Kingdom in 1971 (Prokop and Galanski, 2003).
The different types of geometry utilised in scanners are identified by their “generation”.
However, the principle remains the same whereby a projection or view is formed from a
set of rays at a particular angle passing through the body. A sinogram is then formed
from the multiple projections over different angles around a slice of the body, from which
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the final image is reconstructed.
CT Scanner Generations
The prototype first generation CT scanner (Figure A.3) developed by Godfrey Hounsfield
was based on a translate-rotate principle. A pencil X-ray beam passed through the body
and was detected by a single detector on the opposite side of the body. The X-ray tube
and detector were coupled and hence moved together. The X-ray tube and detector were
translated (160 times) across an entire slice to produce one complete projection. They
were then rotated one degree to complete the next projection. This was continued until
the body was scanned from 180 different angles. This type of scanner was restricted to
imaging of the brain and the head was actually surrounded by a water bag to handle the
change in flux in areas adjacent to the head (Beckmann, 2006; Bushberg et al., 2001).
Each slice took 4.5 to 20 minutes to scan (Beckmann, 2006).
The next generation of scanner (Figure A.4) employed a small fan-beam of X-rays and
was also known as a translate-rotate scanner. A linear array of detectors was used, but
translation (six times) was still required as the fan beam was not wide enough to encompass
the entire slice of the body to be imaged. Each rotation was increased to 30 degrees
and a minimum scan time per slice of 18 seconds was achieved (Bushberg et al., 2001).
This allowed whole body imaging as the timeframes were comparable to a breath hold,
eliminating motion artefacts caused by the respiratory cycle.
Third generation scanners (Figure A.5) were based on a rotate-rotate movement where
the tube and detectors move synchronously. A fan beam of X-rays was again utilised,
but now encompassed the entire patient, hence avoiding translation movement of the tube
and detectors. The number of detectors in the array increased (>800 in modern scanners)
to accommodate the wider fan beam and were positioned along an arc. The X-ray tube
and detector array still rotated together through a complete 360 degree revolution. In
this type of scanner a single rotation could be obtained in seconds and in more modern
scanners in under 0.5 second (Bushberg et al., 2001).
Scanners in the fourth generation (Figure A.6), termed rotate-stationary, incorporate a
fixed ring of detectors fully encircling the patient. In modern scanners more than 4,800
detectors are located in the ring (Bushberg et al., 2001). The X-ray tube is positioned
within the detector ring and rotates 360 degrees around the patient. The leading and
trailing edge of the fan beam is used to calibrate the individual detectors during the
scan. Each projection is derived from all rays acquired by a single detector for the various
tube positions. Scanning times per rotation are approximately one second (Goldman,
2007b).
Fifth generation (Figure A.7) or cardiac scanners have no moving parts and hence are
termed stationary-stationary. The X-ray tube is replaced with an electron gun and a
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Figure A.3: First generation CT scanner (translate-rotate).
Figure A.4: Second generation CT scanner (translate-rotate).
Figure A.5: Third generation CT scanner (rotate-rotate).
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tungsten anode ring surrounds the patient. The electron beam is magnetically steered
towards the target and the X-ray fan beam intercepted by a ring of detectors. Four slices
can be produced simultaneously in approximately 50 milliseconds, which allows fast frame
rate movies of the beating heart (Bushberg et al., 2001). The very fast acquisition times
result directly from the absence of moving components.
Helical Scanning
In the early nineties, advances in slip ring technology led to the introduction of helical
scanning (sometimes referred to as spiral CT). The slip rings maintain electrical connection
during continuous rotations to allow the X-ray tube to operate and data to be transferred
without necessitating stopping between scan positions. Instead of the patient remaining
stationary during a scan and stepping the table forward between rotations, the patient
is moved continuously through the gantry and the X-ray tube rotates around the patient
(Figure A.8).
The pitch describes the spacing between scanned points, such that contiguous slices will
have a pitch of one (as is the case for axial sequential scanning). Pitch P is defined
as:
P =
table feed per gantry rotation
beam collimation
(A.2)
The beam collimation is simply the number of slices or sections multiplied by the slice
width. For single row detector CT (SDCT) scanning the collimation is equivalent to the
slice width. When the pitch is less than one, slices will be overlapped increasing patient
dose, while for a pitch greater than one, gaps are produced in the spiral. The advantages
of partial scanning along the z-axis with a pitch greater than one are faster scan times
and less motion.
MDCT
One of the greatest advances in CT technology occurred in 1998 with the introduction
of multiple row detector CT (MDCT) scanners. These scanners have the capability of
acquiring multiple slices simultaneously (4, 8, 16, 32, 64, etc.), which better utilises the
X-ray beam and optimises the heat loading of the tube. In 2008, the first 320 row MDCT
scanner was installed in Australia (Stark, 2008). MDCT scanners are particularly ben-
eficial for paediatric patients, trauma and cardiac imaging due to fast acquisition times
(approximately 0.5 second rotation time). The multiple detector rows allow simultaneous
measurements, which are reconstructed into multiple slices. MDCT scanners also allow
increased scan length for the same scan time. More than 1,000 MDCT scanners had been
installed worldwide by the end of the year 2000 (Prokop and Galanski, 2003).
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Figure A.6: Fourth generation CT scanner (rotate-stationary).
Figure A.7: Fifth generation electron beam CT (stationary-stationary) (from Kalender
(2005)).
Figure A.8: Helical CT scanning with different pitch factors (partially adapted from
Goldman (2007b)).
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In MDCT scanners the X-ray tube and detector configuration is typically of third genera-
tion scanner design. In addition to the multiple detector elements (array) in the scan plane,
a bank of solid state detectors is also positioned along the z-axis (Figure A.9). The rows
of detectors in the z-direction can be grouped together in various configurations to feed
into single data acquisition channels. Technically, the number of data acquisition channels
corresponds to each set of data projections. For example, GE “four slice” CT scanners
have 16 rows of detectors along the z-axis, but only four data acquisition channels.
The detector configurations fall into three categories: uniform/mosaic/matrix; non-uniform/
variable/adaptive; and hybrid. The uniform (or mosaic or matrix) detectors have detec-
tor elements of equal dimension (Figure A.10a). These are used in the GE Healthcare
(Waukesha, Wisconsin, US) four and eight MDCT scanners and are continuing to find
use in newer scanners (Cody and Mahesh, 2007; Flohr et al., 2005). Non-uniform (or
variable or adaptive) configurations, initially used by Siemens (Erlangen, Germany) and
Philips Healthcare (Andover, Massachusetts, US), increased detector efficiency by reduc-
ing the dead space between elements (Figure A.10b). Toshiba Medical Systems (Otawara,
Tochigi, Japan) introduced the hybrid configuration used in several scanner designs today
(Figure A.10c) (Cody and Mahesh, 2007; Flohr et al., 2005).
One of the major distinctions between SDCT and MDCT is the collimation of the X-ray
beam. In both systems the X-ray beam is first collimated by the aperture of the X-ray
tube housing. A fixed collimator is then located further away from the aperture, but before
the patient, which limits penumbral effects (Section A.2) and defines the beam according
to the desired slice width for SDCT or total beam collimation for MDCT. In MDCT the
detector width or aperture defines the slice width instead of the pre-patient collimator.
In SDCT scanners a post-patient collimator can be used at the detector to achieve very
thin slices, which can be a geometric limitation of the design of the pre-patient collimator
(Hsieh, 2003). An additional post-patient collimator in the form of an anti-scatter grid
made of highly attenuating plates can be located in front of the detector. Both types of
post-patient collimation will reduce dose efficiency, but improve image quality.
Over-Beaming
The finite size of the focal spot results in a penumbra at the edges of the X-ray beam
with areas of reduced intensity (Figure A.11). With a single row array of detectors in
SDCT, the detector extends beyond the beam width so that the entire X-ray beam is used
(including the penumbra) to form the image (Figure A.12), unless post-patient collimation
is used to better define narrow slice widths (Toth, 2002). In an MDCT system, the full
X-ray beam including the penumbra is attenuated by the patient and hence contributes to
dose, but the penumbral region does not expose the detectors (Figure A.12). Discarding
the periphery of the beam in MDCT ensures uniform irradiation of the bank of detectors,
preventing artefacts in the image and allowing three dimensional image reformations. This
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Figure A.9: Single row detector CT (SDCT) with only one detector element along the
z-axis and an array of detector elements across the patient and multiple row detector CT
(MDCT) with multiple detector rows along the z-axis, while still retaining an array across
the patient.
Figure A.10: Detector array designs (a) uniform, (b) non-uniform, (c) hybrid (adapted
from Cody and Mahesh (2007)).
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characteristic of MDCT is known as over-beaming (Heggie et al., 2006). The penumbra of
an X-ray beam is constant and hence the “wasted dose” (Flohr et al., 2005; Lewis, 2005)
will be greater for a narrow collimation (total beam width), defined by the number of
slices multiplied by the slice width.
The dose efficiency of the scanner is a product of the detector efficiency (Section A.1) and
the z-axis geometric efficiency. The efficiency along the z-axis is dependent on the amount
of the beam used to form the image, which will be affected by post-patient collimation if
present and particularly by over-beaming in MDCT scanners. This can be expressed as
(Lewis, 2005; Toth, 2002):
z-axis geometric efficiency =
area under z-axis dose profile falling within active detectors
area under total z-axis dose profile
(A.3)
Most modern scanners now display the z-axis geometric efficiency on the display console.
For one type of 16 MDCT scanner, for example, a beam collimation of 10 mm will have
a z-axis efficiency of 83%, while a collimation of 20 mm will have an efficiency of 97%
(Lewis, 2005).
Dual Energy CT
A more recent development in CT scanner design is dual energy CT, which is now available
for clinical use from several manufacturers. The method of using different CT energies
to identify materials was recognised in the seventies, but previously limited by scanner
design (Takahashi et al., 2008). The technique exploits the energy dependence of X-ray
attenuation in different materials. Typically CT energy pairs of 80 kVp and 140 kVp are
used (Coursey et al., 2010). Iodine is particularly suited to this technique with a k-edge at
33.2 keV, which maximises the photoelectric effect at the 80 kVp beam energy (effective
beam energy around 45-50 keV). At 140 kVp, for iodine, the dominant X-ray interaction
process is Compton scatter and therefore a distinct difference in the amount of attenuation
will be evident. Muscle, for example, has a less distinct attenuation difference between
the two different scanning energies (Coursey et al., 2010).
The difference in attenuation of some materials between two energies potentially allows
characterisation of elemental composition by using this CT technique. For example, uric
acid, iodine and calcium can be distinguished from soft tissue using two energies (Coursey
et al., 2010). Uric acid detection in kidney stones has been demonstrated (Primak et al.,
2007) and this concept has been extended to the characterisation of uric acid in gout
(Bacani et al., 2009). Furthermore, it has been shown that urinary stones can be identified
in a contrast scan using the dual energy method to produce an iodine subtracted image
(Takahashi et al., 2008). This avoids a non-contrast scan and reduces patient dose as the
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Figure A.11: Penumbra with reduced and inhomogeneous intensity caused by a finite
focal size compared with a point source (adapted from Johns and Cunningham (1983)).
Figure A.12: For a single row detector array in an SDCT scanner the entire beam is used
including the penumbra to generate the image (left). For a multiple rows of detectors in
an MDCT scanner the penumbral region of the beam is discarded to ensure the detectors
are uniformly irradiated (right).
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dual energy scan dose is comparable to the dose for a single energy scan at 120 kVp. These
applications demonstrate the potential of dual energy techniques, although its use is not
yet widespread.
Tube Current Modulation
An important technique for dose reduction, now available on most scanners, is the ability
to alter the tube current during the CT scan (Gudjonsdottir et al., 2010). In 1981, Haaga
et al. (1981) outlined the principle of tube current modulation, which was first introduced
commercially by GE Healthcare (Waukesha, Wisconsin, US) in 1994 (McCollough et al.,
2006). Techniques for modulating the tube current generally also include an automatic
exposure control (AEC) that accounts for the overall patient size (AAPM, 2011). Three
methods of modulation techniques are available and most modern scanners use a combi-
nation of these. They are typically labelled with proprietary names and are summarised
in Table A.2. The three techniques involve algorithms for modulating the tube current
based on the patient’s size (AEC), angularly (in the x-y plane) or longitudinally (along
the z-axis).
Table A.2: Automatic tube current modulation techniques for different manufacturers
(AAPM, 2011; Lee et al., 2008b; Lewis, 2005).
Manufacturer Proprietary name Modulation
adjustment
(x, y, z
planes)
Method
for control
User input
Siemens CARE Dose 4D x, y, z Scout and
real time
Quality reference
mAsCARE Dose x, y
GE SmartmA x, y, z Scout Noise index
AutomA z
Philips D-DOM x, y Scout Reference image
Z-DOM z
Toshiba SUREExposure 3D x, y, z Scout Standard deviation
SUREExposure z
When taking into account the patient’s size, the tube current is set to a single value for
each patient so as to achieve the same level of noise for every patient regardless of their
size. This method utilises the projection radiograph (also referred to as scout view) to
determine the modulation required. In earlier systems, it could be achieved manually by
the operator adapting the current for each patient based on their size prior to the scan.
Using this technique independent of other modulation techniques will result in a single
current for the entire scan. Hence, it is typically used in combination with the other
modulation techniques.
Longitudinal modulation allows for tube current variations in anatomic regions along the
z-axis. This is particularly useful for areas such as the abdomen, which require a higher
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current to achieve the same level of noise as other low attenuation areas like the lung.
The aim of longitudinal modulation is to achieve relatively uniform image quality and
adapts the current to meet a user defined quantity, which is manufacturer dependent.
The patient size is generally calculated from a single topogram (scout) view, which is the
2D radiograph taken prior to the actual CT scan.
Angular modulation takes into account the attenuation of photons at different angles
through the body in the x-y plane. The current is varied to ensure a uniform photon flux
on the detectors from all projections. The modulation typically varies sinusoidally and is
based on the topogram view, or in some scanners is modulated in real time from the last
180°of projection data. For lateral projections the current will be higher, while for AP
and posterior-anterior (PA) the current will be lower. For example, without modulation,
the low attenuation in the AP direction through the shoulders results in a higher detected
intensity, whereas the high attenuation provided by the shoulders in the lateral direction
results in a lower detected intensity. The consequence of low measured beam intensity
is increased image noise due to high statistical fluctuations (quantum noise). Therefore,
current in the AP direction can reasonably be reduced, while in the lateral direction
increased to maintain constant image noise and reduce dose. The benefits not only relate
to dose savings, but also to a reduction in streak artefacts.
A.3 CT Image Formation and Display
Despite the variation in CT scanner and detector design, the same mathematical pro-
cesses are applied in order to reconstruct the image from the measured data. The linear
attenuation coefficient is determined from the detected X-ray beam intensities for each
pixel (smallest 2D element in the image) by mathematical reconstruction of the data and
displayed accordingly on a grey scale.
The attenuation of a beam of X-ray photons in a material is described by:
I = I0e
−µt (A.4)
where I is the detected X-ray intensity, I0 the initial X-ray intensity, µ is the linear
attenuation coefficient, and t the absorber thickness. The initial or incident X-ray beam
intensity can be determined from routine calibration scans.
When considering a polychromatic beam (as is the case with an X-ray beam) and an
inhomogeneous object (human body) this equation becomes:
I =
∫ Emax
0
I0(E)e
− ∫ t0 µ(E)dsdE (A.5)
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The dependence on energy E is apparent and to overcome this each linear attenuation
coefficient is normalised to water and scaled to calculate a value displayed on a gray scale.
This quantity is referred to as the CT-number in Hounsfield Units (HU):
HU = 1000
µm − µwater
µwater
(A.6)
where µm and µwater are the linear attenuation coefficients (measured in inverse cen-
timetres) for the medium and water respectively. The linear attenuation coefficient for
water (µwater) is determined periodically by calibration scans of a phantom. A typical
CT-number range for clinical use is from –1024 to +3071 HU, (cortical bone is between
600-3000, air is -1000 (Heggie et al., 1997)).
Numerous computational methods exist to calculate the linear attenuation coefficient
for each pixel [µ(x, y)]. These are broadly defined into two categories – iterative meth-
ods and back projection convolution methods (or equivalent Fourier techniques) (Webb,
1988).
Iterative methods
Iterative methods were utilised initially, but have since been replaced with the filtered back
projection technique due to the considerable computation time required. However, there
is currently a revival of iterative techniques with a new category of statistical iterative
reconstruction methods starting to become available on the market (adaptive statistical
iterative reconstruction (ASIR) and model based iterative reconstruction (MBIR), GE
Healthcare; iterative reconstruction in image space (IRIS), Siemens; and iDose, Philips
Healthcare) (Hara et al., 2009; Marin et al., 2010; Silva et al., 2010).
In the early iterative methods, the values of the linear attenuation coefficients for each pixel
were approximated and adjusted iteratively until the calculated projections most closely
resembled the measured projections. For a small matrix, the linear attenuation coefficients
could be solved exactly using simultaneous equations. For example, Figure A.13 shows
that for a 2x2 matrix, the four unknown linear attenuation coefficients (µ1 - µ4) can be
easily calculated from the four equations.
For larger matrices, an estimate of each pixel value is made and compared with the true
ray sum (Sn) until the accuracy reaches an acceptable level. However, for large matri-
ces the computational power required for the substantial data sets still exceeds current
capabilities.
Back Projection
The mathematician Johann Radon recognised in 1917 the basic principle that the internal
structure of an object can be reconstructed from multiple projections of that object. This
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method is commonly referred to as back projection. An infinite number of projections
would be required to define the object completely. However, by combining the information
from a finite number of projections, an accurate description of the object is possible. This
is the premise of image formation in modern CT. The basis of this method is to “smear”
the ray sum or line integral back along the same path in the image. As this is carried out
for all rays, areas of higher attenuation will be reinforced and the image will begin to take
form.
Figure A.14 shows the back projection of the ray sums (S1 and S2) in a single projection
(P1) for a simple 2x2 matrix with four pixels, each with a different linear attenuation
coefficient (µ1 - µ4). As further projections are smeared across the matrix, the pixel
values will more accurately reflect their true value.
For an image defined by a map of linear attenuation coefficients µ(x, y), the Radon trans-
form is a series of line integrals (ray sums) through µ(x, y) defined by r and θ (e.g.
x = r cos(θ) and y = r sin(θ)) to give:
R [µ] (r, θ) =
∫ +∞
−∞
∫ +∞
−∞
µ(x, y)δ(x cos θ + y sin θ − r)dxdy (A.7)
where δ is the Dirac delta function and Figure A.15 shows the co-ordinate system for the
Radon transform.
Before reconstruction of the image, a display of the raw data acquired for each slice can
be viewed as a sinogram R(r, θ)). Since the sinogram R(r, θ) is known, the image can
be reconstructed by finding µ(x, y). In order to reconstruct the image, the inverse Radon
transform is applied. This effectively back projects the value of each ray sum into all pixels
in that ray, as demonstrated in Figure A.14. The combination of all back projections
produces an image of the object, which is only an approximation due to the finite number
of projections. Heavy blurring will be evident in the reconstructed image and can be seen
as a star-like artefact. Increasing the number of projections will improve the image quality,
but spokes and blurring will always be apparent using this method.
These artefacts arise from the back projection process itself and are due to the functional
dependence on the distance (1/r). The blurring can be removed by first filtering the data
prior to applying the back projection. This modification of the reconstruction process is
referred to as filtered back projection. A one-dimensional Fourier transform is applied
to each projection, which is then multiplied by a kernel, before performing an inverse
Fourier transform. Note that in the spatial domain the same function can be performed
by convolving the spatial domain projection with a convolution kernel. Processing of
the data is faster when performed in the frequency domain, hence the necessity of using
Fourier transforms. The filtered projection (in the spatial domain) is then back projected
onto the image matrix as usual. Various filters can be applied, the most common being a
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Figure A.13: Iterative method for calculation of pixel linear attenuation coefficients
(adapted from Kalendar (2005)).
Figure A.14: Back projection of two line integrals (S1 and S2) from a single projec-
tion (P1). Repeating this process for all projections will eventually calculate the linear
attenuation coefficients (µ1 - µ4).
Figure A.15: Radon transform.
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ramp filter which effectively compensates for the inherent artefacts in the back projection
method. Other filters, such as the Shepp-Logan and Hamming, can additionally be used
to compensate for the increased noise at higher frequencies.
Helical CT Interpolation
For helical CT, an additional z-axis interpolation processing step is necessary to form
a planar data set in the desired reconstruction plane. For SDCT, a planar data set is
calculated for each location along the z-axis where data from either side of the recon-
structed plane (separated by 360°) are weighted accordingly. This method is referred to as
360°linear interpolation (LI) (Hui, 1999; Kalendar, 2005). Similarly, utilising the redun-
dancy in data from a 360°rotation (each line integral is measured twice as the tube moves
around the patient), another method called 180°LI can also be used.
For MDCT, as the number of detector rows increases, the X-ray beam must be considered
as a cone beam, rather than a planar 2D fan beam. Generally, scanners with greater
than four rows require different reconstruction techniques to account for the cone beam
(Kalendar, 2005) and these methods are reviewed in the literature (Flohr et al., 2005). The
inherent problem with a wider beam is that objects that are not central to the detector
array will be projected onto different detector rows. However, some MDCT scanners can
utilise interpolation for narrow beam angles. Another technique called z-filtering is used in
MDCT scanners, which uses the interpolation method, but does not restrict the calculation
to the adjacent projections only (Flohr et al., 2005; van der Molen and Geleijns, 2007). A
selectable width for z-filtering can be chosen retrospectively (Kalendar, 2005).
Over-Ranging
Additional data is acquired at each end of the desired scan volume to allow for interpolation
and this results in the patient being exposed to radiation not displayed in the data set.
Clinically, if the scan volume is selected to avoid critical (radiosensitive) organs or tissues
then these may be inadvertently included. This feature of helical scanning is sometimes
referred to as an end effect or over-ranging and typically requires an extra rotation at the
start and end of the scan volume (Heggie et al., 2006), although the actual over-range
length is also determined by factors such as the reconstruction section width (van der
Molen and Geleijns, 2007). The extent of over-ranging depends on the table feed per
rotation and will be greater for larger beam collimations and/or higher pitch (Schilham
et al., 2010). However, it should be noted that over-ranging and over-beaming offset
each other to some extent, since over-beaming is greater for narrow beam collimations
(Section A.2). The effects of over-ranging are more pronounced in shorter scan lengths,
often encountered in paediatric CT.
Some manufacturers are addressing over-ranging in newer scanners with a dynamic colli-
mator with independent blades that block the over-ranging (Siemens and Philips Health-
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care) or a hybrid reconstruction algorithm which allows image reconstruction beyond the
conventional imaged volume (GE Healthcare) (Schilham et al., 2010).
Image Display
After reconstruction of the data and calculation of CT-numbers for each pixel, the image
still requires digitisation of the information to be displayed in an image format of 2D
pixels. A CT image is typically 512x512 pixels for adequate spatial resolution, although
this also depends on the reconstructed field of view (Bushberg et al., 2001). For the range
of CT numbers, 4096 shades of grey can be used to define each pixel to provide good
contrast resolution (Kalendar, 2005). This equates to 12 bits (4096=212) of information
per pixel to represent the data in a digital image format. This requires 315 kilobytes (kB)
per image and a CT scan made up of a series of images will be many megabytes of data
storage.
The human eye can only discern 30-90 shades of grey (Bushberg et al., 2001) and hence
computer monitors, which can generally display 256 shades of grey (8 bits), are more than
sufficient for viewing CT images. Furthermore, the grey scale range can be adjusted by the
user with windowing and levelling. The window width defines the range of CT-numbers
that will be allocated a shade of grey, while the level specifies the central CT-number
around which the window is displayed. All CT-numbers falling outside of the window will
be displayed as black (less than the minimum of the window) or white (greater than the
maximum window value). Hence, the complete grey scale is assigned to a desired CT-
number interval. Windowing and levelling is an interactive real time tool that can assist
with displaying the image.
A.4 CT Image Quality
Optimum image quality is achieved by limiting noise and maximising resolution, both
spatial and low contrast. Spatial and low contrast resolution are generally improved at
the expense of one another. Therefore, a balance between the two is required without
excessively limiting either resolving power. Furthermore, there are many causes of artefact,
or systematic discrepancies, in an image. The reduction and/or elimination of these are
essential to improving the quality of imaging.
Noise
The noise in an image is primarily due to quantum mottle (number of photons used to
construct the image) and is stochastic in nature. Other sources of noise include electronic
noise from the detector system and structural noise arising from the reconstruction process,
although quantum noise is dominant (Goldman, 2007b). According to Poisson statistics,
the quantum noise is quantified by the standard deviation (σ) of photons detected, which
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is defined as:
σ =
√
N (A.8)
where N represents the number of detected photons. The image noise is hence proportional
to 1
/√
N and the signal to noise ratio (SNR) is defined as:
SNR =
N
σ
=
√
N (A.9)
The noise can be reduced and the SNR improved by increasing the voltage or mAs (either
the tube current or the scan time) while all other parameters are held constant. The
square root dependence of the SNR is important, since the mAs must increase by a factor
of four (large dose increase) to reduce the noise by a factor of two. Increasing the tube
voltage will cause more photons to penetrate the patient and hence reach the detector,
therefore decreasing the noise. The number of photons can also be increased (and hence
the noise reduced) by selecting a thicker slice width.
Spatial Resolution
The ability to resolve small details in an image is a measure of the spatial resolution. The
size of detector elements is one of the main limiting factors in the x-y (image) plane. The
distance between the centre of each detector element (detector pitch) must be smaller by a
factor of two or more than the smallest resolvable detail to ensure that the desired spatial
resolution is achieved. The Nyquist frequency (FN ) determines the highest frequency that
can be imaged and is represented by:
FN =
1
2∆
(A.10)
where ∆ is the detector pitch. The detector aperture width will also cause blurring, by
averaging the signal over that width. Blurring in the scan plane will additionally result
from the penumbra due to the finite size of the focal spot and also from the continuous
movement of the focus during the measurement (Hsieh, 2003; Huda and Slone, 2003;
Kalendar, 2005).
Undersampling of the X-ray beam can lead to aliasing artefacts in the image and hence
a decrease in spatial resolution. This has been addressed with the use of a flying focal
spot and/or quarter detector shift. A flying focal spot design shifts the electron beam
slightly during the rotation to move the focal position on the anode surface to obtain a
separate set of projections offset from the first, which effectively interleaves the projections
and increases the sampling rate. The alternative technique involves moving the detector
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elements a quarter of a detector width from the central ray, which doubles the sampling
rate as the offset equates to half the sampling distance between the ray paths in each
180°rotation.
The number of pixels used to display the image will also affect the spatial resolution. The
pixel size is determined by the displayed field of view (FOV). The FOV can be the same as
or smaller than the diameter of the field that was used to acquire the image. For a typical
512x512 matrix and a 35 cm displayed FOV, the pixel size is 0.7 mm. Therefore, the size
of the FOV used for the reconstructed image will affect the spatial resolution.
Another important factor is the filter selection for reconstruction of the image. A bone
algorithm can be used to provide better spatial resolution by accentuating higher frequen-
cies. The use of this filter, however, is offset by the substantial increase in noise. Other
filters are available such as a smoothing or soft tissue kernel, which blur the noise and
provide better low contrast resolution.
In the z-direction the slice thickness determines the resolution. For SDCT detectors this is
generally defined by the beam collimation, while for MDCT scanners it is equivalent to the
detector aperture along the z-axis. The profile of the slice would ideally be rectangular,
but instead tends to be more Gaussian in shape affecting spatial resolution. Larger slice
thickness will decrease overall spatial resolution. However, narrow slices will capture
fewer photons and therefore lead to increased noise. When selecting an appropriate slice
thickness, the competing influences on spatial and contrast resolution must be taken into
account. Furthermore, helical scanning with larger values of pitch, will cause the full width
half maximum (FWHM) of the slice profile to increase.
Traditionally spatial resolution in the scan plane was much better than in the longitudinal
direction. Detector element spacing in single row scanners was much smaller than the
width of the detector in the z-axis direction, providing superior resolution in the scan
plane. However, with MDCT scanners thinner slices are achievable and isotropic resolution
in each direction is attainable. This allows multi-planar reformatting (MPR) of images in
the coronal and sagittal planes and 3D image reconstructions.
Low Contrast Resolution
Low contrast detectability is one of the greatest advantages of CT, particularly compared
with conventional radiography. The SNR in the CT images influences the ability to resolve
low contrast objects. Contrast is therefore affected by factors contributing to noise in the
image. One of the simplest ways of decreasing noise is to increase the mAs. However, this
is at the significant cost of increased dose to the patient.
To optimise low contrast resolution, ideally thicker slice width and larger pixel size should
be used. These parameters provide better counting statistics in each voxel (volume ele-
ment) by increasing SNR and allow differentiation between similar attenuation coefficients.
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However, the selection of these factors degrades the spatial resolution and a compromise
between the two is required depending on the clinical indications and the diagnostic infor-
mation sought. Low spatial resolution will also obscure small low contrast objects.
The reconstruction algorithm can be used to improve the contrast by using a smooth
filter which blurs the noise and hence is useful for imaging soft tissue where low contrast
detectability is essential. As discussed previously, better spatial resolution will be achieved
using a different filter, such as the bone filter, which enhances noise, but decreases low
contrast detectability.
Artefacts
The presence of artefacts can seriously degrade the image quality and may even affect
the ability to extract diagnostic information from an image. Even more problematic is
the capacity of some artefacts to actually mimic pathology, which may lead to incorrect
diagnosis. There are various sources of artefacts in a CT image including those from
physics-based processes, from the patient and from the scanner itself and some of these
have already been discussed in previous sections. Artefacts will manifest in the recon-
structed image as streaks, shading, rings and distortion (Barrett and Keat, 2004). These
can be removed by either eliminating or suppressing the source of the artefact or correcting
for the effect.
The CT X-ray beam transmitted through a patient is polychromatic, or has a spectrum of
energies, and selective attenuation of the lower energy photons occurs as it is transmitted
through the patient. Hence, the average photon energy will increase with the distance
travelled through the patient. This process is called beam hardening and occurs more
through the thicker central parts of the patient. This effect is evidenced in the image by
a brighter ring towards the edge of the image and is referred to as a cupping artefact. As
previously discussed, a bow-tie filter addresses this issue and correction algorithms can
also be used.
Streaking in the image can occur from photon starvation due to high attenuation of the
beam. This can occur, for example, in transverse imaging where the shoulders highly
attenuate the X-ray beam. This results in an insufficient number of photons reaching the
detector and hence very low contrast resolution for these projections. This artefact can be
addressed using a modulated tube current (Section A.2). Alternatively a software correc-
tion can be applied to smooth the projection above a selected attenuation threshold.
Each voxel is a finite volume and can therefore be composed of more than one tissue
type. These will all contribute to the effective attenuation coefficient calculated for that
voxel and the resulting CT-number will be a weighted average representing all component
tissues. Artefacts arising from this averaging, called the partial volume effect, can easily
be overcome by using a thin slice, which is particularly necessary where the anatomy is
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changing quickly. However, decreasing the slice width is accompanied by an increase in
noise.
Patient based artefacts arise from the presence of metallic objects, such as pacemakers,
hip implants, or dental fillings. The CT-number calculated for a metallic object will
be outside the possible range as a result of the increased density. This can cause quite
significant streaking in the reconstructed image. Apart from attempting to avoid imaging
of metallic objects, the artefact can be corrected using a software correction. However,
the resulting image will still have limited detail in the area immediately surrounding the
metal object.
Patient motion results in streaking and shading and can be due to both voluntary and
involuntary motion. Voluntary motion, particularly in paediatric patients, can be reduced
by using positioning aids and minimising scanning time or even using a general anaesthetic.
Shorter scan times also allow the patient to hold their breath, minimising any motion
attributable to the respiratory cycle. Organ movement, particularly the heart, can cause
motion artefacts. This motion can be compensated for with software algorithms and
placing less weighting on the beginning and end projections which tend to display greatest
discrepancies (Barrett and Keat, 2004). With larger, obese patients there is the possibility
that they will be outside the limits of the scan plane. This leads to hyperdense artefact
areas in the image.
It is evident that the possible sources of artefacts in a reconstructed image are numerous.
However, these are generally treated successfully and have a minimal effect on image
quality. As Barrett and Keat (2004) state, design features and software corrections can
minimise some types of artefacts, but careful patient positioning and optimum selection
of scanning parameters are the most important factors in avoiding CT artefacts.
A.5 Formalism for CT Dosimetry
The radiation dose to the patient from a CT examination is dependent on the individual
scanner design and geometry, as well as the technical factors used. CT dose quantities have
been defined that allow evaluations of scanner and protocol performance. However, these
quantities do not represent the dose to an individual patient, but rather are calculated
using two standardised polymethyl methacrylate (PMMA) homogeneous phantoms (16 cm
and 32 cm diameter) and are intended to be indicative of patient dose. Using standardised
measures allows a relative comparison between different protocols on a single scanner or
between different scanners by the same or other manufacturers. Furthermore, comparisons
can be made between sites and across jurisdictions.
The CT dosimetry formalism based on the CT dose index (CTDI) is the most commonly
used today. However, the International Atomic Energy Agency (IAEA) have recently
adopted (Einstein et al., 2007b) the terminology detailed by the International Commission
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on Radiation Units and Measurement (ICRU) in Report 74 (ICRU, 2005). This uses
more precise definitions recognising, for example, that dosimetry measurements are of air
kerma rather than absorbed dose (Einstein et al., 2007b). A brief outline of the dosimetry
quantities currently displayed on CT scanners follows.
Ideally, the dose profile of a single rotation consisting of N slices or sections with width T ,
would be rectangular. However, due to scattered radiation and beam divergence (penum-
bral effect) the profile exhibits tails (Figure A.16). The FWHM of the dose distribution
will be greater for larger patients and wider beam collimations due to increased scatter
(Kalendar, 2005).
For multiple contiguous rotations of the X-ray tube the tails in each dose profile will
contribute to adjacent regions and therefore the peak dose cannot be used as an accurate
descriptor of the dose distribution (Figure A.17). Instead, the multiple scan average dose
(MSAD) was defined to properly account for the contribution from all scan regions to a
central portion of the multiple scan dose profile. The MSAD is typically determined from
measurements with thermoluminescence dosimeters (TLDs) and has units of gray (Gy)
(one gray is the absorption of one joule (J) of energy per unit mass (kg) of the medium)
(Bauhs et al., 2008).
In 1981 the CTDI, which can be measured using a pencil ionisation chamber, was suggested
as a measure to approximate the MSAD (Shope et al., 1981). It represents the area under
the dose profile as a function of position along the z-axis, D(z), divided by the total beam
collimation, which is the number of sections or slices (N) multiplied by the section width
(T ) in each rotation:
CTDI =
1
NT
∫ +∞
−∞
D(z)dz (A.11)
Due to the symmetry of dose deposition from the tails of adjacent rotations, a measurement
can be made of a single rotation only, which will be equivalent to the dose in that volume
including the contributions from the tails of all adjacent rotations (Goldman, 2007a). This
assumes that the measurement device captures the entire tail for the single rotation being
measured.
To standardise the quantity so that it is a useful comparative measure and based on the
commercial availability of ionisation chambers for the measurement, a variety of CTDI
quantities have been suggested. The most commonly used today is the CTDI100, which
utilises a 100 mm long ionisation chamber to perform the measurement. It is defined
as:
CTDI100 =
1
NT
∫ +50mm
−50mm
D(z)dz (A.12)
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Figure A.16: Radiation dose distribution for a single X-ray tube rotation showing tails
from scattered radiation and beam divergence.
Figure A.17: Radiation dose distribution from multiple adjacent rotations of the X-ray
tube showing tails from scattered radiation and beam divergence.
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where N is the number of sections/slices acquired per rotation and T is the section thick-
ness, as previously used. Using a 100 mm long ionisation chamber, the CTDI100 is mea-
sured in air at the isocentre of the scanner for a single rotation centred on the chamber
and calculated using:
CTDI100 =
fCXL
NT
(A.13)
where f is the conversion factor from exposure to an absorbed dose in air (8.76 mGy/R),
C is the calibration factor for the electrometer used with the ionisation chamber, X is
the measured exposure in Roentgen (1 R = 2.58 x 10−4 C/kg) acquired from a single
360°rotation with beam profile NT , and L is the active length of the ionisation chamber.
The L/NT normalisation factor accounts for partial volume irradiation of the ionisation
chamber.
For most modern scanners a standard 100 mm pencil ionisation chamber is long enough
to intercept the length of both tails in a single profile. However, with fan beams becoming
wider in newer scanner designs, this concept is being challenged (Bauhs et al., 2008;
Geleijns et al., 2009; Goldman, 2007a).
The dose distribution in the x-y plane depends on the attenuation provided by the patient’s
body. CT is quite different from plain projection radiography, because of the 360°exposure
of the patient. In projection radiography the patient will receive the highest dose proximal
to the X-ray tube, whereas in CT the dose will be significantly higher around the entire
periphery of the patient. For a CT scan, the dose towards the centre of the body will
be approximately half of the dose at the patient’s surface due to self-shielding. However,
it has been shown that for small phantoms representing paediatric sizes or equivalent to
an adult head, the dose is nearly uniformly deposited throughout the phantom (Nickoloff,
2002; Nickoloff et al., 2003).
To take into account the varying depth dose distribution, CTDI measurements are made
in PMMA phantoms and weighted to account for the non-uniform dose to the centre.
Two standardised phantoms are used representing an adult head (16 cm diameter) and
an adult body (32 cm diameter to represent the abdomen). Both phantoms are 15 cm in
length. The head phantom can also be used to represent a child’s body. Another quantity,
the weighted CTDI (CTDIw), is used to take into account the dose at the periphery
(CTDI100,p) and the centre (CTDI100,c) of the phantoms. It is an average of the absorbed
dose in the x-y plane and is calculated using:
CTDIw =
2
3CTDI100,p +
1
3CTDI100,c (A.14)
These quantities have not taken into account the pitch (P ) or spacing of the rotations for
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helical scanning as a result of the table feed during each rotation (l). For helical CT, the
pitch is defined as in equation A.2 as:
P =
table feed per gantry rotation
beam collimation
=
I
NT
(A.15)
A volumetric CTDI (CTDIvol) is used to take account of the pitch and is given by:
CTDIvol =
CTDIw
P
(A.16)
This parameter is now displayed on all CT consoles and represents an average absorbed
dose over the x-y-z planes. However, it does not take into account the length of the
scanned region (L) for the entire CT scan. The dose length product (DLP) provides a
better indicator of the total amount of radiation deposited in the patient and is typically
measured in mGy·cm:
DLP = CTDIvol · L (A.17)
DLP is displayed with CTDIvol on the control console. They are useful, real time measures
for comparing protocols. However, it is important to understand that DLP and CTDIvol
reflect the scan parameters used in the protocols and are measured in phantoms. They
should not be used for risk assessments (Frush et al., 2003; ICRP, 2007a).
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Appendix B
Effective Dose Computation
The mean organ or tissue absorbed dose (DT ) is the mean total energy imparted in a
tissue or organ (εT ) divided by the mass of that organ or tissue (mT ), given by (ICRP,
2007b):
DT =
εT
mT
(B.1)
Absorbed dose is measured in joules per kilogram (J·kg−1) or gray (Gy). The equivalent
dose (HT ) is calculated from the mean organ and tissue absorbed doses due to radiation R
in organ or tissue T (DT,R) by multiplying by a radiation weighting factor (wR) dependent
on the type of radiation, given by (ICRP, 2007b):
HT =
∑
R
wR ·DT,R (B.2)
For X-ray photons, the radiation weighting factor is one (ICRP, 1991, 2007b). Effective
dose is defined as the sum of the equivalent doses in specific organs and tissues weighted
by a tissue weighting factor (wT ), which accounts for varying organ radiosensitivity and
was defined in ICRP Publication 60 (ICRP 60 (ICRP, 1991)) as:
E =
∑
T
wT ·HT =
∑
T
wT
∑
R
wR ·DT,R (B.3)
such that
∑
wT = 1. The values of the tissue weighting factors, from the first ICRP
Recommendations (ICRP Publication 26) to the two recent revisions (ICRP Publications
60 and 103) are shown in Table B.1.
ICRP Publication 103 (ICRP 103 (ICRP, 2007b)) later included sex-specific definitions
of equivalent dose when calculating these using the hybrid phantom models for Reference
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Table B.1: Tissue weighting factors from ICRP Publi-
cations 26, 60 and 103 (ICRP, 1977, 1991, 2007b).
Organ or Tissue ICRP 26 ICRP 60 ICRP 103
Bone marrow (red) 0.12 0.12 0.12
Colon - 0.12 0.12
Lung 0.12 0.12 0.12
Stomach - 0.12 0.12
Breast 0.15 0.05 0.12
Remainder Tissues 0.30 0.05 0.12
Gonads 0.25 0.20 0.08
Bladder 0.05 0.04
Oesophagus - 0.05 0.04
Liver - 0.05 0.04
Thyroid 0.03 0.05 0.04
Bone surface 0.03 0.01 0.01
Brain - - 0.01
Salivary glands - - 0.01
Skin - 0.01 0.01
Total 1 1 1
Male and Female. According to ICRP 103, the effective dose (E) is an average of the dose
for males and females, given by (ICRP, 2007b):
E =
∑
T
wT
[
HMT +H
F
T
2
]
(B.4)
where wT is the tissue weighting factor and H
M
T , H
F
T are the equivalent doses for organs
or tissues T of the male and female (M,F ) respectively. ICRP 103 includes the prostate
in the equivalent dose for males and the uterus/cervix for females. An earlier, different
sex-specific effective dose definition was given in ICRP Publication 74 (ICRP, 1996b)
as:
E = wbreastHbreast,F +
∑
T 6=breast
wT
[
HT,M +HT,F
2
]
(B.5)
Some authors (Hunold et al., 2003; Nishizawa et al., 2008; Stamm and Nagel, 2011a) use
this definition of effective dose, with Stamm and Nagel (2011a) stating that the contribu-
tion of breast dose is not taken into account for males as the stochastic risk is negligible
due to the small size of the organ. However, Nagel (2002) also comments that excluding
the breast in the calculation of the dose to a male may cause issues if it is not clearly
stated and defined, particularly since the tissue weighting factors consequently sum to less
than one for males.
The tissue weighting factors are sex- and age-averaged values for the specified tissues
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and organs, including the male and female breast and the gonads (testes and ovaries).
Therefore, it is stated in ICRP 103 (ICRP, 2007b) that it is not reasonable to treat the
contribution of the male and female doses separately when considering effective dose and
equation (B.3) should be used. It is pertinent to use equation (B.4) when determining
sex-averaged equivalent doses for the effective dose calculation. An analysis of the age-
averaging of ICRP 60 tissue weighting factors found that the effective dose did not change
considerably if age dependent factors were used (Almen and Mattsson, 1996). However,
when calculating effective dose for children, the age-averaging of the tissue weighting
factors should be recognised.
The organs included in the effective dose calculation are divided into primary and re-
mainder organs based on epidemiological information regarding radiation induced cancer
risk. Table B.2 lists the primary and remainder organs and tissues according to ICRP
Publications 26, 60 and 103.
Table B.2: Primary and remainder organs for effective dose com-
putation as listed in ICRP Publications 26, 60 and 103 (ICRP,
1977, 1991, 2007b).
Primary organs and
tissues
Remainder organs and
tissues
ICRP 26 Red bone marrow, lung,
breast, gonads, thyroid,
bone surface
The five most highly ir-
radiated other organs and
tissues
ICRP 60 Red bone marrow, colon,
lung, stomach, breast, go-
nads, bladder, oesopha-
gus, liver, thyroid, bone
surface, skin
Adrenals, brain, upper
large intestine, kidney,
muscle, pancreas, small
intestine, spleen, thymus,
uterus
ICRP 103 Red bone marrow, colon,
lung, stomach, breast, go-
nads, bladder, oesopha-
gus, liver, thyroid, bone
surface, skin, brain, sali-
vary glands
Adrenals, kidney, muscle,
pancreas, small intes-
tine, spleen, thymus,
uterus/cervix, extratho-
racic (ET) region, gall
bladder, heart, lymphatic
nodes, oral mucosa,
prostate
In ICRP 60 the remainder dose is the weighted average of the equivalent dose of all
remainder tissues and organs. However, if a single one of the remainder organs or tissues
received an equivalent dose in excess of the highest dose for the non-remainder organs and
tissues then a specific weighting factor of 0.025 should be applied to that organ or tissue
and a weighting factor of 0.025 applied to the average dose in the rest of the remainder.
In ICRP 103, the remainder dose is sex-specific such that the equivalent dose for the
remainder (Hrmd) for males (M) is given by:
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HMrmd =
1
13
13∑
T
HMT (B.6)
And for females (F ) is given by:
HFrmd =
1
13
13∑
T
HFT (B.7)
where T are the remainder tissues specified in ICRP 103 (ICRP, 2007b). There are 12 com-
mon remainder tissues, with the addition of the prostate for males and the uterus/cervix
for females.
In ICRP Publication 69 (ICRP, 1995) the ICRP 60 effective dose definition was clarified
by the ICRP by removing the upper large intestine from the list of remainder organs as it
was already included in the colon in the primary list of organs. The colon equivalent dose
was then defined as the mass average of the doses to the upper and lower large intestine
of the gastrointestinal tract. Furthermore, the extrathoracic airways were added to the
remainder in ICRP Publication 71, although the change to effective dose is negligible
(ICRP, 1996b)
In this thesis, equation (B.3) is used to calculate effective dose. The organs and tissues
specified in the definition of effective dose according to ICRP 60 (without inclusion of
subsequent changes) and the revised recommendations in ICRP 103 are both utilised and
indicated accordingly.
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Introduction to
Thermoluminescence Dosimetry
C.1 Thermoluminescence Dosimetry
One of the most accurate methods for dose measurement is thermoluminescence dosimetry.
Thermoluminescence is the property of an insulating (or semiconductor) crystal to emit
light when heated after being exposed to ionising radiation. When an insulator absorbs
energy during irradiation, some electrons will be raised from the valence band (outer most
band filled with electrons) to the conduction band (lowest empty energy band). A positive
hole is left in the valence band and most electrons will immediately return to this band
and emit visible light via either fluorescence (instantaneous emission) or phosphorescence
(delayed emission). Prior to this recombination, the free electron and hole can move
independently in their respective bands.
When impurities are added to the crystal, electrons may be caught in traps when moving
between the valence and conduction bands. When electrons are trapped in these impurity
levels, the material must be stimulated by some form of radiation to release the electron by
raising it to the conduction band from where it can return to the valence band. If visible
or infra-red stimulation is required the subsequently emitted photon radiation is called
optically stimulated luminescence (OSL). When heat is applied, the resulting luminescence
is called thermoluminescence. The amount of light measured is proportional to the amount
of ionising radiation absorbed by the material. Hence, a measurement of exposure can be
made.
Common forms (Cember and Johnson, 2009) of thermoluminescence material include LiF,
CaF2:Mn, CaSO4:Tm, Li2B4O7:Cu, LiF:Mg,Ti. These are provided in various forms
(Johns and Cunningham, 1983) including powder, rods, or chips and are referred to as
thermoluminescence dosemeters (TLDs). Lithium fluoride (LiF, effective atomic number
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8.31) is most commonly used for personal dosimetry and medical applications as it has
similar characteristics to tissue (effective atomic number 7.64) (Johns and Cunningham,
1983). Its response range is from 10−5 Gy to 103 Gy and over such a wide range TLDs can
vary in sensitivity. This can be problematic for radiotherapy applications where LiF:Mg,Ti
is commonly used. The dose response of the TLD material is linear–supralinear–sublinear,
with supralinearity evident above 1 Gy (Moscovitch and Horowitz, 2007). Therefore, it is
always necessary to calibrate to a known dose and calculate relative sensitivities.
For reproducibility of measurement, it is essential that a protocol for using TLDs is estab-
lished and followed closely. Prior to use, TLDs require annealing to remove any residual
effects of previous irradiations (Khan, 2003). After irradiation, the TLD is again heated,
typically in a TLD reader specifically designed for the purpose. The TLDs are placed in
a carousel or on a planchet and heated in the reader to a reproducible temperature at
a uniform rate. The light emitted is measured by a photomultiplier tube, which is then
converted to an electrical current and amplified. The results produce a glow curve where
the area under this curve is proportional to the total dose received by the TLD.
Peaks in the glow curve are representative of the different binding energies of electrons in
different trapping sites. By measuring the total light output and calibrating to a known
dose of radiation the dose received by each TLD can be calculated. There will be some
spontaneous fading of the TLD, since even at room temperature some electrons will fall
out of traps to the valence band (Cember and Johnson, 2009).
C.2 Advantages and Disadvantages
Thermoluminescence dosimetry is widely employed in medical dosimetry applications for
assessing dose to both patients and occupationally exposed personnel. The tissue equiv-
alence of a range of TLD materials and the various physical forms available provide flex-
ibility in its use (Kron et al., 1999). In addition, due to the small size of some forms of
TLD (for example, chips and rods) it is possible to insert TLDs into locations where ion
chambers or other types of radiation detectors cannot be used. This may include direct
insertion into tissue or cavities of the body (Khan, 2003). It is common for radiother-
apy departments to have TLD capabilities for experimental dose assessment (Johns and
Cunningham, 1983). TLDs are also used in diagnostic radiology applications (Broadhead
et al., 1997; Dong et al., 2002), although less frequently. Due to the small size of a TLD
chip they can be used without affecting image quality.
TLD cards are commonly used for personnel dosimetry. TLD materials are sufficiently
robust and have minimal fading allowing them to be distributed amongst personnel for
a period of time, commonly three months. They are used as a passive dosemeter accu-
mulating dose over the wearing period to provide a cumulative assessment of exposure.
Using different filtration materials in the holder for the TLD card allows energy discrim-
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ination. One disadvantage compared to a film dosemeter is that an image is not formed.
For example, it is simpler to assess on film if the dosemeter has been uniformly directly
irradiated or whether an exposure is predominantly attributable to scattered radiation.
Ring dosimeters can be utilised for assessing dose to the hands in the laboratory when
using unsealed radioactive sources or in some high dose fluoroscopy procedures such as
interventional cardiology or angiography where the clinician’s hands are close to the pri-
mary X-ray beam. One of the disadvantages of TLDs for personnel dosimetry can be the
occurrence of spurious signals from contaminants (Al-Haj et al., 2007), although overall
they are relatively impervious.
A significant disadvantage of TLD dosimetry is that it is labour intensive and not real
time. It is essential that the annealing, including cool down, and read out processes are
reproducible to avoid significant systematic errors arising. Furthermore, repeat calibration
is necessary to continually assess the effects of the radiation and thermal history of individ-
ual TLDs. To some extent, automatic readers have reduced the time involved in reading
out TLDs. However, dosimetry with TLDs typically remains a multi-day process.
Despite some limitations thermoluminescence dosimetry remains the gold standard for
radiation dosimetry.
C.3 High Sensitivity TLDs
A different type of TLD material is now finding application in lower dose medical dosimetry
typical of diagnostic radiology applications. Lithium fluoride doped with magnesium,
copper and phosphorous (LiF:Mg,Cu,P) has a much lower detection range and higher
sensitivity. The glow curve consists of three low temperature peaks (70-160°C), a main
dosimetry peak at about 220°C and a high temperature peak at 300°C (Moscovitch and
Horowitz, 2007). Duggan et al. (2004) contend that LiF:Mg,Cu,P is equal to or superior
to any other detector used for in vivo dosimetry in the low energy range.
LiF:Mg,Cu,P is 10-35 times more sensitive than conventional TLD material (LiF:Mg,Ti)
used for medical dosimetry (Davis et al., 2003; Dong et al., 2002; Glennie, 2003; Kron et al.,
1996; Moscovitch and Horowitz, 2007). Additionally, LiF:Mg,Cu,P does not exhibit the
supralinearity with dose typical of LiF:Mg,Ti and the signal has minimal short term fading
after irradiation (Bos, 2001; Harris et al., 1997; Luo and Rotunda, 2006; Moscovitch and
Horowitz, 2007; Olko et al., 1993; Ramlo et al., 2007). The dose response of LiF:Mg,Cu,P
is linear–sub-linear, with linearity extending from 1 µGy to 10 Gy (Moscovitch, 1999). As
shown in Figure C.1 the energy response is relatively linear (Duggan, 2002; Duggan et al.,
2004; Kron et al., 1996), particularly when compared with LiF:Mg,Ti.
The mass energy absorption coefficient ratio for LiF to air increases with decreasing energy
in the low keV region (Moscovitch and Horowitz, 2007). As Moscovitch and Horowitz
(2007) state, it may be expected that the response of LiF is correspondingly higher in
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this region. Furthermore, since both LiF:Mg,Ti and LiF:Mg,Cu,P have the same effective
atomic number the response would be expected to be the same (Moscovitch and Horowitz,
2007). This is in fact not the case (Figure C.1). The thermoluminescence response of
LiF:Mg,Ti is higher at lower photon energies. Moscovitch and Horowitz (2007) explain
that this is due to the supralinearity of LiF:Mg,Ti and the “microscopic dose distribution
within photon induced secondary electrons”. Without the supralinearity, LiF:Mg,Cu,P
response in the lower keV region is lower.
Figure C.1 also shows an under-response of LiF:Mg,Cu,P at about 190 keV, which again
is not predicted by the ratio of mass energy absorption coefficients. Olko et al. (1993)
confirmed the hypothesis of Pradhan and Bhatt (1989) that the thermoluminescence ef-
ficiency of LiF:Mg,Cu,P is directly related to the density of ionisation. In the main CT
diagnostic energy range, between 50 and 120 keV, the dominant photon interaction pro-
cess for low Z elements changes from the photoelectric effect to Compton scattering (Johns
and Cunningham, 1983). This is accompanied by a change in the ionisation density re-
sulting from the different secondary electron energies and ranges. Using lineal energy
(mean track-averaged linear energy transfer) Olko et al. (1993) showed that there is a
maximum in ionisation density in LiF:Mg,Cu,P at about 80 keV, which correlates with a
saturation in thermoluminescence response (Moscovitch, 1999). This corresponds with the
experimentally identified local minimum in thermoluminescence response (Horowitz and
Olko, 2004; Olko et al., 1993, 1994). The theoretical minimum is lower than that found
experimentally and modelled by Duggan et al. (2004), who provide a good summary of
the range of minimum responses found experimentally (50-190 keV).
Overall, the sensitivity and linear energy and dose response of LiF:Mg,Cu,P in the low keV
and dose region make it a suitable choice for dosimetry in diagnostic radiology. Dosimetric
studies using the high sensitivity TLD material are starting to emerge in this field (Brisse
et al., 2009b; Dong et al., 2002; Duggan et al., 2003; Loubele et al., 2009; Theodorakou
and Horrocks, 2003).
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Figure C.1: Energy response for LiF:Mg,Ti and LiF:Mg,Cu,P chips based on energy fit
models provided by Duggan et al. (2004).
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International Paediatric CT
Diagnostic Reference Levels
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Table D.1: Comparison between paediatric CT diagnostic reference levels (DRLs) from Europe (2000 (Shrimpton and Wall,
2000) and 2001 (Bongartz et al., 2004; Shrimpton et al., 2005)), the United Kingdom (UK 2003 (Shrimpton et al., 2005, 2006)),
Switzerland (2005 (Verdun et al., 2008)), Germany (2006 (Galanski et al., 2007)), and Greece (2009 (Yakoumakis et al., 2009)).
Region Agea(years) CTDIvol (mGy)
b DLP (mGy·cm)b
Europe
2001
UK
2003
Switz.
2005
Germany
2006
Europe
2000
Europe
2001
UK
2003
Switz.
2005
Germany
2006
Greece
2009
Head 0-1 (<1) 31 30 20 33 300 333 270 270 390
5 (1-5) 47 45 30 40 600 374 470 420 520 650d
10 (5-10) 50 40 50 750 620 560 710 975
15 (10-15) 60 65 60 60 1050 930 1000 920
Chest 0-1 (<1) 12c 12 5 3.5 200 156c 200 110 55
5 (1-5) 12c 13 8 5.5 400 152c 230 200 110 336d
10 (5-10) 20 10 8.5 600 370 220 210 578
15 (10-15) 10* 14* 12 6.8* 580* 460 205*
Abdomen 0-1 (<1) 7 5 170 130 145
5 (1-5) 9 8 250 300 255 840d
10 (5-10) 13 13 500 380 475 1120
15 (10-15) 15* 14* 16 10* 560* 500 500*
a Age groups relate to UK and European DRLs (Bongartz et al., 2004; Shrimpton and Wall, 2000; Shrimpton et al., 2005, 2006). Bracketed age groups
are for Switzerland and Germany (Galanski et al., 2007; Verdun et al., 2008).
b Calculated values of CTDIvol and DLP for CT on children relate to the 16 cm dosimetry phantom, except for those values marked with an asterisk
(*) which relate to the 32 cm dosimetry phantom. Shrimpton et al. (2000) assume that practice for children aged over 10 years will be broadly
similar to that for adult patients and hence the adult reference values are used. It is not defined in the Swiss study whether values are in terms of
the 16 cm or 32 cm phantom (Verdun et al., 2008). It is assumed, based on the methodology and values obtained that it is the smaller phantom.
c Dose data for chest examinations originally referred to the 32 cm dosimetry phantom and have been corrected by multiplication by a factor of about
two in order to allow comparison with corresponding data referring to the 16 cm dosimetry phantom, as recommended in NRPB Report 67
(Shrimpton et al., 2005).
d Calculated values of DLP use a 12 cm phantom, instead of the 16 cm CT dosimetry phantom, for 5 year olds (Yakoumakis et al., 2009).
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Phantom Composition and
Dimensions
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Table E.1: CIRS Model 706-D anthropomorphic phantom materials (10 year old child) (CIRS, 2006).
C O H N Ca P Mg Cl Al Physical
Density
(g/cc)
Electron
Density
(x1023 g/cc)
Bone 0.4015 0.3406 0.0507 0.0106 0.1545 0.0000 0.0413 0.0005 0.0000 1.54 4.878
Soft tissue 0.5744 0.2459 0.0847 0.0165 0.0000 0.0000 0.0762 0.0019 0.0000 1.05 3.434
Spinal cord 0.5427 0.2659 0.0736 0.0217 0.0000 0.0000 0.0937 0.0022 0.0000 1.07 3.448
Spinal disks 0.4627 0.3082 0.0675 0.0188 0.0000 0.0000 0.1407 0.0020 0.0000 1.15 3.694
Lung 0.6336 0.2046 0.0832 0.0315 0.0000 0.0000 0.0000 0.0137 0.0329 0.20 0.650
Brain 0.5360 0.2649 0.0816 0.0153 0.0000 0.0000 0.0998 0.0019 0.0000 1.07 3.470
Table E.2: Comparison of elemental composition of CIRS and PCXMC anthropomorphic phantoms of a 10
year old child.
C O H N Ca P Mg Cl Al Physical
Density
(g/cc)
Bone (CIRS) 0.4015 0.3406 0.0507 0.0106 0.1545 0.0000 0.0413 0.0005 0.0000 1.54
Skeleton (PCXMC) 0.2548 0.4789 0.0734 0.0306 0.1036 0.0587 - - - 1.40
Soft tissue (CIRS) 0.5744 0.2459 0.0847 0.0165 0.0000 0.0000 0.0762 0.0019 0.0000 1.05
Soft tissue (PCXMC) 0.2266 0.6353 0.1045 0.0249 0.0024 0.0077 - - - 1.04
Lung (CIRS) 0.6336 0.2046 0.0832 0.0315 0.0000 0.0000 0.0000 0.0137 0.0329 0.20
Lung (PCXMC) 0.1023 0.7575 0.1013 0.0287 0.0024 0.0077 - - - 0.296
a In PCXMC the number of elements has been reduced from that in Cristy and Eckerman (1987) by grouping the elements
Na, Mg, P, S and Cl together and treating them as phosphorus (Tapiovaara and Siiskonen, 2008). All elements of atomic
number from that of K or higher have been grouped together and treated as calcium.
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Table E.3: Characteristics of CIRS, CT-Expo and PCXMC anthro-
pomorphic phantoms representing children.
CIRS
phantom
10 yo
CT-Expo
phantom
7 yo
PCXMC
phantom
10 yo
Weight (kg) 32 22 32
Total height (cm) 140 115 140
Trunk height (cm) 52 43 51
Trunk thickness (cm) 17 18 17
Trunk width (cm) (no arms) 20 33 24
Leg length (cm) - 51 66
a Zankl et al. (1991).
b Tapiovaara and Siiskonen (2008).
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Figure E.1: Comparison of elemental composition of CIRS and PCXMC phantoms of a
10 year old child.
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Appendix F
TLD Phantom Measurement
Locations
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Table F.1: Measurement locations in anthropomorphic phantoms from various studies for determining effective dose.
Organ/Tissue This Study Groves
et al.
Hunold
et al.
Hurwitz
et al.
Hollingsworth
et al.
Kawaura
et al.
Scalzetti
et al.
Scalzetti
et al.
Scaledb
ICRP Publication: ICRP 60, 103 ICRP 60 ICRP 60 ICRP 60 ICRP 60 ICRP 60 ICRP 60, 103
Dosimetry Method: TLD TLD TLD MOSFET MOSFET Photodiodes NA
Bone marrow (red) 10 1 20 4 5 8
Colon 4 6 8 1 5 14 7
Lung 10 3 12 2 3 2 34 16
Stomach 6 3 2 2 1 1 13 6
Breast 4 3 2 2 2 1 4 2
Gonads 4 5 8 2 2 4 2
Bladder 3 3 2 1 1 6 3
Oesophagus 3 3 4 2 1 2 3 1
Liver 9 3 2 2 1 2 19 9
Thyroid 2 3 2 2 1 1 2 1
Bone surface 0c 3 4d
Brain 6 3 16 8
Salivary glands 2 3 1
Skin 6 3 4 2
Sub-Total 69 42 66 16 18 31 118 56
a Groves et al. (2004); Hunold et al. (2003); Hurwitz et al. (2007b); Hollingsworth et al. (2007); Kawaura et al. (2006); Scalzetti et al. (2008).
b Since the Scalzetti et al. (2008) recommendations for TLD placement is the only reference to address the organs and tissues in ICRP 103 (ICRP,
2007b), the number of measurement locations has been scaled to the number of TLDs available for this thesis to allow comparison.
c The absorbed dose to the bone surface was calculated from the bone marrow absorbed dose.
d Kawaura et al. (2006) place some photodiodes directly in locations to estimate the bone surface absorbed dose (e.g. ribs), while also using some
measurements from the bone marrow (e.g. sternum). In total 10 measurement locations are used to determine the bone surface absorbed dose,
with some overlap with the bone marrow measurement locations.
e The absorbed dose to the ET region was approximated by the thyroid absorbed dose.
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Table F.1: Measurement locations in anthropomorphic phantoms. (continued)
Organ/Tissue This Study Groves
et al.
Hunold
et al.
Hurwitz
et al.
Hollingsworth
et al.
Kawaura
et al.
Scalzetti
et al.
Scalzetti
et al.
Scaled
ICRP Publication: ICRP 60, 103 ICRP 60 ICRP 60 ICRP 60 ICRP 60 ICRP 60 ICRP 60, 103
Dosimetry Method: TLD TLD TLD MOSFET MOSFET Photodiodes NA
Remainder Tissues
Adrenals 2 3 2 2 1
ET region 0e
Gall bladder 2 3 1
Heart 1f 8 4
Kidneys 3 3 1 16 8
Lymphatic nodes 0g
Muscle 0h 2
Oral mucosa 0i 4 2
Pancreas 2 3 4 2
Prostate 1 2 1
Small intestine 2 3 1 1 16 8
Spleen 2 3 2 1 8 4
Thymus 2 1 2 2 1
Uterus/cervix 2 3 1 2 1
Lensj 2 2 1
Sub-Total 21 21 6 2 3m 69 34
Total in phantom 90 65k 66 22l 20 34 187 90
a Groves et al. (2004); Hunold et al. (2003); Hurwitz et al. (2007b); Hollingsworth et al. (2007); Kawaura et al. (2006); Scalzetti et al. (2008).
f The TLD placed in the heart was also used as a fourth TLD for the oesophagus calculation. The heart is not specified on the CIRS phantom.
g The absorbed dose to the lymphatic nodes was approximated by the muscle absorbed dose.
h The absorbed dose to the muscle was calculated from the absorbed dose to all soft tissue measured by the TLDs.
i The absorbed dose to the oral mucosa was approximated by the salivary glands absorbed dose.
j The lens of the eye is not listed by the ICRP (1991; 2007b) as one of the tissues and organs to be considered for stochastic risk. However, it has
been included so that deterministic effects can be assessed.
k Groves et al. (2004) use a total of 65 TLDs in the phantom. However, they do not individually specify the locations of these. It could only be
determined where 63 of these had been placed and these are listed in the Table above.
l Hurwitz et al. (2007b) state that a total of 20 MOSFETs were used for effective dose determination. However, the total number for the locations
listed in the study is 22.
m Kawaura et al. (2006) use some measurement locations from the main organs/tissues to estimate remainder organ absorbed doses. The thymus
absorbed dose is approximated from the sternum/clavicles bone marrow absorbed dose; the pancreas absorbed dose is approximated by the
transverse colon absorbed dose; and the adrenals and kidney absorbed doses are approximated by one of the liver absorbed dose measurement
locations.
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Figure F.1: TLD locations shown with white markers on the physical anthropomorphic
phantom representing a 10 year old child used for measurements in this thesis.
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Appendix G
Factors for Red Bone Marrow and
Bone Surface Dosimetry
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Table G.1: Active marrow in bone groups expressed as percentage of active marrow in the whole body for different ages
(derived from Cristy (Cristy, 1981; Cristy and Eckerman, 1987)).
Skeletal Region Percentage of Active Marrow by Mass
10 yo 40 yo
Skull (cranium + mandible) 12.72 8.32
Scapulae 2.89 2.85
Clavicles 0.89 0.79
Ribs + sternum 13.02 19.22
Upper spine (cervical vertebrae C1-C5) 1.80 2.66
Middle spine (cervical vertebrae C6-C7 + all thoracic vertebrae) 11.79 17.41
Lower spine (lumbar vertebrae L1-L4) 6.63 9.79
Pelvis (sacrum + os coxae + lumbar vertebra L5 + 50% of upper half of femora) 28.73 33.31
Upper leg (50% of upper half of femora) 4.72 3.35
Middle leg (lower half of femora) 6.14 0
Lower leg (tibiae, fibulae, patellae + ankle and foot bones) 5.51 0
Upper arm (upper half of humeri) 2.49 2.29
Middle arm (lower half of humeri) 1.62 0
Lower arm (radii and ulnae + wrist and hand bones) 1.06 0
Skeleton (total) 100.01 99.99
a Highlighted regions indicate the locations selected for bone marrow measurement in the anthropomorphic phantom used in this thesis.
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Table G.2: Red bone marrow dose enhancement factors for individual bones weighted over the CT spectrum
(derived from King and Spiers (1985)) using the bone matching described in Eckerman and Stabin (2000).
Skeletal Region Bone Matchinga Dose Enhancement Factor
(RBM Measurement Location) 9 yob
Skull Parietal Bone 0.28
Scapulae 0.6 iliac crest + 0.4 lumbar vertebra L3 0.10
Ribs Ribs 0.07
Middle spine 0.5 cervical vertebra C4 + lumbar vertebra L3 0.14
Lower spine Lumbar vertebra L3 0.10
Pelvis 0.6 iliac crest + 0.4 lumbar vertebra L3 0.10
a Matching of bone sets in King and Spiers (1985) to the bone measurement locations used in this thesis using the method of
Eckerman and Stabin (2000)
b For tabulated dose enhancement factors for individual bones, the closest age provided is nine years old, which it is assumed
will be very similar to the factors for a 10 year old, the age group considered in this thesis.
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YTable G.3: Percentage distribution by mass of active marrow (Cristy and Eckerman, 1987), inactive marrow and trabecular bone
(Eckerman and Stabin, 2000) in different bones for a 10 year old child.
Skeletal Region Percentage Distribution by Mass
Active
Marrow in
Each Bone to
Total Active
Marrow
Inactive
Marrow in Each
Bone to Total
Inactive
Marrow
Trabecular
Bone in Each
Bone to Total
Trabecular
Bone
Skull (cranium + mandible) 12.72 7.16 5.2
Scapulae 2.89 1.64 0.8
Clavicles 0.89 0.53 0.2
Ribs + sternum 13.02 3.42 2.7
Upper spine (cervical vertebrae C1-C5) 1.80 0.47 11.3
Middle spine (cervical vertebrae C6-C7 + all thoracic vertebrae) 11.79 3.10 25.6
Lower spine (lumbar vertebrae L1-L4) 6.63 1.74 7.3
Pelvis (sacrum + os coxae + lumbar vertebra L5 + 50% of upper half of femora) 28.73 11.87 6.8
Upper leg (50% of upper half of femora) 4.72 3.31 13.1
Middle leg (lower half of femora) 6.14 10.08 14.1
Lower leg (tibiae, fibulae, patellae + ankle and foot bones) 5.51 40.05 5.7
Upper arm (upper half of humeri) 2.49 1.74 2.7
Middle arm (lower half of humeri) 1.62 2.64 2.3
Lower arm (radii and ulnae + wrist and hand bones) 1.06 12.25 2.1
Skeleton (total) 100.01 100 99.9
a Highlighted regions indicate the locations selected for bone marrow measurement in the anthropomorphic phantom used in this thesis.
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Table G.4: Derived mass of active marrow, inactive marrow and trabecular bone to give total spongiosa mass in different bones
for a 10 year old child.
Skeletal Region Mass (g)
Active
Marrow
Inactive
Marrow
Trabecular
Bone
Spongiosa
(Total)
Skull (cranium + mandible) 80.14 45.11 23.92 149.16
Scapulae 18.21 10.33 3.68 32.22
Clavicles 5.61 3.34 0.92 9.87
Ribs + sternum 82.03 21.55 12.42 115.99
Upper spine (cervical vertebrae C1-C5) 11.34 2.96 51.98 66.28
Middle spine (cervical vertebrae C6-C7 + all thoracic vertebrae) 74.28 19.53 117.76 211.57
Lower spine (lumbar vertebrae L1-L4) 41.77 10.96 33.58 86.31
Pelvis (sacrum + os coxae + lumbar vertebra L5 + 50% of upper half of femora) 181.00 74.78 31.28 287.06
Upper leg (50% of upper half of femora) 29.74 20.85 60.26 110.85
Middle leg (lower half of femora) 38.68 63.50 64.86 167.05
Lower leg (tibiae, fibulae, patellae + ankle and foot bones) 34.71 252.32 26.22 313.25
Upper arm (upper half of humeri) 15.69 10.96 12.42 39.07
Middle arm (lower half of humeri) 10.21 16.63 10.58 37.42
Lower arm (radii and ulnae + wrist and hand bones) 6.68 77.18 9.66 93.51
Skeleton (total) 630 630 460 1720
a Highlighted regions indicate the locations selected for bone marrow measurement in the anthropomorphic phantom used in this thesis.
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Table G.5: Derived percentage distribution by mass of bone spongiosa in terms of active marrow, inactive marrow
and trabecular bone for a 10 year old child.
Skeletal Region Percentage Distribution by Mass
(to Total Spongiosa in Each Bone)
Active
Marrow
Inactive
Marrow
Trabecular
Bone
Skull (cranium + mandible) 54 30 16
Scapulae 57 32 11
Clavicles 57 34 09
Ribs + sternum 71 19 11
Upper spine (cervical vertebrae C1-C5) 17 4 78
Middle spine (cervical vertebrae C6-C7 + all thoracic vertebrae) 35 9 56
Lower spine (lumbar vertebrae L1-L4) 48 13 39
Pelvis (sacrum + os coxae + lumbar vertebra L5 + 50% of upper half of femora) 63 26 11
Upper leg (50% of upper half of femora) 27 19 54
Middle leg (lower half of femora) 23 38 39
Lower leg (tibiae, fibulae, patellae + ankle and foot bones) 11 81 8
Upper arm (upper half of humeri) 40 28 32
Middle arm (lower half of humeri) 27 44 28
Lower arm (radii and ulnae + wrist and hand bones) 7 83 10
Skeleton (total) 37 37 27
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Table G.6: Percentage distribution by mass of spongiosa and ratio of mass energy absorption coeffi-
cients (ICRU, 1992) to tissue for bone measurement locations used in this thesis.
Skeletal Region
(RBM Measurement Location)
Spongiosa Percentage
Distribution by Mass
Ratio of Mass Energy
Absorption Coefficients
(Spongiosa/Tissue)a
Skull 9 1.33
Scapulae 2 1.20
Ribs 7 1.19
Middle spine 12 2.54
Lower spine 5 2.03
Pelvis 17 1.19
a Spectrum weighted ratio of mass energy absorption coefficients for spongiosa using values for adult red and yellow
marrow and values for a 10 year old child for cortical bone.
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Appendix H
Tube Current Modulation –
Phantom
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Figure H.1: Modulated tube current for CT brain examination superimposed on a lateral
topogram view.
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Figure H.2: Modulated tube current for a) CT chest examination and b) CT ab-
domen/pelvis examination. Both are superimposed on anterior-posterior (AP) topogram
views.
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Appendix I
Organ and Tissue Absorbed Doses
– Phantom
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APPENDIX I. ORGAN AND TISSUE ABSORBED DOSES – PHANTOM
Table I.1: TLD measured organ and tissue absorbed doses in an anthropomorphic
phantom of a 10 year old child for a CT brain examination.
Organ/Tissue Absorbed
Dose (mGy)a
Mean±2σ
Absorbed
Dose (mGy)
Range (Min,
Max)b
Absorbed
Dose (mGy)/
100 mAsc
Absorbed
Dose (mGy)/
CTDIvol
(mGy)d
Bone Marrow 6.1±0.3 - 2.7 0.15
Colon 0.026±0.001 (0.012,0.034) <0.1 <0.01
Lung 0.46±0.02 (0.22,1.15) 0.2 0.01
Stomach 0.068±0.003 (0.044,0.105) <0.1 <0.01
Breast 0.27±0.01 (0.27,0.28) 0.1 <0.01
Remainder 0.49±0.02 - 0.2 0.01
Gonads 0.0127±0.0006 - <0.1 <0.01
Bladder 0.0111±0.0006 (0.0087,0.0134) <0.1 <0.01
Oesophagus 0.48±0.02 (0.16,0.97) 0.2 0.01
Liver 0.118±0.005 (0.070,0.160) <0.1 <0.01
Thyroid 1.67±0.07 (1.29,2.05) 0.7 0.04
Bone Surface 5.0±0.2 - 2.2 0.13
Brain 33.6±1.4 (25.9,41.2) 14.6 0.84
Salivary Glands 2.7±0.1 (1.6,3.7) 1.1 0.07
Skin 2.0±0.3 (10.5,43.6) 0.9 0.05
Adrenals 0.094±0.005 (0.081,0.108) <0.1 <0.01
ET Region 1.67±0.07 (1.29,2.05) 0.7 0.04
Gall Bladder 0.054±0.003 (0.045,0.063) <0.1 <0.01
Heart 0.51±0.02 - 0.2 0.01
Kidney 0.064±0.003 (0.048,0.090) <0.1 <0.01
Lymph Nodes 0.53±0.02 - 0.2 0.01
Muscle 0.53±0.02 - 0.2 0.01
Oral Mucosa 2.7±0.1 (1.6,3.7) 1.1 0.07
Pancreas 0.084±0.004 (0.061,0.108) <0.1 <0.01
Prostate 0.0087±0.0007 - <0.1 <0.01
Small Intestine 0.023±0.001 (0.021,0.024) <0.1 <0.01
Spleen 0.156±0.007 (0.127,0.186) <0.1 <0.01
Thymus 0.47±0.02 (0.39,0.55) 0.2 0.01
Uterus / Cervix 0.0126±0.0009 (0.0112,0.0139) <0.1 <0.01
Eye Lenses 19.3±0.9 (14.0,24.6) 8.4 0.48
Testes 0.0115±0.0007 (0.0111,0.012) <0.1 <0.01
Ovaries 0.0139±0.0008 (0.0138,0.0141) <0.1 <0.01
a Errors are expressed as two standard deviations of the combined random and systematic errors.
b Minimum and maximum measured absorbed doses have been provided for organs and tissues in
which multiple TLD measurements were averaged to calculate the absorbed dose.
c mAs (actual mAs, not effective mAs) normalised absorbed dose.
d CTDIvol (16 cm dosimetry phantom) normalised absorbed dose.
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Table I.2: TLD measured organ and tissue absorbed doses in an anthropomorphic
phantom of a 10 year old child for a CT chest examination.
Organ/Tissue Absorbed
Dose (mGy)a
Mean±2σ
Absorbed
Dose (mGy)
Range (Min,
Max)b
Absorbed
Dose (mGy)/
100 mAsc
Absorbed
Dose (mGy)/
CTDIvol
(mGy)d
Bone Marrow 2.4±0.1 - 2.9 0.42
Colon 0.52±0.03 (0.12,1.04) 0.6 0.09
Lung 9.9±0.4 (8.4,11.4) 12.1 1.73
Stomach 4.8±0.2 (1.6,9.8) 5.9 0.83
Breast 9.1±0.4 (8.9,9.3) 11.2 1.59
Remainder 4.4±0.2 - 5.4 0.76
Gonads 0.080±0.004 - 0.1 0.01
Bladder 0.080±0.004 (0.058,0.092) 0.1 0.01
Oesophagus 9.2±0.4 (8.5,10.1) 11.3 1.60
Liver 10.5±0.5 (9.1,11.7) 12.9 1.83
Thyroid 10.9±0.5 (10.4,11.4) 13.4 1.91
Bone Surface 3.4±0.2 - 4.1 0.59
Brain 0.22±0.01 (0.11,0.39) 0.3 0.04
Salivary Glands 1.32±0.06 (0.99,1.66) 1.6 0.23
Skin 1.38±0.09 (6.78,10.21) 1.7 0.24
Adrenals 5.1±0.3 (2.7,7.6) 6.3 0.89
ET Region 10.9±0.5 (10.4,11.4) 13.4 1.91
Gall Bladder 2.7±0.2 (1.8,3.6) 3.4 0.48
Heart 8.6±0.4 - 10.6 1.50
Kidney 1.80±0.09 (0.90,2.83) 2.2 0.31
Lymph Nodes 2.5±0.1 - 3.1 0.45
Muscle 2.5±0.1 - 3.1 0.45
Oral Mucosa 1.32±0.06 (0.99,1.66) 1.6 0.23
Pancreas 6.4±0.3 (3.6,9.1) 7.8 1.12
Prostate 0.057±0.005 - <0.1 0.01
Small Intestine 0.36±0.02 (0.34,0.37) 0.4 0.06
Spleen 9.2±0.4 (8.5,9.9) 11.3 1.60
Thymus 9.3±0.4 (9.2,9.5) 11.5 1.63
Uterus / Cervix 0.115±0.008 (0.089,0.141) 0.1 0.02
Eye Lenses 0.191±0.009 (0.185,0.197) 0.2 0.03
Testes 0.029±0.003 (0.028,0.029) <0.1 <0.01
Ovaries 0.131±0.007 (0.128,0.134) 0.2 0.02
a Errors are expressed as two standard deviations of the combined random and systematic errors.
b Minimum and maximum measured absorbed doses have been provided for organs and tissues in
which multiple TLD measurements were averaged to calculate the absorbed dose.
c mAs (actual mAs, not effective mAs) normalised absorbed dose.
d CTDIvol (32 cm dosimetry phantom) normalised absorbed dose. These can be divided by a factor
of approximately 2 to give absorbed dose normalised to the 16 cm dosimetry phantom.
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Table I.3: TLD measured organ and tissue absorbed doses in an anthropomorphic
phantom of a 10 year old child for a CT abdomen/pelvis examination.
Organ/Tissue Absorbed
Dose (mGy)a
Mean±2σ
Absorbed
Dose (mGy)
Range (Min,
Max)b
Absorbed
Dose (mGy)/
100 mAsc
Absorbed
Dose (mGy)/
CTDIvol
(mGy)d
Bone Marrow 3.2±0.1 - 4.0 0.71
Colon 8.0±0.4 (6.0,8.6) 9.8 1.75
Lung 4.1±0.2 (0.5,7.5) 5.0 0.90
Stomach 8.9±0.4 (8.6,9.6) 10.9 1.96
Breast 1.29±0.06 (1.26,1.32) 1.6 0.28
Remainder 4.9±0.2 - 6.0 1.08
Gonads 3.7±0.2 - 4.6 0.82
Bladder 6.9±0.3 (6.1,7.8) 8.4 1.51
Oesophagus 3.3±0.1 (0.4,7.0) 4.0 0.72
Liver 8.5±0.4 (7.3,9.8) 10.4 1.87
Thyroid 0.24±0.01 (0.20,0.28) 0.3 0.05
Bone Surface 3.6±0.2 - 4.4 0.78
Brain 0.033±0.001 (0.020,0.051) <0.1 <0.01
Salivary Glands 0.117±0.005 (0.083,0.151) 0.1 0.03
Skin 1.7±0.1 (7.2,9.4) 2.0 0.36
Adrenals 6.9±0.3 (6.0,7.7) 8.4 1.51
ET Region 0.24±0.01 (0.20,0.28) 0.3 0.05
Gall Bladder 8.6±0.5 (8.2,9.0) 10.5 1.89
Heart 1.02±0.05 - 1.2 0.22
Kidney 8.3±0.4 (8.1,8.4) 10.1 1.81
Lymph Nodes 2.8±0.1 - 3.4 0.61
Muscle 2.8±0.1 - 3.4 0.61
Oral Mucosa 0.117±0.005 (0.083,0.151) 0.1 0.03
Pancreas 8.7±0.4 (8.7,8.7) 10.6 1.90
Prostate 5.8±0.4 - 7.1 1.27
Small Intestine 8.5±0.4 (7.6,9.4) 10.4 1.87
Spleen 7.9±0.4 (7.7,8.0) 9.6 1.73
Thymus 0.81±0.04 (0.64,0.98) 1.0 0.18
Uterus / Cervix 6.6±0.4 (6.2,7.0) 8.1 1.45
Eye Lenses 0.040±0.002 (0.039,0.041) <0.1 <0.01
Testes 0.99±0.05 (0.90,1.09) 1.2 0.22
Ovaries 6.4±0.3 (6.2,6.7) 7.9 1.41
a Errors are expressed as two standard deviations of the combined random and systematic errors.
b Minimum and maximum measured absorbed doses have been provided for organs and tissues in
which multiple TLD measurements were averaged to calculate the absorbed dose.
c mAs (actual mAs, not effective mAs) normalised absorbed dose.
d CTDIvol (32 cm dosimetry phantom) normalised absorbed dose. These can be divided by a factor
of approximately 2 to give absorbed dose normalised to the 16 cm dosimetry phantom.
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Figure I.1: Mean organ and tissue absorbed doses measured with TLDs loaded in a CIRS anthropomorphic phantom of a 10 year old child
for CT brain (white), CT chest (grey) and CT abdomen/pelvis (black) examinations. Effective dose according to the ICRP 103 definition
is also shown for each CT examination. Error bars are two standard deviations.
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Appendix J
Phantom Scan Regions
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Figure J.1: Phantom diagrams with scan lengths indicated for CT brain, chest and abdomen/pelvis examinations. a) physical phantom
representing a 10 year old child, b) CT-Expo computational phantom representing a 7 year old child, c) ImPACT computational phan-
tom representing an adult, d) PCXMC computational phantom representing a 10 year old child, e) PCXMC simulated “radiograph” for
examination conditions shown in d).
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Appendix K
Paediatric Fitting Parameters and
Conversion Coefficients
Table K.1: Organ and effective dose normalised to 100 mAs for the ORNL 10 year old
and UF 11 year old phantoms as provided in Lee et al. (2007a).
Organ/Tissue Head Chest Abdomen Pelvis
ORNL
10 yo
UF
11 yo
ORNL
10 yo
UF
11 yo
ORNL
10 yo
UF
11 yo
ORNL
10 yo
UF
11 yo
Testes 0.00 0.00 0.02 0.00 0.07 0.06 11.07 8.23
Bone Marrow 2.11 1.88 3.38 2.63 1.82 2.33 2.94 3.15
Colon 0.00 0.01 0.54 0.45 4.87 6.86 6.97 6.48
Lungs 0.10 0.14 12.63 12.04 1.55 2.96 0.06 0.03
Stomach 0.01 0.03 7.14 5.92 10.59 11.12 0.60 0.17
Urinary bladder 0.00 0.00 0.08 0.02 0.48 0.30 11.25 12.16
Liver 0.01 0.04 7.97 7.21 9.90 10.85 0.46 0.13
Oesophagus 0.10 0.21 10.02 8.99 2.89 3.69 0.09 0.04
Thyroid 0.76 0.5 2.78 5.22 0.07 0.37 0.00 0.01
Skin 1.60 1.72 2.37 1.58 1.43 1.71 1.55 1.74
Bone surface 6.45 8.11 7.09 5.01 2.98 3.59 3.16 5.42
Adrenals 0.01 0.03 9.83 4.94 8.81 9.90 0.22 0.17
Brain 14.65 13.94 0.13 0.10 0.01 0.02 0.00 0.00
ET region 0.76 1.96 2.78 1.33 0.07 0.18 0.00 0.00
SI wall 0.00 0.01 0.64 0.47 5.91 10.26 6.80 4.36
Kidney 0.01 0.02 4.74 2.55 10.88 12.30 0.71 0.33
Muscle 0.07 0.81 4.93 1.78 3.35 2.02 4.44 2.70
Pancreas 0.01 0.02 8.86 2.63 9.19 11.32 0.39 0.31
Spleen 0.02 0.04 8.85 7.53 9.94 11.78 0.36 0.12
Thymus 0.12 0.23 12.68 10.79 0.31 0.59 0.02 0.01
Effective Dose (male) 0.76 0.74 4.42 3.82 3.36 4.05 4.18 3.55
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Table K.2: Fitting parameters for estimating organ doses according to equation (5.1)
for CT chest examinations as given by Li et al. (2011a).
Organ/Tissue αT (cm
−1) βT Organ/Tissue αT (cm−1) βT
Lungs -0.050 3.42 Stomach -0.052 3.20
Heart -0.041 3.30 Pancreas -0.101 3.50
Thymus -0.047 3.36 Small intestine -0.200 3.96
Thyroid -0.016 2.76 Large intestine -0.204 4.01
Breast -0.038 3.02 Urinary bladder -0.163 1.01
Oesophagus -0.047 3.25 Prostate -0.175 1.19
Trachea-bronchi -0.045 3.27 Testes -0.250 1.80
Eyes -0.179 1.72 Ovaries -0.157 1.00
Brain -0.153 1.70 Uterus -0.152 0.78
Pharynx-Larynx -0.096 3.50 Vagina -0.146 0.35
Liver -0.064 3.39 Residual soft tissue -0.103 2.88
Gallbladder -0.126 4.06 Bone surface -0.082 3.25
Kidneys -0.091 3.26 RBM -0.054 2.09
Adrenals -0.066 3.24 Skin -0.096 2.34
Spleen -0.063 3.33
Table K.3: Exponential regression coefficients for size-
corrected, scanner-independent organ absorbed dose esti-
mates according to equation (5.3) for abdominal CT as given
by Turner et al. (2011).
Organ/Tissue A0 B0
Liver 3.824 -0.0120
Stomach 3.780 -0.0113
Adrenals 4.029 -0.0128
Kidney 3.969 -0.0124
Pancreas 3.715 -0.0122
Spleen 3.514 -0.0111
Gall Bladder 3.994 -0.0115
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Table K.4: Normalised effective dose per dose length product
(DLP) coefficients for adults and paediatric patients for several
body regions (Shrimpton et al., 2006).
Scan Area k (mSv·mGy−1·cm−1)
0 yoa 1 yoa 5 yoa 10 yoa Adultb
Head and neck 0.013 0.0085 0.0057 0.0042 0.0031
Head 0.011 0.0067 0.0040 0.0032 0.0021
Neck 0.017 0.012 0.011 0.0079 0.0059
Chest 0.039 0.026 0.018 0.013 0.014
Abdomen and pelvis 0.049 0.030 0.020 0.015 0.015
Trunk 0.044 0.028 0.019 0.014 0.015
a All paediatric conversion coefficients are for DLP values derived from
the 16 cm dosimetry phantom.
b All adult conversion coefficients are for DLP values derived from the
32 cm dosimetry phantom, except for the head and/or neck which are
based on the 16 cm dosimetry phantom.
Table K.5: Normalised effective dose per dose length prod-
uct (DLP) for adults and paediatric patients for several
body regions and ICRP 60 and ICRP 103 (Deak et al.,
2010).
Scan Area k (mSv·mGy−1·cm−1)
Newborn 1 yo 5 yo 10 yo Adult
ICRP Publication 60
Headb 0.0077 0.0047 0.0031 0.0023 0.0016
Neckb 0.0228 0.0189 0.0137 0.0107 0.0057
Chestc 0.0651 0.0427 0.0291 0.0217 0.0136
Abdomenc 0.0817 0.0522 0.0354 0.0249 0.0155
Pelvisc 0.0876 0.0564 0.0380 0.0283 0.0167
ICRP Publication 103
Headb 0.0085 0.0053 0.0035 0.0027 0.0019
Neckb 0.0206 0.0166 0.0120 0.0094 0.0051
Chestc 0.0706 0.0467 0.0314 0.0234 0.0145
Abdomenc 0.0804 0.0514 0.0349 0.0246 0.0153
Pelvisc 0.0672 0.0431 0.0294 0.0216 0.0129
a All conversion coefficients are for an X-ray tube voltage of
120 kVp.
b For head and neck regions, the conversion coefficients are for
DLP values derived from the 16 cm dosimetry phantom.
c For all body regions for both adults and children, the conversion
coefficients are for DLP values derived from the 32 cm dosimetry
phantom.
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Table K.6: Fitting parameters for calculating size-dependent DLP conver-
sion coefficients according to equation (5.5) (Chapple et al., 2002).
Scan Area y0 (mSv·mGy
−1
·cm−1) A1 (mSv·mGy−1·cm−1) t1 (cm)
Head 0.00351 0.877 14.2
Chest 0.00736 0.272 4.07
Abdomen 0.00832 0.811 2.87
Pelvis -0.0419 0.114 25.3
a Conversion coefficients derived using these fitting parameters and equation (5.5) are
for DLP values derived from the 16 cm dosimetry phantom.
Table K.7: Normalised effective dose per weighted CTDI
(CTDIw) for adults and paediatric patients for several body re-
gions (Shrimpton, 2004).
Scan Area kw (mSv·mGy
−1)
0 yoa 1 yoa 5 yoa 10 yoa Adultb
Head and neck 0.173 0.153 0.113 0.0880 0.0707
Head 0.0882 0.0735 0.0526 0.0417 0.0278
Neck 0.0869 0.0812 0.0769 0.0632 0.0591
Chest 0.354 0.316 0.284 0.264 0.383
Abdomen and pelvis 0.632 0.568 0.499 0.458 0.659
Trunk 0.967 0.853 0.769 0.708 1.03
a All paediatric conversion coefficients are for CTDIw values derived from
the 16 cm dosimetry phantom.
b All adult conversion coefficients are for CTDIw values derived from the
32 cm dosimetry phantom, except for the head and/or neck which are
based on the 16 cm dosimetry phantom.
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RCH Patient Dose Survey – CT
Examination Parameters
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Table L.1: Set examination parameters and mean values for tube current, scan length, CTDIvol and DLP from a survey of patient
records for typical CT examinations.
Examination Age
Groupa
Set Parameters Scan Values (Mean)
kVp Qref
b
(mAs)
Rotation
time (s)
Pitch Detector
Configura-
tion
Beam Col-
limation
(mm)
Effective
mAsb
Scan
Length
(cm)
CTDIvol,16
c
(mGy)
DLP16
c
(mGy·cm)
CT Brain 0-6 m 120 150 0.75 axial 12x1.5 mm 18 91 12.7 17.07 217
6 m-3 y 120 150 0.75 axial 12x1.5 mm 18 105 14.4 19.43 281
3-6 y 120 200 0.75 axial 12x1.5 mm 18 159 14.5 29.98 435
6-10 y 120 240 0.75 axial 12x1.5 mm 18 212 15.3 39.76 608
>10 y 120 270 0.75 axial 12x1.5 mm 18 235 15.3 44.35 679
Combined 120 - 0.75 axial 12x1.5 mm 18 160 14.4 30.12 444
CT Chest <5 y 80 65 0.5 1 16x1.5 mm 24 65 18.8 2.98 57
5-10 y 100 80 0.5 1 16x1.5 mm 24 109 28.7 10.31 296
>10 y 120 80 0.5 1 16x1.5 mm 24 157 34.6 22.90 799
Combined - - 0.5 1 16x1.5 mm 24 110 27.4 12.06 384
CT
Abdomen/
Pelvis
<5 y 80 80 0.5 1.25 16x1.5 mm 24 72 32.0 3.30 107
5-10 y 100 80 0.5 1.25 16x1.5 mm 24 103 39.6 9.62 384
>10 y 120 60 0.5 1.25 16x1.5 mm 24 102 46.9 14.92 702
Combined - - 0.5 1.25 16x1.5 mm 24 92 39.5 9.28 398
a Age groups are defined in terms of months (m) or years (y).
b Qref is the Imaging Quality Reference mAs, which is a Siemens specific setting used for automatic tube current modulation (CARE Dose 4D), which
is set by the user for each protocol. This value is adjusted based on image quality requirements and the amount of noise acceptable in the image. It is
defined in terms of the effective mAs (actual mAs divided by pitch).
c Dose indicators for CT chest and abdomen/pelvis examinations were displayed on the CT scanner as CTDIvol,32 and DLP32. These have been
multiplied by a factor of 2.08 according to the methodology of Huda et al. (2010) to give CTDIvol,16 and DLP16. The dose indicators for the CT brain
examinations were already displayed in terms of CTDIvol,16 and DLP16 and therefore do not require correction.
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RCH Patient Dose Survey – Age
and Gender Demographics
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Table M.1: Gender and age distribution for patients included in the RCH dose survey.
Category CT Brain CT Chest CT Abdomen/Pelvis
0-6 m 6 m-3 y 3-6 y 6-10 y >10 y Total <5 y 5-10 y >10 y Total <5 y 5-10 y >10 y Total
No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) No.(%)
All 20 (100) 20 (100) 20 (100) 20 (100) 20 (100) 100 (100) 20 (100) 20 (100) 20 (100) 60 (100) 20 (100) 20 (100) 20 (100) 60 (100)
Sex
Male 10 (50) 12 (60) 12 (60) 15 (75) 12 (60) 61 (61) 11 (55) 17 (85) 10 (50) 38 (63) 10 (50) 12 (60) 14 (70) 36 (60)
Female 10 (50) 8 (40) 8 (40) 5 (25) 8 (40) 39 (39) 9 (45) 3 (15) 10 (50) 22 (37) 10 (50) 8 (40) 6 (30) 24 (40)
Age
0 y 20 (100) 4 (20) 24 (24) 5 (25) 5 (8) 2 (10) 2 (3)
1 y 12 (60) 12 (12) 9 (45) 9 (15) 5 (25) 5 (8)
2 y 3 (15) 1 (5) 4 (4) 3 (15) 3 (5) 4 (20) 4 (7)
3 y 1 (5) 6 (30) 7 (7) 1 (5) 1 (2) 6 (30) 6 (10)
4 y 7 (35) 7 (7) 0 (0) 0 (0) 2 (10) 2 (3)
5 y 5 (25) 5 (5) 2 (10) 2 (3) 1 (5) 3 (15) 4 (7)
6 y 0 (0) 0 (0) 0 (0) 3 (15) 3 (5) 5 (25) 5 (8)
7 y 1 (5) 2 (10) 3 (3) 5 (25) 5 (8) 1 (5) 1 (2)
8 y 5 (25) 5 (5) 3 (15) 3 (5) 4 (20) 4 (7)
9 y 8 (40) 8 (8) 5 (25) 5 (8) 6 (30) 6 (10)
10 y 4 (20) 4 (4) 2 (10) 1 (5) 3 (5) 1 (5) 1 (5) 2 (3)
11 y 1 (5) 4 (20) 5 (5) 2 (10) 2 (3) 2 (10) 2 (3)
12 y 5 (25) 5 (5) 0 (0) 0 (0) 0 (0) 0 (0)
13 y 4 (20) 4 (4) 2 (10) 2 (3) 4 (20) 4 (7)
14 y 0 (0) 0 (0) 3 (15) 3 (5) 3 (15) 3 (5)
15 y 4 (20) 4 (4) 4 (20) 4 (7) 4 (20) 4 (7)
16 y 1 (5) 1 (1) 4 (20) 4 (7) 3 (15) 3 (5)
17 y 2 (10) 2 (2) 3 (15) 3 (5) 3 (15) 3 (5)
18 y 0 (0) 0 (0) 1 (5) 1 (2) 0 (0) 0 (0)
a Age groups are defined in terms of months (m) or years (y).
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Comparison of Doses for Typical
Paediatric CT Examinations
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Table N.1: Comparison of measured organ and tissue absorbed doses from this thesis with values in the literature.
CT Brain CT Chest CT
Abdomen/
Pelvis
CT
Abdomen
This Study Brenner et
al.a
This Study Fujii et al.b Coursey et
al.c
This Study Brenner et
al.a
CT Scanner Siemens
Sensation 16
- Siemens
Sensation 16
Siemens
Sensation 16
GE
LightSpeed 16
Siemens
Sensation 16
-
Device/Method TLD Surveya TLD Photodiode MOSFET TLD Surveya
Phantom Age (years) 10 10 10 6 5 10 10
Tube voltage (kVp) 120 - 120 120 120 120 -
Dose Modulation Care Dose 4D - Care Dose 4D Care Dose 4D None Care Dose 4D -
Current x time (mAs) 259 462 (340)a 78 51 33 80 404 (240)a
Tube rotation time (s) 0.75 - 0.5 0.5 0.5 0.5 -
Beam collimation (mm) 18 - 24 24 20 24 -
Pitch axial - 1 1.125 1.375 1.25 -
Scanned length (cm) 16 11 27 20 - 37 14
Organ/Tissue Absorbed Dose (mGy)
Stomach 0.07 - 4.8 2.9 3.7 8.9 30 (18)a
Colon 0.03 - 0.52 0.4 - 8.0 9 (5)a
Liver 0.12 - 10 5.7 4.0 8.5 28 (16)a
Lung 0.46 - 9.9 7.5 4.3 4.1 -
Breast (Females) 0.27 - 9.1 6.5 4.0 1.3 -
Uterus (Females) 0.01 - 0.12 - - 6.6 -
Ovary (Females 0.01 - 0.13 0.1 - 6.5 10 (6)a
Prostate (Males) 0.01 - 0.06 - - 5.8 -
Bladder 0.01 - 0.08 0.1 - 6.9 -
Brain 34 50 (35)a 0.22 0.1 - 0.03 -
Bone Marrow 6.1 5 (5)a 2.4 2.4 3.6 3.2 8 (4)a
a Brenner et al. (2001a) obtained paediatric organ absorbed doses by scaling adult organ absorbed doses reported in a 1989 British survey (Shrimpton et al.,
1991) by relative age-dependent changes in effective dose estimated by Huda et al. (1997). Although this method has inherent problems for estimating
specific absorbed doses, including averaging over 120 different scanners, they are listed here as the risk estimates calculated by Brenner et al. (2001a) are
quoted frequently in the literature (cited 929 times by 22 May 2010). Values in brackets in the Table are from a newer study by Brenner et al. (2007) based
on a US survey (CRCPD, 2006) from 2000.
b Fujii et al. (2007).
c Coursey et al. (2008).
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Table O.1: Natural male and female cancer incidence and mortality risks compared with those from CT radiation exposure at 10 years of
age, expressed as a percentage risk.
Cancer Site Incidence Mortality
Australiaa ICRP 103b This Studyc Australiaa ICRP 103b This Studyc
CT Brain CT Chest CT APd CT Brain CT Chest CT APd
Males
Stomach 1.37% 1.71% 0.0000% 0.0026% 0.0049% 0.69% 1.05% 0.0000% 0.0014% 0.0027%
Colon 4.74% 3.74% 0.0001% 0.0013% 0.0193% 1.29% 1.67% 0.0000% 0.0006% 0.0094%
Liver 0.84% 0.64% 0.0001% 0.0045% 0.0037% 0.73% 0.51% 0.0000% 0.0033% 0.0026%
Lung 6.25% 7.76% 0.0010% 0.0213% 0.0089% 4.90% 6.81% 0.0010% 0.0216% 0.0090%
Prostate 17.1% - 0.0000% 0.0000% 0.0039% 2.74% - 0.0000% 0.0000% 0.0007%
Bladder 1.85% 3.61% 0.0000% 0.0001% 0.0103% 0.58% 0.74% 0.0000% 0.0000% 0.0022%
Thyroid 0.35% 0.20% 0.0008% 0.0055% 0.0001% 0.05% - - - -
Leukaemia 1.50% 1.28% 0.0073% 0.0028% 0.0039% 0.85% 0.69% 0.0043% 0.0017% 0.0023%
All Cancersf 41.7% 49.2% 0.0206% 0.0598% 0.0712% 18.8% 21.2% 0.0099% 0.0372% 0.0353%
Females
Stomach 0.74% 1.02% 0.0000% 0.0034% 0.0064% 0.47% 0.68% 0.0000% 0.0020% 0.0037%
Colon 5.00% 3.98% 0.0000% 0.0008% 0.0126% 1.25% 1.79% 0.0000% 0.0004% 0.0058%
Liver 0.37% 0.40% 0.0000% 0.0021% 0.0017% 0.39% 0.36% 0.0000% 0.0018% 0.0015%
Lung 4.17% 4.75% 0.0023% 0.0497% 0.0207% 3.23% 3.94% 0.0020% 0.0436% 0.0181%
Breast 11.1% 12.6% 0.0019% 0.0649% 0.0092% 2.63% 3.40% 0.0005% 0.0152% 0.0022%
Uterus 1.92% - 0.0000% 0.0000% 0.0024% 0.11%d - 0.0000% 0.0000% 0.0005%
Ovary 1.30% 2.12% 0.0000% 0.0001% 0.0047% 0.93% 1.23% 0.0000% 0.0001% 0.0025%
Bladder 0.70% 1.29% 0.0000% 0.0001% 0.0104% 0.29% 0.37% 0.0000% 0.0000% 0.0030%
Thyroid 1.06% 0.49% 0.0046% 0.0300% 0.0007% 0.07% - - - -
Leukaemia 1.15% 0.99% 0.0053% 0.0020% 0.0028% 0.66% 0.59% 0.0032% 0.0013% 0.0017%
All Cancersf 33.3% 44.4% 0.0284% 0.1804% 0.0910% 16.7% 19.3% 0.0117% 0.0757% 0.0471%
a Natural cancer incidence and mortality risks for the Australian population in 2006 are provided by the Australian Institute of Health and Welfare (AIHW, 2008a,
2009). The average life expectancy for Australian men and women is 79 and 84 years respectively (ABS, 2008b). The AIHW provides risks to attained age of 75
years or 85 years. The risks in the above Table for men are an average of the risks to attained age 75 years and 85 years and for women the risks are for an attained
age of 85 years. b Male and female Euro-American cancer incidence and mortality annual rates are provided by age (five year brackets) and cancer site in ICRP 103
(2007b). Risks were summed for each age group to 79 years for men and to 84 years for women (ABS, 2008b). The risks in each five year age interval were assumed
constant. c Cancer incidence and mortality risks for this thesis were calculated based on site-specific organ doses measured with TLDs (Chapter 3) multiplied by
the site- and sex-specific BEIR VII Lifetime Attributable Risks (LAR) for exposure at 10 years (NRC, 2006). d CT AP = CT Abdomen/Pelvis. e Mortality risk
for uterine cancer in Australia in 2006 from the AIHW’s Ovarian Cancer Overview (AIHW, 2010). f “All cancers” includes solid cancers and leukaemia listed in the
Table above as well as “other” solid cancers not listed. g Natural cancer incidence and mortality risks are given to two significant figures <1% and three significant
figures for risks ≥1%. Risks from CT examinations are given to four decimal places (precision below one in a million is unnecessary).
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Table O.2: Natural male and female cancer incidence and mortality risks compared with those from CT radiation exposure at 10 years of
age. Risk is expressed in terms of the number of people in the population for whom one will develop non-radiation related cancer (Australia
and ICRP columns) and the number of patients undergoing CT scans that would lead to the development of one radiation-induced cancer.
Cancer Site Incidence Mortality
Australiaa ICRP 103b This Studyc Australiaa ICRP 103b This Studyc
CT Brain CT Chest CT APd CT Brain CT Chest CT APd
Males
Stomach 73 59 2,677,100 38,100 20,300 100 96 4,908,100 69,900 37,300
Colon 0 27 1,570,600 79,600 5,200 78 60 3,235,100 163,900 10,700
Liver 100 200 1,969,200 22,200 27,300 136 200 2,731,400 30,800 37,800
Lung 16 13 101,400 4,700 11,300 20 15 100,000 4,600 11,100
Prostate 6 - 17,211,100 2,618,700 25,800 37 - 96,095,500 14,620,900 144,100
Bladder 54 28 6,006,900 837,100 9,700 200 100 28,157,500 3,924,000 45,500
Thyroid 300 500 119,800 18,300 828,200 1,900 - - - -
Leukaemia 67 78 13,600 35,100 25,700 100 100 23,000 59,300 43,400
All Cancersf 2 2 4,900 1,700 1,400 5 5 10,100 2,700 2,800
Females
Stomach 100 98 2,045,000 29,100 15,500 200 100 3,591,300 51,200 27,300
Colon 20 25 2,395,600 121,400 7,900 80 56 5,185,000 262,700 17,100
Liver 300 300 4,233,700 47,700 58,600 300 300 4,980,800 56,100 69,000
Lung 24 21 43,500 2,000 4,800 31 25 49,500 2,300 5,500
Breast 9 8 51,400 1,500 10,900 38 29 219,100 6,600 46,400
Uterus 52 - 22,071,500 2,411,200 42,000 1,000e - 99,321,600 10,850,500 189,200
Ovary 77 47 9,833,100 1,045,300 21,200 100 81 18,405,600 1,956,500 39,800
Bladder 100 100 5,927,900 826,100 9,600 300 300 20,954,400 2,920,200 33,900
Thyroid 94 200 21,800 3,300 150,600 1,300 - - - -
Leukaemia 87 100 19,000 49,000 35,900 200 200 30,800 79,400 58,200
All Cancersf 3 2 3,500 600 1,100 6 5 8,500 1,300 2,100
a Natural cancer incidence and mortality risks for the Australian population in 2006 are provided by the Australian Institute of Health and Welfare (AIHW, 2008a,
2009). The average life expectancy for Australian men and women is 79 and 84 years respectively (ABS, 2008b). The AIHW provides risks to attained age of 75
years or 85 years. The risks in the above Table for men are an average of the risks to attained age 75 years and 85 years and for women the risks are for an attained
age of 85 years. b Male and female Euro-American cancer incidence and mortality annual rates are provided by age (five year brackets) and cancer site in ICRP 103
(2007b). Risks were summed for each age group to 79 years for men and to 84 years for women (ABS, 2008b). The risks in each five year age interval were assumed
constant. c Cancer incidence and mortality risks for this thesis were calculated based on site-specific organ doses measured with TLDs (Chapter 3) multiplied by
the site- and sex-specific BEIR VII Lifetime Attributable Risks (LAR) for exposure at 10 years (NRC, 2006). d CT AP = CT Abdomen/Pelvis. e Mortality risk for
uterine cancer in Australia in 2006 from the AIHW’s Ovarian Cancer Overview (AIHW, 2010). f “All cancers” includes the solid cancers and leukaemia listed in the
Table above as well as “other” solid cancers not listed. g Natural cancer incidence and mortality risks are given to two significant figures <1% and three significant
figures for risks ≥1%. Risks from CT examinations are given to four decimal places (precision below one in a million is unnecessary). h Risks greater than 1 in 100
have been rounded to the nearest whole number. Risks equal to and above 1 in 100 have been rounded to the nearest 100.
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